

EXHIBIT B

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

The parties reserve all objections to any exhibit or portion thereof listed by either party. By listing an exhibit, the parties do not waive any objection. The parties reserve the right to object depending upon					
Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5000	Email from D. Uelmen to J. Hudnall, et al re: Physician Panel Agenda	BPV-17-01-00000105	BPV-17-01-00000107	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5001	Dec. 2004 Dear Doctor Letter	BPV-17-01-00000188	BPV-17-01-00000189	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5002	Feb. 4, 2005 Conference FDA and BPV re DCL and Recovery Retrievable	BPV-17-01-00000208	BPV-17-01-00000209	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5003	Feb. 8, 2005 Conference FDA and BPV re Recovery Retrievable (K031328)	BPV-17-01-00000210	BPV-17-01-00000211	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5004	Recovery Filter IFU 2003	BPV-17-01-00000246	BPV-17-01-00000248	FRE 401; 402; 403; 602; 702;	
5005	Recovery Filter DFMEA 070010, Rev. 2 DFMEA070010 Rev. 2 Recovery Filter	BPV-17-01-00000249	BPV-17-01-00000262	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5006	Design Review Assessment Status Memo	BPV-17-01-00000297	BPV-17-01-00000302	FRE 401; 402; 403; 602; 702;	401; 402; 403; 901
5007	Oct 18, 2002 letter to the FDA responding to the questions posed by Dr. Harvey at	BPV-17-01-00000334	BPV-17-01-00000340	FRE 401; 402; 403; 602; 702;	401; 402; 403
5008	ETR-04-08-04 (G2 Arm Fatigue Testing Report) ETR-04-08-04 (G2 Arm Fatigue	BPV-17-01-00000781	BPV-17-01-00000787	FRE 401; 402; 403; 602; 702;	
5009	TM1133800 (G2 Filter Arm Fatigue Test Method)	BPV-17-01-00001481	BPV-17-01-00001487	FRE 401; 402; 403; 602; 702;	
5010	Recovery Filter Fault Tree Analysis	BPV-17-01-00002121	BPV-17-01-00002127	FRE 401; 402; 403; 602; 702;	401; 402; 403
5011	SPA-04-04-01 (Remedial Action Plan re RNF Fractures)	BPV-17-01-00002137	BPV-17-01-00002140	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5012	HHE of Dr. Ciavarella July 9, 2004	BPV-17-01-00002145	BPV-17-01-00002145	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5013	May 21, 2002 Memo from Doug Uelmen (re Fracture Investigation)	BPV-17-01-00002207	BPV-17-01-00002216	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5014	ETR-04-06-06 (RF Migration Resistance DOE and Hook Radius Change)	BPV-17-01-00002240	BPV-17-01-00002270	FRE 401; 402; 403; 602; 702;	
5015	ETR-04-10-21 (G2® Acute Animal Feasibility Study)	BPV-17-01-00002335	BPV-17-01-00002344	FRE 401; 402; 403; 602; 702;	
5016	ETR-02-12-01, Rev. 00 (Recovery Filter Magnetic Resonance Safety and	BPV-17-01-00002345	BPV-17-01-00002369	FRE 401; 402; 403; 602; 702;	
5017	Aug. 5, 1999 R&D Technical Report RNF Migration Study, Design Verification	BPV-17-01-00002650	BPV-17-01-00002655	FRE 401; 402; 403; 602; 702;	401; 402; 403
5018	RD-RPT-104 (Analysis of RNF Migration Resistance) (FEA)	BPV-17-01-00002656	BPV-17-01-00002662	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5019	RNF Wire Tensile Test Report	BPV-17-01-00003453	BPV-17-01-00003466	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5020	Aug. 9, 1999 RD-RPT-102 RNF Radial Strength Report	BPV-17-01-00003667	BPV-17-01-00003672	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5021	ETR-04-10-04 (Feasibility: RNF v. G2 and Competitive Product -- migration	BPV-17-01-00003783	BPV-17-01-00003792	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5022	RD-LNB-087 Laboratory Notebook	BPV-17-01-00004149	BPV-17-01-00004290	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5023	Aug. 12, 1999 RD-RPT-095 Test Results for RD-SOP-057 Simulated Use	BPV-17-01-00004856	BPV-17-01-00004863	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5024	Recovery Filter DFMEA 070010, Rev. 4 Recovery Filter DFMEA 070010, Rev. 4	BPV-17-01-00007573	BPV-17-01-00007595	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5025	ETR-05-03-01 G1A Jugular/Subclavian System Design Verification and Validation	BPV-17-01-00008669	BPV-17-01-00008680	FRE 401; 402; 403; 602; 702;	
5026	ETR-05-05-21 G1A Jugular/Subclavian System Design Verification and Validation	BPV-17-01-00008682	BPV-17-01-00008688	FRE 401; 402; 403; 602; 702;	
5027	ETR-05-03-02 G1A Acute Animal Study Report	BPV-17-01-00008690	BPV-17-01-00008694	FRE 401; 402; 403; 602; 702;	
5028	Recovery Filter G1A Femoral System-Design Failure Mode and Effect Analysis	BPV-17-01-00009033	BPV-17-01-00009056	FRE 401; 402; 403; 602; 702;	
5029	ETR-05-03-11 (G2 Migration Resistance Evaluation of NEPG Manufactured	BPV-17-01-00009213	BPV-17-01-00009225	FRE 401; 402; 403; 602; 702;	
5030	Lab notebook 7013 (Recovery Arm Fatigue Feasibility)	BPV-17-01-00009320	BPV-17-01-00009331	FRE 401; 402; 403; 602; 702;	
5031	Lab notebook 7013 (Recovery Arm Fatigue Feasibility) Lab notebook 7013	BPV-17-01-00009381	BPV-17-01-00009398	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5032	ETR-05-01-06 (G2® Femoral System Acute Animal Study Report) (followed TPR-	BPV-17-01-00013631	BPV-17-01-00013639	FRE 401; 402; 403; 602; 702;	
5033	TPR-04-12-20 (Protocol for Animal Model Evaluation of G2)	BPV-17-01-00013788	BPV-17-01-00013799	FRE 401; 402; 403; 602; 702;	
5034	G1A Filter and Femoral Delivery System PPS Revision 0	BPV-17-01-00013929	BPV-17-01-00013958	FRE 401; 402; 403; 602; 702;	
5035	G1A Filter and Femoral Delivery System PPS Revision 1	BPV-17-01-00014097	BPV-17-01-00014126	FRE 401; 402; 403; 602; 702;	
5036	ETR-05-02-11 (Chronic Animal Model Evaluation of Recovery G1A Femoral	BPV-17-01-00014227	BPV-17-01-00014257	FRE 401; 402; 403; 602; 702;	
5037	ETR-05-02-02 (Effects of Changes to the Recovery Filter & The Femoral Delivery	BPV-17-01-00014259	BPV-17-01-00014286	FRE 401; 402; 403; 602; 702;	
5038	Dec 5, 2003 Recovery Filter Design Review Materials	BPV-17-01-00014488	BPV-17-01-00014824	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5039	12.04.03 Special Design Review Objectives for Recovery FMR Launch	BPV-17-01-00014490	BPV-17-01-00014496	FRE 401; 402; 403; 602; 702;	401; 402; 403
5040	Aug. 11, 1999 RD-RPT-094 Pusher Wire Integrity Test Report	BPV-17-01-00014566	BPV-17-01-00014570	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5041	Aug. 18, 1999 RD-RPT-103 RNF Clot Trapping Efficiency Report	BPV-17-01-00014588	BPV-17-01-00014592	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5042	TM1134800 (G2® Filter Migration Resistance Testing Test Method)	BPV-17-01-00015103	BPV-17-01-00015112	FRE 401; 402; 403; 602; 702;	
5043	RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 511)	BPV-17-01-00019372	BPV-17-01-00019375	FRE 401; 402; 403; 602; 702;	401; 402
5044	ETR-05-05-21 (G2® DV&V Report Phase III [for jugular system])	BPV-17-01-00021183	BPV-17-01-00021189	FRE 401; 402; 403; 602; 702;	
5045	ETR-05-03-02 (Recovery Filter Jugular/Subclavian System Acute Animal Study	BPV-17-01-00021191	BPV-17-01-00021195	FRE 401; 402; 403; 602; 702;	
5046	MAUDE and sales data through Q1 2004	BPV-17-01-00023746	BPV-17-01-00023752	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5047	Aug. 2004 Altran Report (Preliminary SEM of Failed Hooks and Legs) (Fracture)	BPV-17-01-00024471	BPV-17-01-00024496	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5048	RA-STD-002, Rev. 08	BPV-17-01-00024667	BPV-17-01-00024684	FRE 401; 402; 403; 602; 702;	
5049	Recovery Filter DFMEA (DFMEA070010, Rev. 2)	BPV-17-01-00024687	BPV-17-01-00024700	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5050	Sept. 2004 Altran Report (Draft Failure Analysis for 11 Complaint Filters)	BPV-17-01-00024718	BPV-17-01-00024794	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5051	Sept. 2004 Altran Report (Draft Evaluation of Two Production Lot Filters and One	BPV-17-01-00024795	BPV-17-01-00024828	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5052	Feb. 14, 2005 Conference FDA and BPV re DDL and Recovery Retrievable	BPV-17-01-00025340	BPV-17-01-00025342	FRE 401; 402; 403; 602; 702;	401; 402; 403
5053	Recovery Filter Design/Development Files Recovery Filter Design/Development	BPV-17-01-00025839	BPV-17-01-00026584	FRE 401; 402; 403; 602; 702;	401; 402; 403
5054	NMT Filter Drawing RD-10261, Rev. 00 (Arms Up)	BPV-17-01-00025912	BPV-17-01-00025912	FRE 401; 402; 403; 602; 702;	
5055	RD-SOP-033 (Rotating-Beam Corrosion Fatigue Testing of Nitinol Wire)	BPV-17-01-00026034	BPV-17-01-00026055	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5056	RD-RPT-029 Technical Review of Phase I Development Activities for RNF (Sept.	BPV-17-01-00026097	BPV-17-01-00026100	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5057	Dec. 30, 1997 RD-RPT-038 Corrosion Fatigue Testing Report	BPV-17-01-00026101	BPV-17-01-00026108	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5058	March 23, 1998 RD-RPT-041 Feasibility Animal Study Summary Results	BPV-17-01-00026109	BPV-17-01-00026116	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5059	April 13, 1998 RD-RPT-045 Feasibility Animal Study Summary Results	BPV-17-01-00026136	BPV-17-01-00026147	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5060	June 17, 1999 RD-RPT-085 Determination of Optimum Welding Parameters	BPV-17-01-00026193	BPV-17-01-00026210	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5061	Feb. 15, 2000 RD-RPT-115 Straight .013" Pusher Wire Deployment Testing and	BPV-17-01-00026268	BPV-17-01-00026276	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5062	Oct. 16, 2001 R&D Technical Report Evaluation of RNF Hook Strength Test (RD-	BPV-17-01-00026324	BPV-17-01-00026329	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5063	June 15, 2000 RD-RPT-123 Creep Evaluation of RNF	BPV-17-01-00026338	BPV-17-01-00026352	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5064	June 11, 2001 RD-RPT-158 RNF Recovery Sheath Bioburden Test Report	BPV-17-01-00026353	BPV-17-01-00026357	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5065	Arms Up Design History File Table of Contents Table of Contents for Removable	BPV-17-01-00026359	BPV-17-01-00026361	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5066	RM-0045, Nitinol Sleeve RM-0045, Nitinol Sleeve	BPV-17-01-00027145	BPV-17-01-00027148	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5067	Nov. 24, 2004 Email FDA to BPV re Recovery IFU and DDL	BPV-17-01-00029512	BPV-17-01-00029516	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5068	Recovery IFU Supporting Documentation	BPV-17-01-00029787	BPV-17-01-00029799	FRE 401; 402; 403; 602; 702;	401; 402; 403
5069	Recovery Filter Fact Book, Volume 01 of 13 Recovery Filter Fact Book, Volume	BPV-17-01-00030232	BPV-17-01-00030315	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5070	NMT Design Inputs, Rev. 03 10/04/99	BPV-17-01-00030283	BPV-17-01-00030295	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5071	Sept. 1997 NMT Design Input Approval	BPV-17-01-00030295	BPV-17-01-00030306	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5072	Recovery Filter Fact Book, Volume 02 of 13 Recovery Filter Fact Book, Volume	BPV-17-01-00030316	BPV-17-01-00030526	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5073	Recovery Filter Fact Book, Volume 03 of 13 Recovery Filter Fact Book, Volume	BPV-17-01-00030527	BPV-17-01-00030882	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5074	RD-RPT-025 (Test Report for Biocompatibility for SNF)	BPV-17-01-00030532	BPV-17-01-00030538	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5075	Recovery Filter Fact Book, Volume 04 of 13 Recovery Filter Fact Book, Volume	BPV-17-01-00030883	BPV-17-01-00031020	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5076	Recovery Filter Fact Book, Volume 05 of 13 Recovery Filter Fact Book, Volume	BPV-17-01-00031021	BPV-17-01-00031049	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5077	Recovery Product Development Operating Plan	BPV-17-01-00031047	BPV-17-01-00031049	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5078	Recovery Filter Fact Book, Volume 06 of 13 Recovery Filter Fact Book, Volume	BPV-17-01-00031050	BPV-17-01-00031500	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5079	RD-SOP-035.03 (SOP re migration resistance testing NMT) R&D SOP: RD-SOP-	BPV-17-01-00031053	BPV-17-01-00031061	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5080	May 13, 1998 RD-SOP-048 In-Vivo Evaluation of Thrombogenic Response to	BPV-17-01-00031077	BPV-17-01-00031082	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5081	RNF Animal Experiment Notes, Feasibility Animal Experiment	BPV-17-01-00031083	BPV-17-01-00031085	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5082	RNF Animal Experiment Notes, Feasibility Animal Experiment	BPV-17-01-00031087	BPV-17-01-00031098	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5083	RNF Animal Experiment Notes, Feasibility Animal Experiment	BPV-17-01-00031099	BPV-17-01-00031113	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5084	RNF Animal Experiment Notes, Feasibility Animal Experiment	BPV-17-01-00031114	BPV-17-01-00031122	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5085	RD-SOP-050.00, RNF Design Verification: In-Vivo Occlusion Migration	BPV-17-01-00031123	BPV-17-01-00031133	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5086	RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 379)	BPV-17-01-00031135	BPV-17-01-00031136	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5087	Data Sheet for RD-SOP-050.00 (Animal 379)	BPV-17-01-00031137	BPV-17-01-00031146	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5088	Data Sheet for RD-SOP-050.00 (Animal 511)	BPV-17-01-00031151	BPV-17-01-00031160	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5089	RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558)	BPV-17-01-00031162	BPV-17-01-00031164	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5090	RNF Design Animal Verification Study: In-Vivo Occlusion Migration Resistance	BPV-17-01-00031165	BPV-17-01-00031174	FRE 401; 402; 403; 602; 702;	401; 402; 403
5091	Dec. 2, 1998 RD-SOP-051.00 RNF Design Verification In-Vivo Evaluation for	BPV-17-01-00031183	BPV-17-01-00031195	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5092	RNF Animal Experiment Notes, Feasibility Animal Experiment RNF Animal	BPV-17-01-00031197	BPV-17-01-00031348	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5093	RD-SOP-052.00, RNF Design Verification: In-Vivo Evaluation for Long-term	BPV-17-01-00031349	BPV-17-01-00031360	FRE 401; 402; 403; 602; 702;	401; 402; 403
5094	RNF Animal Experiment Notes, Feasibility Animal Experiment	BPV-17-01-00031361	BPV-17-01-00031419	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5095	RD-SOP-053.00, RNF Hook Creep Study	BPV-17-01-00031420	BPV-17-01-00031424	FRE 401; 402; 403; 602; 702;	401; 402; 403
5096	June 28, 1999 RD-SOP-054.00 EnduraTec Corrosion/Fatigue Testing Protocol	BPV-17-01-00031425	BPV-17-01-00031431	FRE 401; 402; 403; 602; 702;	
5097	July 29, 1999 RD-SOP-072 RNF Design Verification Radial Strength Protocol	BPV-17-01-00031482	BPV-17-01-00031487	FRE 401; 402; 403; 602; 702;	401; 402
5098	Recovery Filter Fact Book, Volume 07 of 13 Recovery Filter Fact Book, Volume	BPV-17-01-00031501	BPV-17-01-00031903	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5099	Aug. 20, 1999 RD-RPT-088 In-Vivo Testing of RNF for Permanent Use and Early	BPV-17-01-00031503	BPV-17-01-00031511	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5100	RNF Pivotal Animal Clinical Study, Permanent Implant In-Situ Sacrifice Data	BPV-17-01-00031601	BPV-17-01-00031882	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5101	RNF Pivotal Animal Clinical Study Permanent Implant Data Sheets (Animal #48)	BPV-17-01-00031883	BPV-17-01-00031891	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5102	Recovery Filter Fact Book, Volume 08 of 13	BPV-17-01-00031904	BPV-17-01-00032274	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5103	NMT Medical R&D Technical Report Document #RD-RPT-089, Creep Study of	BPV-17-01-00031906	BPV-17-01-00031910	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5104	July 30, 1999 RD-RPT-091 RNF Wire Integrity Report	BPV-17-01-00031965	BPV-17-01-00031970	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5105	Aug. 13, 1999 RD-RPT-093 Crimp and Bond Integrity Test Report	BPV-17-01-00032065	BPV-17-01-00032071	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5106	Aug. 4, 1999 R&D Technical Report EnduraTEC Corrosion/Fatigue Testing of	BPV-17-01-00032217	BPV-17-01-00032220	FRE 401; 402; 403; 602; 702;	
5107	Recovery Filter Fact Book, Volume 09 of 13	BPV-17-01-00032275	BPV-17-01-00032551	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5108	Aug. 9, 1999 R&D Technical Report RNF Hook Strength, Design Verification (RD-	BPV-17-01-00032375	BPV-17-01-00032386	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5109	Aug. 23, 1999 R&D Technical Report Analysis of RNF Migration Resistance (RD-	BPV-17-01-00032545	BPV-17-01-00032551	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5110	Recovery Filter Fact Book, Volume 10 of 13	BPV-17-01-00032552	BPV-17-01-00032804	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5111	Final Pathology Report: In-vivo Evaluation of the RNF for Permanent & Intra-	BPV-17-01-00032555	BPV-17-01-00032567	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5112	In-Vivo Evaluation of the Removable Nitinol Filter System for Permanent & Intra-	BPV-17-01-00032689	BPV-17-01-00032694	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5113	Final Pathology Report: In-vivo Evaluation for Permanent Indication (Vena Cava	BPV-17-01-00032698	BPV-17-01-00032706	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5114	Pathology Report: In-vivo Evaluation of the RNF for Long-term Removal	BPV-17-01-00032758	BPV-17-01-00032773	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5115	Recovery Filter Fact Book, Volume 11 of 13	BPV-17-01-00032805	BPV-17-01-00033163	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5116	April 24, 2000 RD-RPT-121 In-Vivo Technical Testing of RNF for Long-Term	BPV-17-01-00032807	BPV-17-01-00032817	FRE 401; 402; 403; 602; 702;	401; 402; 403
5117	In-Vivo Evaluation of the Removable Nitinol Filter System for Long-Term	BPV-17-01-00032818	BPV-17-01-00032822	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5118	Pivotal Animal Clinical Study: RNF Filter Implant Data Sheets (Animal #26)	BPV-17-01-00032829	BPV-17-01-00033134	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5119	Recovery Filter Fact Book, Volume 12 of 13	BPV-17-01-00033164	BPV-17-01-00034065	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5120	Recovery Filter DFMEA 070010, Rev. 3	BPV-17-01-00033286	BPV-17-01-00033302	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5121	Recovery Filter Fact Book, Volume 13 of 13	BPV-17-01-00034066	BPV-17-01-00034647	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5122	March 28, 2003 Design Review Report	BPV-17-01-00034436	BPV-17-01-00034437	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5123	Design Review II Summary of Design Verification Studies	BPV-17-01-00034445	BPV-17-01-00034446	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5124	Oct. 16, 2003 Risk Assessment RA070011, Rev. 0	BPV-17-01-00034493	BPV-17-01-00034505	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5125	FM-0010.02 FM-0010.02 Recovery Filter FMEA: Implant and Delivery System	BPV-17-01-00034523	BPV-17-01-00034527	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5126	Guidance for Industry and FDA Reviewers/Staff - Guidance for Cardiovascular	BPV-17-01-00034593	BPV-17-01-00034604	FRE 401; 402; 403; 602; 702;	
5127	November 26, 1999 FDA Guidance for Cardiovascular Intravascular Filter 510(k)	BPV-17-01-00034593	BPV-17-01-00034604	FRE 401; 402; 403; 602; 702;	
5128	Dec. 20, 2002 Design Review Assessment Status (Phase 1)	BPV-17-01-00034616	BPV-17-01-00034621	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5129	Design Review Element -- Compliance to Design Input (validating statistical	BPV-17-01-00034622	BPV-17-01-00034630	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5130	FIR-04-09-01 (Recovery Filter Fractures) (includes some Altran Reports)	BPV-17-01-00034657	BPV-17-01-00034855	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5131	FIR-04-09-01 Failure Investigation report - Recovery Filter	BPV-17-01-00034669	BPV-17-01-00034680	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5132	SPA-04-12-01: Addendum 2 (Remedial Action Plan re RNF Migration)	BPV-17-01-00034857	BPV-17-01-00034858	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5133	G2 Filter Stability Rationale (includes info re FEA and fatigue resistance)	BPV-17-01-00035612	BPV-17-01-00035614	FRE 401; 402; 403; 602; 702;	401; 402; 403
5134	RNF Design Review Summary Table Sept. 19, 2002	BPV-17-01-00035870	BPV-17-01-00035871	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5135	12.09.03 Special Design Review Meeting Minutes	BPV-17-01-00036291	BPV-17-01-00036292	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5136	CAE FEA (Nonlinear Structural Simulation of RNF Filter Device Delivery Tube	BPV-17-01-00037348	BPV-17-01-00037356	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5137	Recovery Filter DFMEA 070010, Rev. 0	BPV-17-01-00037462	BPV-17-01-00037476	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5138	DFMEA070010 Rev. 4	BPV-17-01-00038701	BPV-17-01-00038724	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5139	June 25, 2004 Multidisciplinary Focus Group Meeting Transcript	BPV-17-01-00039242	BPV-17-01-00039305	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5140	Memo re RNF Inventory Swap-Out (inventory exchange) for G2	BPV-17-01-00039452	BPV-17-01-00039452	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5141	Summary of Feb. 12, 2005 Bariatric Surgeon Meeting Summary of Feb. 12, 2005	BPV-17-01-00039917	BPV-17-01-00039919	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5142	Jan. 10, 2005 Conference FDA and BPV re DDL and Recovery Retrievable	BPV-17-01-00043382	BPV-17-01-00043402	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5143	Dec. 2004 BPV begins distributing DDL	BPV-17-01-00043383	BPV-17-01-00043402	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5144	Feb. 8, 2005 Fax BPV to FDA re DDL and Recovery Retrievable (K031328)	BPV-17-01-00043415	BPV-17-01-00043416	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5145	Jan. 14, 2004 Design Review Meeting Minutes Response (From Rob Carr to File)	BPV-17-01-00043534	BPV-17-01-00043535	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5146	TPR-05-01-13 (G2® DV&V Protocol)	BPV-17-01-00044081	BPV-17-01-00044116	FRE 401; 402; 403; 602; 702;	
5147	RA-STD-002, Rev. 08	BPV-17-01-00044635	BPV-17-01-00044653	FRE 401; 402; 403; 602; 702;	
5148	Article re Long-Term Retrieval of RNF Article entitled A New Optional Vena	BPV-17-01-00044725	BPV-17-01-00044734	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5149	Dr. Asch Article re Asch Study Article entitled Initial Experiences in Humans with	BPV-17-01-00044735	BPV-17-01-00044744	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802
5150	8/25/2005 - FDA Conference Call Meeting Minutes	BPV-17-01-00045092	BPV-17-01-00045094	FRE 401; 402; 403; 602; 702;	
5151	Feb. 28, 2005 Conference FDA and BPV re new submission	BPV-17-01-00045869	BPV-17-01-00045871	FRE 401; 402; 403; 602; 702;	
5152	March 2005 Emails with FDA	BPV-17-01-00045872	BPV-17-01-00045877	FRE 401; 402; 403; 602; 702;	401; 402; 403
5153	Oct. 13, 2005 Email FDA to BPV re G2 Filter - Jugular Subclavian Delivery Kit	BPV-17-01-00046358	BPV-17-01-00046362	FRE 401; 402; 403; 602; 702;	401; 402; 403
5154	Revised 03/03 -- F-8020 Rev.0 (Bard Peripheral Technologies)	BPV-17-01-00047425	BPV-17-01-00047440	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5155	Oct. 14, 2005 Letter FDA to BPV re G2 Filter - Jugular Subclavian Delivery Kit	BPV-17-01-00048142	BPV-17-01-00048144	FRE 401; 402; 403; 602; 702;	
5156	TPR-05-01-05 (G2 Filter Arm Fatigue DV&V Protocol)	BPV-17-01-00050276	BPV-17-01-00050285	FRE 401; 402; 403; 602; 702;	
5157	Data Sheet (for G2® DV&V Migration Resistance Testing in 28mm IVC)	BPV-17-01-00050526	BPV-17-01-00050535	FRE 401; 402; 403; 602; 702;	
5158	2001 Bard acquires filter line from NMT	BPV-17-01-00051623	BPV-17-01-00051624	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL # 2
5159	December 10, 1999 Letter from FDA re Recovery K993809	BPV-17-01-00051625	BPV-17-01-00051626	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5160	ETR-02-06-02 (Failure Investigation Report re Fracture in Asch Study) (with Rob	BPV-17-01-00052601	BPV-17-01-00052615	FRE 401; 402; 403; 602; 702;	MIL #2
5161	RD-RPT-128 (Investigation re Asch patient migration)	BPV-17-01-00052622	BPV-17-01-00052628	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5162	RD-SOP-059.00 (SOP re Wire Integrity)	BPV-17-01-00053552	BPV-17-01-00053561	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5163	In-Vivo Evaluation of the Removal Nitinol Filter System for Permanent & Intra-	BPV-17-01-00053920	BPV-17-01-00053928	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5164	July 8, 2003 Fax IMPRA to FDA re Recovery Retrievable (K031328)	BPV-17-01-00054002	BPV-17-01-00054076	FRE 401; 402; 403; 602; 702;	401; 402; 403
5165	July 1, 2003 Email FDA to BPV re Recovery Retrievable (K031328)	BPV-17-01-00054093	BPV-17-01-00054093	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5166	July 23, 2003 Email FDA to BPV re Recovery Retrievable (K031328)	BPV-17-01-00054098	BPV-17-01-00054101	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5167	July 23, 2003 Letter BPV to FDA re Recovery Retrievable (K031328)	BPV-17-01-00054109	BPV-17-01-00054110	FRE 401; 402; 403; 602; 702;	401; 402; 403
5168	July 24, 2003 Letter BPV to FDA re Recovery Retrievable (K031328)	BPV-17-01-00054127	BPV-17-01-00054139	FRE 401; 402; 403; 602; 702;	401; 402; 403
5169	Apr. 25, 2003 Recovery Retrievable Abbreviated 510(k) (K031328)	BPV-17-01-00054947	BPV-17-01-00055252	FRE 401; 402; 403; 602; 702;	401; 402; 403
5170	Patient 33 Note (w/fracture) (submitted to FDA)	BPV-17-01-00055205	BPV-17-01-00055205	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5171	RD-SOP-071.00 (SOP re Hook Strength)	BPV-17-01-00056338	BPV-17-01-00056344	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5172	Aug. 2, 1999 RD-RPT-092 Weld Integrity Report	BPV-17-01-00056386	BPV-17-01-00056393	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5173	RD-RPT-088 (Report on RNF In-vivo Testing for Permanent Use and Early	BPV-17-01-00056477	BPV-17-01-00056485	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5174	NMT Due Diligence Materials from Bard Sept. 24, 2001	BPV-17-01-00056704	BPV-17-01-00056719	FRE 401; 402; 403; 602; 702;	401; 402; 403; 901; MIL #2
5175	Hand-written Annotations on response to FDA of Aug. 30, 2002	BPV-17-01-00056930	BPV-17-01-00056930	FRE 401; 402; 403; 602; 702;	401; 402; 403
5176	November 27, 2002 Letter from FDA re Recovery K022236	BPV-17-01-00057704	BPV-17-01-00057707	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802
5177	Nov. 27, 2002 FDA Clearance Letter re Recovery Permanent (K022236)	BPV-17-01-00057709	BPV-17-01-00057711	FRE 401; 402; 403; 602; 702;	
5178	Oct. 25, 2002 Letter IMPRA to FDA re Recovery (K022236)	BPV-17-01-00057722	BPV-17-01-00057728	FRE 401; 402; 403; 602; 702;	401; 402; 403

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5179	Oct. 4, 2002 Letter FDA to IMPRA re Recovery (K022236)	BPV-17-01-00057740	BPV-17-01-00057742	FRE 401; 402; 403; 602; 702;	401; 402; 403
5180	Draft response to October 3, 2002 FDA Teleconference	BPV-17-01-00057744	BPV-17-01-00057748	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5181	September 30, 2002 Fax from FDA	BPV-17-01-00057750	BPV-17-01-00057751	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5182	Aug. 30, 2002 Letter IMPRA to FDA re Recovery (K022236)	BPV-17-01-00057755	BPV-17-01-00057917	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5183	August 30, 2002 Draft Letter to FDA	BPV-17-01-00057755	BPV-17-01-00057771	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5184	September 1997 NMT Cyclic Polarization Testing of Seven Sets of Wire	BPV-17-01-00057784	BPV-17-01-00057870	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5185	RD-SOP-058.00, RNF Weld Integrity, Design Verification	BPV-17-01-00057881	BPV-17-01-00057905	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5186	August 5, 2002 Letter from FDA re Recovery K022236	BPV-17-01-00057919	BPV-17-01-00057930	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5187	Aug. 5, 2002 Letter FDA to IMPRA re Recovery (K022236)	BPV-17-01-00057926	BPV-17-01-00057930	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5188	July 10, 2002 Recovery 510(k) Application Letter	BPV-17-01-00057935	BPV-17-01-00057937	FRE 401; 402; 403; 602; 702;	401; 402; 403
5189	July 10, 2002 IMPRA Recovery Permanent Special 510(k) (K022236)	BPV-17-01-00057953	BPV-17-01-00058037	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5190	July 8, 2002 Recovery 510(k) Submission (partial)	BPV-17-01-00057953	BPV-17-01-00058037	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5191	November 27, 2002 Letter from FDA re Recovery K022236	BPV-17-01-00057953	BPV-17-01-00057953	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5192	July 25, 2003 Abbreviated Recovery 510(k) Submission K031328	BPV-17-01-00058038	BPV-17-01-00058038	FRE 401; 402; 403; 602; 702;	401; 402; 403
5193	Feb. 28, 2005 Letter BPV to FDA re FDA AI re Recovery Retrievable (K031328)	BPV-17-01-00058041	BPV-17-01-00058074	FRE 401; 402; 403; 602; 702;	401; 402; 403
5194	Feb. 8, 2005 Letter FDA to BPV re Recovery Retrievable (K031328)	BPV-17-01-00058077	BPV-17-01-00058077	FRE 401; 402; 403; 602; 702;	401; 402; 403
5195	Nov. 30, 2004 Letter FDA to BPV re Recovery IFU and DDL	BPV-17-01-00058079	BPV-17-01-00058081	FRE 401; 402; 403; 602; 702;	401; 402; 403;
5196	Oct. 5, 2004 Letter BPV to FDA re Recovery IFU and DDL	BPV-17-01-00058083	BPV-17-01-00058120	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5197	July 25, 2003 FDA Clearance Letter re Recovery Retrievable (K031328)	BPV-17-01-00058122	BPV-17-01-00058124	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5198	August 29, 2002 Email to FDA	BPV-17-01-00058715	BPV-17-01-00058720	FRE 401; 402; 403; 602; 702;	401; 402; 403
5199	August 26, 2002 email re FDA letter response	BPV-17-01-00058778	BPV-17-01-00058796	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5200	Draft Clinical Testing Questions	BPV-17-01-00058779	BPV-17-01-00058796	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5201	Feb. 29, 2000 Letter NMT to FDA re Recovery (K993809)	BPV-17-01-00058895	BPV-17-01-00058895	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5202	Feb. 10, 2000 Conference FDA and NMT re Recovery (K993809)	BPV-17-01-00058907	BPV-17-01-00058930	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5203	Notes re Asch Live Case	BPV-17-01-00059057	BPV-17-01-00059059	FRE 401; 402; 403; 602; 702;	401; 402; 403
5204	Aug. 12, 2002 Conference IMPRA and FDA re Recovery (K022236)	BPV-17-01-00059159	BPV-17-01-00059193	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5205	August 12, 2002 FDA teleconference	BPV-17-01-00059159	BPV-17-01-00059175	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5206	RNF Brochure Timeless Performance Complete Compliance Folder	BPV-17-01-00060382	BPV-17-01-00060413	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802
5207	RNF Animal Experiment Notes for RD-SOP-050.00 (Animal 558)	BPV-17-01-00061162	BPV-17-01-00061164	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5208	G2 Filter Sales Training Manual G2 Filter Sales Training Manual	BPV-17-01-00061944	BPV-17-01-00062024	FRE 401; 402; 403; 602; 702;	401; 402; 403
5209	Dec. 17, 2002 Letter BPV to FDA requesting conference re Recovery Retrievable	BPV-17-01-00062069	BPV-17-01-00062070	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5210	RD-RPT-122 Migration Study of 30-31 mm Leg span	BPV-17-01-00067976	BPV-17-01-00067979	FRE 401; 402; 403; 602; 702;	401; 402; 403; 901; MIL #2
5211	June 9, 2000 R&D Technical Report Fatigue Evaluation of RNF (RD-RPT-120)	BPV-17-01-00068038	BPV-17-01-00068061	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5212	RD-RPT-126 (Lake Region SNF Migration Resistance Study)	BPV-17-01-00068118	BPV-17-01-00068122	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5213	SOP-RD-006 (NMT SOP re Design Control)	BPV-17-01-00068128	BPV-17-01-00068160	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5214	Dec. 10, 1999 Letter FDA to NMT re Recovery (K993809)	BPV-17-01-00069470	BPV-17-01-00069471	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5215	Nov. 1, 1999 NMT's Recovery Filter System Special 510(k) (K993809)	BPV-17-01-00069501	BPV-17-01-00069604	FRE 401; 402; 403; 602; 702;	401; 402; 403; 901
5216	RD-LNB-097 (Misc. Vena Cava Filter Research Projects; Includes Results of Early	BPV-17-01-00069978	BPV-17-01-00070029	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5217	RD-SOP-035.02 (SOP re migration resistance testing NMT	BPV-17-01-00070037	BPV-17-01-00070044	FRE 401; 402; 403; 602; 702;	
5218	Data Sheet for Early NMT Competitive Migration Testing (raw data) Lab	BPV-17-01-00070050	BPV-17-01-00070072	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5219	June 23, 1998 NMT Memo re Removable Filter Concepts	BPV-17-01-00070679	BPV-17-01-00070688	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5220	June 15, 1998 Memo re Removable Filter Issues	BPV-17-01-00070715	BPV-17-01-00070716	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5221	June 1, 1999 NMT Meeting Minutes	BPV-17-01-00072602	BPV-17-01-00072604	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5222	January 7, 1999 NMT Meeting Minutes	BPV-17-01-00072605	BPV-17-01-00072606	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5223	April 14, 2000 NMT RNF Design Review II Minutes	BPV-17-01-00072607	BPV-17-01-00072610	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5224	June 12, 1998 NMT Meeting Minutes	BPV-17-01-00072614	BPV-17-01-00072616	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5225	April 30, 1998 NMT RNF Meeting Minutes	BPV-17-01-00072620	BPV-17-01-00072625	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5226	RNF Meeting Notes RNF Meeting notes	BPV-17-01-00072631	BPV-17-01-00072634	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5227	April 30, 1998 Memo re Justification for Restarting Pivotal Animal Study	BPV-17-01-00073163	BPV-17-01-00073165	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5228	April 8, 1998 Memo re Summary of Animal Experiments to be Performed for RNF	BPV-17-01-00073166	BPV-17-01-00073168	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5229	RNF Meeting Notes RNF Meeting notes	BPV-17-01-00073184	BPV-17-01-00073186	FRE 401; 402; 403; 602; 702;	401; 402; 403
5230	RD-RPT-137 (SNF Substantial Equivalence Report)	BPV-17-01-00081987	BPV-17-01-00081998	FRE 401; 402; 403; 602; 702;	401; 402; 403
5231	Design Review III & IV G2 Femoral Process Qualification & Pre-Market Release	BPV-17-01-00082624	BPV-17-01-00082803	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5232	RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-	BPV-17-01-00083886	BPV-17-01-00083889	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5233	RD-SOP-054.00 (Recovery Filter EnduraTEC Fatigue Testing SOP NMT)	BPV-17-01-00084683	BPV-17-01-00084689	FRE 401; 402; 403; 602; 702;	
5234	RD-RPT-099 (Recovery Filter EnduraTEC Fatigue Testing Report NMT)	BPV-17-01-00084690	BPV-17-01-00084693	FRE 401; 402; 403; 602; 702;	
5235	Recovery Filter DFMEA070010 Rev. 1	BPV-17-01-00089681	BPV-17-01-00089694	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5236	Email from Hudson to Benware re Starguide testing	BPV-17-01-00091149	BPV-17-01-00091149	FRE 401; 402; 403; 602; 702;	401; 402; 403
5237	Draft Starguide Report	BPV-17-01-00092792	BPV-17-01-00092795	FRE 401; 402; 403; 602; 702;	401; 402; 403
5238	Slides from Bariatric Surgeons Panel Meeting on Feb. 12, 2005	BPV-17-01-00097071	BPV-17-01-00097103	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5239	Jan. 21, 2005 Conference FDA and BPV re DDL and Recovery Retrievable	BPV-17-01-00097135	BPV-17-01-00097137	FRE 401; 402; 403; 602; 702;	401; 402; 403
5240	MAUDE and Sales data through Q2 2005	BPV-17-01-00097492	BPV-17-01-00097525	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5241	MAUDE and Sales Data through Q2 2004	BPV-17-01-00097589	BPV-17-01-00097622	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5242	Sep. 28, 2004 Conference FDA and BPV re Recovery IFU and DDL	BPV-17-01-00097730	BPV-17-01-00097733	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5243	Sep. 17, 2004 FDA Contact Report re Recovery IFU and DDL	BPV-17-01-00097745	BPV-17-01-00097746	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5244	Mar. 24, 2005 Conference FDA and BPV re DCL and Modified Recovery	BPV-17-01-00097998	BPV-17-01-00098003	FRE 401; 402; 403; 602; 702;	
5245	Jan. 27, 2005 Conference BPV and FDA Phoenix Investigator re DCL and	BPV-17-01-00098579	BPV-17-01-00098582	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5246	Aug. 5, 2005 Conference FDA and BPV re G2 Everest Study (G050134)	BPV-17-01-00098772	BPV-17-01-00098774	FRE 401; 402; 403; 602; 702;	
5247	May 11, 2005 BPV began distributing DCL	BPV-17-01-00100782	BPV-17-01-00100784	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5248	TD-00012 (Characterization of G2® Filter Migration Resistance When Legs are	BPV-17-01-00101562	BPV-17-01-00101567	FRE 401; 402; 403; 602; 702;	106
5249	SPA-04-04-01 (Revised Remedial Action Plan re RNF Fractures)	BPV-17-01-00101586	BPV-17-01-00101587	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5250	Nov. 28, 2004 Internal BPV Email chain re Recovery IFU and DDL	BPV-17-01-00102072	BPV-17-01-00102075	FRE 401; 402; 403; 602; 702;	401; 402; 403
5251	ETR-04-03-19 (RNF Radial Strength v. Competitive Product)	BPV-17-01-00103828	BPV-17-01-00103850	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5252	ETR-04-03-02 (RNF v. Competitive Product -- migration resistance)	BPV-17-01-00103851	BPV-17-01-00103863	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5253	HHE of Dr. Ciavarella November 17, 2004	BPV-17-01-00103875	BPV-17-01-00103878	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5254	DOP00700020, Rev. 4	BPV-17-01-00107427	BPV-17-01-00107568	FRE 401; 402; 403; 602; 702;	
5255	FDA concurrence letter for K940489	BPV-17-01-00109425	BPV-17-01-00109426	FRE 401; 402; 403; 602; 702;	401; 402; 403
5256	NMT's 510(k) (K940489) for the Modified SNF	BPV-17-01-00109427	BPV-17-01-00109533	FRE 401; 402; 403; 602; 702;	401; 402; 403
5257	FDA concurrence letter for K944353	BPV-17-01-00109956	BPV-17-01-00109957	FRE 401; 402; 403; 602; 702;	401; 402; 403
5258	NMT's 510(k) (K944353) to the Simplified SNF (Straight Line System)	BPV-17-01-00109958	BPV-17-01-00110134	FRE 401; 402; 403; 602; 702;	401; 402; 403
5259	Recovery Filter Design/Development Files	BPV-17-01-00110331	BPV-17-01-00111349	FRE 401; 402; 403; 602; 702;	401; 402; 403
5260	NMT's 510(k) (K912144) for the SNF for antecubital insertion	BPV-17-01-00112374	BPV-17-01-00112440	FRE 401; 402; 403; 602; 702;	401; 402; 403
5261	Letter from FDA to NMT regarding K912144	BPV-17-01-00112410	BPV-17-01-00112411	FRE 401; 402; 403; 602; 702;	401; 402; 403
5262	Letter from NMT to FDA regarding K912144 and FDA's June 25, 1991 questions	BPV-17-01-00112412	BPV-17-01-00112420	FRE 401; 402; 403; 602; 702;	401; 402; 403
5263	Letter from Hogan & Hartson to FDA regarding K912144	BPV-17-01-00112421	BPV-17-01-00112440	FRE 401; 402; 403; 602; 702;	401; 402; 403
5264	Letter from Hogan & Hartson to FDA regarding K940489 and FDA's March 4,	BPV-17-01-00112451	BPV-17-01-00112453	FRE 401; 402; 403; 602; 702;	401; 402; 403
5265	Letter from FDA to Hogan & Hartson regarding K940489	BPV-17-01-00112454	BPV-17-01-00112455	FRE 401; 402; 403; 602; 702;	401; 402; 403
5266	FDA concurrence letter for K963016	BPV-17-01-00112560	BPV-17-01-00112561	FRE 401; 402; 403; 602; 702;	401; 402; 403
5267	Letter from Hogan & Hartson to FDA regarding October 7, 1996 conference	BPV-17-01-00112562	BPV-17-01-00112564	FRE 401; 402; 403; 602; 702;	401; 402; 403
5268	NMT's 510(k) (K963016) for modifications to the SNF (submitted by Hogan &	BPV-17-01-00112585	BPV-17-01-00112742	FRE 401; 402; 403; 602; 702;	401; 402; 403
5269	NMT's 510(k) (K970099) for modifications to the SNF and SNF/Straight Line	BPV-17-01-00112743	BPV-17-01-00112934	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5270	Revised Recovery Filter IFU as of December 2004	BPV-17-01-00112988	BPV-17-01-00112990	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5271	NMT Sept. 12, 2000 Memo re Clinical Discussion of Migration from Asch Study	BPV-17-01-00114162	BPV-17-01-00114164	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5272	Nov. 23, 2009 BPV's Eclipse Filter System Special 510(k) (K093659)	BPV-17-01-00116991	BPV-17-01-00117153	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5273	Jan. 14, 2010 FDA Clearance Letter Eclipse Filter (K093659) (Substantial	BPV-17-01-00117156	BPV-17-01-00117158	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5274	July 2, 2008 Letter BPV to FDA Responses re AI Demand re G2 Express	BPV-17-01-00117260	BPV-17-01-00117783	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5275	June 25, 2008 Conference FDA and BPV re AI Demand re G2 Express (K080668)	BPV-17-01-00117271	BPV-17-01-00117272	FRE 401; 402; 403; 602; 702;	401; 402; 403
5276	TD-00272 (Addendum to TD-00192 Product Comparisons through Finite Element	BPV-17-01-00118350	BPV-17-01-00118353	FRE 401; 402; 403; 602; 702;	401; 402; 403
5277	TD-00553 (Finite Element Analysis Comparing the G2/G2 Express Filter with Two	BPV-17-01-00118354	BPV-17-01-00118364	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5278	G2 IFU PK5100030, Rev. 2 08/05 (Femoral)	BPV-17-01-00118365	BPV-17-01-00118368	FRE 401; 402; 403; 602; 702;	
5279	G2 IFU (Femoral) PK5100030 Rev. 3 09/05	BPV-17-01-00118369	BPV-17-01-00118372	FRE 401; 402; 403; 602; 702;	
5280	G2 IFU PK5014091, Rev. 0 09/05 (Jugular)	BPV-17-01-00118373	BPV-17-01-00118377	FRE 401; 402; 403; 602; 702;	
5281	G2 IFU PK5100030, Rev. 4 04/06 (Femoral)	BPV-17-01-00118378	BPV-17-01-00118381	FRE 401; 402; 403; 602; 702;	
5282	G2 IFU PK5100030, Rev. 5 10/06 (Femoral)	BPV-17-01-00118382	BPV-17-01-00118385	FRE 401; 402; 403; 602; 702;	
5283	G2 IFU (Femoral) PK5250500 Rev. 0 01/08	BPV-17-01-00118386	BPV-17-01-00118389	FRE 401; 402; 403; 602; 702;	
5284	G2 IFU PK5260600, Rev. 0 01/08 (Jugular)	BPV-17-01-00118390	BPV-17-01-00118397	FRE 401; 402; 403; 602; 702;	
5285	G2 IFU PK5250500, Rev. 1 07/09 (Femoral)	BPV-17-01-00118398	BPV-17-01-00118401	FRE 401; 402; 403; 602; 702;	
5286	G2 IFU PK5260600, Rev. 1 07/09 (Jugular)	BPV-17-01-00118402	BPV-17-01-00118409	FRE 401; 402; 403; 602; 702;	
5287	Project 8041: Design History File; Everest- Recovery G2, Vol. 1 of 2	BPV-17-01-00118539	BPV-17-01-00118728	FRE 401; 402; 403; 602; 702;	
5288	Sept. 6, 2005 EVEREST Clinical Study Protocol	BPV-17-01-00118623	BPV-17-01-00118694	FRE 401; 402; 403; 602; 702;	
5289	Project 8041: Design History File; Everest- Recovery G2, Vol. 2 of 2	BPV-17-01-00118729	BPV-17-01-00118973	FRE 401; 402; 403; 602; 702;	
5290	TD-00456 (EVEREST Study Final Report)	BPV-17-01-00118807	BPV-17-01-00118902	FRE 401; 402; 403; 602; 702;	
5291	Project File; Project 8002: G2 Recovery Filter; Jugular/Subclavian System, Vol. 1	BPV-17-01-00118974	BPV-17-01-00119449	FRE 401; 402; 403; 602; 702;	
5292	Project File; Project 8002: G2 Recovery Filter; Jugular/Subclavian System, Vol. 2	BPV-17-01-00119450	BPV-17-01-00119908	FRE 401; 402; 403; 602; 702;	
5293	Project File; Project 8002: G2 Recovery Filter; Jugular/Subclavian System, Vol. 3	BPV-17-01-00119909	BPV-17-01-00120436	FRE 401; 402; 403; 602; 702;	
5294	Fact Book; Project 8027: US: G2 Filter System (RF-310F) OUS Recovery Filter	BPV-17-01-00120437	BPV-17-01-00120902	FRE 401; 402; 403; 602; 702;	
5295	G2 Filter Project Initiation Request Form (Project 8027)	BPV-17-01-00120454	BPV-17-01-00120455	FRE 401; 402; 403; 602; 702;	
5296	G2 Filter Product Performance Specification, v.2	BPV-17-01-00120471	BPV-17-01-00120502	FRE 401; 402; 403; 602; 702;	
5297	G2 Filter Regulatory and Clinical Strategy Determination (Jan. 2005)	BPV-17-01-00120511	BPV-17-01-00120522	FRE 401; 402; 403; 602; 702;	
5298	G2 Filter Drawings and Labels	BPV-17-01-00120558	BPV-17-01-00120574	FRE 401; 402; 403; 602; 702;	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5299	Fact Book; Project 8027: US: G2 Filter System (RF-310F) OUS Recovery Filter	BPV-17-01-00120903	BPV-17-01-00121313	FRE 401; 402; 403; 602; 702;	
5300	TPR-04-09-11 An Acute and Chronic In-Vivo Evaluation of the Bard Recovery	BPV-17-01-00120906	BPV-17-01-00120921	FRE 401; 402; 403; 602; 702;	401; 402; 403
5301	ETR-05-01-06 Animal Model Evaluation of Recovery Filter G1A Femoral System	BPV-17-01-00120922	BPV-17-01-00120931	FRE 401; 402; 403; 602; 702;	
5302	TPR 05-01-13 G1A Recovery Filter Femoral System Design Verification and	BPV-17-01-00120932	BPV-17-01-00120960	FRE 401; 402; 403; 602; 702;	
5303	ETR-05-02-05 (G2® DV&V summary testing)	BPV-17-01-00120961	BPV-17-01-00120982	FRE 401; 402; 403; 602; 702;	
5304	ETR 05-02-11 G1A Recovery Filter Femoral System Chronic Animal Study Report	BPV-17-01-00120983	BPV-17-01-00121014	FRE 401; 402; 403; 602; 702;	
5305	RA070025 Risk Assessment for the G1A Filter, v.1	BPV-17-01-00121020	BPV-17-01-00121035	FRE 401; 402; 403; 602; 702;	
5306	DFMEA070022, v.1 (for the G1A)	BPV-17-01-00121036	BPV-17-01-00121060	FRE 401; 402; 403; 602; 702;	
5307	PFMEA for the G1A Recovery Filter Femoral System	BPV-17-01-00121061	BPV-17-01-00121074	FRE 401; 402; 403; 602; 702;	
5308	PV-RF210F G1A Process Qualification Final Report, G1A Filters, RF210F	BPV-17-01-00121077	BPV-17-01-00121088	FRE 401; 402; 403; 602; 702;	
5309	ETR 05-03-11 Migration Resistance Evaluation of "New England Precision	BPV-17-01-00121089	BPV-17-01-00121101	FRE 401; 402; 403; 602; 702;	401; 402; 403
5310	FIR 05-03-05 G1A Filter (RF210F) Process Qualification Failure Investigation for	BPV-17-01-00121102	BPV-17-01-00121109	FRE 401; 402; 403; 602; 702;	
5311	Stability Rationale for G1A	BPV-17-01-00121155	BPV-17-01-00121158	FRE 401; 402; 403; 602; 702;	
5312	E05-009 Adoption for the G1A Recovery Filter Femoral System, v.0	BPV-17-01-00121159	BPV-17-01-00121167	FRE 401; 402; 403; 602; 702;	
5313	Phase 0 Design Review G1A Recovery Filter Femoral Delivery System	BPV-17-01-00121189	BPV-17-01-00121214	FRE 401; 402; 403; 602; 702;	
5314	Phase 1 Design Review G1A Recovery Filter Femoral Delivery System	BPV-17-01-00121215	BPV-17-01-00121225	FRE 401; 402; 403; 602; 702;	
5315	Phase 2 Design Review G1A Recovery Filter Femoral Delivery System	BPV-17-01-00121226	BPV-17-01-00121255	FRE 401; 402; 403; 602; 702;	
5316	Phase 3 Design Review (Design Review 3 & 4) G1A Recovery Filter Femoral	BPV-17-01-00121256	BPV-17-01-00121286	FRE 401; 402; 403; 602; 702;	
5317	G1A Authorization for Market Release (Domestic)	BPV-17-01-00121306	BPV-17-01-00121308	FRE 401; 402; 403; 602; 702;	
5318	G2 Filter Internal Product Information Bulletin (Sept. 7, 2005)	BPV-17-01-00121309	BPV-17-01-00121309	FRE 401; 402; 403; 602; 702;	
5319	Recovery Filter Internal Product Information Bulletin (Sept. 7, 2005)	BPV-17-01-00121310	BPV-17-01-00121310	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5320	Dec. 4, 2006 Conference FDA and BPV re future G2 Filter Retrievable Traditional	BPV-17-01-00122493	BPV-17-01-00122493	FRE 401; 402; 403; 602; 702;	
5321	Dec. 11, 2007 Conference FDA and BPV re G2 Everest Study (G051304)	BPV-17-01-00122495	BPV-17-01-00122495	FRE 401; 402; 403; 602; 702;	
5322	Nov. 2, 2005 FDA Grants Full Approval of G2 Everest Study (G051304)	BPV-17-01-00122502	BPV-17-01-00122502	FRE 401; 402; 403; 602; 702;	
5323	Aug. 8, 2005 FDA Grants BPV Conditional Approval for G2 Everest Study	BPV-17-01-00122505	BPV-17-01-00122508	FRE 401; 402; 403; 602; 702;	
5324	July 8, 2005 BPV's original IDE submission re G2 Everest Study (G050134)	BPV-17-01-00122544	BPV-17-01-00122829	FRE 401; 402; 403; 602; 702;	
5325	Oct. 3, 2005 Letter BPV to FDA re G2 Everest Study (G051034) and Conditional	BPV-17-01-00122845	BPV-17-01-00122932	FRE 401; 402; 403; 602; 702;	
5326	Aug. 25, 2005 Conference FDA and BPV re G2 Everest Study (G050134) and	BPV-17-01-00122930	BPV-17-01-00122932	FRE 401; 402; 403; 602; 702;	
5327	Dec. 2, 2005 Letter BPV to FDA re G2 Everest Study (G051304) Notice of IDE	BPV-17-01-00123040	BPV-17-01-00123067	FRE 401; 402; 403; 602; 702;	
5328	July 11, 2006 Lettre BPV to FDA re G2 Everest Study (G051304) IDE Supplement	BPV-17-01-00123071	BPV-17-01-00123152	FRE 401; 402; 403; 602; 702;	
5329	June 21, 2006 Letter BPV to FDA re G2 Everest Study (G051304) IDE Supplement	BPV-17-01-00123153	BPV-17-01-00123175	FRE 401; 402; 403; 602; 702;	
5330	June 21, 2006 Letter BPV to FDA re G2 Everest Study (G051304)	BPV-17-01-00123183	BPV-17-01-00123210	FRE 401; 402; 403; 602; 702;	
5331	Dec. 6, 2006 Letter BPV to FDA re G2 Everest Study (G051304) IDE Supplement	BPV-17-01-00123217	BPV-17-01-00123217	FRE 401; 402; 403; 602; 702;	
5332	Dec. 8, 2006 Letter BPV to FDA re G2 Everest Study (G051304) IDE Supplement	BPV-17-01-00123233	BPV-17-01-00123249	FRE 401; 402; 403; 602; 702;	
5333	Feb. 2, 2007 Letter BPV to FDA re G2 Everest Study (G051304) Annual Progress	BPV-17-01-00123269	BPV-17-01-00123351	FRE 401; 402; 403; 602; 702;	
5334	Sept. 21, 2007 Letter FDA to BPV Questions re G2 Everest Study (G051304)	BPV-17-01-00123402	BPV-17-01-00123405	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5335	Aug. 23, 2007 Letter BPV to FDA re G2 Everest Study (G051304) Annual	BPV-17-01-00123427	BPV-17-01-00123474	FRE 401; 402; 403; 602; 702;	
5336	Oct. 25, 2007 Letter BPV to FDA re Responses to FDA re G2 Everest Study	BPV-17-01-00123498	BPV-17-01-00123562	FRE 401; 402; 403; 602; 702;	
5337	Mar. 12, 2008 Letter FDA to BPV re G2 Everest Study (G051304) Closing IDE	BPV-17-01-00123564	BPV-17-01-00123565	FRE 401; 402; 403; 602; 702;	
5338	Feb. 12, 2008 Letter BPV to FDA re G2 Everest Study (G051304) Final IDE Report	BPV-17-01-00123573	BPV-17-01-00123588	FRE 401; 402; 403; 602; 702;	
5339	Jan. 15, 2008 FDA Clearance Letter G2 Filter Retrievable (K073090) (Substantial	BPV-17-01-00123590	BPV-17-01-00123592	FRE 401; 402; 403; 602; 702;	
5340	Oct. 31, 2007 BPV's G2 Filter Retrievable Traditional 510(k) (K073090)	BPV-17-01-00123629	BPV-17-01-00125197	FRE 401; 402; 403; 602; 702;	
5341	ETR-06-05-02 G2 Filter Clot Trapping Efficiency Report	BPV-17-01-00123824	BPV-17-01-00123837	FRE 401; 402; 403; 602; 702;	
5342	Special 510(k) Submission K050558- 3/2/2005	BPV-17-01-00125198	BPV-17-01-00125334	FRE 401; 402; 403; 602; 702;	
5343	Aug. 29, 2005 FDA Clearance Letter re G2 Permanent (K050558) (Substantial	BPV-17-01-00125199	BPV-17-01-00125201	FRE 401; 402; 403; 602; 702;	
5344	July 28, 2005 Letter FDA to BPV re AI re Modified Recovery (K050558)	BPV-17-01-00125220	BPV-17-01-00125222	FRE 401; 402; 403; 602; 702;	
5345	June 3, 2005 Email BPV to FDA re proposed IDE G2 Everest Study	BPV-17-01-00125226	BPV-17-01-00125285	FRE 401; 402; 403; 602; 702;	
5346	Apr. 28, 2005 Letter FDA to BPV 30 day extension re FDA AI re Modified	BPV-17-01-00125288	BPV-17-01-00125288	FRE 401; 402; 403; 602; 702;	
5347	Apr. 27, 2005 Letter BPV to FDA 30 day extension re FDA AI re Modified	BPV-17-01-00125289	BPV-17-01-00125289	FRE 401; 402; 403; 602; 702;	
5348	Mar. 30, 2005 Letter FDA to BPV re Modified Recovery (K050558)	BPV-17-01-00125312	BPV-17-01-00125314	FRE 401; 402; 403; 602; 702;	
5349	Mar. 2, 2005 BPV's Modified Recovery Filter Special 510(k) (K050558)	BPV-17-01-00125335	BPV-17-01-00125415	FRE 401; 402; 403; 602; 702;	
5350	June 3, 2005 Letter BPV to FDA re Modified Recovery conversion Traditional	BPV-17-01-00125416	BPV-17-01-00125615	FRE 401; 402; 403; 602; 702;	
5351	May 6, 2005 Conference FDA and BPV re Modified Recovery (K050558)	BPV-17-01-00125422	BPV-17-01-00125424	FRE 401; 402; 403; 602; 702;	
5352	Aug. 10, 2005 Letter BPV to FDA Responses to AI re G2 (K050558)	BPV-17-01-00125616	BPV-17-01-00125633	FRE 401; 402; 403; 602; 702;	
5353	Nov. 25, 2005 FDA Clearance Letter G2 Filter - Jugular (K052578) (Substantial	BPV-17-01-00125637	BPV-17-01-00125639	FRE 401; 402; 403; 602; 702;	
5354	Sept. 19, 2005 BPV's G2 Filter - Jugular Subclavian Delivery Kit Special 510(k)	BPV-17-01-00125658	BPV-17-01-00125749	FRE 401; 402; 403; 602; 702;	
5355	Sept. 21, 2005 Letter BPV to FDA re G2 Filter - Jugular Subclavian Delivery Kit	BPV-17-01-00125750	BPV-17-01-00125772	FRE 401; 402; 403; 602; 702;	
5356	Oct. 25, 2005 Letter BPV to FDA Responses to FDA AI Demand re G2 Filter -	BPV-17-01-00125782	BPV-17-01-00125876	FRE 401; 402; 403; 602; 702;	
5357	Oct. 14, 2005 Conference FDA and BPV re G2 Filter - Jugular Subclavian Delivery	BPV-17-01-00125799	BPV-17-01-00125801	FRE 401; 402; 403; 602; 702;	
5358	Oct. 14, 2005 Email FDA to BPV re G2 Filter - Jugular Subclavian Delivery Kit	BPV-17-01-00125804	BPV-17-01-00125805	FRE 401; 402; 403; 602; 702;	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5359	Nov. 14, 2005 Conference FDA and BPV re Responses re G2 Filter - Jugular	BPV-17-01-00125891	BPV-17-01-00125892	FRE 401; 402; 403; 602; 702;	
5360	Nov. 16, 2005 Letter BPV to FDA Responses to FDA AI Demand re G2 Filter -	BPV-17-01-00125893	BPV-17-01-00125923	FRE 401; 402; 403; 602; 702;	
5361	Sept. 25, 2006 BPV's G2 Filter - Femoral Delivery Kit Special 510(k) (K062887)	BPV-17-01-00125963	BPV-17-01-00126062	FRE 401; 402; 403; 602; 702;	
5362	Oct. 26, 2006 FDA Clearance Letter G2 Filter - Femoral Delivery Kit (K062887)	BPV-17-01-00126184	BPV-17-01-00126187	FRE 401; 402; 403; 602; 702;	
5363	G2 Filter System Brochure	BPV-17-01-00126318	BPV-17-01-00126321	FRE 401; 402; 403; 602; 702;	401; 402; 403
5364	G2 Filter System Patient Questions & Answers	BPV-17-01-00126336	BPV-17-01-00126341	FRE 401; 402; 403; 602; 702;	401; 402; 403
5365	Dr. Binkert Article re EVEREST Study G2 Filter Prospective, Multicenter Study	BPV-17-01-00127751	BPV-17-01-00127755	FRE 401; 402; 403; 602; 702;	
5366	May 8, 2008 Letter BPV to FDA Responses to AI Demand re G2 Express	BPV-17-01-00130268	BPV-17-01-00130441	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5367	June 26, 2008 Letter BPV to FDA Request 30 Day Extension re G2 Express	BPV-17-01-00130442	BPV-17-01-00130448	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5368	July 30, 2008 FDA Clearance Letter G2 Express Filter (K080668) (Substantial	BPV-17-01-00130450	BPV-17-01-00130452	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5369	July 1, 2008 Letter FDA to BPV Granting Extension re G2 Express (K080668)	BPV-17-01-00130459	BPV-17-01-00130459	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5370	June 6, 2008 Letter FDA to BPV re AI Demand re G2 Express (K080668)	BPV-17-01-00130460	BPV-17-01-00130463	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5371	May 6, 2008 Letter FDA to BPV Granting extension re G2 Express (K080668)	BPV-17-01-00130468	BPV-17-01-00130468	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5372	Apr. 8, 2008 Letter FDA to BPV re AI Demand re G2 Express (K080668)	BPV-17-01-00130470	BPV-17-01-00130473	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5373	Mar. 7, 2008 BPV's G2 Express Filter Special 510(k) (K080668)	BPV-17-01-00130498	BPV-17-01-00130730	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5374	Sept. 29, 2008 Letter BPV to FDA re Responses to FDA AI Demand re G2X	BPV-17-01-00130734	BPV-17-01-00130838	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5375	May 5, 2008 Letter BPV to FDA Request 30 day extension re G2 Express	BPV-17-01-00131255	BPV-17-01-00131261	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5376	Oct. 31, 2008 FDA Clearance Letter G2X Filter (K082305) Substantial Equivalence	BPV-17-01-00131282	BPV-17-01-00131284	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5377	Sept. 4, 2008 Email FDA to BPV re FDA AI Demand re G2X (K082305)	BPV-17-01-00131294	BPV-17-01-00131295	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5378	Sept. 8, 2008 Letter FDA to BPV re FDA AI Demand re G2X (K082305)	BPV-17-01-00131298	BPV-17-01-00131299	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5379	Aug. 12, 2008 BPV's G2X Filter Special 510(k) (K082305)	BPV-17-01-00131320	BPV-17-01-00131596	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5380	G2 Express Filter Design/Development Files	BPV-17-01-00132051	BPV-17-01-00135828	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802
5381	Conference between FDA and BPV regarding I050537	BPV-17-01-00132282	BPV-17-01-00132284	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5382	G2 Express BR-8058 Biocompatibility Requirements G2 Express BR-8058	BPV-17-01-00132372	BPV-17-01-00132448	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5383	G2 Express Flat Plate Fatigue and Corrosion Testing TR-07-02-12 G2X Flat Plate	BPV-17-01-00133001	BPV-17-01-00133027	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5384	G2 Express Feasibility Acute Animal study Report TR-07-05-18	BPV-17-01-00133028	BPV-17-01-00133050	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5385	G2 Express Filter Arm Fatigue Comparison TR-07-07-04	BPV-17-01-00133064	BPV-17-01-00133077	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5386	G2 Express v. G2 Tilt Assessment in Varying Cava Sizes TD-00463	BPV-17-01-00133078	BPV-17-01-00133080	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5387	G2 IFU PK5100085, Rev. 0 (Femoral)	BPV-17-01-00137389	BPV-17-01-00137392	FRE 401; 402; 403; 602; 702;	
5388	G2 IFU (Jugular) PK5100090 Rev. 0 03/09	BPV-17-01-00137393	BPV-17-01-00137400	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5389	G2 IFU PK5014091, Rev. 2 10/08 (Jugular)	BPV-17-01-00137425	BPV-17-01-00137432	FRE 401; 402; 403; 602; 702;	
5390	G2 IFU PK5100085, Rev. 2 (Femoral)	BPV-17-01-00137437	BPV-17-01-00137440	FRE 401; 402; 403; 602; 702;	
5391	G2 IFU PK5260600, Rev. 2 10/09 (Jugular)	BPV-17-01-00137441	BPV-17-01-00137448	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5392	Recovery G2 Filter system 1 G2 filter system: indicated for retrieval	BPV-17-01-00137620	BPV-17-01-00137621	FRE 401; 402; 403; 602; 702;	401; 402; 403
5393	2008 - G2 Filter system: Patient Q+A 2008 - G2 Filter system: Patient Q+A	BPV-17-01-00137624	BPV-17-01-00137637	FRE 401; 402; 403; 602; 702;	401; 402; 403
5394	10/2009 - G2 IFU 10-2009	BPV-17-01-00137638	BPV-17-01-00137645	FRE 401; 402; 403; 602; 702;	
5395	G2 DFMEA (Recovery Jugular) 070021, Rev. 0	BPV-17-01-00139544	BPV-17-01-00139562	FRE 401; 402; 403; 602; 702;	
5396	G2 DFMEA (Recovery Jugular) 070021, Rev. 1	BPV-17-01-00139563	BPV-17-01-00139577	FRE 401; 402; 403; 602; 702;	
5397	G2 DFMEA (Recovery Jugular) 070021, Rev. 2	BPV-17-01-00139578	BPV-17-01-00139592	FRE 401; 402; 403; 602; 702;	
5398	G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 3	BPV-17-01-00139593	BPV-17-01-00139607	FRE 401; 402; 403; 602; 702;	
5399	G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 4	BPV-17-01-00139608	BPV-17-01-00139622	FRE 401; 402; 403; 602; 702;	
5400	G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 5	BPV-17-01-00139623	BPV-17-01-00139637	FRE 401; 402; 403; 602; 702;	
5401	G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 6	BPV-17-01-00139638	BPV-17-01-00139652	FRE 401; 402; 403; 602; 702;	
5402	G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 7	BPV-17-01-00139653	BPV-17-01-00139667	FRE 401; 402; 403; 602; 702;	
5403	G2 DFMEA (Recovery G2 Jugular) 070021, Rev. 6 Signature page	BPV-17-01-00139668	BPV-17-01-00139668	FRE 401; 402; 403; 602; 702;	
5404	G2 DFMEA (G2 Jugular) 070021, Rev. 7	BPV-17-01-00139669	BPV-17-01-00139684	FRE 401; 402; 403; 602; 702;	
5405	G2 DFMEA (G2 Jugular) 070021, Rev. 8	BPV-17-01-00139685	BPV-17-01-00139686	FRE 401; 402; 403; 602; 702;	
5406	G2 DFMEA (G2 Jugular) 070021, Rev. 9	BPV-17-01-00139687	BPV-17-01-00139704	FRE 401; 402; 403; 602; 702;	
5407	G2 DFMEA (Femoral) 070022, Rev. 0	BPV-17-01-00139705	BPV-17-01-00139726	FRE 401; 402; 403; 602; 702;	
5408	G2 DFMEA (Femoral) 070022, Rev. 1	BPV-17-01-00139727	BPV-17-01-00139749	FRE 401; 402; 403; 602; 702;	
5409	G2 DFMEA (Femoral) 070022, Rev. 2	BPV-17-01-00139750	BPV-17-01-00139782	FRE 401; 402; 403; 602; 702;	
5410	G2 DFMEA (Femoral) 070022, Rev. 3	BPV-17-01-00139783	BPV-17-01-00139823	FRE 401; 402; 403; 602; 702;	
5411	G2 DFMEA (Femoral) 070022, Rev. 4	BPV-17-01-00139824	BPV-17-01-00139864	FRE 401; 402; 403; 602; 702;	
5412	G2 DFMEA (Femoral) 070022, Rev. 5	BPV-17-01-00139866	BPV-17-01-00139907	FRE 401; 402; 403; 602; 702;	
5413	G2 DFMEA (Femoral) 070031, Rev. 0	BPV-17-01-00139908	BPV-17-01-00139940	FRE 401; 402; 403; 602; 702;	
5414	G2 DFMEA (Femoral) 070031, Rev. 1	BPV-17-01-00139941	BPV-17-01-00139973	FRE 401; 402; 403; 602; 702;	
5415	G2 DFMEA (Femoral) 070031, Rev. 2	BPV-17-01-00139974	BPV-17-01-00140006	FRE 401; 402; 403; 602; 702;	
5416	G2 DFMEA (Femoral) 070031, Rev. 3	BPV-17-01-00140007	BPV-17-01-00140047	FRE 401; 402; 403; 602; 702;	
5417	G2 DFMEA (Femoral) 070031, Rev. 4	BPV-17-01-00140048	BPV-17-01-00140088	FRE 401; 402; 403; 602; 702;	
5418	G2 DFMEA (Femoral) 070031, rev. 5	BPV-17-01-00140090	BPV-17-01-00140128	FRE 401; 402; 403; 602; 702;	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5419	G2 DFMEA (Femoral) 070031, Rev. 6	BPV-17-01-00140129	BPV-17-01-00140160	FRE 401; 402; 403; 602; 702;	
5420	Society of Interventional Radiology Responds to FDA Blood Clot Device (IVC	BPV-17-01-00140458	BPV-17-01-00140458	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802
5421	Aug. 23, 2010 Letter from SIR to Shuren Aug. 23, 2010 Letter from SIR to Shuren	BPV-17-01-00140459	BPV-17-01-00140462	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802
5422	FDA Safety Advisory	BPV-17-01-00140479	BPV-17-01-00140479	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5423	Dec. 17, 2009 Email from Schulz to Moffett Nicholson documents received from	BPV-17-01-00141514	BPV-17-01-00141515	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5424	Dec. 15, 2009 Email from Schulz to Moffett	BPV-17-01-00141516	BPV-17-01-00141516	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5425	Nov. 9, 2009 Email from Chavez to Nicholson	BPV-17-01-00141517	BPV-17-01-00141519	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802
5426	Nov. 9, 2009 Email from Nicholson to Chavez	BPV-17-01-00141520	BPV-17-01-00141522	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802
5427	Dec. 9, 2009 Email from Schulz to Rhinehart	BPV-17-01-00141523	BPV-17-01-00141524	FRE 401; 402; 403; 602; 702;	401; 402; 403
5428	Chart reflecting information on complaint files	BPV-17-01-00141525	BPV-17-01-00141538	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5429	Dec. 1, 2009 Email from Chavez to DelioCox	BPV-17-01-00141539	BPV-17-01-00141541	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5430	Dec. 8, 2009 Email from Schulz to Nicholson	BPV-17-01-00141542	BPV-17-01-00141542	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5431	Dec. 7, 2009 email chain with FDA re IVC filters	BPV-17-01-00141543	BPV-17-01-00141549	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5432	Dec. 2, 2009 email chain with FDA re Nicholson and Meridian®	BPV-17-01-00141592	BPV-17-01-00141595	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5433	FDA re Removing Retrievable Inferior Vena Cava Filters: Initial Communication	BPV-17-01-00141621	BPV-17-01-00141621	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5434	Establishment Inspection Report -- May 20, 2003 Establishment Inspection Report	BPV-17-01-00141829	BPV-17-01-00141838	FRE 401; 402; 403; 602; 702;	
5435	Establishment Inspection Report -- April 5, 2006 Establishment Inspection Report	BPV-17-01-00141839	BPV-17-01-00141852	FRE 401; 402; 403; 602; 702;	
5436	Establishment Inspection Report -- May 4, 2009 Establishment Inspection Report -	BPV-17-01-00141853	BPV-17-01-00141875	FRE 401; 402; 403; 602; 702;	
5437	Eclipse(Femoral) 12.09 - PK100600 Rev. 0a IFU	BPV-17-01-00142881	BPV-17-01-00142887	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5438	G2 Express (femoral) IFU 02.08 - PK5022940 Rev. 0	BPV-17-01-00142916	BPV-17-01-00142919	FRE 401; 402; 403; 602; 702;	
5439	G2X(Femoral) 06.09 - PK5100060 Rev. 4 IFU	BPV-17-01-00142962	BPV-17-01-00142971	FRE 401; 402; 403; 602; 702;	
5440	CQA-STD-24 Rev 08 -- Standard for Product Complaint Handling	BPV-17-01-00143084	BPV-17-01-00143100	FRE 401; 402; 403; 602; 702;	
5441	SOPQ0153100 Rev 00 -- BPV Complaint Handling System	BPV-17-01-00143101	BPV-17-01-00143129	FRE 401; 402; 403; 602; 702;	
5442	sopq0153100 Rev 01 -- BPV Complaint Handling System	BPV-17-01-00143130	BPV-17-01-00143156	FRE 401; 402; 403; 602; 702;	
5443	sopq0153100 Rev 02 -- BPV Complaint Handling System	BPV-17-01-00143157	BPV-17-01-00143182	FRE 401; 402; 403; 602; 702;	
5444	sopq0153100 Rev 03 -- BPV Complaint Handling System	BPV-17-01-00143183	BPV-17-01-00143198	FRE 401; 402; 403; 602; 702;	
5445	sopq0153100 Rev 04 -- BPV Complaint Handling System	BPV-17-01-00143199	BPV-17-01-00143215	FRE 401; 402; 403; 602; 702;	
5446	sopq0153100 Rev 05 -- BPV Complaint Handling System	BPV-17-01-00143216	BPV-17-01-00143232	FRE 401; 402; 403; 602; 702;	
5447	sopq0153100 Rev 06 -- BPV Complaint Handling System	BPV-17-01-00143233	BPV-17-01-00143252	FRE 401; 402; 403; 602; 702;	
5448	sopq0153100 Rev 07 -- BPV Complaint Handling System	BPV-17-01-00143253	BPV-17-01-00143272	FRE 401; 402; 403; 602; 702;	
5449	sopq0153100 Rev 08 -- BPV Complaint Handling System	BPV-17-01-00143273	BPV-17-01-00143290	FRE 401; 402; 403; 602; 702;	
5450	sopq0153100 Rev 09 -- BPV Complaint Handling System	BPV-17-01-00143291	BPV-17-01-00143307	FRE 401; 402; 403; 602; 702;	
5451	sopq0153100 Rev 10 -- BPV Complaint Handling System	BPV-17-01-00143308	BPV-17-01-00143324	FRE 401; 402; 403; 602; 702;	
5452	sopq0153100 Rev 11 -- BPV Complaint Handling System	BPV-17-01-00143325	BPV-17-01-00143342	FRE 401; 402; 403; 602; 702;	
5453	sopq0153100 Rev 12 -- BPV Complaint Handling System	BPV-17-01-00143343	BPV-17-01-00143364	FRE 401; 402; 403; 602; 702;	
5454	sopq0153100 Rev 13 -- BPV Complaint Handling System	BPV-17-01-00143365	BPV-17-01-00143387	FRE 401; 402; 403; 602; 702;	
5455	sopq0153100 Rev 14 -- BPV Complaint Handling System	BPV-17-01-00143388	BPV-17-01-00143415	FRE 401; 402; 403; 602; 702;	
5456	sopq0153100 Rev 15 -- BPV Complaint Handling System PMA Related	BPV-17-01-00143416	BPV-17-01-00143443	FRE 401; 402; 403; 602; 702;	
5457	sopq0153100 Rev 16 -- BPV Complaint Handling System PMA Related	BPV-17-01-00143444	BPV-17-01-00143457	FRE 401; 402; 403; 602; 702;	
5458	SOPQ0153100 Rev 17 -- BPV Complaint Handling System PMA Related	BPV-17-01-00143458	BPV-17-01-00143471	FRE 401; 402; 403; 602; 702;	
5459	SOPQ0153100 Rev 18 -- BPV Complaint Handling System PMA Related	BPV-17-01-00143472	BPV-17-01-00143487	FRE 401; 402; 403; 602; 702;	
5460	SOPQ0700200 Rev 00 -- Complaint Investigation Procedures	BPV-17-01-00143627	BPV-17-01-00143631	FRE 401; 402; 403; 602; 702;	
5461	sopq0700200 Rev 01 -- Complaint Investigation Procedures	BPV-17-01-00143632	BPV-17-01-00143636	FRE 401; 402; 403; 602; 702;	
5462	sopq0700200 Rev 02 -- Complaint Investigation Procedures	BPV-17-01-00143637	BPV-17-01-00143641	FRE 401; 402; 403; 602; 702;	
5463	sopq0700200 Rev 03 -- Complaint Investigation Procedures	BPV-17-01-00143642	BPV-17-01-00143646	FRE 401; 402; 403; 602; 702;	
5464	sopq0700200 Rev 04 -- Complaint Investigation Procedures	BPV-17-01-00143647	BPV-17-01-00143652	FRE 401; 402; 403; 602; 702;	
5465	sopq0700200 Rev 05 -- Complaint Investigation Procedures	BPV-17-01-00143653	BPV-17-01-00143659	FRE 401; 402; 403; 602; 702;	
5466	sopq0700200 Rev 06 -- Complaint Investigation Procedures	BPV-17-01-00143660	BPV-17-01-00143666	FRE 401; 402; 403; 602; 702;	
5467	sopq0700200 Rev 07 -- Complaint Investigation Procedures	BPV-17-01-00143667	BPV-17-01-00143674	FRE 401; 402; 403; 602; 702;	
5468	sopq0700200 Rev 08 -- Complaint Investigation Procedures PMA Related	BPV-17-01-00143675	BPV-17-01-00143684	FRE 401; 402; 403; 602; 702;	
5469	sopq0700200 Rev 09 -- Complaint Investigation Procedures PMA Related	BPV-17-01-00143685	BPV-17-01-00143694	FRE 401; 402; 403; 602; 702;	
5470	sopq0700200 Rev 10 -- Complaint Investigation Procedures PMA Related	BPV-17-01-00143695	BPV-17-01-00143700	FRE 401; 402; 403; 602; 702;	
5471	SOPQ0700200 Rev 11 -- Complaint Investigation Procedures PMA Related	BPV-17-01-00143701	BPV-17-01-00143704	FRE 401; 402; 403; 602; 702;	
5472	SOPQ0700200 Rev 12 -- Complaint Investigation Procedures PMA Related	BPV-17-01-00143705	BPV-17-01-00143708	FRE 401; 402; 403; 602; 702;	
5473	sopq0735600 Rev 0 -- Failure Investigation	BPV-17-01-00143709	BPV-17-01-00143713	FRE 401; 402; 403; 602; 702;	
5474	sopq0735600 Rev 1 -- Failure Investigation	BPV-17-01-00143714	BPV-17-01-00143718	FRE 401; 402; 403; 602; 702;	
5475	sopq0735600 Rev 2 -- Failure Investigation	BPV-17-01-00143719	BPV-17-01-00143724	FRE 401; 402; 403; 602; 702;	
5476	sopq0735600 Rev 3 -- Failure Investigation	BPV-17-01-00143725	BPV-17-01-00143730	FRE 401; 402; 403; 602; 702;	
5477	sopq0735600 Rev 4 -- Failure Investigation	BPV-17-01-00143731	BPV-17-01-00143736	FRE 401; 402; 403; 602; 702;	
5478	sopq0735600 Rev 5 -- Investigation Procedure	BPV-17-01-00143737	BPV-17-01-00143749	FRE 401; 402; 403; 602; 702;	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5479	sopq0735600 Rev 6 -- Investigation Procedure	BPV-17-01-00143750	BPV-17-01-00143762	FRE 401; 402; 403; 602; 702;	
5480	SOPQ0735600 Rev 7 -- Investigation Procedure PMA Related	BPV-17-01-00143763	BPV-17-01-00143778	FRE 401; 402; 403; 602; 702;	
5481	sopq1402000 Rev 5 -- Subject Product Analysis and Remedial Action Assessment	BPV-17-01-00143815	BPV-17-01-00143823	FRE 401; 402; 403; 602; 702;	
5482	sopq1413000 Rev 15 -- CAPA Procedure PMA Related sopq1413000 Rev 15 --	BPV-17-01-00144100	BPV-17-01-00144118	FRE 401; 402; 403; 602; 702;	
5483	sopq1417500 Rev 1 -- Statistical Complaint Trending Procedure PMA Related	BPV-17-01-00144123	BPV-17-01-00144126	FRE 401; 402; 403; 602; 702;	
5484	Recovery Cone® Removal System IFU and related documentation	BPV-17-01-00144315	BPV-17-01-00144318	FRE 401; 402; 403; 602; 702;	
5485	Recovery Cone® IFU and related documentation	BPV-17-01-00144389	BPV-17-01-00144525	FRE 401; 402; 403; 602; 702;	401; 402; 403
5486	Dec. 17, 2009 Letter from BPV to FDA re Eclipse Filter System Response to FDA	BPV-17-01-00145607	BPV-17-01-00145616	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5487	Dec. 17, 2009 Letter BPV to FDA re Responses to FDA AI Demand re Eclipse	BPV-17-01-00145607	BPV-17-01-00145616	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5488	June 21, 2010 Letter from BPV to FDA re Eclipse Filter System Response to FDA	BPV-17-01-00145617	BPV-17-01-00145633	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5489	Meridian Filter System -- Femoral Delivery Kit Special 510(k) (K112497), Aug.	BPV-17-01-00147141	BPV-17-01-00147592	FRE 401; 402; 403; 602; 702;	401; 402; 407
5490	Sept. 30, 2011 Letter from FDA to BPV re Meridian Filter System -- Femoral	BPV-17-01-00147593	BPV-17-01-00147597	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5491	Sept. 30, 2011 Letter from FDA to BPV re Meridian Filter System -- Femoral	BPV-17-01-00147593	BPV-17-01-00147597	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5492	Letter from BPV to FDA re Meridian Filter System Response to FDA Questions,	BPV-17-01-00147598	BPV-17-01-00147607	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5493	Oct. 24, 2011 Letter from FDA to BPV re Meridian Filter System -- Femoral	BPV-17-01-00147608	BPV-17-01-00147610	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5494	Oct. 24, 2011 Letter re Meridian Filter System (K112497) (Substantial	BPV-17-01-00147608	BPV-17-01-00147610	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5495	Meridian IFU (Femoral) 2011.01 - PK5372100 rev. 1	BPV-17-01-00147635	BPV-17-01-00147646	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5496	Meridian IFU (Femoral) 2011.02 - PK5372100 rev. 2	BPV-17-01-00147647	BPV-17-01-00147658	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5497	Meridian IFU (Femoral) 2011.06 - PK5372100 rev. 3	BPV-17-01-00147659	BPV-17-01-00147670	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5498	Meridian (Femoral) 08.11 - PK5372100 Rev. 4 IFU	BPV-17-01-00147671	BPV-17-01-00147682	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5499	Meridian IFU (Jugular) 2011.06 - PK5372400 rev. 2	BPV-17-01-00147707	BPV-17-01-00147718	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5500	Meridian IFU (Jugular) 2011.08 - PK5372400 rev. 3	BPV-17-01-00147719	BPV-17-01-00147730	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5501	Meridian Jugular Subclavian Delivery Kit Traditional 510(k) (K102511) August	BPV-17-01-00150192	BPV-17-01-00151045	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5502	CQA-STD-24 Rev 0 -- Standard for Product Complaint Handling	BPV-17-01-00152637	BPV-17-01-00152661	FRE 401; 402; 403; 602; 702;	
5503	CQA-STD-24 Rev 1 -- Standard for Product Complaint Handling	BPV-17-01-00152662	BPV-17-01-00152677	FRE 401; 402; 403; 602; 702;	
5504	CQA-STD-24 Rev 2 -- Standard for Product Complaint Handling	BPV-17-01-00152678	BPV-17-01-00152694	FRE 401; 402; 403; 602; 702;	
5505	CQA-STD-24 Rev 3 -- Standard for Product Complaint Handling	BPV-17-01-00152695	BPV-17-01-00152713	FRE 401; 402; 403; 602; 702;	
5506	CQA-STD-24 Rev 4 -- Standard for Product Complaint Handling	BPV-17-01-00152714	BPV-17-01-00152734	FRE 401; 402; 403; 602; 702;	
5507	CQA-STD-24 Rev 5 -- Standard for Product Complaint Handling	BPV-17-01-00152735	BPV-17-01-00152822	FRE 401; 402; 403; 602; 702;	
5508	CQA-STD-24 Rev 6 -- Standard for Product Complaint Handling	BPV-17-01-00152823	BPV-17-01-00152838	FRE 401; 402; 403; 602; 702;	
5509	CQA-STD-24 Rev 7 -- Standard for Product Complaint Handling	BPV-17-01-00152839	BPV-17-01-00152855	FRE 401; 402; 403; 602; 702;	
5510	Recovery Filter Subject Product Analysis Migration SPA-04-12-01 Addendum I	BPV-17-01-00153231	BPV-17-01-00153234	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5511	Attachment A to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF	BPV-17-01-00153235	BPV-17-01-00153289	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5512	Attachment B to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF	BPV-17-01-00153344	BPV-17-01-00153410	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5513	Attachment C to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF	BPV-17-01-00153411	BPV-17-01-00153470	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5514	Attachment D to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF	BPV-17-01-00153471	BPV-17-01-00153474	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5515	Attachment E to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF	BPV-17-01-00153475	BPV-17-01-00153478	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5516	Attachment F to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF	BPV-17-01-00153479	BPV-17-01-00153483	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5517	Attachment G to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF	BPV-17-01-00153484	BPV-17-01-00153489	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5518	Attachment H to SPA-04-12-01: Amendment 1 (Remedial Action Plan re RNF	BPV-17-01-00153490	BPV-17-01-00153494	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5519	July 12, 2004 Addendum to the Recovery; Filter Migration Events Spreadsheet (by	BPV-17-01-00153557	BPV-17-01-00153557	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5520	June 25, 2004 Multidisciplinary Focus Group Meeting PPT Slides June 25, 2004	BPV-17-01-00153561	BPV-17-01-00153564	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5521	June 25, 2004 Multidisciplinary Focus Group Meeting PPT Slides June 25, 2004	BPV-17-01-00153565	BPV-17-01-00153565	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5522	June 25, 2004 Multidisciplinary Focus Group Meeting PPT Slides June 25, 2004	BPV-17-01-00153569	BPV-17-01-00153572	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5523	ETR-04-03-05 (RNF Characterization testing comparing GFO v. NMT	BPV-17-01-00153717	BPV-17-01-00153723	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5524	March 10, 2004 Health Hazard Evaluation	BPV-17-01-00153751	BPV-17-01-00153762	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5525	Action Items from March 4, 2004 RNF Migration Meeting	BPV-17-01-00153895	BPV-17-01-00153895	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5526	TPR-04-02-02 (Protocol for RNF Migration Testing v. Competitive) Test Protocol	BPV-17-01-00153896	BPV-17-01-00153909	FRE 401; 402; 403; 602; 702;	401; 402; 403
5527	March 26, 2014 Recovery Filter Migration Physician Review Panel PPT	BPV-17-01-00154014	BPV-17-01-00154047	FRE 401; 402; 403; 602; 702;	401; 402; 403; 601; 602;
5528	Agenda for Feb. 12, 2004 RNF Migration Meeting	BPV-17-01-00154048	BPV-17-01-00154049	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5529	2004 Notebook of Materials re Migration (includes various meeting minutes)	BPV-17-01-00154190	BPV-17-01-00154256	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5530	IFU Comparison Chart IFU Comparison Chart	BPV-17-01-00154520	BPV-17-01-00154564	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1;
5531	March 4, 2004 RNF Migration Meeting Minutes	BPV-17-01-00154665	BPV-17-01-00154667	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5532	April 16, 2004 RNF Migration Meeting Minutes	BPV-17-01-00154730	BPV-17-01-00154731	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5533	Feb. 2004 Notebook of Materials re Migration (includes various meeting minutes)	BPV-17-01-00155031	BPV-17-01-00155073	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5534	Picture of Clot from Feb. 2004 RNF Migration	BPV-17-01-00155041	BPV-17-01-00155045	FRE 401; 402; 403; Cond.	401; 402; 403; 801; 802;
5535	G2 Caudal Migration Failure Investigation Presentation Slides	BPV-17-01-00155091	BPV-17-01-00155170	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5536	Meeting Summary from Filter Expert Panel June 1, 2006	BPV-17-01-00155135	BPV-17-01-00155137	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5537	June 2006 Expert Panel Meeting Slides	BPV-17-01-00155139	BPV-17-01-00155170	FRE 401; 402; 403; 602; 702;	
5538	June 19, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes	BPV-17-01-00155174	BPV-17-01-00155204	FRE 401; 402; 403; Cond.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5539	G2 Caudal Migration Failure Investigation Report Aug. 4, 2005 G2 Filter Caudal	BPV-17-01-00155205	BPV-17-01-00155221	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL # 1
5540	BPV Quality Manual Rev. 0	BPV-17-01-00158946	BPV-17-01-00158969	FRE 401; 402; 403; 602; 702;	
5541	BPV Quality Manual Rev 1	BPV-17-01-00158970	BPV-17-01-00158993	FRE 401; 402; 403; 602; 702;	401; 402; 403
5542	BPV Quality Manual Rev 2	BPV-17-01-00158994	BPV-17-01-00159017	FRE 401; 402; 403; 602; 702;	401; 402; 403
5543	BPV Quality Manual Rev 3	BPV-17-01-00159018	BPV-17-01-00159041	FRE 401; 402; 403; 602; 702;	401; 402; 403
5544	BPV Quality Manual Rev 4	BPV-17-01-00159042	BPV-17-01-00159065	FRE 401; 402; 403; 602; 702;	401; 402; 403
5545	BPV Quality Manual Rev 5	BPV-17-01-00159066	BPV-17-01-00159089	FRE 401; 402; 403; 602; 702;	401; 402; 403
5546	BPV Quality Manual - DOPQ0700300 Rev 6 BPV Quality Manual -	BPV-17-01-00159090	BPV-17-01-00159114	FRE 401; 402; 403; 602; 702;	
5547	SOPN0700080, Rev. 0 (Design Review)	BPV-17-01-00160805	BPV-17-01-00160814	FRE 401; 402; 403; 602; 702;	
5548	Standard Operating Procedure / Division Operating Procedure - SOPN0700080	BPV-17-01-00160860	BPV-17-01-00160869	FRE 401; 402; 403; 602; 702;	
5549	Department of Health and Human Services NOI 2003 Notice of Inspection	BPV-17-01-00162796	BPV-17-01-00162800	FRE 401; 402; 403; 602; 702;	
5550	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-31	BPV-17-01-00162811	BPV-17-01-00162820	FRE 401; 402; 403; 602; 702;	
5551	Standard Operating Procedures / Division Operating Procedures -- DOPQ1102100	BPV-17-01-00162958	BPV-17-01-00162960	FRE 401; 402; 403; 602; 702;	
5552	Establishment Inspection Report -- FDA July 2011	BPV-17-01-00162961	BPV-17-01-00162984	FRE 401; 402; 403; 602; 702;	
5553	Standard Operating Procedures / Division Operating Procedures -- SOPQ1413000	BPV-17-01-00163288	BPV-17-01-00163306	FRE 401; 402; 403; 602; 702;	
5554	Standard Operating Procedures / Division Operating Procedures -- DOPQ0700000	BPV-17-01-00163323	BPV-17-01-00163324	FRE 401; 402; 403; 602; 702;	
5555	Standard Operating Procedures / Division Operating Procedures -- DOPQ0700020	BPV-17-01-00163540	BPV-17-01-00163544	FRE 401; 402; 403; 602; 702;	
5556	Standard Operating Procedures / Division Operating Procedures -- DOPQ0700040	BPV-17-01-00163565	BPV-17-01-00163569	FRE 401; 402; 403; 602; 702;	
5557	Standard Operating Procedures / Division Operating Procedures -- DOPQ0700300	BPV-17-01-00163890	BPV-17-01-00163913	FRE 401; 402; 403; 602; 702;	
5558	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-54	BPV-17-01-00166650	BPV-17-01-00166686	FRE 401; 402; 403; 602; 702;	
5559	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-54	BPV-17-01-00166687	BPV-17-01-00166724	FRE 401; 402; 403; 602; 702;	
5560	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-	BPV-17-01-00166749	BPV-17-01-00166776	FRE 401; 402; 403; 602; 702;	
5561	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-	BPV-17-01-00166777	BPV-17-01-00166806	FRE 401; 402; 403; 602; 702;	
5562	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-	BPV-17-01-00166807	BPV-17-01-00166837	FRE 401; 402; 403; 602; 702;	
5563	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-	BPV-17-01-00166838	BPV-17-01-00166868	FRE 401; 402; 403; 602; 702;	
5564	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-	BPV-17-01-00166869	BPV-17-01-00166901	FRE 401; 402; 403; 602; 702;	
5565	Standard Operating Procedures / Division Operating Procedures -- RA-STD-002	BPV-17-01-00166947	BPV-17-01-00166968	FRE 401; 402; 403; 602; 702;	
5566	Standard Operating Procedures / Division Operating Procedures -- RA-STD-002	BPV-17-01-00166969	BPV-17-01-00166987	FRE 401; 402; 403; 602; 702;	
5567	Lab notebook 7102 (G2 Express ELF Test) Lab Notebook LAB-7102 JOB	BPV-17-01-00167982	BPV-17-01-00168036	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5568	Standard Operating Procedures / Division Operating Procedures - SOPN0700180	BPV-17-01-00169138	BPV-17-01-00169139	FRE 401; 402; 403; 602; 702;	
5569	Standard Operating Procedures / Division Operating Procedures - SOPN0700180	BPV-17-01-00169140	BPV-17-01-00169142	FRE 401; 402; 403; 602; 702;	
5570	Standard Operating Procedures / Division Operating Procedures - SOPN0700180	BPV-17-01-00169143	BPV-17-01-00169145	FRE 401; 402; 403; 602; 702;	
5571	Standard Operating Procedures / Division Operating Procedures - SOPN0700180	BPV-17-01-00169146	BPV-17-01-00169148	FRE 401; 402; 403; 602; 702;	
5572	Standard Operating Procedures / Division Operating Procedures - SOPN0700180	BPV-17-01-00169149	BPV-17-01-00169152	FRE 401; 402; 403; 602; 702;	
5573	Standard Operating Procedures / Division Operating Procedures - SOPN0700180	BPV-17-01-00169153	BPV-17-01-00169156	FRE 401; 402; 403; 602; 702;	
5574	Standard Operating Procedures / Division Operating Procedures - SOPQ0700190	BPV-17-01-00169157	BPV-17-01-00169164	FRE 401; 402; 403; 602; 702;	
5575	Standard Operating Procedures / Division Operating Procedures - SOPQ0700190	BPV-17-01-00169165	BPV-17-01-00169172	FRE 401; 402; 403; 602; 702;	
5576	Standard Operating Procedures / Division Operating Procedures - SOPQ0700190	BPV-17-01-00169173	BPV-17-01-00169180	FRE 401; 402; 403; 602; 702;	
5577	Standard Operating Procedures / Division Operating Procedures - SOPQ0700190	BPV-17-01-00169181	BPV-17-01-00169188	FRE 401; 402; 403; 602; 702;	
5578	Standard Operating Procedures / Division Operating Procedures - SOPQ1417500	BPV-17-01-00169268	BPV-17-01-00169271	FRE 401; 402; 403; 602; 702;	
5579	Standard Operating Procedures / Division Operating Procedures - SOPQ1417500	BPV-17-01-00169272	BPV-17-01-00169275	FRE 401; 402; 403; 602; 702;	
5580	Standard Operating Procedures / Division Operating Procedures - CQA-STD-15	BPV-17-01-00169295	BPV-17-01-00169304	FRE 401; 402; 403; 602; 702;	
5581	02.28.13 Letter from FDA to BPV re PRESERVE Study 522 Eclipse	BPV-17-01-00171669	BPV-17-01-00171670	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802
5582	02.28.13 Letter from FDA to BPV re PRESERVE Study 522 G2	BPV-17-01-00171671	BPV-17-01-00171672	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802
5583	02.28.13 Letter from FDA to BPV re PRESERVE Study 522 G2X	BPV-17-01-00171673	BPV-17-01-00171674	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802
5584	02.28.13 Letter from FDA to BPV re PRESERVE Study 522 Recovery	BPV-17-01-00171675	BPV-17-01-00171676	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5585	02.28.13 Letter from FDA to BPV re PRESERVE Study 522 Simon Nitinol	BPV-17-01-00171677	BPV-17-01-00171678	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802
5586	May 20, 2010 BPV's Eclipse Filter Special 510(k) (K101431)	BPV-17-01-00171679	BPV-17-01-00171793	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5587	June 18, 2010 Letter FDA to BPV re FDA AI Demand re Eclipse (K101431)	BPV-17-01-00171794	BPV-17-01-00171796	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5588	Dec. 15, 2009 Letter FDA to BPV re FDA AI Demand re Eclipse (K093659)	BPV-17-01-00171797	BPV-17-01-00171799	FRE 401; 402; 403; 602; 702;	401; 402; 403
5589	June 22, 2010 -- FDA Clearance Letter for Eclipse Filter (K101431) (Substantial	BPV-17-01-00171815	BPV-17-01-00171817	FRE 401; 402; 403; 602; 702;	401; 402; 403
5590	Meridian Clearance August 24, 2011 (K102511)	BPV-17-01-00171818	BPV-17-01-00171820	FRE 401; 402; 403; 602; 702;	401; 402; 403
5591	FDA CONTACT REPORT 11-18-2010 Meridian 510(k)	BPV-17-01-00171821	BPV-17-01-00171821	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5592	FDA CONTACT REPORT 2-4-2011 MERIDIAN AI Letter and DENALI IDE	BPV-17-01-00171822	BPV-17-01-00171822	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5593	Aug. 14, 2009 Conference FDA and BPV re future Eclipse Filter 510(k)	BPV-17-01-00171823	BPV-17-01-00171824	FRE 401; 402; 403; 602; 702;	401; 402; 403
5594	FDA CONTACT REPORT December 3 2010 Denali pre-IDE supplement &	BPV-17-01-00171825	BPV-17-01-00171828	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5595	FDA CONTACT REPORT December 7 2010 Denali IDE and Meridian AI	BPV-17-01-00171829	BPV-17-01-00171829	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5596	FDA CONTACT REPORT December 8 2010 Meridian AI Fatigue	BPV-17-01-00171830	BPV-17-01-00171832	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5597	Dec. 8, 2010 FDA Contact Report re Meridian	BPV-17-01-00171830	BPV-17-01-00171832	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5598	Feb. 10, 2011 FDA Contact Report (Denali Pre IDE)	BPV-17-01-00171833	BPV-17-01-00171835	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5599	Feb. 10, 2011 FDA Contact Report (Meridian)	BPV-17-01-00171836	BPV-17-01-00171838	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5600	FDA CONTACT REPORT Feb 16 2010 Prophylactic Indication	BPV-17-01-00171839	BPV-17-01-00171840	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5601	Feb. 17, 2011 (Meridian)	BPV-17-01-00171841	BPV-17-01-00171844	FRE 401; 402; 403; 602; 702;	401; 402; 403
5602	FDA CONTACT REPORT January 7 2010 FINAL	BPV-17-01-00171845	BPV-17-01-00171849	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5603	Jan. 8, 2010 (Meridian Pre IDE)	BPV-17-01-00171850	BPV-17-01-00171853	FRE 401; 402; 403; 602; 702;	401; 402; 403
5604	FDA CONTACT REPORT June 29 2010 ASLT for IDE	BPV-17-01-00171854	BPV-17-01-00171854	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5605	FDA CONTACT REPORT March 31 2009 Pre-IDE Meeting Minutes G2 Platinum	BPV-17-01-00171855	BPV-17-01-00171856	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5606	FDA CONTACT REPORT May 17 2011 Meridian	BPV-17-01-00171857	BPV-17-01-00171864	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5607	May 17, 2011 (Meridian)	BPV-17-01-00171857	BPV-17-01-00171864	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5608	May 20, 2010 (Denali Pre IDE)	BPV-17-01-00171865	BPV-17-01-00171867	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5609	May 5, 2010 (Denali Pre IDE)	BPV-17-01-00171868	BPV-17-01-00171871	FRE 401; 402; 403; 602; 702;	401; 402; 403
5610	Nov. 12, 2010 (Meridian)	BPV-17-01-00171872	BPV-17-01-00171873	FRE 401; 402; 403; 602; 702;	401; 402; 403
5611	FDA CONTACT REPORT Nov 17 2009 CRT Online	BPV-17-01-00171874	BPV-17-01-00171874	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5612	Nov. 17, 2009 (Filters and future submissions)	BPV-17-01-00171875	BPV-17-01-00171876	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5613	FDA CONTACT REPORT June 22 2011 Meridian	BPV-17-01-00171877	BPV-17-01-00171879	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5614	June 22, 2011 (Meridian)	BPV-17-01-00171877	BPV-17-01-00171879	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5615	FDA CONTACT REPORT September 27 2011 IVC Filter Discussion and Meridian	BPV-17-01-00171880	BPV-17-01-00171881	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5616	Standard Operating Procedure / Division Operating Procedure - R-004 Rev 03	BPV-17-01-00178223	BPV-17-01-00178253	FRE 401; 402; 403; 602; 702;	
5617	Standard Operating Procedure / Division Operating Procedure - SOPR0700000	BPV-17-01-00178537	BPV-17-01-00178552	FRE 401; 402; 403; 602; 702;	
5618	Standard Operating Procedure / Division Operating Procedure - SOPR0700010	BPV-17-01-00178594	BPV-17-01-00178606	FRE 401; 402; 403; 602; 702;	
5619	Preserve Materials 12-8-10 IVC Filter study	BPV-17-01-00178867	BPV-17-01-00179006	FRE 401; 402; 403; 602; 702;	401; 402; 403
5620	Bard.Preserve.LOI Bard.Preserve.LOI	BPV-17-01-00178911	BPV-17-01-00178911	FRE 401; 402; 403; 602; 702;	401; 402; 403
5621	ETR-06-08-29, Rev. 0 (Caudal Migration Test Method Development and G2 Filter	BPV-17-01-00180551	BPV-17-01-00180573	FRE 401; 402; 403; 602; 702;	
5622	TPR-06-08-29, Rev. 0 (Caudal Migration Test Method Development and G2 Filter	BPV-17-01-00180858	BPV-17-01-00180869	FRE 401; 402; 403; 602; 702;	
5623	Recovery Filter Product Performance Specification (PPS070016 Rev. 0)	BPV-17-01-00186068	BPV-17-01-00186094	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #2
5624	Filter Action Items PPT	BPV-17-01-00188512	BPV-17-01-00188512	FRE 401; 402; 403; 602; 702;	401; 402; 403
5625	Design History File: 8088 Platinum - G2 Compliant	BPV-17-01-00188517	BPV-17-01-00188517	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5626	Spreadsheet of Complications	BPV-17-01-00188520	BPV-17-01-00188520	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5627	BPV EIR 2007 -- Establishment Inspection Report -- FDA January 2007	BPV-17-01-00189119	BPV-17-01-00189123	FRE 401; 402; 403; 602; 702;	
5628	BPV EIR 2007 -- Establishment Inspection Report -- FDA January 2009	BPV-17-01-00189124	BPV-17-01-00189130	FRE 401; 402; 403; 602; 702;	
5629	Nov. 28 2011 EIR -- Establishment Inspection Report -- FDA August 2011	BPV-17-01-00189131	BPV-17-01-00189143	FRE 401; 402; 403; 602; 702;	
5630	Bard Signed Agreement Bard Signed Agreement	BPV-17-01-00189810	BPV-17-01-00189811	FRE 401; 402; 403; 602; 702;	401; 402; 403
5631	DOPN0700010, Rev. 0 (DOP re Risk Assessment)	BPV-17-01-00189812	BPV-17-01-00189818	FRE 401; 402; 403; 602; 702;	
5632	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190036	BPV-17-01-00190046	FRE 401; 402; 403; 602; 702;	
5633	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190047	BPV-17-01-00190057	FRE 401; 402; 403; 602; 702;	
5634	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190058	BPV-17-01-00190068	FRE 401; 402; 403; 602; 702;	
5635	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190069	BPV-17-01-00190079	FRE 401; 402; 403; 602; 702;	
5636	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190080	BPV-17-01-00190089	FRE 401; 402; 403; 602; 702;	
5637	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190090	BPV-17-01-00190106	FRE 401; 402; 403; 602; 702;	
5638	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190107	BPV-17-01-00190128	FRE 401; 402; 403; 602; 702;	
5639	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190129	BPV-17-01-00190151	FRE 401; 402; 403; 602; 702;	
5640	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190152	BPV-17-01-00190174	FRE 401; 402; 403; 602; 702;	
5641	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190175	BPV-17-01-00190198	FRE 401; 402; 403; 602; 702;	
5642	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190199	BPV-17-01-00190222	FRE 401; 402; 403; 602; 702;	
5643	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190223	BPV-17-01-00190247	FRE 401; 402; 403; 602; 702;	
5644	Standard Operating Procedure / Division Operating Procedure - SOPN0700120	BPV-17-01-00190248	BPV-17-01-00190272	FRE 401; 402; 403; 602; 702;	
5645	QMBR--April 2013	BPV-17-01-00191230	BPV-17-01-00191297	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5646	QMBR--Nov. 2013	BPV-17-01-00191684	BPV-17-01-00191763	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407; 801; 802
5647	TD-03970 -- Eclipse and G2X Migration Resistance Test Data	BPV-17-01-00193315	BPV-17-01-00193321	FRE 401; 402; 403; 602; 702;	401; 402; 403
5648	Jan. 5, 2015 FDA 483 Letter to BPV.pdf	BPV-17-01-00193330	BPV-17-01-00193336	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5649	July 13, 2015 FDA Warning Letter to Bard.pdf	BPV-17-01-00193337	BPV-17-01-00193348	FRE 401; 402; 403; 602; 702;	MIL #3
5650	Nov. 25, 2014 FDA 483 Letter to Glens Falls.pdf	BPV-17-01-00193349	BPV-17-01-00193358	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5651	GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Letter.pdf	BPV-17-01-00193359	BPV-17-01-00193361	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5652	GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Exhibit 1.pdf	BPV-17-01-00193362	BPV-17-01-00193371	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5653	GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Exhibit 2.pdf	BPV-17-01-00193372	BPV-17-01-00193414	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5654	GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Exhibit 3.pdf	BPV-17-01-00193415	BPV-17-01-00193418	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5655	GFO FDA 483 Response (1) Dec 17 2014 (Initial)\Attachments\09-01.pdf	BPV-17-01-00194696	BPV-17-01-00194698	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5656	GFO FDA 483 Response (2) Jan 15 2015 Update\FedEx Tracking and Letter.pdf	BPV-17-01-00195057	BPV-17-01-00195064	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5657	GFO FDA 483 Response (2) Jan 15 2015 Update\Exhibit 1.pdf	BPV-17-01-00195065	BPV-17-01-00195078	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5658	GFO FDA 483 Response (2) Jan 15 2015 Update\Exhibit 2.pdf	BPV-17-01-00195079	BPV-17-01-00195081	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5659	GFO FDA 483 Response (2) Jan 15 2015 Update\Exhibit 3.pdf	BPV-17-01-00195082	BPV-17-01-00195091	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5660	GFO FDA 483 Response (3) Feb 18 2015 Update\FDA Response Document	BPV-17-01-00195325	BPV-17-01-00195332	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5661	GFO FDA 483 Response (3) Feb 18 2015 Update\Exhibit 1.pdf	BPV-17-01-00195333	BPV-17-01-00195355	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5662	GFO FDA 483 Response (3) Feb 18 2015 Update\Exhibit 2.pdf	BPV-17-01-00195356	BPV-17-01-00195358	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5663	GFO FDA 483 Response (3) Feb 18 2015 Update\Exhibit 3.pdf	BPV-17-01-00195359	BPV-17-01-00195371	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5664	GFO FDA 483 Response (4) Mar 16 2015 Update\FedEx Tracking and Letter.pdf	BPV-17-01-00195511	BPV-17-01-00195521	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5665	GFO FDA 483 Response (4) Mar 16 2015 Update\Exhibit 1.pdf	BPV-17-01-00195522	BPV-17-01-00195541	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5666	GFO FDA 483 Response (4) Mar 16 2015 Update\Exhibit 2.pdf	BPV-17-01-00195542	BPV-17-01-00195544	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5667	GFO FDA 483 Response (4) Mar 16 2015 Update\Exhibit 3.pdf	BPV-17-01-00195545	BPV-17-01-00195560	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5668	GFO FDA 483 Response (5) Apr 17 2015 Update\FedEx Tracking and Letter.pdf	BPV-17-01-00195699	BPV-17-01-00195709	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5669	GFO FDA 483 Response (5) Apr 17 2015 Update\Exhibit 1.pdf	BPV-17-01-00195710	BPV-17-01-00195733	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5670	GFO FDA 483 Response (5) Apr 17 2015 Update\Exhibit 2.pdf	BPV-17-01-00195734	BPV-17-01-00195736	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5671	GFO FDA 483 Response (5) Apr 17 2015 Update\Exhibit 3.pdf	BPV-17-01-00195737	BPV-17-01-00195756	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5672	GFO FDA 483 Response (6) May 6 2015 Update\FedEx Tracking and Letter.pdf	BPV-17-01-00196023	BPV-17-01-00196033	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5673	GFO FDA 483 Response (6) May 6 2015 Update\Exhibit 1.pdf	BPV-17-01-00196034	BPV-17-01-00196056	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5674	GFO FDA 483 Response (6) May 6 2015 Update\Exhibit 2.pdf	BPV-17-01-00196057	BPV-17-01-00196059	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5675	GFO FDA 483 Response (6) May 6 2015 Update\Exhibit 3.pdf	BPV-17-01-00196060	BPV-17-01-00196079	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5676	GFO FDA 483 Response (7) Jun 19 2015 Update\FedEx Tracking and Letter.pdf	BPV-17-01-00196357	BPV-17-01-00196366	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5677	GFO FDA 483 Response (7) Jun 19 2015 Update\Exhibit 1.pdf	BPV-17-01-00196367	BPV-17-01-00196395	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5678	GFO FDA 483 Response (7) Jun 19 2015 Update\Exhibit 2.pdf	BPV-17-01-00196396	BPV-17-01-00196399	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5679	GFO FDA 483 Response (7) Jun 19 2015 Update\Exhibit 3.pdf	BPV-17-01-00196400	BPV-17-01-00196422	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5680	GFO FDA 483 Response (8) July 17 2015 Update\FedEx Tracking and Letter.pdf	BPV-17-01-00199457	BPV-17-01-00199467	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5681	GFO FDA 483 Response (8) July 17 2015 Update\Exhibit 1.pdf	BPV-17-01-00199468	BPV-17-01-00199496	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5682	GFO FDA 483 Response (8) July 17 2015 Update\Exhibit 2.pdf	BPV-17-01-00199497	BPV-17-01-00199500	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5683	GFO FDA 483 Response (8) July 17 2015 Update\Exhibit 3.pdf	BPV-17-01-00199501	BPV-17-01-00199523	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5684	BPV FDA 483 Response Cover letter and response January 26, 2014	BPV-17-01-00199543	BPV-17-01-00199555	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5685	BPV FDA 483 Response 1 - Attachments.pdf	BPV-17-01-00199556	BPV-17-01-00199800	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5686	Jan. 2015 Retrospective Review of Death Complaints	BPV-17-01-00199738	BPV-17-01-00199772	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5687	Jan. 2015 Retrospective Review of Death Complaints (Serious Injury v.	BPV-17-01-00199773	BPV-17-01-00199800	FRE 401; 402; 403; 602; 702;	401; 402; 403; 801; 802;
5688	BPV FDA 483 Response 2 - Attachments.pdf	BPV-17-01-00199801	BPV-17-01-00199868	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5689	BPV FDA 483 Response 3 - Attachments.pdf	BPV-17-01-00199869	BPV-17-01-00199958	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5690	BPV FDA 483 Update Response February 26, 2015.pdf	BPV-17-01-00199959	BPV-17-01-00200155	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5691	BPV FDA 483 Update Response March 26, 2015.pdf	BPV-17-01-00200156	BPV-17-01-00200338	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5692	BPV FDA 483 Update Response April 24, 2015.pdf	BPV-17-01-00200339	BPV-17-01-00200353	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5693	BPV FDA 483 Update Response May 22, 2015.pdf	BPV-17-01-00200354	BPV-17-01-00200370	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5694	BPV FDA 483 Update Response June 25, 2015.pdf	BPV-17-01-00200371	BPV-17-01-00200383	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5695	Bard Warning Letter Response (August 3 2015) 01 Cover Letter.pdf	BPV-17-01-00200384	BPV-17-01-00200390	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5696	Bard Warning Letter Response (August 3 2015) 02 Warning Letter Response.pdf	BPV-17-01-00200391	BPV-17-01-00200451	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5697	Bard Warning Letter Response (August 3 2015) 03 Appendix 0.pdf	BPV-17-01-00200452	BPV-17-01-00200463	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5698	Bard Warning Letter Response (August 3 2015) 04 Appendix 1.pdf	BPV-17-01-00200464	BPV-17-01-00200606	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5699	Bard Warning Letter Response (August 3 2015) 05 Appendix 2.pdf	BPV-17-01-00200607	BPV-17-01-00200636	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5700	Bard Warning Letter Response (August 3 2015) 06 Appendix 3.pdf	BPV-17-01-00200637	BPV-17-01-00200715	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5701	Bard Warning Letter Response (August 3 2015) 10 Appendix 7.pdf	BPV-17-01-00201984	BPV-17-01-00201990	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5702	Bard Warning Letter Response (August 3 2015) 11 Appendix 8.pdf	BPV-17-01-00201991	BPV-17-01-00202163	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5703	October 6 2015 Update Response to Warning Letter Issued July 13 2015.pdf	BPV-17-01-00202253	BPV-17-01-00202341	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5704	September 3 2015 Update Response to Form 483 issued January 5 2015.pdf	BPV-17-01-00202342	BPV-17-01-00202353	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5705	September 3 2015 Update Response to Form 483 issued November 25 2014.pdf	BPV-17-01-00202354	BPV-17-01-00202873	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5706	September 3 2015 Update Response to Warning Letter issued July 13 2015.pdf	BPV-17-01-00202874	BPV-17-01-00203376	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5707	Recovery Cone Materials -- 001 Recovery Cone 510(k) FINAL.pdf	BPV-17-01-00203377	BPV-17-01-00203857	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5708	Recovery Cone Materials -- FW Continued Distribution of the Recovery Cone	BPV-17-01-00203888	BPV-17-01-00203893	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5709	Recovery Cone Materials -- RC15 Customer Letter.pdf	BPV-17-01-00204002	BPV-17-01-00204003	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5710	Recovery Cone Materials -- Recovery Cone Customer Letter.pdf	BPV-17-01-00204004	BPV-17-01-00204006	FRE 401; 402; 403; 602; 702;	401; 402; 403
5711	Recovery® Cone IFU and related documentation	BPV-17-01-00204007	BPV-17-01-00204138	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5712	FDA Submissions and Correspondence Files Regarding Recovery® Cone	BPV-17-01-00204139	BPV-17-01-002040230	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5713	Recovery Cone Materials -- Dr Bilek letter.pdf	BPV-17-01-00204144	BPV-17-01-00204150	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5714	Recovery Cone Materials -- FDA Meeting K152136 Recovery Cone Question	BPV-17-01-00204184	BPV-17-01-00204190	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5715	July 13 2015 FDA Warning Letter to Bard (unredacted)	BPV-17-01-00204231	BPV-17-01-00204243	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5716	October 6 2015 Update Response to 483 Issued November 25 2014.pdf	BPV-17-01-00204244	BPV-17-01-00204480	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5717	November 20 2015 Update Response to Form 483 issued November 25 2014.pdf	BPV-17-01-00205167	BPV-17-01-00205852	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5718	November 20 2015 Update Response to Warning Letter issued July 13 2015.pdf	BPV-17-01-00205853	BPV-17-01-00206168	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5719	Sept. 2015 Retrospective Review re Follow Up	BPV-17-01-00206131	BPV-17-01-00206168	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5720	RE Bard Peripheral Vascular - clarification question.msg	BPV-17-01-00206170	BPV-17-01-00206171	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5721	FDA response letter 121415.pdf	BPV-17-01-00206172	BPV-17-01-00206175	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5722	FDA Warning Letter Materials -- December 22 2015 GFO 483 Update	BPV-17-01-00206782	BPV-17-01-00206981	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5723	FDA Warning Letter Materials -- December 22 2015 WL Update Response.pdf	BPV-17-01-00206982	BPV-17-01-00207267	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5724	Internal Quality Audit Worksheet (attached to FDA WL response Dec. 2015)	BPV-17-01-00207022	BPV-17-01-00207267	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5725	FDA Warning Letter Materials -- Transmittal Letter.pdf	BPV-17-01-00207268	BPV-17-01-00207268	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5726	FDA 483 #2020394 BPV February 2016.PDF	BPV-17-01-00207269	BPV-17-01-00207271	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5727	FDA 483 GFO March 2016.PDF	BPV-17-01-00207272	BPV-17-01-00207274	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5728	Recovery Cone Materials - K152136 Letter SE FINAL Sent001.pdf	BPV-17-01-00207285	BPV-17-01-00207286	FRE 401; 402; 403; 602; 702;	401; 402; 403
5729	Denali Design Input Summary Rev. 2	BPV-17-01-00209120	BPV-17-01-00209268	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5730	Denali 510(k) submission (K130366) -- Narrative Submission.pdf	BPV-17-01-00213103	BPV-17-01-00213188	FRE 401; 402; 403; 602; 702;	401; 402; 407
5731	Denali 510(k) submission (K130366) -- Appendices Part 1.pdf	BPV-17-01-00213189	BPV-17-01-00213688	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5732	Denali 510(k) submission (K130366) -- Appendices Part 2.pdf	BPV-17-01-00213689	BPV-17-01-00214187	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5733	Denali 510(k) submission (K130366) -- Appendices Part 3.pdf	BPV-17-01-00214188	BPV-17-01-00214587	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5734	Denali 510(k) submission (K130366) -- Appendices Part 4.pdf	BPV-17-01-00214588	BPV-17-01-00215017	FRE 401; 402; 403; 602; 702;	401; 402; 407
5735	Denali 510(k) submission (K130366) -- Appendices Part 5.pdf	BPV-17-01-00215018	BPV-17-01-00215973	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5736	Denali 510(k) submission (K130366) -- Appendices Part 6.pdf	BPV-17-01-00215974	BPV-17-01-00216073	FRE 401; 402; 403; 602; 702;	401; 402; 407
5737	Denali 510(k) submission (K130366) -- Appendices Part 7.pdf	BPV-17-01-00216074	BPV-17-01-00216173	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5738	Denali 510(k) submission (K130366) -- Appendices Part 8.pdf	BPV-17-01-00216174	BPV-17-01-00216473	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407; 801;
5739	Denali 510(k) submission (K130366) -- Appendices Part 9.pdf	BPV-17-01-00216474	BPV-17-01-00216873	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407; 801;
5740	Denali 510(k) submission (K130366) -- Appendices Part 10 Section 1.pdf	BPV-17-01-00216874	BPV-17-01-00217094	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407; 801;
5741	Denali 510(k) (K130366) Clearance Letter dated May 15, 2013.pdf	BPV-17-01-00217095	BPV-17-01-00217097	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5742	Denali 510(k) submission (K130366) -- Appendices Part 10 Section 2.pdf	BPV-17-01-00217098	BPV-17-01-00217321	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5743	Denali Special 510(k) (K143208).pdf	BPV-17-01-00217322	BPV-17-01-00217528	FRE 401; 402; 403; 602; 702;	401; 402; 407
5744	Dec. 9, 2014 Denali Clearance Letter (K143208).PDF	BPV-17-01-00217529	BPV-17-01-00217530	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5745	Dec. 30, 2010 IDE for Denali	BPV-17-01-00217546	BPV-17-01-00219372	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5746	Aug. 9, 2011 BPV 5th IDE Supplement	BPV-17-01-00219373	BPV-17-01-00220196	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5747	Oct. 3, 2011 BPV 7th IDE Supplement	BPV-17-01-00220197	BPV-17-01-00220258	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5748	Nov. 11, 2011 BPV 9th IDE Supplement	BPV-17-01-00220259	BPV-17-01-00220290	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5749	Denali Materials -- Clinical Study Materials -- Denali Final Clinical Study	BPV-17-01-00221894	BPV-17-01-00221985	FRE 401; 402; 403; 602; 702;	401; 402; 407
5750	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-	BPV-17-01-00222487	BPV-17-01-00222522	FRE 401; 402; 403; 602; 702;	
5751	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-	BPV-17-01-00222558	BPV-17-01-00222589	FRE 401; 402; 403; Cond.	
5752	G2 DFMEA (Femoral) 070022, Rev. 6	BPV-17-01-00223198	BPV-17-01-00223237	FRE 401; 402; 403; 602; 702;	
5753	G2 DFMEA (Femoral) 070031, Rev. 7	BPV-17-01-00223238	BPV-17-01-00223268	FRE 401; 402; 403; 602; 702;	
5754	DFMEAs -- Exam Key (Parts I & Part II).pdf	BPV-17-01-00223502	BPV-17-01-00223510	FRE 401; 402; 403; 602; 702;	
5755	DFMEAs -- TD-04451 Rev 0.pdf	BPV-17-01-00223511	BPV-17-01-00223607	FRE 401; 402; 403; 602; 702;	
5756	Audit Materials -- Assessment Report 7766817 7737901A.pdf	BPV-17-01-00223608	BPV-17-01-00223627	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5757	Audit Materials -- Assessment Report 78787507864713 9-13-13.pdf	BPV-17-01-00223628	BPV-17-01-00223654	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5758	Audit Materials -- BSI Assessment Report 8043354 9-19-14A.pdf	BPV-17-01-00223655	BPV-17-01-00223673	FRE 401; 402; 403; 801; 802	401; 402; 403; 801; 802
5759	Audit Materials -- AUD-14-11-14 Final Report.pdf	BPV-17-01-00223674	BPV-17-01-00223676	FRE 401; 402; 403; 801; 802	401; 402; 403; 407
5760	Audit Materials -- 2015 BSI Assessment Report.pdf	BPV-17-01-00223677	BPV-17-01-00223696	FRE 401; 402; 403; 801; 802	401; 402; 403; 407
5761	Audit Materials -- AUD-15-12-04 Complaint Audit Final Report.pdf	BPV-17-01-00223697	BPV-17-01-00223699	FRE 401; 402; 403; 801; 802	401; 402; 403; 407
5762	QMBR--April 2014	BPV-17-01-00227622	BPV-17-01-00227697	FRE 401; 402; 403; 801; 802	401; 402; 403; MIL #1
5763	QMBR--Nov. 2014	BPV-17-01-00228135	BPV-17-01-00228203	FRE 401; 402; 403; 801; 802	401; 402; 403; MIL #1
5764	QMBR--May 2015	BPV-17-01-00228633	BPV-17-01-00228713	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5765	QMBR--Oct. 2015	BPV-17-01-00229057	BPV-17-01-00229141	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #1
5766	QMBR--Feb. 2016	BPV-17-01-00229415	BPV-17-01-00229492	FRE 401; 402; 403; 602; 702;	403; MIL #1
5767	May 10, 2013 FDA email to BPV re revised IFU	BPV-17-01-00229493	BPV-17-01-00229494	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5768	April 6, 2013 email from FDA requesting additional information	BPV-17-01-00229495	BPV-17-01-00229498	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5769	Denali Materials -- K130366 FDA Correspondence -- K130366 Femoral IFU FDA	BPV-17-01-00229499	BPV-17-01-00229510	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5770	Denali Materials -- K130366 FDA Correspondence -- K130366 Patient Brochure	BPV-17-01-00229511	BPV-17-01-00229512	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5771	May 6, 2013 email to FDA responding to questions	BPV-17-01-00229537	BPV-17-01-00229613	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5772	Denali Materials -- K130366 FDA Correspondence -- Denali Femoral IFU PE rate	BPV-17-01-00229546	BPV-17-01-00229557	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5773	Denali Materials -- K130366 FDA Correspondence -- Denali Femoral IFU PE rate	BPV-17-01-00229558	BPV-17-01-00229569	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5774	Denali Materials -- K130366 FDA Correspondence -- Denali IFU Clinical	BPV-17-01-00229570	BPV-17-01-00229574	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5775	Denali Materials -- K130366 FDA Correspondence -- Denali Jugular IFU PE rate	BPV-17-01-00229575	BPV-17-01-00229586	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5776	Denali Materials -- K130366 FDA Correspondence -- Denali Jugular IFU PE rate	BPV-17-01-00229587	BPV-17-01-00229598	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5777	April 24, 2013 email to FDA responding to questions	BPV-17-01-00229624	BPV-17-01-00229651	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5778	April 15, 2013 email to FDA responding to questions	BPV-17-01-00229652	BPV-17-01-00229767	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5779	Denali Materials – K130366 FDA Correspondence – Femoral IFU Red-line.pdf	BPV-17-01-00229669	BPV-17-01-00229704	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5780	Denali Materials – K130366 FDA Correspondence – Femoral IFU.pdf	BPV-17-01-00229705	BPV-17-01-00229716	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5781	Denali Materials – K130366 FDA Correspondence – Femoral Label Set.pdf	BPV-17-01-00229717	BPV-17-01-00229717	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5782	Denali Materials – K130366 FDA Correspondence – Jugular IFU Red-line.pdf	BPV-17-01-00229718	BPV-17-01-00229750	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5783	Denali Materials – K130366 FDA Correspondence – Jugular IFU.pdf	BPV-17-01-00229751	BPV-17-01-00229762	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5784	Denali Materials – K130366 FDA Correspondence – Jugular Label Set.pdf	BPV-17-01-00229763	BPV-17-01-00229763	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5785	Denali Materials – K130366 FDA Correspondence – Patient Brochure and Implant	BPV-17-01-00229764	BPV-17-01-00229767	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5786	May 6, 2013 email to FDA responding to questions	BPV-17-01-00229784	BPV-17-01-00229799	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5787	Denali Materials – K130366 FDA Correspondence – Femoral IFU FDA 050213.pdf	BPV-17-01-00229788	BPV-17-01-00229799	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5788	May 8, 2013 email to FDA with redlined IFU	BPV-17-01-00229823	BPV-17-01-00229838	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5789	Denali Materials – K130366 FDA Correspondence – Denali IFU Clinical	BPV-17-01-00229834	BPV-17-01-00229838	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5790	May 14, 2013 emails with FDA re animal study description in 510(k) summary	BPV-17-01-00229839	BPV-17-01-00229853	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5791	May 10, 2013 email to FDA with revised 510(k) summary	BPV-17-01-00229854	BPV-17-01-00229868	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5792	April 15, 2013 email to FDA responding to questions	BPV-17-01-00229894	BPV-17-01-00229998	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5793	March 14-19 emails with FDA re Denali 510(k)	BPV-17-01-00230014	BPV-17-01-00230021	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5794	Denali Materials – Clinical Study Materials – Denali Final Clinical Study	BPV-17-01-00230031	BPV-17-01-00230122	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5795	Feb. 16, 2011 BPV IDE Supplement #1 appendices	BPV-17-01-00230123	BPV-17-01-00230269	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5796	Feb. 16, 2011 BPV IDE Supplement #1	BPV-17-01-00230270	BPV-17-01-00230281	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5797	Jan. 31, 2012 IDE Annual Report	BPV-17-01-00230629	BPV-17-01-00230644	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5798	Nov. 13, 2012 BPV 13th IDE Supplement	BPV-17-01-00230655	BPV-17-01-00230749	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5799	March 1, 2013 BPV response to FDA questions re annual IDE report	BPV-17-01-00230755	BPV-17-01-00230831	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5800	Jan. 10, 2013 BPV Annual IDE Report	BPV-17-01-00230832	BPV-17-01-00230904	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5801	Jan. 30, 2014 BPV IDE Annual Report	BPV-17-01-00230921	BPV-17-01-00230999	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5802	Jan. 30, 2015 BPV Annual IDE Report	BPV-17-01-00231017	BPV-17-01-00231170	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5803	Jan. 29, 2016 BPV IDE Final Annual Report	BPV-17-01-00231188	BPV-17-01-00231623	FRE 401; 402; 403; 602; 702;	401; 402; 403
5804	Sept. 9, 2011 FDA letter conditional approval of IDE	BPV-17-01-00231734	BPV-17-01-00231736	FRE 401; 402; 403; 602; 702;	401; 402; 403
5805	Feb. 7, 2013 FDA Letter with questions re IDE annual report	BPV-17-01-00231737	BPV-17-01-00231739	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5806	March 17, 2011 FDA letter with conditional approval of IDE	BPV-17-01-00231740	BPV-17-01-00231741	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5807	Dec. 14, 2012 FDA Letter approving IDE change	BPV-17-01-00231742	BPV-17-01-00231746	FRE 401; 402; 403; 602; 702;	401; 402; 403
5808	Feb. 16, 2016 FDA email re final IDE and annual report	BPV-17-01-00231748	BPV-17-01-00231749	FRE 401; 402; 403; 602; 702;	401; 402; 403
5809	Feb. 26, 2016 FDA letter closing Denali IDE	BPV-17-01-00231750	BPV-17-01-00231750	FRE 401; 402; 403; 602; 702;	401; 402; 403
5810	Feb. 18, 2016 BPV email responding to questions of Feb. 16	BPV-17-01-00231751	BPV-17-01-00231756	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5811	Audit Materials – Bard PV Re-assessment Report 10-19-2010.pdf	BPV-17-01-00234048	BPV-17-01-00234063	FRE 401; 402; 403; 602; 702;	401; 402; 403
5812	Audit Materials – Assessment Report 7597321B 12-15-11.pdf	BPV-17-01-00234064	BPV-17-01-00234078	FRE 401; 402; 403; 801; 802	401; 402; 403
5813	Audit Materials – AUD-16-03-02 Complaint Files Internal Audit Report	BPV-17-01-00234079	BPV-17-01-00234083	FRE 401; 402; 403; 801; 802	401; 402; 403
5814	BPV Response - March 11, 2016.pdf	BPV-17-01-00234084	BPV-17-01-00234190	FRE 401; 402; 403; 801; 802	401; 402; 403; MIL #3
5815	483 Response March 22, 2016.pdf	BPV-17-01-00234191	BPV-17-01-00234264	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5816	RE BPV 483 Response.msg	BPV-17-01-00234266	BPV-17-01-00234271	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5817	Additional materials related to the FDA Warning Letter and 483s	BPV-17-01-00234310	BPV-17-01-00234394	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3
5818	BPV 483 Response Update 20160414.pdf	BPV-17-01-00234378	BPV-17-01-00234394	FRE 401; 402; 403; 602; 702;	401; 402; 403; MIL #3;
5819	Denali (Femoral) 2011.08 - PK5410500 rev. 1 IFU	BPV-17-01-00236429	BPV-17-01-00236436	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5820	Denali (Femoral) 2012.02 - PK5410500 rev. 2 IFU	BPV-17-01-00236437	BPV-17-01-00236446	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5821	Denali (Femoral) 2013.03 - PK5410500 rev. 3 IFU	BPV-17-01-00236447	BPV-17-01-00236458	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5822	Denali (Femoral) 2013.04 - PK5410500 rev. 4 IFU	BPV-17-01-00236459	BPV-17-01-00236470	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5823	Denali (Jugular) 2011.08 - PK5380500 rev. 1 IFU	BPV-17-01-00236471	BPV-17-01-00236478	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5824	Denali (Jugular) 2012.02 - PK5380500 rev. 2 IFU	BPV-17-01-00236479	BPV-17-01-00236490	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5825	Denali (Jugular) 2013.03 - PK5380500 rev. 3 IFU	BPV-17-01-00236490	BPV-17-01-00236502	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5826	Denali (Jugular) 2013.04 - PK5380500 rev. 4 IFU	BPV-17-01-00236503	BPV-17-01-00236514	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5827	G2X (Femoral) 2008.06 - PK5100060 rev. 1 IFU	BPV-17-01-00236515	BPV-17-01-00236526	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5828	Meridian (Femoral) 2013.02 - PK5372100 rev. 5 IFU	BPV-17-01-00236551	BPV-17-01-00236562	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5829	Meridian (Jugular) 2013.02 - PK5372400 rev. 4 IFU	BPV-17-01-00236563	BPV-17-01-00236574	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5830	Denali Materials – Clinical Study Materials – Audits – Denali audit March 2013.pdf	BPV-17-01-00236637	BPV-17-01-00236641	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407
5831	Denali Materials – Clinical Study Materials – Audits – Denali audit September 2011.pdf	BPV-17-01-00236642	BPV-17-01-00236644	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407;
5832	Denali Materials – Clinical Study Materials – Audits – Denali site Audit.pdf	BPV-17-01-00236645	BPV-17-01-00236650	FRE 401; 402; 403; 602; 702;	401; 402; 403; 407;

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5833	Establishment Inspection Reports (EIRs) – AUD-14-02-01 EIR Feb 2014.pdf	BPV-17-01-00237045	BPV-17-01-00237050	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5834	Establishment Inspection Reports (EIRs) – FDA Establishment Inspection Report Dated 2.19.16.pdf	BPV-17-01-00237051	BPV-17-01-00237086	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5835	FDA Warning Letter Materials – BPV 483 Response Update 20160527.pdf	BPV-17-01-00237087	BPV-17-01-00237120	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3;
5836	FDA Warning Letter Materials – Signed Final - Cover and Response to FDA's 5-25-16 Letter.pdf	BPV-17-01-00237121	BPV-17-01-00237126	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3;
5837	SNF Materials – K963014 Clearance Letter.pdf	BPV-17-01-00237177	BPV-17-01-00237178	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
5838	SNF Materials – K970099 Clearance Letter.pdf	BPV-17-01-00237179	BPV-17-01-00237181	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
5839	SNF Materials – All Filter Data 8-20-12 Draft.xls	BPV-17-01-00237456	BPV-17-01-00237456	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5840	SNF Materials – Competitor Rate Analysis.xls 8-22-12.xls	BPV-17-01-00237457	BPV-17-01-00237457	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5841	SNF Materials – Filter Analysis 8-23-12.PPTX	BPV-17-01-00237458	BPV-17-01-00237458	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5842	FDA Warning Letter Materials – Feb. 3, 2016 updated response to Warning Letter	BPV-17-01-00237516	BPV-17-01-00237884	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3;
5843	FDA Warning Letter Materials – May 25, 2016 Letter from FDA with follow-up re Warning Letter	BPV-17-01-00237885	BPV-17-01-00237887	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5844	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-24 Rev 9.pdf	BPV-17-01-00237888	BPV-17-01-00238002	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5845	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-24 Rev 10.pdf	BPV-17-01-00238003	BPV-17-01-00238114	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5846	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-24 Rev 11.pdf	BPV-17-01-00238115	BPV-17-01-00238233	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5847	Standard Operating Procedures / Division Operating Procedures -- CQA-STD-54 Rev 3.pdf	BPV-17-01-00238234	BPV-17-01-00238304	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5848	G2 DFMEA (G2 Jugular) 070021, Rev. 10	BPV-17-01-00261441	BPV-17-01-00261441	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5849	SOPN0700120 Rev 13.docx	BPV-17-01-00261442	BPV-17-01-00261468	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5850	SOPN0700120 Rev 14.docx	BPV-17-01-00261469	BPV-17-01-00261494	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5851	TD-04698 Re_Retrospective IVC Filter Review.pdf	BPV-17-01-00261496	BPV-17-01-00261505	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3;
5852	FDA Communications -- FDA Ltr Denali IVC Filter 9.28.16.pdf	BPV-17-01-00261506	BPV-17-01-00261508	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5853	FDA Communications -- FDA Ltr Denali -Juglar Sub Del Sys 9.28.16.pdf	BPV-17-01-00261509	BPV-17-01-00261511	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5854	FDA Communications -- 001_SimonNitinolFilterSystem_PS140002.pdf	BPV-17-01-00261512	BPV-17-01-00261512	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
5855	FDA Communications -- PS140002A7 - Bard Peripheral Perivascular - email receipt.msg	BPV-17-01-00261513	BPV-17-01-00261514	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
5856	FDA Communications -- RE PRESERVE - please provide contact for SAEs.msg	BPV-17-01-00261515	BPV-17-01-00261521	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
5857	FDA Communications -- 001_Denali Special 510(k).pdf	BPV-17-01-00261522	BPV-17-01-00261590	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5858	FDA Communications -- Acceptance Review From FDA.pdf	BPV-17-01-00261591	BPV-17-01-00261591	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5859	FDA Communications -- FDA Decision Letter - Bard Peripheral Perivascular - PS140002A7.msg	BPV-17-01-00261592	BPV-17-01-00261592	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5860	FDA Communications -- PS140002.A7 - OTHER2 - 8.3.16.pdf	BPV-17-01-00261593	BPV-17-01-00261594	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5861	FDA Communications -- FW K160866 Review Complete.msg	BPV-17-01-00261595	BPV-17-01-00261595	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5862	FDA Communications -- K160866.510kSummary.Final_Sent001.pdf	BPV-17-01-00261596	BPV-17-01-00261598	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5863	FDA Communications -- K160866.IFU.FINAL_Sent001.pdf	BPV-17-01-00261599	BPV-17-01-00261599	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5864	FDA Communications -- K160866.Letter.SE.FINAL_Sent001.pdf	BPV-17-01-00261600	BPV-17-01-00261601	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5865	FDA Communications -- RE K160866 Special 510(k) to add 2-year study data to label (1).msg	BPV-17-01-00261602	BPV-17-01-00261603	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
5866	FDA Communications -- Femoral IFU Redlined.docx	BPV-17-01-00261604	BPV-17-01-00261621	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5867	FDA Communications -- RE K160866 Special 510(k) to add 2-year study data to label (2).msg	BPV-17-01-00261622	BPV-17-01-00261626	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5868	FDA Communications -- Femoral IFU Updated Redlines.docx	BPV-17-01-00261627	BPV-17-01-00261643	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5869	FDA Communications -- RE K160866 Special 510(k) to add 2-year study data to label (3).msg	BPV-17-01-00261644	BPV-17-01-00261646	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5870	FDA Communications -- Femoral IFU FDA comments.docx	BPV-17-01-00261647	BPV-17-01-00261664	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5871	FDA Communications -- RE K160866 Special 510(k) to add 2-year study data to label.msg	BPV-17-01-00261665	BPV-17-01-00261669	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5872	FDA Warning Close Out Letter	BPV-17-01-00261679	BPV-17-01-00261680	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5873	FDA Establishment Inspection Report EIR (01/05/2015)	BPV-17-01-00261714	BPV-17-01-00261739	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5874	Bard filter rate information December 2016	BPV-17-01-00261741	BPV-17-01-00261741	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	MIL #1
5875	Bard filter rate information December 2016	BPV-17-01-00261742	BPV-17-01-00261742	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	MIL #1
5876	COOKFOIA Materials downloaded from Cook Medical IVC Filter Litigation PACER Docket (FDA Price Memos)	BPV-17-01-00262219	BPV-17-01-00262449	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5877	1996 Memo from Veronica Price	BPV-17-01-00262283	BPV-17-01-00262292	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5878	2004 Memo from Veronica Price	BPV-17-01-00262399	BPV-17-01-00262408	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5879	April 11, 2006 Letter to FDA re Caudal Migration	BPV-COMP-00004805	BPV-COMP-00004817	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 601; 602; 801; 802; MIL #1
5880	March 23, 2006 Letter to FDA re G2 Caudal Migration	BPV-COMP-TW-00000716	BPV-COMP-TW-00000717	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 601; 602; 801; 802; MIL #1
5881	May 11, 2006 Letter to FDA re Caudal Migration	BPV-COMP-TW-00000797	BPV-COMP-TW-00000799	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 601; 602; 801; 802; MIL #1
5882	May 12, 2004 Email from Carr re RNF jigs	BPVE-01-00009906	BPVE-01-00009907	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5883	July 26, 2005 Conference FDA and BPV re Modified Recovery (K050558)	BPVE-01-00034138	BPVE-01-00034138	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5884	May, 27, 2005 Conference FDA and BPV re Modified Recovery (K050558)	BPVE-01-00034167	BPVE-01-00034168	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5885	Conference between BPV and FDA regarding K050558	BPVE-01-00081180	BPVE-01-00081181	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5886	Aug. 29, 2005 Email BPV to FDA re G2 (K050558)	BPVE-01-00154718	BPVE-01-00154723	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5887	Aug. 19, 2005 Email BPV to FDA re G2 (K050558)	BPVE-01-00155084	BPVE-01-00155088	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5888	July 28, 2005 Conference FDA and BPV re AI re Modified Recovery (K050558)	BPVE-01-00155254	BPVE-01-00155255	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5889	Aug. 22, 2005 Email BPV to FDA re G2 (K050558)	BPVE-01-00155392	BPVE-01-00155396	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5890	G2 IFU PK5100030, Rev. 0 05/08 (Femoral)	BPVE-01-00156395	BPVE-01-00156398	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5891	July 27, 2005 Email chain BPV and FDA re Modified Recovery (K050558)	BPVE-01-00157774	BPVE-01-00157777	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5892	Email from BPV to FDA regarding K050558	BPVE-01-00155084	BPVE-01-00155091	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5893	Conference between FDA and BPV regarding K050558	BPVE-01-00034167	BPVE-01-00034168	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5894	Email from BPV to FDA K050558	BPVE-01-00155392	BPVE-01-00155400	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5895	Email from BPV to FDA regarding K050558	BPVE-01-00155510	BPVE-01-00155522	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5896	Conference between BPV and FDA regarding K050558	BPVE-01-00155254	BPVE-01-00155255	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5897	Email chain between BPV and FDA regarding K050558	BPVE-01-00157774	BPVE-01-00157777	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5898	Conference between BPV and FDA regarding K050558	BPVE-01-00156137	BPVE-01-00156141	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5899	July 26, 2005 Contact Report, BPV and FDA regarding K050558	BPVE-01-00159552	BPVE-01-00159552	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5900	Oct. 21, 2005 Conference FDA and BPV re G2 Everest Study (G051034) and future submission	BPVE-01-00275704	BPVE-01-00275704	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5901	ETR-04-03-10 (RNF Characterization testing Migration Resistance when Legs are Crossed or Hooks Removed)	BPVE-01-00276108	BPVE-01-00276118	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5902	Article Entitled "US FDA Clinical Data Summary of the Simon Nitinol Filter Article Entitled "US FDA Clinical Data Summary of the Simon Nitinol Filter	BPVE-01-00280772	BPVE-01-00280787	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5903	Email from BPV to FDA regarding K031328 and DCL	BPVE-01-00290753	BPVE-01-00290753	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5904	Jan. 22, 2005 Email from BPV to FDA re DCL and Recovery Retrievable (K031328)	BPVE-01-00303306	BPVE-01-00303318	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5905	March 24, 2005, Meeting with FDA Agenda	BPV-17-01-00039306	BPV-17-01-00039308	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5906	PPT with Summary of Design Modifications for G2 PPT with Summary of Design Modifications for G2	BPVE-01-00324256	BPVE-01-00324262	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5907	PPT Entitled Recovery Filter Design Enhancements (re G2)	BPVE-01-00324300	BPVE-01-00324317	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5908	G2 IFU PK5100030, Rev. 1 05/08 (Femoral)	BPVE-01-00364587	BPVE-01-00364590	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5909	ETR-04-03-18 (RNF Characterization testing of Migration Resistance when Filter is Tilted)	BPVE-01-00375842	BPVE-01-00375847	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5910	Email from Benware to Hudson, Carr (cc to Fitzpatrick) enclosing final Starguide Report	BPVE-01-00414580	BPVE-01-00414586	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5911	EPRO-02-01 (BPT SOP re DFMEA)	BPVE-01-00424142	BPVE-01-00424154	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5912	Testing PPT re Migration Testing in 2004	BPVE-01-00424853	BPVE-01-00424898	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5913	June 9, 2005 email with Dear Colleague Letter Tracking Chart	BPVE-01-00427547	BPVE-01-00427620	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5914	June 7, 2005 email with Dear Colleague Letter Tracking Chart	BPVE-01-00428174	BPVE-01-00428176	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5915	May 11, 2005 Dear Colleague Letter	BPVE-01-00429852	BPVE-01-00429854	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5916	Dear Colleague Letter DCL Tracking Chart	BPVE-01-00430092	BPVE-01-00430161	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5917	Data Chart used by Natalie Wong in May 2004 email chain with Doug Uelmen regarding draft data set for statistician	BPVE-01-00435200	BPVE-01-00435201	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5918	May 27, 2004 Email chain between Natalie Wong and Doug Uelmen regarding draft data set for statistician	BPVE-01-00436072	BPVE-01-00436076	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5919	U.S. Patent No. US 6,258,026 B1 for "Removable Embolus Blood Clot Filter and Filter Delivery Unit", submitted by Ravenscroft et al., dated 7/10/2001	BPVE-01-00503712	BPVE-01-00503720	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5920	Reformatted version of the data chart used by Natalie Wong in May 2004 email chain with Doug Uelment regarding draft data set for statistician.	BPVE-01-00511131	BPVE-01-00511132	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
5921	Graphs and statistical summary forwarded to Doug Uelmen by Natalie Wong in May 2004 email chain.	BPVE-01-00511142	BPVE-01-00511143	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5922	Dec. 9, 2004 email re Dear Doctor Letter	BPVE-01-00531407	BPVE-01-00531408	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5923	September 2010 Letter to Clinicians re FDA PHN	BPVE-01-00582009	BPVE-01-00582009	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5924	Sept 2, 2010 Bard Filter Clinical Overview to Sales Force (Cover Letter Packet)	BPVE-01-00602630	BPVE-01-00602670	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5925	G2X IFU (Jugular) 2008.07 - PK5100070 rev. 1	BPVE-01-00635351	BPVE-01-00635362	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5926	G2X IFU (Jugular) 2009.06 - PK5100070 rev. 4	BPVE-01-00678895	BPVE-01-00678906	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5927	G2 Risk Benefit Analysis (RBA-0003, Rev. 2)	BPVE-01-00687949	BPVE-01-00687954	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5928	TP-07-12-01 (DV& V Flat Plate Fatigue and Corrosion Examination Test Protocol G2 Express Filter)	BPVE-01-00689527	BPVE-01-00689536	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5929	TR-07-12-01 (Test Report re G2 Express DV& V Flat Plate Fatigue and Corrosion)	BPVE-01-00689537	BPVE-01-00689554	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5930	TM1141300 (Filter Wire Weld Tensile Strength Testing)	BPVE-01-00738469	BPVE-01-00738475	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5931	G2X (Jugular) 2009.10 - PK5100070 rev. 5 IFU	BPVE-01-00738603	BPVE-01-00738626	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5932	QMBR--Jan. 2011	BPVE-01-00752804	BPVE-01-00752862	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5933	April 24, 2009 email noting withdrawal of G2® Expand 510(k)	BPVE-01-00756463	BPVE-01-00756463	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5934	TP 07-02-12 (Flat Plate Fatigue Testing Protocol)	BPVE-01-00769120	BPVE-01-00769127	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5935	TD-00275 (Comparison of Nonsymmetrical Loading on the G2 Filter Device in Two Orientations Using FEA by William James Harrison, WJH Engineering)	BPVE-01-00817105	BPVE-01-00817112	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5936	TD-00468 (G2 Flat Plate Baseline Characterization Test Analysis of Detached Arm)	BPVE-01-00817119	BPVE-01-00817121	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5937	TD-00192 (Product Comparisons through Finite Element Analysis and Testing by William James Harrison, WJH Engineering)	BPVE-01-00818418	BPVE-01-00818444	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5938	April 3, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-00958858	BPVE-01-00958859	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5939	March 31, 2006 Meeting Minutes re G2 caudal migration	BPVE-01-00958862	BPVE-01-00958865	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5940	PowerPoint slide regarding filter failure investigations	BPVE-01-00987656	BPVE-01-00987656	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5941	April 11, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01023545	BPVE-01-01023547	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5942	January 7, 2010 FDA PowerPoint Presentation	BPVE-01-01-059923	BPVE-01-01-059923	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5943	Filters Complaint History PPT	BPVE-01-01081449	BPVE-01-01081468	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5944	June 25, 2004 Multidisciplinary Focus Group Meeting Summary	BPVE-01-01089531	BPVE-01-01089535	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5945	April 2006 letter to FDA re G2 caudal migration	BPVE-01-01189125	BPVE-01-01189126	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5946	QMBR--July 2006	BPVE-01-01247634	BPVE-01-01247733	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5947	QMBR--Dec. 2005	BPVE-01-01251390	BPVE-01-01251428	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5948	April 1, 2009 letter from FDA requesting additional information re G2® for prophylactic indication	BPVE-01-01288903	BPVE-01-01288906	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5949	ETR-06-05-02 (Test report re G2® Clot Trapping Efficiency)	BPVE-01-01341174	BPVE-01-01341187	FRE 401; 402; 403; Cond.	
5950	TP-07-07-04 (G2® Express Filter Arm Fatigue Comparison Study)	BPVE-01-01366605	BPVE-01-01366609	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5951	Nov. 16, 2010 email to FDA enclosing fatigue testing info re Meridian	BPVE-01-01404251	BPVE-01-01404291	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5952	QMBR--Jan. 2007	BPVE-01-01514237	BPVE-01-01514293	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5953	TR-07-08-16 (G2® Express Acute GLP Animal Study Report)	BPVE-01-01558318	BPVE-01-01558336	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5954	June 30, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01655405	BPVE-01-01655405	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5955	May 9, 2006 Email from Natalie Wong to Brian Hudson forwarding responses to FDA requests for information.	BPVE-01-01656254	BPVE-01-01656263	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5956	June 12, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01656285	BPVE-01-01656286	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5957	June 21, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01656342	BPVE-01-01656343	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5958	March 3, 2006 Caudal Migration Meeting Minutes	BPVE-01-01656463	BPVE-01-01656465	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5959	April 18, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01656607	BPVE-01-01656609	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5960	April 28, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01658660	BPVE-01-01658661	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5961	May 18, 2006 G2 Caudal Migration Meeting Minutes	BPVE-01-01658763	BPVE-01-01658764	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5962	TD-00060 (formerly ETR-04-05-06) (RNF Characterization testing of Migration Resistance in Oval and D shaped IVC)	BPVE-01-01692728	BPVE-01-01692763	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5963	November 20, 2008 Presentation entitled "G2 and G2X Fracture Analysis"	BPVE-01-01750592	BPVE-01-01750610	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5964	TM1141700 (Filter Flat Plate Fatigue Test Method)	BPVE-01-01785500	BPVE-01-01785516	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5965	QMBR--Feb. 2008	BPVE-01-01823827	BPVE-01-01823868	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5966	Oct. 26, 2010 Letter from FDA to BPV re Meridian Jugular (K102511)	BPVE-01-01977697	BPVE-01-01977704	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5967	G2 Risk Benefit Analysis (RBA-0003, Rev. 0)	BPVE-01-01981272	BPVE-01-01981274	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5968	Meridian (Jugular) 2010.10 - PK5372400 rev. 0 IFU	BPVE-01-02030224	BPVE-01-02030235	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5969	Email chain with McDermott and Allen re G2 Investigators Meeting and Sale of RNF and G2	BPVEFILTER-01-00001808	BPVEFILTER-01-00001808	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	403; 801; 802
5970	HHE re G2 Caudal Migration February 15, 2006	BPVEFILTER-01-00008355	BPVEFILTER-01-00008357	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5971	February 8, 2006 Email re Micky Graves	BPVEFILTER-01-00010053	BPVEFILTER-01-00010055	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901
5972	Feb. 12, 2004 email re sales communique and rate information	BPVEFILTER-01-00010245	BPVEFILTER-01-00010289	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5973	Feb. 1, 2011 Letter from FDA to BPV re Meridian Jugular (K102511)	BPVEFILTER-01-00016497	BPVEFILTER-01-00016501	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5974	Complication Rate Chart	BPVEFILTER-01-00037664		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901; MIL #1
5975	QMBR Jan. 2010	BPVEFILTER-01-00043094	BPVEFILTER-01-00043094	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5976	QMBR Feb. 2009	BPVEFILTER-01-00043106	BPVEFILTER-01-00043106	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5977	QMBR May 2011	BPVEFILTER-01-00043457	BPVEFILTER-01-00043457	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
5978	QMBR April 2012	BPVEFILTER-01-00043466	BPVEFILTER-01-00043466	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5979	QMBR Sept. 2012	BPVEFILTER-01-00043467	BPVEFILTER-01-00043467	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
5980	Eclipse (Jugular) 2010.02 - PK5100700 rev. 1 IFU	BPVEFILTER-01-00050423	BPVEFILTER-01-00050434	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5981	G2X (Jugular) 2009.03 - PK5100100 rev. 0 IFU	BPVEFILTER-01-00050447	BPVEFILTER-01-00050458	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5982	Complication Rate Chart (2010) – page from BPVEFILTER-01-00050487	BPVEFILTER-01-00050487	BPVEFILTER-01-00050487	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5983	EVEREST Adjudication Manual of Operations	BPVEFILTER-01-00051397	BPVEFILTER-01-00051464	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5984	TPR-06-05-02 (SOP re G2® Clot Trapping Efficiency)	BPVEFILTER-01-00079006	BPVEFILTER-01-00079013	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5985	Meridian (Jugular) 2011.08 - PK5372400 rev. 3 IFU	BPVEFILTER-01-00106442	BPVEFILTER-01-00106454	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
5986	May 17, 2011 PPT to FDA re Meridian®	BPVEFILTER-01-00136505		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5987	May 17, 2011 PPT to FDA re Meridian	BPVEFILTER-01-00136505	BPVEFILTER-01-00136505	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5988	Filters Complaint History PPT	BPVEFILTER-01-00206819	BPVEFILTER-01-00206819	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
5989	FM1287100 Rev. 0 (MDR Reportability Guidelines)	BPVEFILTER-01-00220237	BPVEFILTER-01-00220251	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5990	FM1287100 Rev. 2 (MDR Reportability Guidelines)	BPVEFILTER-01-00223960	BPVEFILTER-01-00223974	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5991	FM1287100 Rev. 5 (MDR Reportability Guidelines)	BPVEFILTER-01-00224213	BPVEFILTER-01-00224222	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5992	FM1287100 Rev. 1 (MDR Reportability Guidelines)	BPVEFILTER-01-00263062	BPVEFILTER-01-00263074	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5993	TD-04382 Rev. 1 (List of Actions for MDR and Complaint Handling in Response to WL and 483)	BPVEFILTER-01-00263396	BPVEFILTER-01-00263407	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5994	TD-04316 Nov. 4, 2015 FDA and Bard Teleconference	BPVEFILTER-01-00263409	BPVEFILTER-01-00263418	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5995	TD-04326 Oct. 26, 2015 FDA and Bard Teleconference	BPVEFILTER-01-00263419	BPVEFILTER-01-00263422	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #3
5996	FM1287100 Rev. 3 (MDR Reportability Guidelines)	BPVEFILTER-01-00264236	BPVEFILTER-01-00264250	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5997	FM1287100 Rev. 0 (MDR Reportability Guidelines)	BPVEFILTER-01-00264871	BPVEFILTER-01-00264885	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
5998	Feb. 1, 2011 FDA Conditional Approval of IDE with 31 questions	BPVEFILTER-01-00367553	BPVEFILTER-01-00367563	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
5999	August 2010 Letter to Clinicians re FDA PHN	BPVEFILTER-01-00496214	BPVEFILTER-01-00496214	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6000	March 21, 2011 email from FDA re Questions 18 and 24	BPVEFILTER-01-00703650	BPVEFILTER-01-00703657	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6001	May 5, 2010 email enclosing PPT slides for meeting	BPVEFILTER-01-00703843	BPVEFILTER-01-00703877	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6002	Filters Complaint History PPT	BPVEFILTER-01-01081449	BPVEFILTER-01-01081449	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6003	May 13, 2010 email and meeting minutes re Denali Pre-IDE	BPVEFILTER-01-01110191	BPVEFILTER-01-011101916	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6004	Sept. 30, 2011 email to FDA enclosing responses to AI (K112497)	BPVEFILTER-01-01138155	BPVEFILTER-01-01138155	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6005	March 19, 2010 email to FDA enclosing Denali Pre-IDE	BPVEFILTER-01-01138499	BPVEFILTER-01-01138571	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6006	June 16, 2011 email from custodial file of Joni Creal with Appendix 1-6	BPVEFILTER-01-01138842	BPVEFILTER-01-01138951	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6007	March 16, 2011 email confirming FDA re biocompatibility	BPVEFILTER-01-01141999	BPVEFILTER-01-01142002	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6008	Nov. 3, 2011 letter from FDA requesting more info	BPVEFILTER-01-01153526	BPVEFILTER-01-01153528	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6009	June 27, 2011 email from custodial file of Joni Creal with Appendix 14 Part A	BPVEFILTER-01-01156092	BPVEFILTER-01-01156185	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6010	Dec. 10, 2010 email to FDA confirming Denali regulatory strategy	BPVEFILTER-01-01165336	BPVEFILTER-01-01165336	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6011	Feb. 22, 2011 email to FDA re biocompatibility questions 27-31	BPVEFILTER-01-01166624	BPVEFILTER-01-01166624	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6012	Dec. 4, 2012 email and attachment to FDA responding to informal questions	BPVEFILTER-01-01170973	BPVEFILTER-01-01170977	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6013	Dec. 27, 2010 Letter from BPV to FDA re Meridian	BPVEFILTER-01-01201729	BPVEFILTER-01-01201779	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6014	March 11, 2011 email to FDA with proposed response to Nos. 18 and 24	BPVEFILTER-01-01205839	BPVEFILTER-01-01205845	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6015	Feb. 22, 2011 email with FDA re chromosomal aberration testing (Question 3 from Feb. 1 letter)	BPVEFILTER-01-01853704	BPVEFILTER-01-01853705	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6016	Nov. 5, 2015 email to Chad Modra re FDA and MDRs	BPVEFILTER-07-00088570	BPVEFILTER-07-00088570	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6017	Dec. 3, 2009 Meridian Pre-IDE Meeting Request	BPVEFILTER-08-00026072	BPVEFILTER-08-00026125	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6018	May 20-23, 2011 email chain re deficiencies 8 and 9	BPVEFILTER-08-00065051	BPVEFILTER-08-00065053	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6019	June 27, 2011 email from custodial file of Joni Creal with Appendix 3-5	BPVEFILTER-08-00074784	BPVEFILTER-08-00074827	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6020	22 -- - June 27, 2011 email from custodial file of Joni Creal with Appendix 1 & 2	BPVEFILTER-08-00075953	BPVEFILTER-08-00076043	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6021	May 23, 2011 Letter to FDA re Meridian FDA Questions Feb. 1, 2011 Nos 1-7, 10-13	BPVEFILTER-08-00076994	BPVEFILTER-08-00077147	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6022	May 23, 2011 Letter to FDA (Appendix 6)	BPVEFILTER-08-00077067	BPVEFILTER-08-00077067	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6023	May 23, 2011 Letter from BPV to FDA (Appendix 8)	BPVEFILTER-08-00077146	BPVEFILTER-08-00077146	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6024	May 23, 2011 Letter from BPV to FDA (Appendix 8)	BPVEFILTER-08-00076994	BPVEFILTER-08-00077147	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6025	August 17, 2011 email with FDA re Meridian IFU changes	BPVEFILTER-08-00077841	BPVEFILTER-08-00077854	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6026	June 27, 2011 email from custodial file of Joni Creal with Appendix 12 & 13	BPVEFILTER-08-00080312	BPVEFILTER-08-00080407	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6027	June 27, 2011 email from custodial file of Joni Creal with Appendix 10 & 11	BPVEFILTER-08-00081986	BPVEFILTER-08-00082031	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6028	Native Attachment	BPVEFILTER-08-00081986	BPVEFILTER-08-00081986	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6029	June 27, 2011 email from custodial file of Joni Creal with Appendix 8 & 9	BPVEFILTER-08-00083555	BPVEFILTER-08-00083592	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6030	24 -- - June 27, 2011 email from custodial file of Joni Creal with Appendix 6 & 7	BPVEFILTER-08-00085241	BPVEFILTER-08-00085294	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6031	Dec. 27, 2010 Appendices to Letter to FDA	BPVEFILTER-11-00002394	BPVEFILTER-11-00002960	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6032	RNF Filter Drawing SA-0030, Rev. 00	BPVEFILTER-11-00027120	BPVEFILTER-11-00027120	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6033	NMT Table of Contents for RNF Design History File Phase II (Arms Up)	BPVEFILTER-11-00224944	BPVEFILTER-11-00224947	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6034	December 20, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page	BPVEFILTER-11-00237600	BPVEFILTER-11-00237600	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6035	August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes Signature Page	BPVEFILTER-11-00237601	BPVEFILTER-11-00237601	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6036	June 7, 2010 FDA Contact Report (Denali Pre-IDE Meeting)	BPVEFILTER-11-00254025	BPVEFILTER-11-00254027	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6037	Nov. 5, 2015 email to Chad Modra re FDA and MDRs	BPVEFILTER-13-00000701	BPVEFILTER-13-00000703	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6038	Nov. 30, 2015 email chain with FDA re MDR Reporting	BPVEFILTER-13-00001127	BPVEFILTER-13-00001130	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6039	TM1139500 Caudal Migration Push Test Method	BPVEFILTER-15-00006980	BPVEFILTER-15-00006991	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6040	TM1139200 Rev 0, In Vitro Filter Clot Trapping Efficiency Test Method	BPVEFILTER-20-00039633	BPVEFILTER-20-00039643	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6041	TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol	BPVEFILTER-20-00046765	BPVEFILTER-20-00046772	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6042	G2 (Jugular) 2008.01 - PK5260600 Rev. 0 IFU	BPVEFILTER-22-00013682	BPVEFILTER-22-00013689	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6043	June 2014 Clinical Evaluation Report of SNF Filter	BPVEFILTER-30-00230977	BPVEFILTER-30-00231013	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6044	June 27, 2011 email from custodial file of Joni Creal with Appendix 14 Part B	BPVEFILTER-35-00027113	BPVEFILTER-35-00027173	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6045	December 20, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes	BPVEFILTER-35-00097831	BPVEFILTER-35-00097838	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6046	August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes	BPVEFILTER-35-00097856	BPVEFILTER-35-00097876	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6049	2007.02.20 Response to Questions about the Recall of G2 Filter System- Jugular/ Subclavian Delivery Kit	FDA_PRODUCTION_00000001	FDA_PRODUCTION_00000003	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6050	2006.12.01 Health Hazard Evaluation - Updated	FDA_PRODUCTION_00000004	FDA_PRODUCTION_00000005	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6051	2006.12.22 G2 Filter System – Jugular/ Subclavian Delivery Kit	FDA_PRODUCTION_00000006	FDA_PRODUCTION_00000024	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6052	2008.10.23 Summary and Termination Validation	FDA_PRODUCTION_00000025	FDA_PRODUCTION_00000029	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6053	2008.09.22 Bard Peripheral Vascular (BPV) Recalls	FDA_PRODUCTION_00000030	FDA_PRODUCTION_00000033	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6054	2007.01.16 Bard G2 Filter System – Jugular/ Subclavian Delivery Kit	FDA_PRODUCTION_00000034	FDA_PRODUCTION_00000035	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6055	2006.12.20 Urgent Production Recall Notification	FDA_PRODUCTION_00000036	FDA_PRODUCTION_00000037	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6056	2007.02.02 Recall Z-0393-2007 Bard G2 Filter System – Jugular/ Subclavian Delivery Kit, Catalog Number RF-320J	FDA_PRODUCTION_00000038	FDA_PRODUCTION_00000039	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6057	2006.12.12 Recall Enterprise System Recall Details	FDA_PRODUCTION_00000040	FDA_PRODUCTION_00000047	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6058	K050558	FDA_PRODUCTION_00000048	FDA_PRODUCTION_00000375	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6059	Aug. 29, 2005 Fax BPV to FDA re G2 (K050558)	FDA_PRODUCTION_00000150	FDA_PRODUCTION_00000157	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6060	Aug. 26, 2005 Fax FDA to BPV re G2 (K050558)	FDA_PRODUCTION_00000158	FDA_PRODUCTION_00000164	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6061	Aug. 22, 2005 Internal FDA memo reviewing BPV's Responses to FDA AI re G2 (K050558)	FDA_PRODUCTION_00000165	FDA_PRODUCTION_00000168	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6062	Aug. 22, 2005 Bard email to FDA enclosing revised IFU	FDA_PRODUCTION_00000173	FDA_PRODUCTION_00000177	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6063	July 26, 2005 FDA Reviewer Memo for G2 510(k) (K050558)	FDA_PRODUCTION_00000178	FDA_PRODUCTION_00000183	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6064	July 26, 2005 Internal FDA memo re BPV Responses to FDA AI re Modified Recovery (K050558)	FDA_PRODUCTION_00000179	FDA_PRODUCTION_00000183	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6065	May 2, 2005 Internal FDA memo reviewing animal study re Modified Recovery (K050558)	FDA_PRODUCTION_00000185	FDA_PRODUCTION_00000191	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6066	Apr. 19, 2005 BPV's Informal Responses to FDA AI Letter re Modified Recovery (K050558)	FDA_PRODUCTION_00000193	FDA_PRODUCTION_00000201	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6067	BPV's Informal Responses to FDA AI Letter re Modified Recovery (K050558)	FDA_PRODUCTION_00000193	FDA_PRODUCTION_00000201	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6068	March 28, 2005 FDA Reviewer Memo for G2 510(k) (K050558)	FDA_PRODUCTION_00000206	FDA_PRODUCTION_00000220	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6069	Mar. 29, 2005 Internal FDA memo re Modified Recovery (K050558)	FDA_PRODUCTION_00000206	FDA_PRODUCTION_00000220	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6070	2005.08.29 Summary of Safety and Effectiveness	FDA_PRODUCTION_00000376	FDA_PRODUCTION_00000954	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6071	Maude Adverse Event Report: Bard Peripheral Vascular Bard G2 Filter System Femoral IVC Filter	FDA_PRODUCTION_00000955	FDA_PRODUCTION_00000984	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6072	2006.12.22 G2 Filter System – Jugular/ Subclavian Delivery Kit	FDA_PRODUCTION_00000985	FDA_PRODUCTION_00001003	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6073	FDA file re Recovery; Filter obtained from FOIA services	FDA_PRODUCTION_00001004	FDA_PRODUCTION_00001370	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6074	Nov. 29, 2004 FDA Reviewer Memo re Dear Doctor Letter	FDA_PRODUCTION_00001017	FDA_PRODUCTION_00001017	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6075	Nov. 10, 2004 FDA Internal Memo re Dear Doctor Letter	FDA_PRODUCTION_00001019	FDA_PRODUCTION_00001021	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6076	Nov. 10, 2004 Internal FDA Email chain re Recovery IFU and DDL	FDA_PRODUCTION_00001022	FDA_PRODUCTION_00001027	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6077	July 25, 2003 Internal FDA Memo re Recovery Retrievable (K031328)	FDA_PRODUCTION_00001201	FDA_PRODUCTION_00001208	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6078	July 22, 2004 Internal FDA Memorandum re Recovery Retrievable (K031328)	FDA_PRODUCTION_00001209	FDA_PRODUCTION_00001215	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6079	Internal FDA Memorandum re Recovery Retrievable (K031328)	FDA_PRODUCTION_00001209	FDA_PRODUCTION_00001215	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6080	July 17, 2003 Email strings re FDA request for information concerning sterilization	FDA_PRODUCTION_00001228	FDA_PRODUCTION_00001368	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6081	Email chain FDA and BPV re Recovery Retrievable (K031328)	FDA_PRODUCTION_00001288		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6082	FDA_PRODUCTION_00001288 -- July 2, 2003 Email chain FDA and BPV re Recovery Retrievable (K031328)	FDA_PRODUCTION_00001288	FDA_PRODUCTION_00001291	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6083	July 2003 FDA Internal Reviewer Memo re Recovery; Filter 510(k)	FDA_PRODUCTION_00001369	FDA_PRODUCTION_00001370	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6084	FDA file re Eclipse Filter obtained from FOIA services	FDA_PRODUCTION_00001371	FDA_PRODUCTION_00001548	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6085	K022236.pdf	FDA_PRODUCTION_00001549	FDA_PRODUCTION_00001686	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6086	K080669 - 510K G2 Express Filter System.pdf	FDA_PRODUCTION_00001687	FDA_PRODUCTION_00002112	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6087	K101431 - Eclipse.pdf	FDA_PRODUCTION_00002113	FDA_PRODUCTION_00002276	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6088	K894703.pdf	FDA_PRODUCTION_00002277	FDA_PRODUCTION_00002734	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6089	Product Development Cycle PPT	Public Document		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6090	Selected medical records for York Hospital study patient 87	YH04460	YH04460	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6091	Selected medical records for York Hospital study patient 87	YH04464	YH04464	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6092	Selected medical records for York Hospital study patient 87	YH04560	YH04565	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6093	Selected medical records for York Hospital study patient 87	YH04598	YH04601	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6094	Selected medical records for York Hospital study patient 87	YH04654	YH04655	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6095	Selected medical records for York Hospital study patient 87	YH04684	YH04686	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6096	Selected medical records for York Hospital study patient 87	YH04748	YH04749	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6097	York Hospital procedure log from surgical suite	YH04750	YH04759	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6098	York Hospital procedure log from interventional radiology suite	YH04760	YH04761	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6099	Selected records for York Hospital study patient 40	YH04768	YH04768	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6100	Selected medical records for York Hospital study patient 87	YH04780	YH04780	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6101	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH04804	YH04806	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6102	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH04813	YH04815	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6103	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH04833	YH04835	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6104	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH04851	YH04853	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6105	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH04941	YH04943	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6106	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH04953	YH04955	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6107	Selected medical records for York Hospital Study patient 36	YH05019	YH05020	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6108	Selected records for York Hospital study patient 40	YH05042	YH05045	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6109	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH05042	YH05044	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6110	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH05125	YH05132	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6111	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH05190	YH05191	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6112	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH05214	YH05215	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6113	Selected medical records for York Hospital Study patient 76	YH05274	YH05274	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6114	Selected medical records for York Hospital Study patient 76	YH05276	YH05277	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6115	Selected medical records for York Hospital Study patient 77	YH05278	YH05283	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6116	Selected medical records for York Hospital Study patient 84	YH05326	YH05327	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6117	Selected medical records for York Hospital study patient 85	YH05328	YH05329	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6118	Selected medical records for York Hospital study patient 85	YH05333	YH05337	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6119	Selected medical records for York Hospital study patient 85	YH05342	YH05344	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6120	IVC filter insertion records on the 13 patients with filter fractures listed in Table 2 of the Nicholson study	YH05353	YH05355	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6121	Selected medical records for York Hospital study patient 87	YH05358	YH05360	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6122	Letters from FDA to Dr. Nicholson regarding complaints	YH05361	YH05370	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6123	Letter from FDA to Dr. Nicholson regarding complaint	YH05371	YH05371	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6124	Letter from FDA to Dr. Nicholson regarding MedWatch report	YH05372	YH05374	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6125	Email between York Hospital researchers regarding assessment of rate of fracture	YH05733	Yh05735	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6126	York Hospital November 11, 2009, Meeting Minutes	YH05943	YH05953	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6127	York Hospital January 14, 2009, Meeting Minutes	YH06002	YH06014	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6128	Letter from York Hospital to Dr. Nicholson regarding IRB review and oversight of York Hospital Study	YH06023	YH06023	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6129	Letter from Schulz to Moffett regarding visit at York	YH06475	YH06475	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6130	Email from Bard to York Hospital regarding York Hospital Study	YH06477	YH06477	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6131	Emails between Bard and Barbara Delio-Cox regarding York Hospital Study	YH06478	YH06478	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6132	Emails between Bard and Barbara Delio-Cox regarding York Hospital Study	YH06488	YH06490	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6133	Emails between York Hospital employees regarding meeting with Dr. Nicholson and FDA	YH06640	YH06641	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6134	Emails between York Hospital employees about non-consenting patients	YH06683	YH06684	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6135	Chart of York Hospital study patients	YH06741	YH06742	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6136	Chart of York Hospital study patients	YH06743	YH06744	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6137	Selected medical records for York Hospital Study patient 86	YH11131	YH11131	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6138	Selected medical records for York Hospital Study patient 86	YH11139	YH11140	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6139	Selected medical records for York Hospital study patient 85	YH12110	YH12114	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6140	Emails between York Hospital and Dr. Nicholson regarding press coverage of publication of York Hospital Study	YORK_SUBPOENA_B_NICHOLSON_000013	YORK_SUBPOENA_B_NICHOLSON_000014	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6141	Emails between Dr. Nicholson and FDA regarding York Hospital Study	YORK_SUBPOENA_B_NICHOLSON_000017	YORK_SUBPOENA_B_NICHOLSON_000019	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6142	Email from FDA to Dr. Nicholson regarding Study	YORK_SUBPOENA_B_NICHOLSON_000173	YORK_SUBPOENA_B_NICHOLSON_000174	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6143	York Hospital Study Protocol	YORK_SUBPOENA_B_NICHOLSON_000180	YORK_SUBPOENA_B_NICHOLSON_000192	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6144	Emails between York Hospital researchers regarding study protocol	YORK_SUBPOENA_B_NICHOLSON_000196	YORK_SUBPOENA_B_NICHOLSON_000198	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6145	Emails between Dr. Nicholson and colleague regarding study publication Dec. 17, 2009 Email to Nicholson re Embolized Filters	YORK_SUBPOENA_B_NICHOLSON_000216	YORK_SUBPOENA_B_NICHOLSON_000216	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6146	Email from FDA to Dr. Nicholson regarding Study	YORK_SUBPOENA_B_NICHOLSON_000225	YORK_SUBPOENA_B_NICHOLSON_000225	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6147	Email from Archives of Internal Medicine to Dr. Nicholson	YORK_SUBPOENA_B_NICHOLSON_000230	YORK_SUBPOENA_B_NICHOLSON_000230	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6148	Email from Bard to Dr. Nicholson regarding York Hospital Study	YORK_SUBPOENA_B_NICHOLSON_000236	YORK_SUBPOENA_B_NICHOLSON_000236	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6149	Email from Dr. Nicholson to co-author of York Hospital Study	YORK_SUBPOENA_B_NICHOLSON_000270	YORK_SUBPOENA_B_NICHOLSON_000271	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6150	Email from FDA to Dr. Nicholson regarding Bard IVC filters	YORK_SUBPOENA_B_NICHOLSON_000272	YORK_SUBPOENA_B_NICHOLSON_000272	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6151	Email from York Hospital to Dr. Nicholson attaching surgical procedure log	YORK_SUBPOENA_B_NICHOLSON_000279	YORK_SUBPOENA_B_NICHOLSON_000289	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6152	Emails between York Hospital and Dr. Nicholson regarding number of Bard filters used at the hospital	YORK_SUBPOENA_B_NICHOLSON_000314	YORK_SUBPOENA_B_NICHOLSON_000318	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6153	Email from JAMA to Dr. Nicholson regarding publication of York Hospital Study manuscript	YORK_SUBPOENA_B_NICHOLSON_000319	YORK_SUBPOENA_B_NICHOLSON_000321	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6154	Email to Nicholson from Walcott regarding FDA MedWatch Report	YORK_SUBPOENA_B_NICHOLSON_000380	YORK_SUBPOENA_B_NICHOLSON_000380	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6155	Email from Delio Cox to Walcott regarding fracture report	YORK_SUBPOENA_B_NICHOLSON_000382	YORK_SUBPOENA_B_NICHOLSON_000383	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6156	Email from Edward to Nicholson regarding email to Castronuovo May 13, 2008 Email from Nicholson re Recovery and G2 Filters	YORK_SUBPOENA_B_NICHOLSON_000384	YORK_SUBPOENA_B_NICHOLSON_000385	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6157	Email from Dr. Nicholson to FDA regarding Study	YORK_SUBPOENA_B_NICHOLSON_000396	YORK_SUBPOENA_B_NICHOLSON_000440	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6158	Email from Bard to Dr. Nicholson regarding York Hospital Study	YORK_SUBPOENA_B_NICHOLSON_000441	YORK_SUBPOENA_B_NICHOLSON_000441	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6159	Email from FDA to Dr. Nicholson regarding Study	YORK_SUBPOENA_B_NICHOLSON_000445	YORK_SUBPOENA_B_NICHOLSON_000446	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6160	Email from Bard to Dr. Nicholson regarding York Hospital Study	YORK_SUBPOENA_B_NICHOLSON_000450	YORK_SUBPOENA_B_NICHOLSON_000450	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6161	Emails between York Hospital and Dr. Nicholson regarding HIPAA	YORK_SUBPOENA_B_NICHOLSON_000451	YORK_SUBPOENA_B_NICHOLSON_000453	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6162	Email from York Hospital to Dr. Nicholson regarding patients in study	YORK_SUBPOENA_B_NICHOLSON_000458	YORK_SUBPOENA_B_NICHOLSON_000459	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6163	Email from NEJM to Dr. Nicholson	YORK_SUBPOENA_B_NICHOLSON_000462	YORK_SUBPOENA_B_NICHOLSON_000462	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6164	Email from Bard to Dr. Nicholson regarding York Hospital Study	YORK_SUBPOENA_B_NICHOLSON_000466	YORK_SUBPOENA_B_NICHOLSON_000468	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6165	Emails between Dr. Nicholson and Dr. Lynch regarding IVC filter patient	YORK_SUBPOENA_B_NICHOLSON_000494	YORK_SUBPOENA_B_NICHOLSON_000496	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6166	Email from Dr. Nicholson to FDA regarding Study	YORK_SUBPOENA_B_NICHOLSON_000497	YORK_SUBPOENA_B_NICHOLSON_000499	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6167	Emails between Dr. Nicholson and colleague regarding publication of York Hospital Study	YORK_SUBPOENA_B_NICHOLSON_000500	YORK_SUBPOENA_B_NICHOLSON_000501	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6168	Email from FDA to Dr. Nicholson regarding Study	YORK_SUBPOENA_B_NICHOLSON_000511	YORK_SUBPOENA_B_NICHOLSON_000512	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6169	Email from Dr. Nicholson to FDA regarding Study	YORK_SUBPOENA_B_NICHOLSON_000517	YORK_SUBPOENA_B_NICHOLSON_000517	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6170	Emails between Dr. Nicholson and the Archives of Internal Medicine regarding publication of York Hospital Study	YORK_SUBPOENA_B_NICHOLSON_000535	YORK_SUBPOENA_B_NICHOLSON_000535	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6171	Email from Dr. Nicholson to FDA regarding York Hospital Study	YORK_SUBPOENA_B_NICHOLSON_000573	YORK_SUBPOENA_B_NICHOLSON_000574	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6172	Email from Dr. Nicholson to FDA regarding Study	YORK_SUBPOENA_B_NICHOLSON_000636	YORK_SUBPOENA_B_NICHOLSON_000636	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6173	Note from Dr. Nicholson to an editor attaching table of his study patients	YORK_SUBPOENA_B_NICHOLSON_000750	YORK_SUBPOENA_B_NICHOLSON_000759	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6174	Draft of Dr. Nicholson article	YORK_SUBPOENA_B_NICHOLSON_000851	YORK_SUBPOENA_B_NICHOLSON_000874	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6175	Email from Dr. Nicholson to Christopher Tuohy regarding statistical analysis of York Hospital Study	YORK_SUBPOENA_Tuohy_000001	YORK_SUBPOENA_Tuohy_000002	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6176	Carol Vierling, 5/11/16 deposition Exhibit 122			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6177	Carol Vierling, 5/11/16 deposition Exhibit 212			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6178	Carol Vierling, 5/11/16 deposition Exhibit 226			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901; MIL #2
6179	Carol Vierling, 5/11/16 deposition Exhibit 227			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901; MIL #2
6180	Carol Vierling, 5/11/16 deposition Exhibit 236			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6181	Carol Vierling, 5/11/16 deposition Exhibit 240			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #2
6182	Carol Vierling, 5/11/16 deposition Exhibit 244			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #2

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6183	Carol Vierling, 5/11/16 deposition Exhibit 245			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6184	Carol Vierling, 5/11/16 deposition Exhibit 247			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6185	Kay Fuller, 1/11/16 deposition Exhibit 140			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6186	Kay Fuller, 1/11/16 deposition Exhibit 153			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6187	Kay Fuller, 1/11/16 deposition, Exhibit 161			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6188	Kay Fuller, 1/11/16 deposition Exhibit 164			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6189	Kay Fuller, 1/11/16 deposition Exhibit 168			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6190	Carol Vierling, 5/05/11 deposition Exhibit 226			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6191	Carol Vierling, 5/5/11 deposition Exhibit 242			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6192	Carol Vierling, 5/5/11 deposition Exhibit 247			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6193	Mary Edwards, 8/19/16 deposition Exhibit 355			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6194	Mary Edwards, 8/19/16 deposition Exhibit 356			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6195	Mary Edwards, 8/19/16 deposition Exhibit 357			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6196	Mary Edwards, 8/19/16 deposition Exhibit 358			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6197	Mary Edwards, 8/19/16 deposition Exhibit 360			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6198	David Ciavarella, 11/12/13 deposition Exhibit 21			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6199	David Ciavarella, 11/12/13 deposition Exhibit 23			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6200	David Ciavarella, 11/12/13 deposition Exhibit 35			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6201	David Ciavarella, 11/12/13 deposition Exhibit 39			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6202	Gin Schulz, 1/30/14 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6203	Gin Schulz, 1/30/14 deposition Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6204	Gin Schulz, 1/30/14 deposition Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6205	Gin Schulz, 1/30/14 deposition Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6206	Gin Schulz, 1/30/14 deposition Exhibit 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6207	Gin Schulz, 1/30/14 deposition Exhibit 17			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6208	Robert Ferrara, 4/7/17 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 601; 602; 801; 802; 901
6209	Robert Ferrara, 4/7/17 deposition Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 601; 602; 801; 802; MIL #1
6230	Scott Trerotola, 1/20/17 deposition Exhibit 688			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6231	S. William Stavropoulos, 2/1/17 deposition Exhibit 827			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6232	Robert Ritchie. 5/23/11 deposition Exhibit 01	BPV-DEP-00009657	BPV-DEP-00009852	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106
6233	Robert Ritchie. 5/23/11 deposition Exhibit 02	BPV-DEP-00009853	BPV-DEP-00009907	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6234	Robert Ritchie. 5/23/11 deposition Exhibit 03	BPV-DEP-00009908	BPV-DEP-00009908	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6235	Robert Ritchie. 5/23/11 deposition Exhibit 04	BPV-DEP-00009909	BPV-DEP-00009933	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6236	Robert Ritchie. 5/23/11 deposition Exhibit 05	BPV-DEP-00009934	BPV-DEP-00009937	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6237	Robert Ritchie. 5/23/11 deposition Exhibit 06	BPV-DEP-00009938	BPV-DEP-00009950	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6238	Robert Ritchie. 5/23/11 deposition Exhibit 07	BPV-DEP-00009951	BPV-DEP-00009955	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6239	Robert Ritchie. 5/23/11 deposition Exhibit 08	BPV-DEP-00009956	BPV-DEP-00009956	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6240	Robert Ritchie. 5/23/11 deposition Exhibit 09	BPV-DEP-00009957	BPV-DEP-00009971	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6241	Robert Ritchie. 5/23/11 deposition Exhibit 10	BPV-DEP-00009972	BPV-DEP-00009977	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6242	Robert Ritchie. 5/23/11 deposition Exhibit 11	BPV-DEP-00009978	BPV-DEP-00009979	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6243	Robert McMeeking. 5/24/11 deposition Exhibit 1	BPV-DEP-00009534	BPV-DEP-00009602	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6244	Robert McMeeking. 5/24/11 deposition Exhibit 2	BPV-DEP-00009603	BPV-DEP-00009606	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6245	Robert McMeeking. 5/24/11 deposition Exhibit 3	BPV-DEP-00009607	BPV-DEP-00009635	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6246	Robert McMeeking. 5/24/11 deposition Exhibit 4	BPV-DEP-00009636	BPV-DEP-00009640	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6247	Robert McMeeking. 5/24/11 deposition Exhibit 5	BPV-DEP-00009641	BPV-DEP-00009642	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6248	Robert McMeeking. 5/24/11 deposition Exhibit 6	BPV-DEP-00009643	BPV-DEP-00009647	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6249	Robert McMeeking. 5/24/11 deposition Exhibit 7	BPV-DEP-00009648	BPV-DEP-00009656	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6250	Robert Ritchie. 4/2/12 deposition Exhibit 01	BPV-DEP-00010222	BPV-DEP-00010225	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 701; 801; 802; 901; MIL #1
6251	Robert Ritchie. 4/2/12 deposition Exhibit 02	BPV-DEP-00010226	BPV-DEP-00010226	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6252	Robert Ritchie. 4/2/12 deposition Exhibit 03	BPV-DEP-00010227	BPV-DEP-00010227	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; MIL #1
6253	Robert Ritchie. 4/2/12 deposition Exhibit 04	BPV-DEP-00010228	BPV-DEP-00010229	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802;
6254	Robert Ritchie. 4/2/12 deposition Exhibit 05	BPV-DEP-00010230	BPV-DEP-00010230	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 901; MIL #1;
6255	Robert Ritchie. 4/2/12 deposition Exhibit 06	BPV-DEP-00010231	BPV-DEP-00010231	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802;
6256	Robert Ritchie. 4/2/12 deposition Exhibit 07	BPV-DEP-00010232	BPV-DEP-00010256	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802;
6257	Robert Ritchie. 4/2/12 deposition Exhibit 08	BPV-DEP-00010257	BPV-DEP-00010284	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6258	Robert Ritchie. 4/2/12 deposition Exhibit 09	BPV-DEP-00010285	BPV-DEP-00010305	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6259	Robert Ritchie. 4/2/12 deposition Exhibit 10	BPV-DEP-00010306	BPV-DEP-00010368	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1;
6260	Robert Ritchie. 4/2/12 deposition Exhibit 11	BPV-DEP-00010369	BPV-DEP-00010404	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1;

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6261	Robert McMeeking, 4/22/14 deposition Exhibit 01	BPV-DEP-00028338	BPV-DEP-00028342	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802;
6262	Robert McMeeking, 4/22/14 deposition Exhibit 02	BPV-DEP-00028343	BPV-DEP-00028358	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
6263	Robert McMeeking, 4/22/14 deposition Exhibit 03	BPV-DEP-00028359	BPV-DEP-00028359	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802;
6264	Robert McMeeking, 4/22/14 deposition Exhibit 04	BPV-DEP-00028360	BPV-DEP-00028360	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
6265	Robert McMeeking, 4/22/14 deposition Exhibit 05	BPV-DEP-00028361	BPV-DEP-00028361	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802;
6266	Robert McMeeking, 4/22/14 deposition Exhibit 06	BPV-DEP-00028362	BPV-DEP-00028362	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407;
6267	Robert McMeeking, 4/22/14 deposition Exhibit 07	BPV-DEP-00028363	BPV-DEP-00028363	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403;
6268	Robert Ritchie, 5/8/14 deposition Exhibit 01	BPV-DEP-00028466	BPV-DEP-00028527	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802;
6269	Robert Ritchie, 5/8/14 deposition Exhibit 02	BPV-DEP-00028528	BPV-DEP-00028588	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802;
6270	Robert Ritchie, 5/8/14 deposition Exhibit 03	BPV-DEP-00028589	BPV-DEP-00028590	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1;
6271	Robert Ritchie, 5/8/14 deposition Exhibit 04	BPV-DEP-00028591	BPV-DEP-00028592	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 901; MIL #1;
6272	Robert Ritchie, 5/8/14 deposition Exhibit 05	BPV-DEP-00028593	BPV-DEP-00028593	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1;
6273	Robert Ritchie, 5/8/14 deposition Exhibit 06	BPV-DEP-00028594	BPV-DEP-00028617	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802;
6274	Robert Ritchie, 5/8/14 deposition Exhibit 07	BPV-DEP-00028618	BPV-DEP-00028678	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1;
6275	Suzanne Parisian, 6/13/14 deposition Exhibit 01	BPV-DEP-00041040	BPV-DEP-00041045	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1;
6276	Suzanne Parisian, 6/13/14 deposition Exhibit 02	BPV-DEP-00041046	BPV-DEP-00041048	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1;
6277	Suzanne Parisian, 6/13/14 deposition Exhibit 03	BPV-DEP-00041049	BPV-DEP-00041052	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6278	Suzanne Parisian, 6/13/14 deposition Exhibit 04	BPV-DEP-00041053	BPV-DEP-00041242	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6279	Suzanne Parisian, 6/13/14 deposition Exhibit 05	BPV-DEP-00041243	BPV-DEP-00041460	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6280	Suzanne Parisian, 6/13/14 deposition Exhibit 06	BPV-DEP-00041461	BPV-DEP-00041624	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6281	Suzanne Parisian, 6/13/14 deposition Exhibit 07	BPV-DEP-00041625	BPV-DEP-00041640	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6282	Suzanne Parisian, 6/13/14 deposition Exhibit 08	BPV-DEP-00041641	BPV-DEP-00041657	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
6283	Suzanne Parisian, 6/13/14 deposition Exhibit 09	BPV-DEP-00041658	BPV-DEP-00041662	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6284	Suzanne Parisian, 6/13/14 deposition Exhibit 10	BPV-DEP-00041663	BPV-DEP-00041667	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6285	Suzanne Parisian, 6/13/14 deposition Exhibit 11	BPV-DEP-00041668	BPV-DEP-00041761	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6286	Suzanne Parisian, 6/13/14 deposition Exhibit 12	BPV-DEP-00041762	BPV-DEP-00041837	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802; 901
6287	Suzanne Parisian, 6/13/14 deposition Exhibit 13	BPV-DEP-00041838	BPV-DEP-00041865	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802; 901
6288	Suzanne Parisian, 6/13/14 deposition Exhibit 14	BPV-DEP-00041866	BPV-DEP-00041866	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6289	Suzanne Parisian, 6/13/14 deposition Exhibit 15	BPV-DEP-00041867	BPV-DEP-00041867	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6290	Suzanne Parisian, 6/13/14 deposition Exhibit 16	BPV-DEP-00041868	BPV-DEP-00041904	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6291	Suzanne Parisian, 6/13/14 deposition Exhibit 17	BPV-DEP-00041905	BPV-DEP-00041908	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6292	Suzanne Parisian, 6/13/14 deposition Exhibit 18	BPV-DEP-00041909	BPV-DEP-00041924	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6293	Suzanne Parisian, 9/25/14 deposition Exhibit 01	BPV-DEP-00031113	BPV-DEP-00031123	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6294	Suzanne Parisian, 9/25/14 deposition Exhibit 02	BPV-DEP-00031124	BPV-DEP-00031317	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6295	Suzanne Parisian, 9/25/14 deposition Exhibit 03	BPV-DEP-00031318	BPV-DEP-00031318	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6296	Suzanne Parisian, 9/25/14 deposition Exhibit 04	BPV-DEP-00031319	BPV-DEP-00031336	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6297	Suzanne Parisian, 9/25/14 deposition Exhibit 05	BPV-DEP-00031337	BPV-DEP-00031341	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6298	Suzanne Parisian, 12/18/14 deposition - CD	BPV-DEP-00035522	BPV-DEP-00035523	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6299	Suzanne Parisian, 12/18/14 deposition Exhibit 01	BPV-DEP-00035096	BPV-DEP-00035339	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6300	Suzanne Parisian, 12/18/14 deposition Exhibit 02	BPV-DEP-00035340	BPV-DEP-00035344	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6301	Suzanne Parisian, 12/18/14 deposition Exhibit 03	BPV-DEP-00035345	BPV-DEP-00035360	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6302	Suzanne Parisian, 12/18/14 deposition Exhibit 04	BPV-DEP-00035361	BPV-DEP-00035382	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6303	Suzanne Parisian, 12/18/14 deposition Exhibit 05	BPV-DEP-00035383	BPV-DEP-00035388	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6304	Suzanne Parisian, 12/18/14 deposition Exhibit 06	BPV-DEP-00035389	BPV-DEP-00035397	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6305	Suzanne Parisian, 12/18/14 deposition Exhibit 07	BPV-DEP-00035398	BPV-DEP-00035400	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6306	Suzanne Parisian, 12/18/14 deposition Exhibit 08	BPV-DEP-00035401	BPV-DEP-00035405	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6307	Suzanne Parisian, 12/18/14 deposition Exhibit 09	BPV-DEP-00035406	BPV-DEP-00035469	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6308	Suzanne Parisian, 12/18/14 deposition Exhibit 10	BPV-DEP-00035470	BPV-DEP-00035470	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6309	Suzanne Parisian, 12/18/14 deposition Exhibit 11	BPV-DEP-00035471	BPV-DEP-00035475	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6310	Suzanne Parisian, 12/18/14 deposition Exhibit 12	BPV-DEP-00035476	BPV-DEP-00035498	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6311	Suzanne Parisian, 12/18/14 deposition Exhibit 13	BPV-DEP-00035499	BPV-DEP-00035501	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6312	Suzanne Parisian, 12/18/14 deposition Exhibit 14	BPV-DEP-00035502	BPV-DEP-00035502	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6313	Suzanne Parisian, 12/18/14 deposition Exhibit 15	BPV-DEP-00035503	BPV-DEP-00035521	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 403; 404(b); 410; 609; MIL #1
6314	Robert McMeeking, 4/24/15 deposition Exhibit 01	BPV-DEP-00043190	BPV-DEP-00043194	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6315	Robert McMeeking, 4/24/15 deposition Exhibit 02	BPV-DEP-00043195	BPV-DEP-00043199	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6316	Robert McMeeking, 4/24/15 deposition Exhibit 03	BPV-DEP-00043200	BPV-DEP-00043204	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6317	Robert McMeeking, 4/24/15 deposition Exhibit 04	BPV-DEP-00043205	BPV-DEP-00043327	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6318	Robert McMeeking, 4/24/15 deposition Exhibit 05	BPV-DEP-00043328	BPV-DEP-00043445	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6319	Robert McMeeking, 4/24/15 deposition Exhibit 06	BPV-DEP-00043446	BPV-DEP-00043532	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6320	Robert McMeeking, 4/24/15 deposition Exhibit 07	BPV-DEP-00043533	BPV-DEP-00043542	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6321	Robert McMeeking, 4/24/15 deposition Exhibit 08	BPV-DEP-00043543	BPV-DEP-00043552	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6322	Robert McMeeking, 4/24/15 deposition Exhibit 09	BPV-DEP-00043553	BPV-DEP-00043560	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6323	Robert Ritchie, 5/1/15 deposition Exhibit 01	BPV-DEP-00045670	BPV-DEP-00045673	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
6324	Robert Ritchie, 5/1/15 deposition Exhibit 02	BPV-DEP-00045674	BPV-DEP-00045675	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6325	Robert Ritchie, 5/1/15 deposition Exhibit 03	BPV-DEP-00045676	BPV-DEP-00045679	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6326	Robert Ritchie, 5/1/15 deposition Exhibit 04	BPV-DEP-00045680	BPV-DEP-00045681	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6327	Robert Ritchie, 5/1/15 deposition Exhibit 05	BPV-DEP-00045682	BPV-DEP-00045687	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6328	Robert Ritchie, 5/5/15 deposition Exhibit 01	BPV-DEP-00045828	BPV-DEP-00045833	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6329	Robert Ritchie, 5/5/15 deposition Exhibit 02	BPV-DEP-00045834	BPV-DEP-00045839	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6330	Robert Ritchie, 5/5/15 deposition Exhibit 03	BPV-DEP-00045840	BPV-DEP-00046029	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6331	Robert Ritchie, 5/5/15 deposition Exhibit 04	BPV-DEP-00046030	BPV-DEP-00046293	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6332	Robert Ritchie, 5/5/15 deposition Exhibit 05	BPV-DEP-00046294	BPV-DEP-00046309	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6333	Robert Ritchie, 5/5/15 deposition Exhibit 06	BPV-DEP-00046310	BPV-DEP-00046343	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 901
6334	Robert Ritchie, 5/5/15 deposition Exhibit 07	BPV-DEP-00046344	BPV-DEP-00046357	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6335	Robert Ritchie, 5/5/15 deposition Exhibit 08	BPV-DEP-00046358	BPV-DEP-00046792	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6336	Robert Ritchie, 5/5/15 deposition Exhibit 09	BPV-DEP-00046793	BPV-DEP-00046810	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6337	Robert Ritchie, 5/5/15 deposition Exhibit 10	BPV-DEP-00046811	BPV-DEP-00046811	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6338	Robert Ritchie, 5/5/15 deposition Exhibit 11	BPV-DEP-00046812	BPV-DEP-00046814	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6339	Robert Ritchie, 5/5/15 deposition Exhibit 12	BPV-DEP-00046815	BPV-DEP-00046815	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6340	Robert Ritchie, 5/5/15 deposition Exhibit 13	BPV-DEP-00046816	BPV-DEP-00046816	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901
6341	Robert Ritchie, 5/5/15 deposition Exhibit 14	BPV-DEP-00046817	BPV-DEP-00046826	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901
6342	Derek Muehrcke, 7/21/16 deposition Exhibit 01	BPV-DEP-00065247	BPV-DEP-00065251	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901
6343	Derek Muehrcke, 7/21/16 deposition Exhibit 02	BPV-DEP-00065252	BPV-DEP-00065264	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6344	Derek Muehrcke, 7/21/16 deposition Exhibit 03	BPV-DEP-00065265	BPV-DEP-00065266	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6345	Derek Muehrcke, 7/21/16 deposition Exhibit 04	BPV-DEP-00065267	BPV-DEP-00065272	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6346	Derek Muehrcke, 7/21/16 deposition Exhibit 05	BPV-DEP-00065273	BPV-DEP-00065275	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6347	Derek Muehrcke, 7/21/16 deposition Exhibit 06	BPV-DEP-00065276	BPV-DEP-00065276	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6348	Derek Muehrcke, 7/21/16 deposition Exhibit 07	BPV-DEP-00065277	BPV-DEP-00065277	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6349	Derek Muehrcke, 7/21/16 deposition Exhibit 08	BPV-DEP-00065278	BPV-DEP-00065287	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6350	Derek Muehrcke, 7/21/16 deposition Exhibit 09	BPV-DEP-00065288	BPV-DEP-00065294	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6351	Derek Muehrcke, 7/21/16 deposition Exhibit 10	BPV-DEP-00065295	BPV-DEP-00065295	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6352	Derek Muehrcke, 7/21/16 deposition Exhibit 11	BPV-DEP-00065296	BPV-DEP-00065307	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6353	Derek Muehrcke, 7/21/16 deposition Exhibit 12	BPV-DEP-00065308	BPV-DEP-00065308	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6354	Derek Muehrcke, 7/21/16 deposition Exhibit 13	BPV-DEP-00065309	BPV-DEP-00065309	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6355	Derek Muehrcke, 7/21/16 deposition Exhibit 14	BPV-DEP-00065310	BPV-DEP-00065314	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6356	Derek Muehrcke, 7/21/16 deposition Exhibit 15	BPV-DEP-00065315	BPV-DEP-00065317	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6357	Derek Muehrcke, 7/21/16 deposition Exhibit 16	BPV-DEP-00065318	BPV-DEP-00065318	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	403; 702; 703; 801; 802; MIL #1
6358	Derek Muehrcke, 7/21/16 deposition Exhibit 17	BPV-DEP-00065319	BPV-DEP-00065327	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6359	Derek Muehrcke, 7/21/16 deposition Exhibit 18	BPV-DEP-00065328	BPV-DEP-00065328	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6360	Derek Muehrcke, 7/21/16 deposition Exhibit 19	BPV-DEP-00065329	BPV-DEP-00065349	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6361	Derek Muehrcke, 7/21/16 deposition Exhibit 20	BPV-DEP-00065350	BPV-DEP-00065351	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	702; 703; 801; 802
6362	Rebecca Betensky, 7/26/16 deposition Exhibit 01	BPV-DEP-00065517	BPV-DEP-00065521	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6363	Rebecca Betensky, 7/26/16 deposition Exhibit 02	BPV-DEP-00065522	BPV-DEP-00065551	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6364	Rebecca Betensky, 7/26/16 deposition Exhibit 03	BPV-DEP-00065552	BPV-DEP-00065589	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6365	Rebecca Betensky, 7/26/16 deposition Exhibit 04	BPV-DEP-00065590	BPV-DEP-00065590	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6366	Rebecca Betensky, 7/26/16 deposition Exhibit 05	BPV-DEP-00065591	BPV-DEP-00065610	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 901
6367	Rebecca Betensky, 7/26/16 deposition Exhibit 06	BPV-DEP-00065611	BPV-DEP-00065611	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6368	Mark Eisenberg, 8/17/16 deposition Exhibit 01	BPV-DEP-00066353	BPV-DEP-00066357	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6369	Mark Eisenberg, 8/17/16 deposition Exhibit 02	BPV-DEP-00066358	BPV-DEP-00066358	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #2
6370	Mark Eisenberg, 8/17/16 deposition Exhibit 03	BPV-DEP-00066359	BPV-DEP-00066364	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6371	Mark Eisenberg, 8/17/16 deposition Exhibit 04	BPV-DEP-00066365	BPV-DEP-00066368	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6372	Mark Eisenberg, 8/17/16 deposition Exhibit 05	BPV-DEP-00066369	BPV-DEP-00066406	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6373	Mark Eisenberg, 8/17/16 deposition Exhibit 06	BPV-DEP-00066407	BPV-DEP-00066488	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6374	Mark Eisenberg, 8/17/16 deposition Exhibit 07	BPV-DEP-00066489	BPV-DEP-00066508	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403
6375	Mark Wilson, 1/31/17 deposition Exhibit 795			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6376	Mark Wilson, 1/31/17 deposition Exhibit 796			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6377	Mark Wilson, 1/31/17 deposition Exhibit 797			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403
6378	Mark Wilson, 1/31/17 deposition Exhibit 798			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6379	Mark Wilson, 1/31/17 deposition Exhibit 800			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901
6380	Mark Wilson, 1/31/17 deposition Exhibit 801			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6381	Mark Wilson, 1/31/17 deposition Exhibit 802			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #2
6382	Mark Wilson, 1/31/17 deposition Exhibit 803			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6383	Robert Ritchie, 6/9/17 deposition Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	801; 802
6384	Robert Ritchie, 6/9/17 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 404(b); 410; 609; 702; 703; 801; 802; MIL #1
6385	Robert Ritchie, 6/9/17 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; MIL #1
6386	Robert Ritchie, 6/9/17 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6387	Robert Ritchie, 6/9/17 deposition Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; 901; MIL #1
6388	Robert Ritchie, 6/9/17 deposition Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6389	Robert Ritchie, 6/9/17 deposition Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6390	Robert Ritchie, 6/9/17 deposition Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6391	Robert Ritchie, 6/9/17 deposition Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6392	Robert Ritchie, 6/9/17 deposition Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6393	Robert Ritchie, 6/9/17 deposition Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6394	Thomas Kinney, 6/17/17 deposition Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703
6395	Thomas Kinney, 6/17/17 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6396	Thomas Kinney, 6/17/17 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6397	Thomas Kinney, 6/17/17 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6398	Thomas Kinney, 6/17/17 deposition Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6399	Thomas Kinney, 6/17/17 deposition Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6400	Thomas Kinney, 6/17/17 deposition Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6401	Thomas Kinney, 6/17/17 deposition Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6402	Thomas Kinney, 6/17/17 deposition Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 601; 602; 801; 802
6403	Thomas Kinney, 6/17/17 deposition Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6404	Thomas Kinney, 6/17/17 deposition Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6405	Thomas Kinney, 6/17/17 deposition Exhibit 11r			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 702; 703; 801; 802; MIL #1
6406	Thomas Kinney, 6/17/17 deposition Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 702; 703; 801; 802; MIL #1
6407	Thomas Kinney, 6/17/17 deposition Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6408	Thomas Kinney, 6/17/17 deposition Exhibit 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6409	Thomas Kinney, 6/17/17 deposition Exhibit 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 702; 703; 801; 802; MIL #1
6410	Thomas Kinney, 6/17/17 deposition Exhibit 16			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 702; 703; 801; 802; MIL #1
6411	Thomas Kinney, 6/17/17 deposition Exhibit 17			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6412	Thomas Kinney, 6/17/17 deposition Exhibit 18			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6413	Thomas Kinney, 6/17/17 deposition Exhibit 19			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6414	Thomas Kinney, 6/17/17 deposition Exhibit 20			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6415	Thomas Kinney, 6/17/17 deposition Exhibit 21			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6416	Thomas Kinney, 6/17/17 deposition Exhibit 22			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6417	David Garcia, 6/21/17 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	407; 801; 802
6418	David Garcia, 6/21/17 deposition Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	407; 801; 802
6419	David Garcia, 6/21/17 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	407; 801; 802
6420	David Garcia, 6/21/17 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6421	David Garcia, 6/21/17 deposition Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6422	David Garcia, 6/21/17 deposition Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6423	David Garcia, 6/21/17 deposition Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6424	David Garcia, 6/21/17 deposition Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6425	David Garcia, 6/21/17 deposition Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6426	David Garcia, 6/21/17 deposition Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6427	David Garcia, 6/21/17 deposition Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6428	David Garcia, 6/21/17 deposition Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6429	Suzanne Parisian, 6/21/17 deposition Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1
6430	Suzanne Parisian, 6/21/17 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1; MIL #2
6431	Suzanne Parisian, 6/21/17 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6432	Suzanne Parisian, 6/21/17 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6433	Suzanne Parisian, 6/21/17 deposition Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6434	Suzanne Parisian, 6/21/17 deposition Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6435	Suzanne Parisian, 6/21/17 deposition Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6436	Suzanne Parisian, 6/21/17 deposition Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6437	Mark Eisenberg, 7/6/17 deposition Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403
6438	Mark Eisenberg, 7/6/17 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6439	Mark Eisenberg, 7/6/17 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6440	Mark Eisenberg, 7/6/17 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6441	Mark Eisenberg, 7/6/17 deposition Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6442	Mark Eisenberg, 7/6/17 deposition Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6443	Mark Eisenberg, 7/6/17 deposition Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6444	Mark Eisenberg, 7/6/17 deposition Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6445	Mark Eisenberg, 7/6/17 deposition Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6446	Mark Eisenberg, 7/6/17 deposition Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6447	Mark Eisenberg, 7/6/17 deposition Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6448	Mark Eisenberg, 7/6/17 deposition Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6449	Mark Eisenberg, 7/6/17 deposition Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6450	Robert McMeeking, 7/6/17 deposition Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6451	Robert McMeeking, 7/6/17 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 203; 801; 802
6452	Robert McMeeking, 7/6/17 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6453	Robert McMeeking, 7/6/17 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6454	Robert McMeeking, 7/6/17 deposition Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407
6455	Robert McMeeking, 7/6/17 deposition Exhibit 05a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #3
6456	Robert McMeeking, 7/6/17 deposition Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802
6457	Robert McMeeking, 7/6/17 deposition Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6458	Robert McMeeking, 7/6/17 deposition Exhibit 07a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6459	Robert McMeeking, 7/6/17 deposition Exhibit 07b			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6460	Robert McMeeking, 7/6/17 deposition Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6461	Robert McMeeking, 7/6/17 deposition Exhibit 08a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6462	Robert McMeeking, 7/6/17 deposition Exhibit 08b			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6463	Robert McMeeking, 7/6/17 deposition Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802
6464	Robert McMeeking, 7/6/17 deposition Exhibit 09a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
6465	Robert McMeeking, 7/6/17 deposition Exhibit 09b			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6466	Robert McMeeking, 7/6/17 deposition Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6467	Robert McMeeking, 7/6/17 deposition Exhibit 10a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6468	Robert McMeeking, 7/6/17 deposition Exhibit 10b			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6469	Robert McMeeking, 7/6/17 deposition Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6470	Robert McMeeking, 7/6/17 deposition Exhibit 11a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6471	Robert McMeeking, 7/6/17 deposition Exhibit 11b			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6472	Robert McMeeking, 7/6/17 deposition Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6473	Robert McMeeking, 7/6/17 deposition Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6474	Robert McMeeking, 7/6/17 deposition Exhibit 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6475	Robert McMeeking, 7/6/17 deposition Exhibit 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6476	Robert McMeeking, 7/6/17 deposition Exhibit 16			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6477	Robert McMeeking, 7/6/17 deposition Exhibit 17			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6478	Robert McMeeking, 7/6/17 deposition Exhibit 18			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6479	Anne Roberts, 7/7/17 deposition Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802
6480	Anne Roberts, 7/7/17 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6481	Anne Roberts, 7/7/17 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6482	Anne Roberts, 7/7/17 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6483	Anne Roberts, 7/7/17 deposition Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6484	Anne Roberts, 7/7/17 deposition Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6485	Anne Roberts, 7/7/17 deposition Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6486	Anne Roberts, 7/7/17 deposition Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6487	Anne Roberts, 7/7/17 deposition Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6488	Anne Roberts, 7/7/17 deposition Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6489	Anne Roberts, 7/7/17 deposition Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6490	Anne Roberts, 7/7/17 deposition Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6491	Anne Roberts, 7/7/17 deposition Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6492	Anne Roberts, 7/7/17 deposition Exhibit 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6493	Anne Roberts, 7/7/17 deposition Exhibit 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6494	Sanjeeva Kalva, 7/11/17 deposition Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6495	Sanjeeva Kalva, 7/11/17 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6496	Sanjeeva Kalva, 7/11/17 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6497	Sanjeeva Kalva, 7/11/17 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6498	Sanjeeva Kalva, 7/11/17 deposition Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6499	Sanjeeva Kalva, 7/11/17 deposition Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6500	Sanjeeva Kalva, 7/11/17 deposition Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 404(b); 407; 408(a); 410; 411; 501; 502; 601; 602; 609; 701; 702; 703; 801; 802; 901; 902; 1001-1004; 1005; MIL 1; MIL #2; MIL #3; MIL #4; MIL #5
6501	Sanjeeva Kalva, 7/11/17 deposition Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6502	Sanjeeva Kalva, 7/11/17 deposition Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6503	Sanjeeva Kalva, 7/11/17 deposition Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6504	Sanjeeva Kalva, 7/11/17 deposition Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	106; 401; 402; 403; 801; 802
6505	Sanjeeva Kalva, 7/11/17 deposition Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6506	Sanjeeva Kalva, 7/11/17 deposition Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6507	Sanjeeva Kalva, 7/11/17 deposition Exhibit 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6508	Sanjeeva Kalva, 7/11/17 deposition Exhibit 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6509	Sanjeeva Kalva, 7/11/17 deposition Exhibit 16			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; MIL #1
6510	Derek Muehrcke, 7/24/17 deposition Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 407; 801; 802; MIL #1
6511	Derek Muehrcke, 7/24/17 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6512	Derek Muehrcke, 7/24/17 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6513	Derek Muehrcke, 7/24/17 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6514	Derek Muehrcke, 7/24/17 deposition Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
6515	Derek Muehrcke, 7/24/17 deposition Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6516	Derek Muehrcke, 7/24/17 deposition Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6517	Derek Muehrcke, 7/24/17 deposition Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6518	Derek Muehrcke, 7/24/17 deposition Exhibit 34			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1; MIL #2
6519	Derek Muehrcke, 7/24/17 deposition Exhibit 35			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6520	Derek Muehrcke, 7/24/17 deposition Exhibit 36			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 407
6521	Derek Muehrcke, 7/24/17 deposition Exhibit 37			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 407
6522	Derek Muehrcke, 7/24/17 deposition Exhibit 38			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 407
6523	Derek Muehrcke, 7/24/17 deposition Exhibit 39			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6524	James Matthew Sims, 7/26/17 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6525	David Kessler, 7/31/17 deposition Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6526	David Kessler, 7/31/17 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6527	David Kessler, 7/31/17 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6528	David Kessler, 7/31/17 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6529	David Kessler, 7/31/17 deposition Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6530	David Kessler, 7/31/17 deposition Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6531	David Kessler, 7/31/17 deposition Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6532	David Kessler, 7/31/17 deposition Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6533	David Kessler, 7/31/17 deposition Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6534	David Kessler, 7/31/17 deposition Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6535	David Kessler, 7/31/17 deposition Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6536	David Kessler, 7/31/17 deposition Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6537	David Kessler, 7/31/17 deposition Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6538	Robert Ritchie, 8/4/17 deposition Exhibit 6007			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6539	Robert Ritchie, 8/4/17 deposition Exhibit 6008			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6540	Robert Ritchie, 8/4/17 deposition Exhibit 6009			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6541	Robert Ritchie, 8/4/17 deposition Exhibit 6010			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6542	Robert Ritchie, 8/4/17 deposition Exhibit 6011			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6543	Robert Ritchie, 8/4/17 deposition Exhibit 6012			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6544	Robert Ritchie, 8/4/17 deposition Exhibit 6013			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6545	Robert Ritchie, 8/4/17 deposition Exhibit 6014			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6546	Darren Hurst, 8/7/17 deposition Exhibit 16			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6547	Darren Hurst, 8/7/17 deposition Exhibit 17			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6548	Darren Hurst, 8/7/17 deposition Exhibit 18			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6549	Darren Hurst, 8/7/17 deposition Exhibit 19			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6550	Darren Hurst, 8/7/17 deposition Exhibit 20			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6551	Darren Hurst, 8/7/17 deposition Exhibit 21			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6552	Darren Hurst, 8/7/17 deposition Exhibit 22			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6553	Darren Hurst, 8/7/17 deposition Exhibit 23			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6554	Darren Hurst, 8/7/17 deposition Exhibit 24			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6555	Darren Hurst, 8/7/17 deposition Exhibit 25			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6556	Darren Hurst, 8/7/17 deposition Exhibit 26			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6557	Lora White, 8/16/17 deposition Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6558	Lora White, 8/16/17 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6559	Lora White, 8/16/17 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6560	Lora White, 8/16/17 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6561	Lora White, 8/16/17 deposition Exhibit 05			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6562	Lora White, 8/16/17 deposition Exhibit 06			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6563	Lora White, 8/16/17 deposition Exhibit 07			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6564	Lora White, 8/16/17 deposition Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6565	Lora White, 8/16/17 deposition Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6566	Lora White, 8/16/17 deposition Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6567	Lora White, 8/16/17 deposition Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6568	William Nicholson, 3/21/11 deposition Exhibit 01.pdf	BPV-DEP-00047917	BPV-DEP-00047922	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6569	William Nicholson, 3/21/11 deposition Exhibit 02.pdf	BPV-DEP-00047923	BPV-DEP-00047929	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6570	William Nicholson, 3/21/11 deposition Exhibit 03.pdf	BPV-DEP-00047930	BPV-DEP-00047942	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6571	William Nicholson, 3/21/11 deposition Exhibit 04.pdf	BPV-DEP-00047943	BPV-DEP-00047945	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6572	William Nicholson, 3/21/11 deposition Exhibit 05.pdf	BPV-DEP-00047946	BPV-DEP-00047952	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6573	William Nicholson, 3/21/11 deposition Exhibit 06.pdf	BPV-DEP-00047953	BPV-DEP-00047963	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6574	William Nicholson, 3/21/11 deposition Exhibit 07.pdf	BPV-DEP-00047964	BPV-DEP-00047965	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6575	William Nicholson, 3/21/11 deposition Exhibit 08.pdf	BPV-DEP-00047966	BPV-DEP-00047966	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6576	William Nicholson, 3/21/11 deposition Exhibit 09.pdf	BPV-DEP-00047967	BPV-DEP-00047971	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6577	William Nicholson, 3/21/11 deposition Exhibit 10.pdf	BPV-DEP-00047972	BPV-DEP-00047978	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6578	William Nicholson, 3/21/11 deposition Exhibit 11.pdf	BPV-DEP-00047979	BPV-DEP-00047991	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6579	William Nicholson, 3/21/11 deposition Exhibit 12.pdf	BPV-DEP-00047992	BPV-DEP-00048036	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6580	William Nicholson, 3/21/11 deposition Exhibit 13.pdf	BPV-DEP-00048037	BPV-DEP-00048046	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6581	William Nicholson, 3/21/11 deposition Exhibit 14.pdf	BPV-DEP-00048047	BPV-DEP-00048048	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6582	William Nicholson, 3/21/11 deposition Exhibit 15.pdf	BPV-DEP-00048049	BPV-DEP-00048072	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6583	William Nicholson, 3/21/11 deposition Exhibit 16.pdf	BPV-DEP-00048073	BPV-DEP-00048074	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6584	William Nicholson, 3/21/11 deposition Exhibit 17.pdf	BPV-DEP-00048075	BPV-DEP-00048076	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6585	William Nicholson, 3/21/11 deposition Exhibit 18.pdf	BPV-DEP-00048077	BPV-DEP-00048091	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6586	William Nicholson, 3/21/11 deposition Exhibit 19.pdf	BPV-DEP-00048092	BPV-DEP-00048094	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6587	William Nicholson, 3/21/11 deposition Exhibit 20.pdf	BPV-DEP-00048095	BPV-DEP-00048097	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802
6588	William Nicholson, 3/21/11 deposition Exhibit 21.pdf	BPV-DEP-00048098	BPV-DEP-00048098	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6589	William Nicholson, 3/21/11 deposition Exhibit 22.pdf	BPV-DEP-00048099	BPV-DEP-00048099	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6590	William Nicholson, 3/21/11 deposition Exhibit 23.pdf	BPV-DEP-00048100	BPV-DEP-00048122	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6591	William Nicholson, 3/21/11 deposition Exhibit 25.pdf	BPV-DEP-00048123	BPV-DEP-00048123	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6592	William Nicholson, 3/21/11 deposition Exhibit 26.pdf	BPV-DEP-00048124	BPV-DEP-00048124	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6593	William Nicholson, 3/21/11 deposition Exhibit 27.pdf	BPV-DEP-00048125	BPV-DEP-00048126	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6594	William Nicholson, 3/21/11 deposition Exhibit 28.pdf	BPV-DEP-00048127	BPV-DEP-00048130	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6595	William Nicholson, 3/21/11 deposition Exhibit 29.pdf	BPV-DEP-00048131	BPV-DEP-00048132	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6596	William Nicholson, 3/21/11 deposition Exhibit 30.pdf	BPV-DEP-00048133	BPV-DEP-00048133	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6597	William Nicholson, 3/21/11 deposition Exhibit 31.pdf	BPV-DEP-00048134	BPV-DEP-00048134	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6598	William Nicholson, 3/21/11 deposition Exhibit 32.pdf	BPV-DEP-00048135	BPV-DEP-00048136	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6599	William Nicholson, 3/21/11 deposition Exhibit 33.pdf	BPV-DEP-00048137	BPV-DEP-00048137	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6600	William Nicholson, 3/21/11 deposition Exhibit 34.pdf	BPV-DEP-00048138	BPV-DEP-00048139	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6601	William Nicholson, 3/21/11 deposition Exhibit 35.pdf	BPV-DEP-00048140	BPV-DEP-00048141	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6602	William Nicholson, 3/21/11 deposition Exhibit 36.pdf	BPV-DEP-00048142	BPV-DEP-00048143	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6603	William Nicholson, 3/21/11 deposition Exhibit 37.pdf	BPV-DEP-00048144	BPV-DEP-00048144	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6604	William Nicholson, 3/21/11 deposition Exhibit 38.pdf	BPV-DEP-00048145	BPV-DEP-00048147	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6605	William Nicholson, 3/21/11 deposition Exhibit 39.pdf	BPV-DEP-00048148	BPV-DEP-00048149	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6606	William Nicholson, 3/21/11 deposition Exhibit 40.pdf	BPV-DEP-00048150	BPV-DEP-00048150	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6607	William Nicholson, 3/21/11 deposition Exhibit 41.pdf	BPV-DEP-00048151	BPV-DEP-00048151	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6608	William Nicholson, 3/21/11 deposition Exhibit 42.pdf	BPV-DEP-00048152	BPV-DEP-00048170	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6609	William Nicholson, 3/21/11 deposition Exhibit 43.pdf	BPV-DEP-00048171	BPV-DEP-00048171	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6610	William Nicholson, 3/21/11 deposition Exhibit 44.pdf	BPV-DEP-00048172	BPV-DEP-00048173	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6611	William Nicholson, 3/21/11 deposition Exhibit 45.pdf	BPV-DEP-00048174	BPV-DEP-00048175	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6612	William Nicholson, 3/21/11 deposition Exhibit 46.pdf	BPV-DEP-00048176	BPV-DEP-00048180	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6613	William Nicholson, 3/21/11 deposition Exhibit 47.pdf	BPV-DEP-00048181	BPV-DEP-00048181	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6614	William Nicholson, 3/21/11 deposition Exhibit 48.pdf	BPV-DEP-00048182	BPV-DEP-00048182	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6615	William Nicholson, 10/4/11 Defendant Exhibit 1.pdf	BPV-DEP-00048333	BPV-DEP-00048333	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6616	William Nicholson, 10/4/11 Plaintiff Exhibit 1.pdf	BPV-DEP-00048334	BPV-DEP-00048338	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6617	William Nicholson, 10/4/11 Plaintiff Exhibit 2.pdf	BPV-DEP-00048339	BPV-DEP-00048376	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6618	Barbara Delio-Cox, 4/28/11 deposition Exhibit 01	BPV-DEP-00048475	BPV-DEP-00048475	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6619	Barbara Delio-Cox, 4/28/11 deposition Exhibit 02	BPV-DEP-00048476	BPV-DEP-00048476	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6620	Barbara Delio-Cox, 4/28/11 deposition Exhibit 03	BPV-DEP-00048477	BPV-DEP-00048477	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6621	Barbara Delio-Cox, 4/28/11 deposition Exhibit 04	BPV-DEP-00048478	BPV-DEP-00048478	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6622	Barbara Delio-Cox, 4/28/11 deposition Exhibit 05	BPV-DEP-00048479	BPV-DEP-00048479	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6623	Barbara Delio-Cox, 4/28/11 deposition Exhibit 06	BPV-DEP-00048480	BPV-DEP-00048480	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6624	Barbara Delio-Cox, 4/28/11 deposition Exhibit 07	BPV-DEP-00048481	BPV-DEP-00048481	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6625	Barbara Delio-Cox, 4/28/11 deposition Exhibit 08	BPV-DEP-00048482	BPV-DEP-00048482	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6626	Barbara Delio-Cox, 4/28/11 deposition Exhibit 09	BPV-DEP-00048483	BPV-DEP-00048483	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6627	Barbara Delio-Cox, 4/28/11 deposition Exhibit 10	BPV-DEP-00048484	BPV-DEP-00048484	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6628	Barbara Delio-Cox, 4/28/11 deposition Exhibit 11	BPV-DEP-00048485	BPV-DEP-00048485	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6629	Barbara Delio-Cox, 4/28/11 deposition Exhibit 12	BPV-DEP-00048486	BPV-DEP-00048486	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6630	Barbara Delio-Cox, 4/28/11 deposition Exhibit 13	BPV-DEP-00048487	BPV-DEP-00048487	FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6631	Kush Desai, 6/6/2017 deposition Exhibit 01			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6632	Kush Desai, 6/6/2017 deposition Exhibit 02			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6633	Kush Desai, 6/6/2017 deposition Exhibit 03			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6634	Kush Desai, 6/6/2017 deposition Exhibit 04			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802
6635	Kush Desai, 6/6/2017 deposition Exhibit 08			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6636	Kush Desai, 6/6/2017 deposition Exhibit 09			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
6637	Kush Desai, 6/6/2017 deposition Exhibit 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
6638	Kush Desai, 6/6/2017 deposition Exhibit 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
6639	Kush Desai, 6/6/2017 deposition Exhibit 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6640	Kush Desai, 6/6/2017 deposition Exhibit 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6641	Kush Desai, 6/6/2017 deposition Exhibit 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6642	Natalie Wong, 10/18/16 deposition Exhibit 537			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 801; 802; MIL #1
6835	"Should you worry about the radiation from CT scans?" https://www.washingtonpost.com/national/health-science/how-much-to-worry-about-the-radiation-from-ct-scans/2016/01/04/8dfb80cc-8a30-11e5-be39-0034bb576eeestory.html?utmterm=.67f42f94c11d Accessed on February 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6836	2016 Revised ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism. https://www.acr.org/~media/a569be8f18ae4cfaa2868b6e0984dbd8.pdf Accessed January 16, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6837	Aarabi B, Harrop JS, Tator CH, Alexander M, Dettori JR, Grossman RG, Fehlings MG, Mirvis SE, Shanmuganathan K, Zacherl KM, Burau KD, Frankowski RF, Toups E, Shaffrey CI, Guest JD, Harkema SJ, Habashi NM, Andrews P, Johnson MM, Rosner MK. Predictors of Pulmonary Complications in Blunt Traumatic Spinal Cord Injury. J Neurosurg Spine. 2012 Sep;17(1 Suppl):38-45. doi:	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6838	Abtahian F, Hawkins BM, Ryan DP. Inferior vena cava filter usage, complications, and retrieval rate in cancer patients. Am J Med 2014; 127:1111-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6839	ACR Appropriateness Criteria® radiologic management of inferior vena cava filters. Available at: http://guidelines.gov/content.aspx?id=15730#Section420 .	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6840	ACR SIR, Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism (2014)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6841	ACR-SIR Practice guideline on informed consent for image-guided procedures 2011 https://www.sirweb.org/globalassets/aasociety-of-interventional-radiology-home-	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6842	ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism. Revised 2016.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6843	ACR-SIR-SPR Practice Parameter on Informed Consent for Image-Guided Procedures. Revised 2016. https://www.acr.org/~media/ACR/Files/Practice-Parameters/InformedConsent-ImagGuided.pdf	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6844	Adair JD, Harvey KP, Mahmood A. Inferior vena cava filter migration to right ventricle with destruction of tricuspid valve: a case report. J Trauma. 2008 Feb;64(2):509-11. doi: 10.1097/TA.0b013e318058251c.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6845	Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral Apixaban for the Treatment of Acute Thromboembolism. N Engl J Med. 2013 Aug 29;369(9):799-808. doi: 10.1056/NEJMoa1302507. Epub 2013 Jul 1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6846	Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; AMPLIFY-EXT Investigators. Apixaban for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2013 Feb 21;368(8):699-708. doi: 10.1056/NEJMoa1207541. Epub 2012 Dec 8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6847	Ahmad I, Yeddula K, Wicky S, Kalva SP. Clinical sequelae of thrombus in an inferior vena cava filter. <i>Cardiovasc Intervent Radiol.</i> 2010 Apr;33(2):285-9. doi: 10.1007/s00270-009-9664-x. Epub 2009 Aug 18.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6848	Alam M, Levine TB. Echocardiographic features of Embolized inferior venacaval filter to the right ventricle: a case report. <i>Angiology.</i> 1993 Apr;44(4):338-40.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6849	Albrecht RM, Garwe T, Carter SM, Maurer AJ. Retrievable inferior vena cava filters in trauma patients: factor that influence removal rate and an argument for institutional protocols. <i>Am J Surg</i> 2012; 203:297-302.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6850	Albright HL. Thrombophlebitis: The Problem of Treatment. <i>N Engl J Med.</i> 1947 Jun 19;236(25):928-33. doi: 10.1056/NEJM194706192362502.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6851	Allen CJ, Murray CR, Meizoso JP, Ginzburg E, Schulman CI, Lineen EB, Namias N, Proctor KG. Surveillance and Early Management of Deep Vein Thrombosis Decreases Rate of Pulmonary Embolism in High-Risk Trauma Patients. <i>J Am Coll Surg.</i> 2016 Jan;222(1):65-72. doi: 10.1016/j.jamcollsurg.2015.10.014. Epub 2015 Nov 4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6852	Allen TL, Carter JL, Morris BJ, Harker CP, Stevens MH. Retrievable vena cava filters in trauma patients for high-risk prophylaxis and prevention of pulmonary embolism. <i>Am J Surg.</i> 2005 Jun;189(6):656-61.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6853	Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JE. Mortality in patients treated for pulmonary embolism. <i>JAMA</i> 1976;236(13):1477-1480.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6854	American Venous Forum. Upcoming IVC Filter Data From the American Venous Registry [not a peer-reviewed article]	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6855	Amole AO, Kathuria MK, Ozkan OS, Gill AS, Ozkan EO. Lumbar artery laceration with retroperitoneal hematoma after placement of a G-2 inferior vena cava filter. <i>Cardiovasc Intervent Radiol.</i> 2008 Nov-Dec;31(6):1257-9. doi: 10.1007/s00270-008-9365-x. Epub 2008 Jun 10.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6856	An T, Moon E, Bullen J, Kapoor B, Wu A, Sands M, Wang W. Prevalence and Clinical Consequences of Fracture and Fragment Migration of the Bard G2 Filter: Imaging and Clinical Follow-up in 684 Implantations. <i>J Vasc Interv Radiol.</i> 2014 Jun;25(6):941-8. doi: 10.1016/j.jvir.2014.01.035. Epub 2014 Mar 18.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6857	Anderson FA Jr, Spencer FA. Risk Factors for Venous Thromboembolism. <i>Circulation.</i> 2003 Jun 17;107(23 Suppl 1):I9-16.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6858	Anderson FA Jr, Hirsh J, White K, Fitzgerald RH Jr; Hip and Knee Registry Investigators. Temporal trends in prevention of venous thromboembolism following primary total hip or knee arthroplasty 1996-2001: findings from the Hip and Knee Registry. <i>Chest</i> 124 (Suppl): S349-S356, 2003	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6859	Anderson FA, Jr, Wheeler HB, Goldberg RJ, et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. <i>Arch Intern Med</i> 1991; 151: 933-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6860	Andreoli JM, Lewandowski RJ, Vogelzang RL, Ryu RK. Comparison of complication rates associated with permanent and retrievable inferior vena cava filters: a review of the MAUDE database. <i>J Vasc Interv Radiol.</i> 2014 Aug;25(8):1181-5. doi: 10.1016/j.jvir.2014.04.016. Epub 2014 Jun 11.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6861	Andreoli JM, Thornburg BG, Hickey RM. Inferior Vena Cava Filter Related Thrombus Deep Vein Thrombosis Data and Management. <i>Semin Intervent Radiol.</i> 2016 Jun;33(2):101-4. doi: 10.1055/s-0036-1581087.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6862	Angel LF, Tapson V, Galgon RE, Restrepo MI, Kaufman J. Systematic Review of the Use of Retrievable Inferior Vena Cava Filters. <i>J Vasc Interv Radiol.</i> 2011 Nov;22(11):1522-1530.e3. doi: 10.1016/j.jvir.2011.08.024.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6863	Antevil JL, Sise MJ, Sack DI, Sasadeusz KJ, Swanson SM, Rivera L, Lome BR, Weingarten KE, Kaminski SS. Retrievable Vena Cava Filters for Preventing Pulmonary Embolism in Trauma Patients: A Cautionary Tale. <i>J Trauma.</i> 2006 Jan;60(1):35-40.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6864	Araki T, Ishihara C. Images in cardiovascular medicine. Retroperitoneal Hematoma After Inferior Vena Cava Filter Insertion. <i>Circulation.</i> 2007 Sep	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6865	Arjomand H, Surabhi S, Wolf NM. Right ventricular foreign body: percutaneous transvenous retrieval of a Greenfield filter from the right ventricle--a case report. <i>Angiology.</i> 2003. 54(1): 109-13.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6866	Aryafar H, Kinney TB. Optional inferior vena cava filters in the trauma patient. <i>Semin Intervent Radiol.</i> 2010 Mar;27(1):68-80. doi: 10.1055/s-0030-1247890.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6867	Asch MR. Initial experience in humans with a new retrievable inferior vena cava filter. <i>Radiology.</i> 2002 Dec;225(3):835-44.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6868	Assifi MM, Bagameri G, Dimuzio PJ, Eisenberg JA. Management of infected caval filter with simultaneous aortic pseudoaneurysm and retroperitoneal perforation: a case report and literature review. <i>Vascular.</i> 2012 Aug;20(4):225-8. doi: 10.1258/vasc.2011.cr0310. Epub 2012 Jun 11.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6869	Athanasoulis CA, Kaufman JA, Halpern EF, Waltman AC, Geller SC, Fan CM. Inferior vena caval filters: review of a 26-year single-center clinical experience. <i>Radiology.</i> 2000 Jul;216(1):54-66.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6870	Attar S, Boyd D, Layne E, McLaughlin J, Mansberger AR, Cowley RA. Alterations in coagulation in coagulation and fibrinolytic systems following trauma. <i>J Trauma</i> 1969; 9:939-965.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6871	Avgerinos ED, Bath J, Stevens J, McDaniel B, Marone L, Dillavou E, Cho JS, Makaroun MS, Chaer RA. Technical and patient-related characteristics associated with challenging retrieval of inferior vena cava filters. <i>Eur J Vasc Endovasc Surg.</i> 2013 Sep;46(3):353-9. doi: 10.1016/j.ejvs.2013.06.007. Epub 2013 Jul 5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6872	Aw-Zoretic J, Collins JD. Considerations for Imaging the Inferior Vena Cava (IVC) with without IVC Filters. <i>Semin Intervent Radiol.</i> 2016 Jun;33(2):109-21. doi: 10.1055/s-0036-1583207.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6873	Bach JR, Zaneuski R, Lee H. Cardiac arrhythmias from a malpositioned Greenfield filter in a traumatic quadriplegic. <i>Am J Phys Med Rehabil.</i> 1990 Oct;69(5):251-3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6874	Balas EA. Information Systems Can Prevent Errors and Improve Quality. <i>J Am Med Inform Assoc.</i> 2001 Jul-Aug;8(4):398-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6875	Ballew KA, Philbrick JT, Becker DM. Vena cava filter devices. <i>Clin Chest Med.</i> 1995 Jun;16(2):295-305.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6876	Bandle J, Shackford SR, Sise CB, Knudson MM; CLOTT Study Group. Variability is the Standard: The management of Venous Thromboembolic Disease Following Trauma. <i>J Trauma Acute Care Surg.</i> 2014 Jan;76(1):213-6. doi: 10.1097/TA.0b013e3182aa2fa9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6877	Bard Denali Vena Cava Filter. Femoral Vein Approach. Instructions for Use. http://www.bardpv.com/wp-content/uploads/2014/02/DenaliBAW5410500-US-FEM.pdf Accessed on January 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6878	Bard Eclipse Vena Cava Filter. Femoral Vein Approach. Instructions for Use. http://www.bardpv.com/wp-content/uploads/2014/02/EclipseVenaCavaFilterFemIFU.pdf Accessed on January 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6879	Bard G2 Filter System. Femoral Vein Approach. Instructions for Use. http://www.bardpv.com/filterfacts/pdf/ifus/G2-Fem-BAW5250500-R2.pdf Accessed September 1, 2016.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6880	Bariatric Surgery Guidelines, Medical Guidelines for Clinical Practice Guidelines for the Perioperative Nutritional, Metabolic, and Nonsurgical Support of the Bariatric Patient - 2013 Update	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6881	Barral FG. Vena cava filters: why, when, what and how? <i>J Cardiovasc Surg (Torino).</i> 2008 Feb;49(1):35-49.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6882	Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. <i>Lancet</i> 1960;1(7138):1309-1312.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6883	Bauer G. The introduction of heparin therapy in cases of early thrombosis. <i>Circulation</i> 1959;19(1):108-109.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6884	Becattini C, Agnelli G. Acute pulmonary embolism: risk stratification in the emergency department. <i>Intern Emerg Med</i> 2007;2(2):119-129.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6885	Becker DM, Philbrick JT, Selby JB. Inferior Vena Cava Filters. Indications, safety, effectiveness. <i>Arch Intern Med.</i> 1992 Oct;152(10):1985-94.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6886	Bélénotti P, Sarlon-Bartoli G, Bartoli MA, Benyammine A, Thevenin B, Muller C, Serratrice J, Magnan PE, Weiller PJ. Vena cava filter migration: an unappreciated complication. About four cases and review of the literature. <i>Ann Vasc Surg.</i> 2011 Nov;25(8):1141.e9-14. doi: 10.1016/j.avsg.2011.03.016.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6887	Benenati, Society of Interventional Radiology letter re: FDA Public Health Notification - Removing Retrievable Inferior Vena Cava Filters: Initial Communication	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6888	Benenati, Society of Interventional Radiology Responds to FDA Blood Clot Device (IVC Filter) Advisory	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6889	Berci V, Bottomley JR, Thomas SM, Taneja S, Gaines PA, Cleveland TJ. Long-term retrievability of IVC filters: should we abandon permanent devices? Cardiovasc Intervent Radiol. 2007 Sep-Oct;30(5):820-7. Epub 2007 Sep 1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6890	Bikdeli B, Ross JS, Krumholz HM. Data Desert for Inferior Vena Caval Filters: Limited Evidence, Supervision, and Research. JAMA Cardiol. 2017 Jan 1;2(1):3-4. doi: 10.1001/jamacardio.2016.3764.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6891	Billett H.H., Jacobs L.G., Madsen E.M., Giannattasio E.R., Mahesh S., Cohen H.W. Efficacy of inferior vena cava filters in anticoagulated patients. J Thromb Haemost. 2007;5:1848-1853.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6892	Binkert CA, Drooz AT, Caridi JG, Sands MJ, Bjarnason H, Lynch FC, Rilling WS, Zambuto DA, Stavropoulos SW, Venbrux AC, Kaufman JA. Technical success and safety of retrieval of the G2 filter in a prospective, multicenter study. J Vasc Interv Radiol. 2009 Nov;20(11):1449-53. doi: 10.1016/j.jvir.2009.08.007.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6893	Binkert CA, Sasadeusz K, Stavropoulos SW. Retrievability of the Recovery Vena Cava Filter after Dwell Times Longer than 180 Days. J Vasc Interv Radiol. 2006 Feb;17(2 Pt 1):299-302.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6894	Birkmeyer NJ, Finks JF, English WJ, Carlin AM, Hawasli AA, Genaw JA, Wood MH, Share DA, Birkmeyer JD; Michigan Bariatric Surgery Collaborative. Risks and Benefits of Prophylactic Inferior Vena Cava Filters in Patients Undergoing Bariatric Surgery. J Hosp Med. 2013 Apr;8(4):173-7. doi: 10.1002/jhm.2013. Epub 2013 Feb 8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6895	Birkmeyer NJ, Share D, Baser O, Carlin AM, Finks JF, Pesta CM, Genaw JA, Birkmeyer JD; Michigan Bariatric Surgery Collaborative. Preoperative placement of inferior vena cava filters and outcomes after gastric bypass surgery. Ann Surg. 2010 Aug;252(2):313-8. doi: 10.1097/SLA.0b013e3181e61e4f.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6896	Bjarnason H, Yedlicka JW Jr, Hunter DW, Castañeda-Zuñiga WR, Amplatz K. In vitro metal fatigue testing of inferior vena cava filters. Invest Radiol. 1994 Sep;29(9):817-21.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6897	Blaszcyk H, Wollan PC, Witkiewicz AK, Björnsson J. Death from pulmonary thromboembolism in severe obesity: lack of association with established genetic and clinical risk factors. Virchows Arch. 1999 Jun;434(6):529-32.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6898	Blebea J, Wilson R, Waybill P, Neumyer MM, Blebea JS, Anderson KM, Atnip RG. Deep Vein Thrombosis After Percutaneous Insertion of Vena Caval Filters. J Vasc Surg. 1999 Nov;30(5):821-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6899	Bochenek KM, Aruny JE, Tal MG. Right Atrial Migration and percutaneous retrieval of a Gunther Tulip inferior vena cava filter. J Vasc Interv Radiol. 2003 Sep;14(9 Pt 1):1207-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6900	Bos A, Van Ha T, van Beek D, Ginsburg M, Zangan S, Navuluri R, Lorenz J, Funaki B. Strut Penetration: Local Complications, Breakthrough Pulmonary Embolism, and Retrieval Failure in Patients with Celect Vena Cava Filters. J Vasc Interv Radiol. 2015 Jan;26(1):101-6. doi: 10.1016/j.jvir.2014.09.010. Epub 2014	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6901	Bos AS, Tullius T, Patel M, Leef JA, Navuluri R, Lorenz JM, Van Ha TG. Indwelling and Retrieval Complications of Denali and Celect Inferior Vena Cava Filters. J Vasc Interv Radiol. 2016 Jul;27(7):1021-6. doi:	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6902	Brathwaite CE, Mure AJ, O'Malley KF, Spence RK, Ross SE. Complications of Anticoagulation for Pulmonary Embolism in Low Risk Trauma Patients. Chest. 1993 Sep;104(3):718-20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6903	Braun MA, Collins MB, Sarrafzadeh M, Koslow AR. Percutaneous retrieval of tandem right atrial Greenfield filters. AJR Am J Roentgenol. 1991 Jul;157(1):199.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6904	Brenner DJ, Hall EJ. Computed tomography – an increasing source of radiation exposure. N Engl J Med 2007; 357:2277-84.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6905	Brotman DJ, Shihab HM, Prakasa KR, Kebede S, Haut ER, Sharma R, Shermock K, Chelladurai Y, Singh S, Segal JB. Pharmacologic and Mechanical Strategies for Preventing Venous Thromboembolism After Bariatric Surgery A Systematic Review and Meta-analysis. JAMA Surg. 2013 Jul;148(7):675-86. doi: 10.1001/jamasurg.2013.72.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6906	Brown AP, Miller MJ, Smith TP. Caval Penetration with Retroperitoneal Hemorrhage Following Placement of an Inferior Vena Cava (IVC) Filter. Semin Intervent Radiol. 2007 Sep;24(3):312-5. doi: 10.1055/s-2007-985741.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6907	Brown SL, Bright RA, Tavis DR. Medical Device Epidemiology and Surveillance – Patient Safety is the Bottom Line. Expert Rev Med Devices. 2004 Sep;1(1):1-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6908	Buckley O, DeVore A, Ersoy H, Sobieszczek P, Auger W, Kwong R, Rybicki F, Goldhaber S. "Embolism after Inferior Vena Cava Filter Mesh Fragmentation," Letter to the Editor, November 2010 JVIR, Vol. 21, Number 11, 1782-3, DOI: 10.1016/j.jvir.2010.07.021.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6909	Bull PG, Mendel H, Schlegl A. Günther vena caval filter: clinical appraisal. J Vasc Interv Radiol. 1992 May;3(2):395-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6910	Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW; Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis. Ann Intern Med. 2004 Jun 1;140(11):867-73.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6911	Burge AJ, Freeman KD, Klapper PJ, Haramati LB. Increased diagnosis of pulmonary embolism without a corresponding decline in mortality during the CT era. Clin Radiol 2008;63(4):381–386.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6912	Bustamante M, Abascal F, Garcia-Valtuille R, González-Tutor A, Gómez JM. Sudden death in a patient caused by migration of an Antheor vena cava filter to the heart. J Vasc Interv Radiol. 1998. 9(3): 521-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6913	Cain PG. Comment on "Treatment of venous disease--the innovators". J Vasc Surg. 1995 Sep;22(3):341-3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6914	Cantwell CP, Pennypacker J, Singh H, Scorza LB, Waybill PN, Lynch FC. Comparison of the recovery and G2 filter as retrievable inferior vena cava filters. J Vasc Interv Radiol. 2009 Sep;20(9):1193-9. doi: 10.1016/j.jvir.2009.05.037. Epub	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6915	Caplin DM, Nikolic B, Kalva SP, Ganguli S, Saad WE, Zuckerman DA. Quality Improvement Guidelines for the Performance of Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism. J Vasc Interv Radiol. 2011 Nov;22(11):1499-506. doi: 10.1016/j.jvir.2011.07.012. Epub 2011 Sep 3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
6916	Cappelli F, Vignini S, Baldereschi GJ. ALN inferior vena cava filter upside down rotation with chest caval migration in an asymptomatic patient. J Invasive Cardiol. 2010 Aug;22(8):E153-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6917	Carabasi RA 3rd, Moritz MJ, Jarrell BE. Complications encountered with the use of the Greenfield filter. Am J Surg. 1987 Aug;154(2):163-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6918	Carlin AM, Tyburski JG, Wilson RF, Steffes C. Prophylactic and therapeutic inferior vena cava filters to prevent pulmonary emboli in trauma patients. Arch Surg. 2002 May;137(5):521-5; discussion 525-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6919	Carman TL, Alahmad A. Update on vena cava filters. Curr Treat Options Cardiovasc Med. 2008 Apr;10(2):101-11.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6920	Castaneda F, Herrera M, Cragg AH, Salamonowitz E, Lund G, Castaneda-Zuniga WR, Amplatz K. Migration of a Kimray-Greenfield filter to the right ventricle. Radiology. 1983 Dec;149(3):690.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6921	Center for Devices and Radiological Health. Food and Drug Administration. The MAUDE - Manufacturer and User Facility Device Experience Web Homepage. Available from: 142. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/search.CFM .	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6922	Centers for Disease Control and Prevention. Principles of Epidemiology in Public Health Practice, Third Edition An Introduction to Applied Epidemiology and Biostatistics https://www.cdc.gov/ophs/csels/dsepd/ss1978/lesson3/section2.html accessed on March 6, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6923	Chana-Rodriguez F, Mañanes RP, Rojo-Manaute J, Haro JAC, Vaquero-Martín J. Methods and Guidelines for Venous Thromboembolism Prevention in Polytrauma Patients with Pelvic and Acetabular Fractures. <i>Open Orthop J</i> . 2015; 9: 313–320.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6924	Charalel RA, Durack JC, Mao J, Ross JS, Meltzer AJ, Sedrakyan A. Statewide Inferior Vena Cava Filter Placement, Complications, and Retrievals: Epidemiology and Recent Trends. <i>Med Care</i> . 2018 Mar;56(3):260-265. doi: 10.1097/MLR.0000000000000867.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6925	Charles HW, Black M, Kovacs S, Gohari A, Arampulikan J, McCann JW, Clark TW, Bashar M, Steiger D. G2 Inferior Vena Cava Filter: Retrievalability and Safety. <i>J Vasc Interv Radiol</i> . 2009 Aug;20(8):1046-51. doi: 10.1016/j.jvir.2009.03.046. Epub 2009 Jun 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6926	Charlton-Ouw KM, Leake SS, Sola CN, Sandhu HK, Albarado R, Holcomb JB, Miller CC 3rd, Safi HJ, Azizzadeh A. Technical and financial feasibility of an inferior vena cava filter retrieval program at a level one trauma center. <i>Ann Vasc Surg</i> . 2015 Jan;29(1):84-9. doi: 10.1016/j.avsg.2014.05.018. Epub 2014 Jun 12.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6927	Chen D, Apple DF Jr, Hudson LM, Bode R. Medical Complications During Acute Rehabilitation Following Spinal Cord Injury – Current Experience of the Model Systems. <i>Arch Phys Med Rehabil</i> . 1999 Nov;80(11):1397-401.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6928	Cherry RA, Nichols PA, Snively TM, David MT, Lynch FC. Prophylactic inferior vena cava filters: do they make a difference in trauma patients? <i>J Trauma</i> . 2008 Sep;65(3):544-8. doi: 10.1097/TA.0b013e31817f980f.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6929	Cheung MC, Asch MR, Gandhi S, Kingdom JC. Temporary Inferior Vena Cava Filter Use in Pregnancy. <i>J Thromb Haemost</i> . 2005 May;3(5):1096-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6930	Chitwood WR Jr, Chiang KS, Williams JM, Zeri RS, Semer DA. Embolectomy of a Bird's Nest vena cava filter. <i>Ann Thorac Surg</i> . 1994 Dec;58(6):1766-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6931	Cipolla J, Weger NS, Sharma R, Schrag SP, Sarani B, Truitt M, Lorenzo M, Sims CA, Kim PK, Torigian D, Temple-Lykens B, Sicoutis CP, Stawicki SP. Complications of vena cava filters: A comprehensive clinical review. <i>OPUS 12 Scientist</i> 2008 Vol. 2, No. 2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6932	CIRA, CIRA Statement on IVC Filter Safety Concern Noted by Health Canada	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6933	CLOTS, Effectiveness of intermittent pneumatic compression in reduction of risk of DVT	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6934	Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, Turpie AG, Egberts JF, Lensing AW; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. <i>BMJ</i> . 2006 Feb 11;332(7537):325-9. Epub 2006 Jan 26.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6935	Connolly PH, Balachandran VP, Trost D, Bush HL Jr. Open Surgical Inferior Vena Cava Filter Retrieval for Caval Perforation and a Novel Technique for minimal cavotomy filter extraction. <i>J Vasc Surg</i> . 2012 Jul;56(1):256-9; discussion 259. doi: 10.1016/j.jvs.2011.12.065. Epub 2012 Apr 12.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6936	Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. <i>N Engl J Med</i> . 2009 Sep 17;361(12):1139-51. doi: 10.1056/NEJMoa0905561. Epub 2009 Aug 30.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6937	Cook AD, Gross BW, Osler TM, Rittenhouse KJ, Bradburn EH, Shackford SR, Rogers FB. Vena Cava Filter Use in Trauma and Rates of Pulmonary Embolism, 2003-2015. <i>JAMA Surg</i> . 2017 Aug 1;152(8):724-732. doi: 10.1093/ajph.2017.07.001.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6938	Corriere, M.A., et al., Vena cava filters and inferior vena cava thrombosis. <i>J Vasc Surg</i> . 2007. 45(4): 789-94.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6939	Cura, M., Computed tomography evaluation of inferior vena cava Bard G2 filters. (Meeting Abstract). 2010: S3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6940	Cuschieri, Inflammation and the Host Response to Injury a Large Scale Collaborative Project: Patient-Oriented Research Core Standard Operating Procedure for Clinical Care X. Guidelines for Venous Thromboembolism	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6941	Cynamon J, Bakal CW, Epstein SB, Gabelman G. Percutaneous removal of a titanium Greenfield filter. <i>AJR Am J Roentgenol</i> . 1992 Oct;159(4):777-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6942	Damascelli B, Ticha V, Patelli G, et al. Use of a retrievable vena cava filter with low-intensity anticoagulation for prevention of pulmonary embolism in patients with cancer: an observational study in 106 cases. <i>J Vasc Interv Radiol</i> 2011;	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6943	Dardik A, Campbell KA, Yeo CJ, Lipsett PA. Vena cava filter ensnarement and delayed migration: an unusual series of cases. <i>J Vasc Surg</i> . 1997 Nov;26(5):869-74.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6944	Das M, Panter L, Wynn GJ, Taylor RM, Connor N, Mills JD, Kirchhof P, Gupta D. Primary Care Atrial Fibrillation Service – Outcomes from Consultant-Led Anticoagulation Assessment Clinics in the Primary Care Setting in the UK. <i>BMJ Open</i> . 2015 Dec 9;5(12):e009267. doi: 10.1136/bmjopen-2015-009267.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6945	Davies MG, Hart JP, El-Sayed HF. Efficacy of prophylactic inferior vena caval filters in prevention of pulmonary embolism in the absence of deep venous thrombosis. <i>J Vasc Surg Venous Lymphat Disord</i> . 2016 Jan;4(1):127-130.e1. doi: 10.1016/j.jvsv.2015.05.008. Epub 2015 Jul 16	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6946	Davison BD, Grassi CJ. TrapEase Inferior Vena Cava Filter Placed via the Basilic Arm Vein: A New Antecubital Access. <i>J Vasc Interv Radiol</i> . 2002 Jan;13(1):107-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6947	Dazley JM, Wain R, Vellinga RM, Cohen B, Agulnick MA. Prophylactic Inferior Vena Cava Filters Prevent Pulmonary Embolisms in High- Risk Patients Undergoing Major Spinal Surgery. <i>J Spinal Disord Tech</i> . 2012 Jun;25(4):190-5. doi: 10.1097/BSD.0b013e31821532bd.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6948	de Gonzalez AB, Mahesh M, Kim K-P; et al. Projected cancer risks from computed tomographic scans performed in the United States in 2007. <i>Arch Intern Med</i> . 2009; 169(22):2071-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6949	de Villiers L, Mackenzie S, Gibbs H, Leggett D, Neels M, Harper J., Initial Australian Experience with the Recovery Inferior Vena Cava Filter in Patients with Increased Risk of thromboembolic disease. <i>J Med Imaging Radiat Oncol</i> . 2008 Apr;52(2):124-9. doi: 10.1111/j.1440-1673.2008.01929.x.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6950	De Waele JJ, De Pauw M, Van Belleghem Y, Van Nooten G., Diagnosis of myocardial perforation by a Greenfield filter made by transesophageal echocardiography. <i>J Am Soc Echocardiogr</i> . 2002 Apr;15(4):374-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6951	Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. <i>N Engl J Med</i> . 1998;338:409-415.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6952	Defraigne JO, Vahdat O, Lacroix H, Limet R. Proximal migration of vena caval filters: report of two cases with operative retrieval. <i>Ann Vasc Surg</i> . 1995	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6953	Deitelzweig S.B., Johnson B.H., Lin J., Schulman K.L.; Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. <i>Am J Hematol</i> . 2011;86:217-220.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6954	Dennis JW, Menawat S, Von Thron J, Fallon WF Jr, Vinsant GO, Laneve LM, Jagger C, Frykberg ER. Efficacy of Deep Venous Thrombosis Prophylaxis in Trauma Patients and Identification of High-Risk Groups. <i>J Trauma</i> . 1993 Jul;35(1):132-8; discussion 138-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6955	Desai KR, Errea M, Ryu RK, Lewandowski RJ. Extraordinary Cases in Inferior Vena Cava Filter Retrieval. <i>Semin Intervent Radiol</i> . 2016 Jun;33(2):149-56. doi: 10.1055/s-0036-1582120.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6956	Desai KR, Lewandowski RJ, Salem R, Mouli SK, Karp JK, Laws JL, Ryu RK. Retrieval of Inferior Vena Cava Filters With Prolonged Dwell Time: A Single-Center Experience in 648 Retrieval Procedures. <i>JAMA Intern Med</i> . 2015 Sep;175(9):1572-4. doi: 10.1001/jamainternmed.2015.2561.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6957	Desai SS, Naddaf A, Pan J, Hood D, Hodgson KJ. Impact of Consensus Statements and Reimbursement on Vena Cava Filter Utilization. <i>J Vasc Surg</i> . 2016 Aug;64(2):425-429. doi: 10.1016/j.jvs.2016.01.046. Epub 2016 Mar 4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6958	Desai TR, Morcos OC, Lind BB, Schindler N, Caprini JA, Hahn D, Warner D, Gupta N. Complications of indwelling retrievable versus permanent inferior vena cava filters. J Vasc Surg Venous Lymphat Disord. 2014 Apr;2(2):166-73. doi: 10.1016/j.jvsv.2013.10.050. Epub 2014 Jan 16.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6959	Desai KR, Pandhi MB, Seedial SM, Errea MF, Salem R, Ryu RK, Lewandowski RJ. Retrievable IVC Filters: Comprehensive Review of Device-related Complications and Advanced Retrieval Techniques. Radiographics. 2017 Jul-Aug;37(4):1236-1245. doi: 10.1148/rg.2017160167.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6960	Desjardins B, Kamath SH, Williams D. Fragmentation, embolization, and left ventricular perforation of a recovery filter. J Vasc Interv Radiol. 2010 Aug;21(8):1293-6. doi: 10.1016/j.jvir.2010.04.019. Epub 2010 Jul 3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6961	Deso SE, Idakoji IA, Muelly MC, Kuo WT. Creation of an iOS and Android Mobile Application for Inferior Vena Cava (IVC) Filters. Semin Intervent Radiol. 2016 Jun;33(2):137-43. doi: 10.1055/s-0036-1583206.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6962	Deso SE, Idakoji IA, Kuo WT. Evidence-Based Evaluation of Inferior Vena Cava Filter Complications Based on Filter Type. Semin Intervent Radiol. 2016 Jun;33(2):93-100. doi: 10.1055/s-0036-1583208.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6963	DeVivo MJ, Krause JS, Lammertse DP. Recent Trends in Mortality and Causes of Death Among Persons with Spinal Cord Injury. Arch Phys Med Rehabil. 1999 Nov;80(11):1411-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6964	DeYoung E, Minocha J. Inferior Vena Cava Filters: Guidelines, Best Practice, and Expanding Indications. Semin Intervent Radiol. 2016 Jun;33(2):65-70. doi: 10.1055/s-0036-1581088.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6965	Dhand S, Stulberg SD, Puri L, Karp J, Ryu RK, Lewandowski RJ. The Role of Potentially Retrievable Inferior Vena Cava Filters in High-Risk Patients Undergoing Joint Arthroplasty. J Clin Diagn Res. 2015 Dec;9(12):TC01-3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6966	Dimick, J.B., D.O. Staiger and J.D. Birkmeyer, Ranking hospitals on surgical mortality: the importance of reliability adjustment. Health Serv Res, 2010. 45(6 Pt 1): 1614-29.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6967	Dinglasan LA, Oh JC, Schmitt JE, Trerotola SO, Shlansky-Goldberg RD, Stavropoulos SW. Radiology. Complicated inferior vena cava filter retrievals: associated factors identified at preretrieval CT. 2013 Jan;266(1):347-54. doi: 10.1148/radiol.12120372. Epub 2012 Oct 9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6968	Dinglasan LA, Trerotola SO, Shlansky-Goldberg RD, Mondschein J, Stavropoulos SW. Removal of Fractured Inferior Vena Cava Filters: Feasibility and Outcomes. J Vasc Interv Radiol. 2012 Feb;23(2):181-7. doi: 10.1016/j.jvir.2011.10.023. Epub 2011 Dec 16.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6969	Doe C, Ryu RK. Anatomic and Technical Considerations: Inferior Vena Cava Filter Placement. Semin Intervent Radiol. 2016 Jun;33(2):88-92. doi: 10.1055/s-0036-1581089.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6970	Dorsey, Migrated Kimray-Greenfield filter lodged in the right ventricle: surgical removal and transatrial reinsertion	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6971	Dossett, Unwarranted National Variation in the Use of Prophylactic Inferior Vena Cava Filters After Trauma: An analysis of the National Trauma Databank	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6972	Dowell, Celest Inferior Vena Cava Wall Strut Perforation Begets Additional Strut Perforation	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6973	Dreyer, Inferior vena cava filter migration to the right ventricle: a case report and review of filter migration and misdeployment	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6974	Duffett L, Carrier M. Inferior vena cava filters. J Thromb Haemost. 2017 Jan;15(1):3-12. doi: 10.1111/jth.13564. Epub 2016 Dec 26.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6975	Duffett LD, Gándara E, Cheung A, Bose G, Forster AJ, Wells PS. Outcomes of patients requiring insertion of an inferior vena cava filter: a retrospective observational study. Blood Coagul Fibrinolysis. 2014. 25(3): 266-71.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6976	Duggirala HJ, Herz ND, Caños DA, Sullivan RA, Schaaf R, Pinnow E, Marinac-Dabic D. Disproportionality analysis for signal detection of implantable cardioverter-defibrillator-related adverse events in the Food and Drug Administration Medical Device Reporting System. Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):87-93. doi: 10.1002/pds.2261. Epub 2011 Nov 18.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6977	Duperier, Acute Complications Associated with Greenfield Filter Insertion in High-Risk Trauma Patients	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6978	Durack JC, Westphalen AC, Kekulawela S, Bhanu SB, Avrin DE, Gordon RL, Kerlan RK. Perforation of the IVC, Rule Rather Than Exception, After Longer Indwelling Times for the Gunther Tulip and Celect Retrievable Filters. Cardiovasc Intervent Radiol. 2012 Apr;35(2):299-308. doi: 10.1007/s00270-011-0151-9. Epub 2011 Mar 30.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6979	Duszak Jr R, Parker L, Levin DC, Rao VM. Placement and removal of inferior vena cava filters: national trends in the Medicare population. Am Coll Radiol 2011; 8 (7) 483-489.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6980	Eifler AC, Lewandowski RJ, Gupta R, Karp J, Salem R, Lee J, Ryu RK. Optional or Permanent: Clinical Factors that Optimize Inferior Vena Cava Filter Utilization. J Vasc Interv Radiol. 2013 Jan;24(1):35-40. doi: 10.1016/j.jvir.2012.09.021. Epub 2012 Nov 22.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6981	EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovela F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23;363(26):2499-510. doi: 10.1056/NEJMoa1007903. Epub 2010 Dec 3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6982	EINSTEIN-PE Investigators, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6983	Emaminia A, Fedoruk LM, Hagspiel KD, Bozlar U, Kron IL. Inferior vena cava filter migration to the heart. Ann Thorac Surg. 2008 Nov;86(5):1664-5. doi: 10.1016/j.athoracsurg.2008.04.063.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6984	Engmann E, Asch MR. Clinical experience with the antecubital Simon nitinol IVC filter. J Vasc Interv Radiol. 1998 Sep-Oct;9(5):774-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6985	Eriksson, Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6986	Errea M, Lewandowski R, Salem R, Karp J, Desai K. Device-specific adverse event rates in retrievable inferior vena cava filters: a systematic review and meta-analysis. Abstract 205. JVIR Scientific Session, March 7, 2017, S90-S91.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6987	Esparez, Fibrin Cap Disruption: An Adjunctive Technique for Inferior Vena Cava Filter Retrieval	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6988	Ezekowitz, Comparison of Dabigatran and Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6989	Falck-Ytter, Prevention of VTE in orthopedic surgery patients	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6990	Fan, K., et al., High-Performance Signal Detection for Adverse Drug Events using MapReduce Paradigm. AMIA Annu Symp Proc, 2010. 2010: 902-6	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6991	FDA Safety - Inferior Vena Cava (IVC) Filters: Initial Communication: Risk of Adverse Events with Long Term Use, 08/09/2010.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6992	FDA Safety Communications, Removing Retrievable Inferior Vena Cava Filters. 05/06/2014. http://wayback.archive-it.org/7993/20170722215731/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm396377.htm	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6993	FDA Safety Communications, Removing Retrievable Inferior Vena Cava Filters: Initial Communication. 08/09/2010. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm221676.htm	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6994	FDA, Device Post Market Surveillance. http://www.fda.gov/MedicalDevices/Safety/CDRHPmarketSurveillance/default.htm Accessed on January 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
6995	FDA, MAUDE: Manufacturer and user facility device experience. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6996	FDA, National Evaluation System for health Technology. http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/ucm301912.htm Accessed on January 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6997	Fedullo PF, Roberts A. Placement of vena cava filters and their complications. UpToDate 2017. https://www.uptodate.com/contents/placement-of-vena-cava-filters-and-their-complications	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6998	Feezor RJ, Huber TS, Welborn MB 3rd, Schell SR. Duodenal perforation with an inferior vena cava filter- an unusual cause of abdominal pain. J Vasc Surg. 2002 May;35(5):1010-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
6999	Feigal DW, Gardner SN, McClellan M. Ensuring Safe and Effective Medical Devices. N Engl J Med. 2003 Jan 16;348(3):191-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7000	Ferguson EJ, Lurie F, Brown M. Low Retrieval Rates of Temporary Inferior Vena Cava Filters in Trauma Patients. Am Surg. 2015 Apr;81(4):428-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7001	Ferreiro C, Abad-Cervero JF, Lopez-Pino MA. Fracture and migration of an Anthor vena cava filter. J Vasc Interv Radiol. 1996 Jan-Feb;7(1):149-50.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7002	Ferris EJ, McCowan TC, Carver DK, McFarland DR. Percutaneous inferior vena caval filters: follow-up of seven designs in 320 patients. Radiology. 1993 Sep;188(3):851-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7003	Fotiadis NI, Sabharwal T, Dourado R, Fikrat S, Adam A. Technical error during deployment leads to vena cava filter migration and massive pulmonary embolism. Cardiovasc Intervent Radiol. 2008 Jul;31 Suppl 2:S174-6. Epub 2007 Aug 29.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7004	Frezza EE, Wachtel MS. A Simple Venous Thromboembolism Prophylaxis Protocol for Patients Undergoing Bariatric Surgery. Obesity (Silver Spring). 2006 Nov;14(11):1961-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7005	Friedell ML, Goldenkranz RJ, Parsonnet V, Alpert J, Brief DK, Brenner BJ, Aueron FM. Migration of a Greenfield filter to the pulmonary artery: a case report. J Vasc Surg. 1986 Jun;3(6):929-31.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7006	Friese J, Leake B, Fleming CJ, Woodrum DA, Bjarnason H, Misra S, McKusick MA, McPhail I, Stockland A. Increased in-hospital mortality in patients with pe/DVT and IVC filter. Abstract No. 53. JVIR Scientific Session, S26	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7007	Frisbie JH, Sharma GV, Brahma P, Hess MJ, Hayes JA. Recurrent Pulmonary Embolism and Pulmonary Hypertension in Chronic Tetraplegia. Spinal Cord. 2005 Oct;43(10):625-30.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7008	Frisbie JH, Sharma GV. The Prevalence of Pulmonary Embolism in Chronically Paralyzed Subjects: A Review of Available Evidence. Spinal Cord. 2012 Jun;50(6):400-3. doi: 10.1038/sc.2011.154. Epub 2011 Dec 13.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7009	Funaki B, Funaki C. Embolization of High Flow Arteriovenous Malformation. Semin Intervent Radiol. 2016 Jun;33(2):157-60. doi: 10.1055/s-0036-1582125.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7010	Funaki, B. Filter migration to right heart. Semin Intervent Radiol. 2007 Sep;24(3):356-60. doi: 10.1055/s-2007-985751.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7011	Furtado CD, Aguirre DA, Sirlin CB, et al. Whole-body CT screening: spectrum of findings and recommendations in 1192 patients. Radiology 2005; 237(2):385-94.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7012	Galanau JP, Laroche JP, Righini M. The history and historical treatments of deep vein thrombosis. J Thromb Haemost. 2013 Mar;11(3):402-11. doi: 10.1111/jth.12127.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7013	Galhotra S, Amesur NB, Zajko AB, Simmons RL. Migration of the Gunther Tulip inferior vena cava filter to the chest. J Vasc Interv Radiol. 2007 Dec;18(12):1581-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7014	Gargiulo NJ 3rd, O'Connor DJ, Veith FJ, Lipsitz EC, Vemulapalli P, Gibbs K, Suggs WD. Long-Term Outcome of Inferior Vena Cava Filter Placement in Patients Undergoing Gastric Bypass. Ann Vasc Surg. 2010 Oct;24(7):946-9. doi: 10.1016/j.avsg.2010.05.004.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7015	Gargiulo NJ 3rd, Veith FJ, Lipsitz EC, Suggs WD, Ohki T, Goodman E. Experience with inferior vena cava filter placement in patients undergoing open gastric bypass procedures. J Vasc Surg. 2006 Dec;44(6):1301-5. Epub 2006 Oct 20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7016	Gaspard SF, Gaspard DJ. Retrievable Inferior Vena Cava Filters Are Rarely Removed. Am Surg. 2009 May;75(5):426-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7017	Gasparis AP, Spentzouris G, Meisner RJ, et al. Improving retrieval rates of temporary inferior vena cava filters. J Vasc Surg 2011; 54:34S-8S.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7018	Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A Prospective Study of Venous Thromboembolism After Major Trauma. N Engl J Med. 1994 Dec 15;331(24):1601-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7019	Geerts WH, Jay RM, Code KI, et al: A Comparison of Low-dose Heparin with Low-molecular Weight Heparin as Prophylaxis against Venous Thromboembolism after Major Trauma. N. Eng. J. Med. 1996; 335: 701-707.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7020	Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of Venous Thromboembolism, The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Geerts WH1, Pineo GF, Heit JA, Bergqvist D, Lassen MR, Colwell CW, Ray JG.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7021	Gelzinis, T., et al., Intracardiac migration of retrievable vena cava filter. J Cardiothorac Vasc Anesth. 2009. 23(3): 381-3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7022	Ghanim A.J., Daskalakis C., Eschelmann D.J., Kraft W.K. A five-year, retrospective, comparison review of survival in neurosurgical patients diagnosed with venous thromboembolism and treated with either inferior vena cava filters or anticoagulants. J Thromb Thrombolysis. 2007;24:247-254.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7023	Ghatan CE, Ryu RK. Permanent versus Retrievable Inferior Vena Cava Filters: Rethinking the "One-Filter-for-All" Approach to Mechanical Thromboembolic Prophylaxis. Semin Intervent Radiol. 2016 Jun;33(2):75-8. doi: 10.1055/s-0036-1582123.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7024	Girard P, Stern JB, Parent F. Medical literature and vena cava filters: so far so weak. Chest. 2002 Sep;122(3):963-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7025	Giroux M-F. Ask the experts: what is your practice's current IVC filter retrieval protocol, and in which cases do you deviate from it? Endovascular Today October 2015, pp. 53-58.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7026	Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. Epub 2013 Nov 19.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7027	Godat LN, Kobayashi L, Chang D, Coimbra R: Can We Ever Stop Worrying About Venous Thromboembolism After Trauma? <i>Trauma</i> 2015; 78: 475-481.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7028	Goei AD, Josephs SC, Kinney TB, Ray CE Jr, Sacks D. Improving the tracking and removal of retrievable inferior vena cava filters. Semin Intervent Radiol. 2011 Mar;28(1):118-27. doi: 10.1055/s-0031-1273946.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7029	Goldhaber SZ, et al: A prospective study of risk factors for pulmonary embolism in women. JAMA 277:642-645, 1997.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7030	Gómez-Outes A, Terleira-Fernández AI, Lecumberri R, Suárez-Gea ML, Vargas-Castrillón E. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2014 Oct;134(4):774-82. doi: 10.1016/j.thromres.2014.06.020. Epub 2014 Jul 6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7031	Gosin JS, Graham AM, Ciocca RG, Hammond JS. Efficacy of Prophylactic Vena Cava Filters in High-Risk Trauma Patients. Ann Vasc Surg. 1997 Jan;11(1):100-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7032	Gould MK, Garcia DA, Wren SM, Karanickolas PJ, Arcelus JI, Heit JA, Samama CM. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e227S-e277S. doi: 10.1378/chest.11-2297.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7033	Grande WJ, Trerotola SO, Reilly PM. et al. Experience with the Recovery Filter as a Retrievable Inferior Vena Cava Filter. J Vasc Interv Radiol. 2005;16:1189 – 1193.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7034	Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Gerdas M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoA1107039. Epub 2011 Aug 27.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7035	Granke K, Abraham FM, McDowell DE. Vena cava filter disruption and central migration due to accidental guidewire manipulation: a case report. Ann Vasc Surg. 1996 Jan;10(1):49-53.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7036	Grassi CJ, Goldhaber SZ. Interruption of the inferior vena cava for prevention of pulmonary embolism: transvenous filter devices. Herz. 1989 Jun;14(3):182-91.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7037	Grassi CJ, Matsumoto AH, Teitelbaum GP. Vena Caval Occlusion after Simon Nitinol Filter Placement: Identification with MR Imaging in Patients with Malignancy. J Vasc Interv Radiol. 1992 Aug;3(3):535-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7038	Grassi CJ, Swan TL, Cardella JF, Meranze SG, Oglevie SB, Omary RA, Roberts AC, Sacks D, Silverstein MI, Towbin RB, Lewis CA. Quality improvement guidelines for percutaneous permanent inferior vena cava filter placement for the prevention of pulmonary embolism. J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S271-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7039	Grassi CJ. Inferior Vena Caval Filters Analysis of Five Currently Available Devices. AJR Am J Roentgenol. 1991 Apr;156(4):813-21.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7040	Greenfield LJ, Cho KJ, Proctor M, Bonn J, Bookstein JJ, Castaneda-Zuniga WR, Cutler B, Ferris EJ, Keller F, McCowan T, et al. Results of a multicenter study of the modified hook titanium Greenfield filter. J Vasc Surg. 1991 Sep;14(3):253-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7041	Greenfield LJ, Cho KJ, Tauscher JR. Evolution of Hook Design for Fixation of the Titanium Greenfield Filter. J Vasc Surg. 1990 Sep;12(3):345-53.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7042	Greenfield LJ, Proctor MC, Cho KJ, Cutler BS, Ferris EJ, McFarland D, Sobel M, Tisnado J. Extended Evaluation of the Titanium Greenfield Vena Caval Filter. J Vasc Surg. 1994 Sep;20(3):458-64; discussion 464-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7043	Greenfield LJ, Proctor MC. The Percutaneous Greenfield Filter- Outcomes and Practice Patterns. J Vasc Surg. 2000 Nov;32(5):888-93.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7044	Greenfield LJ, Proctor MC. Twenty Year Clinical Experience with Greenfield Filter. 1995; Cardiovasc. Surg. 3:199-205.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7045	Greenfield LJ, Zocco J, Wilk J, Schroeder TM, Elkins RC. Clinical experience with the Kim-Ray Greenfield vena caval filter. Ann Surg. 1977 Jun;185(6):692-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7046	Greenfield LJ. Historical Reminiscence: Origin of the Greenfield Filter. Am Surg. 2010 Dec;76(12):1319-20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7047	Groom H, Hopkins DP, Pabst LJ, Murphy Morgan J, Patel M, Calonge N, Coyle R, Dombkowski K, Groom AV, Kurilo MB, Rasulnia B, Shefer A, Town C, Wortley PM, Zucker J; Community Preventive Services Task Force. Immunization Information Systems to Increase Vaccination Rates - A Community Guide Systematic Review. J Public Health Manag Pract. 2015 May-Jun;21(3):227-48. doi: 10.1097/PHH.0000000000000069.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7048	Guidance for the Industry - Good Pharmacovigilance Practices and Pharmacoeconomic assessment, March 2005 https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071696.pdf	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7049	Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ, American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb. 141 (2 Suppl):7S-47S.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7050	Guyatt GH, et al: Approach to outcome measurement in the prevention of thrombosis in surgical and medical patients: antithrombotic therapy and prevention of thrombosis, 9th Ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141 (Suppl):3185S-3194S, 2012.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7051	Haddadian, B., et al., Sudden cardiac death caused by migration of a TrapEase inferior vena cava filter: case report and review of the literature. Clin Cardiol, 2008. 31(2): 84-7	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7052	Hahn D. Retrievable Filter Update: The Denali Vena Cava Filter Semin Intervent Radiol. 2015;32(4): 379-383.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7053	Halkett GK, Jiwa M, Lobb EA. Patients' Perspectives on the Role of Their General Practitioner After Receiving an Advanced Cancer Diagnosis. Eur J Cancer Care (Engl). 2015 Sep;24(5):662-72. doi: 10.1111/ecc.12224. Epub 2014 Aug 6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7054	Halmi, Preoperative placement of retrievable inferior vena cava filters in bariatric surgery	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7055	Hammond, Audit of the use of IVC filters in the UK: experience from three centres over 12 years	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7056	Harries SR, Wells IP, Roobottom CA. Long-term follow-up of the antheor inferior vena cava filter. Clin Radiol. 1998 May;53(5):350-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7057	Hauben, M., Signal detection in the pharmaceutical industry: integrating clinical and computational approaches. Drug Saf. 2007. 30(7): 627-30.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7058	Haut ER, Garcia LJ, Shihab HM, Brotman DJ, Stevens KA, Sharma R, Chelladurai Y, Akande TO, Shermock KM, Kebede S, Segal JB, Singh S. The effectiveness of prophylactic inferior vena cava filters in trauma patients: a systematic review and meta-analysis. JAMA Surg. 2014 Feb;149(2):194-202. doi: 10.1001/jamasurg.2013.3970.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7059	Headrick JR Jr, Barker DE, Pate LM, Horne K, Russell WL, Burns RP. The Role of Ultrasonography and Inferior Vena Cava Filter Placement in High-Risk Trauma Patients. Am Surg. 1997 Jan;63(1):1-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7060	Health Canada, Inferior Vena Cava Filters - Risk of Serious Complications	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7061	Heit JA, et al: The epidemiology of venous thromboembolism in the community. Thrombi Haemost 86:452-463, 2001.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7062	Helling TS, Kaswan S, Miller SL. Practice patterns in the use of retrievable inferior vena cava filters in a trauma population: A single-center experience. J Trauma 2009; 67:1293-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7063	Hemmila MR, Osborne NH, Henke PK, Kepros JP, Patel SG, Cain-Nielsen AH, Birkmeyer NJ. Prophylactic Inferior Vena Cava Filter Placement Does Not Result in a Survival Benefit for Trauma Patients. Ann Surg. 2015 Oct;262(4):577-85. doi: 10.1097/SLA.0000000000001434.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7064	Ho KM, Tan JA, Burrell M, Rao S, Misur P. Venous Thrombotic, Thromboembolic, and Mechanical Complications After Retrievable Inferior Vena Cava Filters for Major Trauma. Br J Anaesth. 2015 Jan;114(1):63-9. doi: 10.1093/bja/aeu195. Epub 2014 Jun 30.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7065	Hoff WS, Hoey BA, Wainwright GA, Reed JF, Ball DS, Ringold M, Grossman MD. Early Experience with Retrievable Inferior Vena Cava Filters in High-Risk Trauma Patients. J Am Coll Surg. 2004 Dec;199(6):869-74.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7066	Hoffer, E.K., et al., Safety and efficacy of the Gunther Tulip retrievable vena cava filter: midterm outcomes. Cardiovasc Intervent Radiol. 2013. 36(4): 998-1005	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7067	Hokusai-VTE Investigators, Buller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwöcho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7068	Huisman MV, Quinlan DJ, Dahl OE, Schulman S. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials. Circ Cardiovasc Qual Outcomes. 2010 Nov;3(6):652-60. doi: 10.1161/CIRCOUTCOMES.110.957712. Epub 2010 Oct 5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7069	Hull JE, Han J, Giessel GM. Retrieval of the recovery filter after arm perforation, fracture, and migration to the right ventricle. J Vasc Interv Radiol. 2008 Jul;19(7):1107-11. doi: 10.1016/j.jvir.2008.03.011. Epub 2008 May 2. Review.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7070	Hull JE, Robertson SW. Bard Recovery filter: evaluation and management of vena cava limb perforation, fracture, and migration. J Vasc Interv Radiol. 2009 Jan;20(1):52-60. doi: 10.1016/j.jvir.2008.09.032. Epub 2008 Nov 21.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7071	Iliescu B, Haskal ZJ. Advanced Techniques for Removal of Retrievable Inferior Vena Cava Filters. Cardiovasc Interv Radiol. 2012 Aug;35(4):741-50. doi: 10.1007/s00270-011-0205-z. Epub 2011 Jun 15.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7072	Image Wisely. http://www.imagewisely.org Accessed on February 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7073	IMS Health. IMS Health Hospital Supply Index. Available from: http://www.imshealth.com/deployedfiles/imshealth/Global/North%20America/United%20States/Medical Device US/IMS Hospital Supply Index.pdf .	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7074	Inuzuka, K., et al., Hemorrhagic shock with delayed retroperitoneal hemorrhage after deployment of an inferior vena cava filter: report of a case. Surg Today, 2007. 37(7): 618-21.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7075	Irwin E, Byrnes M, Schultz S, et al. A systematic method for follow-up improves removal rates for retrievable inferior vena cava filters in a trauma patient population. J Trauma 2010; 69:866-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7076	Izutani, H., et al., Migration of an inferior vena cava filter to the right ventricle and literature review. Can J Cardiol. 2004. 20(2): 233-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7077	Jaff M.R., McMurtry M.S., Archer S.L., Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123:1788-1830.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7078	Jaff MR, Kaufman J. A measured approach to vena cava filter use – respect rather than regret. JAMA Cardiol. 2017; 2(1):5-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7079	James KV, Sobolewski AP, Lohr JM, Welling RE. Tricuspid insufficiency after intracardiac migration of a Greenfield filter: case report and review of the literature. J Vasc Surg. 1996 Sep;24(3):494-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7080	Jassar AS, Nicotera SP, Levin N, Vernick WJ, Szeto WY. Inferior vena cava filter migration to the right ventricle. J Card Surg. 2011 Mar;26(2):170-2. doi: 10.1111/j.1540-8191.2010.01194.x. Epub 2011 Feb 8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7081	Jia Z, Fuller TA, McKinney JM, Paz-Fumagalli R, Frey GT, Sella DM, Van Ha T, Wang W. Utility of Retrievable Inferior Vena Cava Filters: A Systematic Literature Review and Analysis of the Reasons for Nonretrieval of Filters with Temporary Indications. Cardiovasc Interv Radiol. 2018 Jan 22. doi: 10.1007/s00270-018-1880-9. [Epub ahead of print].	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7082	Jia Z, Wu A, Tam M et al. Caval Penetration by Inferior Vena Cava Filters: A Systematic Literature Review of Clinical Significance and Management. Circulation. 2015;132:944-52.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7083	Joels CS, Sing RF, Heniford BT. Complications of Inferior Vena Cava Filters. Am Surg. 2003 Aug;69(8):654-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7084	Johnson MS. Vena cava filter fracture: unplanned obsolescence. J Vasc Interv Radiol. 2012 Feb;23(2):196-8. doi: 10.1016/j.jvir.2011.12.004.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7085	Jones T, Ugaldé V, Franks P, Zhou H, White RH. Venous Thromboembolism After Spinal Cord Injury: Incidence, Time Course, and Associated Risk Factors in 16,240 Adults and Children. Arch Phys Med Rehabil. 2005 Dec;86(12):2240-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7086	Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e195S-e226S. doi: 10.1378/chest.11-2296.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7087	Kakkar V.V., Howe C.T., Flanc C., Clarke M.B.; Natural history of postoperative deep-vein thrombosis. Lancet. 1969;2:230-232.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7088	Kalva SP, Athanasoulis CA, Fan CM, Curvelo M, Geller SC, Greenfield AJ, Waltman AC, Wisky S. Recovery Vena Cava Filter: Experience in 96 Patients. Cardiovasc Interv Radiol (2006) 29:559-564.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7089	Kalva SP, Chlapoutaki C, Wicky S, Greenfield AJ, Waltman AC, Athanasoulis CA. Suprarenal Inferior Vena Cava Filters: A 20 Year Single Center Experience. J Vasc Interv Radiol. 2008 Jul;19(7):1041-7. doi: 10.1016/j.jvir.2008.03.026. Epub 2008 May 27.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7090	Kamath SD, McMahon BJ. Update on Anticoagulation: What the Interventional Radiologist Needs to Know. Semin Intervent Radiol. 2016 Jun;33(2):122-31. doi: 10.1055/s-0036-1582124.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7091	Kardys CM, Stoner MC, Manwaring ML, Barker M, Macdonald KG, Pender JR, Chapman WH 3rd. Safety and efficacy of intravascular ultrasound-guided inferior vena cava filter in super obese bariatric patients. Surg Obes Relat Dis. 2008 Jan-Feb;4(1):50-4. Epub 2007 Dec 11.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7092	Kardys CM, Stoner MC, Manwaring ML, Bogey WM, Parker FM, Powell S. The Use of Intravascular Ultrasound Imaging to Improve Use of Inferior Vena Cava Filters in a High-Risk Bariatric Population. J Vasc Surg. 2007 Dec;46(6):1248-52. Epub 2007 Oct 24.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7093	Karmy-Jones R, Jurkovich GJ, Velmahos GC, Burdick T, Spaniolas K, Todd SR, McNally M, Jacoby RC, Link D, Janczyk RJ, Ivasec FA, McCann M, Obeid F, Hoff WS, McQuay N Jr, Tieu BH, Schreiber MA, Nirula R, Brasel K, Dunn JA, Gambrell D, Huckfeldt R, Harper J, Schaffer KB, Tominaga GT, Vences FY, Sperling D, Hoyt D, Coimbra R, Rosengart MR, Forsythe R, Cothren C, Moore EE, Haut ER, Hayanga AJ, Hird L, White C, Grossman J, Nagy K, Livaudais W, Wood R, Zengerink I, Kortbeek JB. Practice patterns and outcomes of retrievable vena cava filters in trauma patients: an AAST multicenter study. J Trauma. 2007	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7094	Karp JK, Desai KR, Salem R, et al. A dedicated inferior vena cava filter service line: how to optimize your practice. Semin Intervent Radiol 2016; 33:105-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7095	Katsamouris AA, Waltman AC, Delichatsios MA, Athanasoulis CA. Inferior vena cava filters: in vitro comparison of clot trapping and flow dynamics. Radiology. 1988 Feb;166(2):361-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7096	Kaufman JA, Kinney TB, Streiff MB, Sing RF, Proctor MC, Becker D, Cipolle M, Comerota AJ, Millward SF, Rogers FB, Sacks D, Venbrux AC. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol. 2006 Mar;17(3):449-59.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7097	Kaufman JA, Rundback JH, Kee ST, Geerts W, Gillespie D, Kahn SR, Kearon C, Rectenwald J, Rogers FB, Stavropoulos SW, Streiff M, Vedantham S, Venbrux A. Development of a Research Agenda for Inferior Vena Cava Filters: Proceedings from a Multidisciplinary Research Consensus Panel. J Vasc Interv Radiol. 2009 Jun;20(6):697-707. doi: 10.1016/j.jvir.2009.03.007.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7098	Kaufman JA. Optional Vena Cava Filters: What, Why, and When. Vascular. 2007 Sep-Oct;15(5):304-13.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7099	Kazmers A, Jacobs LA, Perkins AJ. Pulmonary embolism in Veterans Affairs Medical Centers: is vena cava interruption underutilized? Am Surg. 1999; 65:1171-	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7100	Kearon C, Akl EA, Omelas J, Blaivas A, Jimenez D, Bounameaux H, Huisman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JR, Wells P, Woller SC, Moores L. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-52.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7101	Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic Therapy for Venous Thromboembolism Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun;133(6 Suppl):454S-545S. doi: 10.1378/chest.08-0658.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7102	Kearon C., Akl E.A., Comerota A.J., American College of Chest Physicians Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141 :e419S-e494S.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7103	Keeling WB, Haines K, Stone PA, Armstrong PA, Murr MM, Shames ML. Current Indications for Preoperative Inferior Vena Cava Filter Insertion in Patients Undergoing Surgery for Morbid Obesity. Obes Surg. 2005 Aug;15(7):1009-12.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7104	Keller EJ, Vogelzang RL. Providing Context: Medical Device Litigation and Inferior Vena Cava Filters. <i>Semin Intervent Radiol.</i> 2016 Jun;33(2):132-6. doi: 10.1055/s-0036-1581086.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7105	Khansarinia S, Dennis JW, Veldenz HC, Butcher JL, Hartland L. Prophylactic Greenfield Filter Placement in Selected High-Risk Trauma Patients. <i>J Vasc Surg.</i> 1995 Sep;22(3):231-5; discussion 235-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7106	Kiefer RM, Pandey N, Trerotola SO, Nadolski GJ, Stavropoulos SW. The Value of Rotational Venography Versus Anterior Posterior Venography in 100 Consecutive IVC Filter Retrievals. <i>Cardiovasc Intervent Radiol.</i> 2016 Mar;39(3):394-9. doi: 10.1007/s00270-015-1183-3. Epub 2015 Jul 29.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7107	Kiguchi MM, Dillavou ED. IVC filters: challenges and future directions. <i>Adv Vasc Med</i> 2014; 2014:1-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7108	Kim H, Sarg I, Jang JH: Outcomes of Retrievable Inferior Vena Cava Filters in Patients with Deep Vein Thrombosis and Transient Contraindication for Anticoagulation. 2015; <i>Ann. Of Surgical Treatment and Research</i> ; 89(1):30-36.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7109	Kim, H.S., et al., A comparison of clinical outcomes with retrievable and permanent inferior vena cava filters. <i>J Vasc Interv Radiol.</i> 2008. 19(3): 393-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7110	Kinney TB, Rose SC, Valji K, Oglevie SB, Roberts AC. Does Cervical Spinal Cord Injury Induce a Higher Incidence of Complications after prophylactic Greenfield inferior vena cava filter usage? <i>J Vasc Interv Radiol.</i> 1996 Nov-Dec;7(6):907-15.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7111	Kinney TB. Primum non nocere. <i>J Vasc Interv Radiol.</i> 2012 Dec;23(12):1564-5. doi: 10.1016/j.jvir.2012.10.003.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7112	Kinney TB. Update on inferior vena cava filters. <i>J Vasc Interv Radiol.</i> 2003 Apr;14(4):425-40.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7113	Kitchens CS, Konkle BA and Kessler CM. Consultative Hemostasis and Thrombosis, 3rd Edition.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7114	Knudson MM, Ikossi DG. Thromboembolism After Trauma. <i>Curr Opin Crit Care.</i> 2004 Dec;10(6):539-48.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7115	Ko SH, Reynolds BR, Nicholas DH, et al. Institutional protocol improves retrievable inferior vena cava filter recovery rate. <i>Surgery</i> 2009; 146:809-16.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7116	KrauthD et al: Safety and efficacy of long-term oral anticoagulation in cancer patients. <i>Cancer</i> 59:983-985, 1987.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7117	Kuo W, Robertson S. Bard Denali Inferior Vena Cava Filter Fracture and Embolization Resulting in Cardiac Tamponade: A Device Failure Analysis. <i>J Vasc Interv Radiol.</i> 2015 Jan;26(1):111-5.e1. doi: 10.1016/j.jvir.2014.08.001.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7118	Kuo WT, Cupp JS, Louie JD, Sze DY, Kothary N, Hwang GL, Hofmann L. Retrieval of permanently-embedded IVC filters and description of the laser-assisted sheath technique: Radiographic-histopathologic correlation (Abstract No. 4). <i>Journal of Vascular and Interventional Radiology</i> , Feb. 2010, Volume 21, Issue 2, Suppl., Page S4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7119	Kuo WT, Cupp JS. The Excimer Laser Sheath Technique for Embedded Inferior Vena Cava Filter Removal. <i>J Vasc Interv Radiol.</i> 2010 Dec;21(12):1896-9. doi: 10.1016/j.jvir.2010.08.013. Epub 2010 Nov 3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7120	Kuo WT, Odegaard JI, Rosenberg JK, Hofmann LV. Laser Assisted Removal of Embedded Vena Cava Filters: A 5 Year First in Human Study. <i>Chest.</i> 2017 Feb;151(2):417-424. doi: 10.1016/j.chest.2016.09.029. Epub 2016 Oct 8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7121	Kuo WT, Robertson SW, Odegaard JI, Hofmann LV. Complex retrieval of fractured, embedded, and penetrating inferior vena cava filters: a prospective study with histologic and electron microscopic analysis. <i>J Vasc Interv Radiol.</i> 2013 May;24(5):622-630.e1; quiz 631. doi: 10.1016/j.jvir.2013.01.008. Epub 2013 Mar 21.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7122	Kuo WT, Tong RT, Hwang GL, Louie JD, Lebowitz EA, Sze DY, Hofmann LV. High-risk retrieval of adherent and chronically implanted IVC filters: techniques for removal and management of thrombotic complications. <i>J Vasc Interv Radiol.</i> 2009 Dec;20(12):1548-56. doi: 10.1016/j.jvir.2009.08.024. Epub 2009 Oct 27.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7123	Kuo, W.T. and Robertson, S.W. Bard Denali inferior vena cava filter fracture and embolization resulting in cardiac tamponade: a device failure analysis. <i>J Vasc Interv Radiol.</i> 2015; 26: 111–115.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7124	Kuo, W.T., C.T. Loh and D.Y. Sze, Emergency retrieval of a G2 filter after complete migration into the right ventricle. J Vasc Interv Radiol. 2007. 18(9): 1177-	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7125	Kuy S, Dua A, Lee CJ, Patel B, Desai SS, Dua A, Szabo A, Patel PJ. National Trends in Utilization of Inferior Vena Cava Filters in the United States, 2000-2009. J Vasc Surg Venous Lymphat Disord. 2014 Jan;2(1):15-20. doi: 10.1016/j.jvs.2013.08.007. Epub 2013 Dec 12.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7126	Laborda A, Sierre S, Malvè M, De Blas I, Ioakeim I, Kuo WT, De Gregorio MA. Influence of Breathing Movements and Valsalva Maneuver on Vena Caval Dynamics. World J Radiol. 2014 Oct 28;6(10):833-9. doi: 10.4329/wjr.v6.i10.833.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7127	Lampert R. Managing with Pacemakers and Implantable Cardioverter Defibrillators. Circulation. 2013 Oct 1;128(14):1576-85. doi: 10.1161/CIRCULATIONAHA.113.001555.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7128	Lang W, Schweiger H, Hofmann-Preiss K. Results of Long-Term Venacavography Study After Placement of a Greenfield Vena Caval Filter. J Cardiovasc Surg (Torino). 1992 Sep-Oct;33(5):573-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7129	Langan EM 3rd, Miller RS, Casey WJ 3rd, Carsten CG 3rd, Graham RM, Taylor SM. Prophylactic Inferior Vena Cava Filters in Trauma Patients at High Risk: Follow-up Examination and Risk/Benefit Assessment. J Vasc Surg. 1999	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7130	Laplanche JS, Contractor FM, Kiproff PM, Khoury MB. Migration of the Simon nitinol vena cava filter to the chest. AJR Am J Roentgenol 1993; 160(2):385-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7131	Lassen MR, Gallus A, Raskob GE, Pinedo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus Enoxaparin for Thromboprophylaxis after Hip Replacement. N Engl J Med. 2010 Dec 23;363(26):2487-98. doi: 10.1056/NEJMoa1006885.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7132	Lavan O, Rimon U, Simon D, et al: The use of optional inferior vena cava filters of type Optease in trauma patients — a single type of filter in a single medical center. 2015 Thromb. Res. 135:873-876.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7133	Laws JL, Lewandowski RJ, Ryu RK, Desai KR. Retrieval of Inferior Vena Cava Filters: Technical Considerations. Semin Intervent Radiol. 2016 Jun;33(2):144-8. doi: 10.1055/s-0036-1582119.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7134	Leach TA, Pastena JA, Swan KG, Tikellis JJ, Blackwood JM, Odom JW. Surgical Prophylaxis for Pulmonary Embolism. Am Surg. 1994 Apr;60(4):292-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7135	Leask RL, Johnston KW, Ojha M. In Vitro Hemodynamic Evaluation of a Simon Nitinol Vena Cava Filter: Possible Explanation of IVC Occlusion. J Vasc Interv Radiol. 2001 May;12(5):613-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7136	Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7137	Lee MJ, Valenti D, deGregorio MA, et al. The CIRSE retrievable IVC filter registry: retrieval success rates in practice. Cardiovasc Intervent Radiol 2015;	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7138	Leeper WR, Murphy PB, Vogt KN, et al: Are Retrievable Vena Cava Filters Placed in Trauma Patients Really Retrievable. Eur. J. Trauma Emergency Surg. 2016; 42:459-464.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7139	LeFevre ML; U.S. Preventive Services Task Force. Screening for Abdominal Aortic Aneurysm – US Preventative Services Task Force Recommendation Statement. Ann Intern Med. 2014 Aug 19;161(4):281-90. doi: 10.7326/M14-1204.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7140	Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004 Aug 17;110(7):874-9. Epub 2004 Aug 2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7141	Lessne ML, Sing RF. Counterpoint: Do the Benefits Outweigh the Risks for Most Patients Under Consideration for Inferior Vena Cava Filters? No. Chest. 2016 Dec;150(6):1182-1184. doi: 10.1016/j.chest.2016.08.1477. Epub 2016 Oct 20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7142	Lewandowski, R.J., et al., Abstract No. 54: A prospective study of 467 IVC filter placements: is there a difference between optional and permanent filters? J Vasc Interv Radiol. 2012. 23(3): S25	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7143	Li W, Gorecki P, Semaan E, Briggs W, Tortolani AJ, D'Ayala M. Concurrent prophylactic placement of inferior vena cava filter in gastric bypass and adjustable banding operations in the Bariatric Outcomes Longitudinal Database. J Vasc Surg. 2012 Jun;55(6):1690-5. doi: 10.1016/j.jvs.2011.12.056. Epub 2012 Feb 22.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7144	Li W, Gorecki P, Semaan E, Briggs W, Tortolani AJ, D'Ayala M. Concurrent prophylactic placement of inferior vena cava filter in gastric bypass and adjustable banding operations in the Bariatric Outcomes Longitudinal Database. J Vasc Surg. 2012 Jun;55(6):1690-5. doi: 10.1016/j.jvs.2011.12.056. Epub 2012 Feb 22.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7145	Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S, Crowther M. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e495S-e530S. doi: 10.1378/chest.11-2303. Review. Erratum in: Chest. 2015 Dec;148(6):1529.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7146	Lloyd GL, Singh MJ, Messing EM. An Unusual Cause of an Enhancing Retroperitoneal Mass. Urology. 2012 Apr;79(4):e61-2. doi: 10.1016/j.urology.2011.06.042. Epub 2011 Sep 25.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7147	Lynch FC, Kekulawela S. Removal of the G2 Filter: Differences between Implantation Times Greater and Less than 180 Days. J Vasc Interv Radiol. 2009 Sep;20(9):1200-9. doi: 10.1016/j.jvir.2009.05.039. Epub 2009 Jul 29.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7148	Lynch FC. A method for following patients with retrievable inferior vena cava filters: results and lessons learned from the first 1,100 patients. J Vasc Interv Radiol 2011; 22:1507-12.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7149	Lynch FC. Balloon-assisted Removal of Tilted Inferior Vena Cava Filters with Embedded Tips. J Vasc Interv Radiol. 2009; 20: 1210-1214.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7150	Lyon SM, Riojas GE, Uberoi R, Patel J, Lipp ME, Plant GR, De Gregorio MA, Günther RW, Voorhees WD, McCann-Brown JA. Short- and Long-term Retrievability of the Celect Vena Cava Filter: Results from a Multi-institutional Registry. J Vasc Interv Radiol. 2009 Nov;20(11):1441-8. doi:	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7151	Majdalany BS, Khaja MS, Williams DM. Bard Denali filter fractures. J Vasc Interv Radiol. 2016; 27: 1099-1101.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7152	Malgor RD, Hines GL, Terrana L, Labropoulos N. Persistent Abdominal Pain Caused by an Inferior Vena Cava Filter Protruding Into the Duodenum and the Aortic Wall. Ann Vasc Surg. 2012 Aug;26(6):858.e3-6. doi: 10.1016/j.avsg.2011.11.038. Epub 2012 May 23.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7153	Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA. Collaborative Modeling of the Benefits and Harms Associated with Different US Breast Cancer Screening Strategies. Ann Intern Med. 2016 Feb 16;164(4):215-25. doi: 10.7326/M15-1536.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7154	MAUDE Manufacturer and User Facility Device Experience. U.S. Food & Drug Administration. Accessible via: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm . Accessed April 4, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7155	Maxwell RA, Chavarria-Aguilar M, Cockerham WT, Lewis PL, Barker DE, Durham RM, Ciraulo DL, Richart CM. Routine Prophylactic Vena Cava Filtration Is Not Indicated after Acute Spinal Cord Injury. J Trauma. 2002 May;52(5):902-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7156	McCowan TC, Ferris EJ, Carver DK, Molpus WM. Complications of the nitinol vena caval filter. J Vasc Interv Radiol. 1992 May;3(2):401-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7157	McKenney K, Boneva D, Deeter M, Barquist E, Ang D, Kaye M. Trauma Admission CT as a Road Map for IVC Filters. Int Surg. 2014 Nov-Dec;99(6):734-8. doi: 10.9738/INTSURG-D-13-00192.1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7158	McLoney ED, Krishnasamy VP, Castle JC, Yang X, Guy G. Complications of Celest, Günther tulip, and Greenfield inferior vena cava filters on CT follow-up: a single-institution experience. J Vasc Interv Radiol. 2013 Nov;24(11):1723-9. doi: 10.1016/j.jvir.2013.07.023. Epub 2013 Sep 13.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7159	McMurtry AL, Owings JT, Anderson JT, Battistella FD, Gosselin R. Increased Use of Prophylactic Vena Cava Filters in Trauma Patients Failed to Decrease Overall Incidence of Pulmonary Embolism. J Am Coll Surg. 1999 Sep;189(3):314-20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7160	Mehanni, S., M. Higley and R.C. Schenning, Expectoration of an inferior vena cava filter strut. BMJ Case Rep. 2016. 2016.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7161	Melinek J, Livingston E, Cortina G, Fishbein MC. Autopsy Findings Following Gastric Bypass Surgery for Morbid Obesity. Arch Pathol Lab Med. 2002 Sep;126(9):1091-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7162	Meyer A, Schönleben F, Heinz M, Lang W. Perforated Inferior Vena Cava Filters as the Cause of Unclear Abdominal Pain. Ann Vasc Surg. 2013 Apr;27(3):354.e9-354.e12. doi: 10.1016/j.avsg.2012.08.006.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7163	Michetti CP, Franco E, Coleman J, Bradford A, Trickey AW. Deep Vein Thrombosis Screening and Risk Factors in a High-Risk Trauma Population. J Surg Res. 2015 Dec;199(2):545-51. doi: 10.1016/j.jss.2015.04.069. Epub 2015 Apr 27.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7164	Miller KE. Indications for Vena Cava Filters for Recurrent DVT. Am Fam Physician. 2003 Feb 1;67(3):593.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7165	Miller, C.L. and R.J. Wechsler. CT evaluation of Kimray-Greenfield filter complications. AJR Am J Roentgenol, 1986. 147(1): 45-50.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7166	Millward SF, Grassi CJ, Kinney TB, Kundu S, Becker GJ, Cardella JF, Martin LG, Silberzweig JE, Sacks D. Reporting standards for inferior vena caval filter placement and patient follow-up: supplement for temporary and retrievable/optional filters. J Vasc Interv Radiol. 2009 Jul;20(7 Suppl):S374-6. doi: 10.1016/j.jvir.2010.09.003. Epub 2010 Oct 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7167	Millward SF. Temporary and Retrievable Inferior Vena Cava Filters: Current Status. J Vasc Interv Radiol. 1998 May-Jun;9(3):381-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7168	Minocha J, Idakoji I, Riaz A, Karp J, Gupta R, Chrisman HB, Salem R, Ryu RK, Lewandowski RJ. Improving inferior vena cava filter retrieval rates: impact of a dedicated inferior vena cava filter clinic. J Vasc Interv Radiol. 2010 Dec;21(12):1847-51. doi: 10.1016/j.jvir.2010.09.003. Epub 2010 Oct 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7169	Mismetti P, Laporte S, Pellerin O, Ennezat PV, Couturaud F, Elias A, Falvo N, Meneveau N, Quere I, Roy PM, Sanchez O, Schmidt J, Seinturier C, Sevestre MA, Beregi JP, Tardy B, Lacroix P, Presles E, Leizorovicz A, Decousus H, Barral F, Meyer G; PREPIC2 Study Group. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial. JAMA. 2015 Apr 28;313(16):1627-35. doi: 10.1001/jama.2015.3780.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7170	Mitchell WB, Bonn J. Percutaneous retrieval of a Greenfield filter after migration to the left pulmonary artery. J Vasc Interv Radiol. 2005 Jul;16(7):1013-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7171	Mitsunaga, M.M. and H.-C. Yoon, Fracture Rate and Serious Complications of Vena Cava Filters. Open Journal of Radiology, 2013. 03(02): 85-90	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7172	Mohan G, Kasmani R, Okoli K, Elkambergy H. Right atrial foreign body: transvenous migration of Greenfield filter. Interact Cardiovasc Thorac Surg. 2009 Feb;8(2):245-6. doi: 10.1510/ievt.2008.189605. Epub 2008 Nov 17.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7173	Montgomery JP, Kaufman JA. A Critical Review of Available Retrievable Inferior Vena Cava Filters and Future Directions. Semin Intervent Radiol. 2016 Jun;33(2):79-87. doi: 10.1055/s-0036-1582121.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7174	Montgomery JP, Kaufman JA. Inferior Vena Cava Filters: Indications, Outcomes, and Evidence. Curr Treat Options Cardiovasc Med. 2015 Sep;17(9):401. doi: 10.1007/s11936-015-0401-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7175	Moore FD, et al: Anticoagulants, venous thromboembolism, and the cancer patient. Arch Surg 116:405-407, 1981	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7176	Moore R, Dagher FJ, Tavares S, Attar S. Migration of Kim-Ray Greenfield Umbrella to the heart. South Med J. 1983 Jul;76(7):946-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7177	Moore, Feliciano, Mattox. Trauma, Fifth Edition	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7178	Morales JP, Li X, Irony TZ, Ibrahim NG, Moynahan M, Cavanaugh KJ. Decision analysis of retrievable inferior vena cava filters in patients with pulmonary embolism. J Vasc Surg Venous Lymphat Disord. 2013 Oct;1(4):376-84. doi: 10.1016/j.jvsv.2013.04.005. Epub 2013 Jul 4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7179	Morris CS, Cushman M. Perforation of the inferior vena cava by a Greenfield filter. Journal of Thrombosis and Haemostasis 2008; 6:1835-1836.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7180	Morris CS, LaRosa J, and VanAman ME. Technically difficult percutaneous Kimray-Greenfield filter insertions. Presented at the 48th annual meeting, Ohio State Radiological Society; 1988 May 13; Toledo, OH.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7181	Morris CS, Rogers FB, Najarian KE, Bhavre AD, Shackford SR. Current trends in vena caval filtration with the introduction of a retrievable filter at a level I trauma center. J Trauma 2004; 57:32-36	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7182	Muriel A, Jimenez D, Aujesky D, et al. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol 2014; 63:1675-83.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7183	Mutyalu. Realistic expectations and candidate selection for entry level vascular technologist in a busy laboratory	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7184	Myerburg RJ, Feigal DW Jr, Lindsay BD. Life threatening Malfunction of Implantable Cardiac Devices. N Engl J Med. 2006 Jun 1;354(22):2309-11. Epub 2006 May 15.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7185	Narayan A, Hong K, Streiff M, Kim HS. (2008). Abstract No. 68: Safety and Efficacy of Retrievable vs Permanent IVC Filters in Oncology Patients – A Case Control Study. Journal of Vascular and Interventional Radiology - J VASC INTERVEN RADIOL. 19. . 10.1016/j.jvir.2007.12.076.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7186	Nathani N, Barzallo M, Mungee S. Myopericarditis secondary to embolization of fractured inferior vena cava filter limbs. J Invasive Cardiol. 2010 Dec;22(12):E225-	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7187	National Cancer Institute. https://www.cancer.gov/about-cancer/diagnosis-staging/ct-scans-fact-sheet Accessed on February 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7188	Nazzal M, Abbas J, Nazzal M. A complication of a G2 Bard filter. J Vasc Interv Radiol. 2010 Nov;21(11):1784-5. doi: 10.1016/j.jvir.2010.07.010. Epub 2010 Sep 29.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7189	Nazzal M, Chan E, Nazzal M, Abbas J, Erikson G, Sediqe S, Gohara S. Complications related to inferior vena cava filters: a single-center experience. Ann Vasc Surg. 2010 May;24(4):480-6. doi: 10.1016/j.avsg.2009.07.015. Epub 2009	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7190	NCRP Report No. 160, Ionizing Radiation Exposure of the Population of the United States. http://ncrponline.org/publications/reports/ncrp-report-160/ Accessed on March 15, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7191	Nelson HD, Cantor A, Humphrey L, Fu R, Pappas M, Daeges M, Griffin J. Screening for Breast Cancer: A Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation [Internet]. Agency for Healthcare Research and Quality (US); 2016 Jan. Report No.: 14-05201-EF-1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7192	Nicholson AA, Ettles DF, Paddon AJ, Dyet JF. Long-term Follow-up of the Bird's Nest IVC Filter. Clin Radiol. 1999 Nov;54(11):759-64.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7193	Nicholson W, Nicholson WJ, Tolerico P, Taylor B, Solomon S, Schryver T, McCullum K, Goldberg H, Mills J, Schuler B, Shears L, Siddoway L, Agarwal N, Tuohy C. Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Perforation and Tamponade. Arch Intern Med. 2010 Nov 8;170(20):1827-31. doi: 10.1001/archinternmed.2010.316. Epub 2010 Aug 9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7194	Nicholson W. Refrain, Recover, Replace. J Vasc Interv Radiol 2012; 23:195-196.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7195	Nicholson W. Correction to Article About Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters. ARCH INTERN MED/VOL 172 (NO. 12), June 25, 2012.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7196	Nissim L, Romano W. Successful Retrieval from Right Ventricular Wall of an Embolized Bard Meridian Filter Fragment. J Vasc Interv Radiol. 2013 Dec;24(12):1933-4. doi: 10.1016/j.jvir.2013.09.001.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7197	Obeid FN, et al: Efficacy of prophylactic inferior vena cava filter placement in bariatric surgery. Sug Obes Relat Dis 3:606-610, 2007.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7198	Offner PJ, Hawkes A, Madayag R, Seale F, Maines C. The Role of Temporary Inferior Vena Cava Filters in Critically Ill Surgical Patients. Arch Surg. 2003 Jun;138(6):591-4; discussion 594-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7199	Oh J, Stavropoulos SW, Trerotola S, Soulen MC, Shlansky-Goldberg R, Nemeth A, Mondschein J, Solomon JA. Removal of retrievable IVC filters with CT findings indicating filter strut perforation. Abstract No. 5. Journal of Vascular and Interventional Radiology, February 2010, Volume 21, Issue 2, Supplement, Page	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7200	Oh JC, Trerotola SO, Dagli M, Shlansky-Goldberg RD, Soulen MC, Itkin M, Mondschein J, Solomon J, Stavropoulos SW. Removal of retrievable inferior vena cava filters with computed tomography findings indicating tenting or penetration of the inferior vena cava wall. J Vasc Interv Radiol. 2011 Jan;22(1):70-4. doi: 10.1016/j.jvir.2010.09.021. Epub 2010 Nov 24.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7201	Oliva VL, Perreault P, Giroux MF, Bouchard L, Therasse E, Soulez G. Recovery G2 inferior vena cava filter: technical success and safety of retrieval. J Vasc Interv Radiol. 2008 Jun;19(6):884-9. doi: 10.1016/j.jvir.2008.02.025. Epub 2008 Apr 18.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7202	Oliva VL, Soulez G, Therasse E, Giroux M, Perreault P, Bouchard L, Denbow N. Recovery G2 vena cava filter retrievability study. Scientific Poster, Cardiovascular and Interventional Radiological Society of Europe, P235.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7203	Olorunsola OG, Kohi MP, Fidelman N, et al. Caval penetration by retrievable inferior vena cava filters: a retrospective comparison of Option and Günther Tulip filters. J Vasc Interv Radiol 2013;24:566-571.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7204	Olorunsola OG, Kohi MP, Fidelman N, Westphalen AC, Kolli PK, Taylor AG, Gordon RL, LaBerge JM, Kerlan RK. Caval Penetration by Retrievable Inferior Vena Cava Filters: A Retrospective Comparison of Option and Gunther Tulip Filters. J Vasc Interv Radiol. 2013 Apr;24(4):566-71. doi: 10.1016/j.jvir.2012.12.024. Epub 2013 Feb 23.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7205	O'Malley KF, Ross SE.; Pulmonary Embolism in Major Trauma Patients. J Trauma 1990; 30:748-750.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7206	Osker T, Rogers FB: 1997: Prophylaxis after Major Trauma. Letter to the Editor. N. Eng. J. Med. Pg 586.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7207	Ota, S., et al., The Gunther-Tulip retrievable IVC filter: clinical experience in 118 consecutive patients. Circ J, 2008. 72(2): 287-92.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7208	Overby DW, Kohn GP, Cahan MA, Dixon RG, Stavas JM, Moll S, Burke CT, Colton KJ, Farrell TM. Risk-Group Targeted Inferior Vena Cava Filter Placement in Gastric Bypass Patients. Obes Surg. 2009 Apr;19(4):451-5. doi: 10.1007/s11695-008-9794-2. Epub 2009 Jan 6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7209	Owens CA, Bui JT, Knuttinen MG, Gaba RC, Carrillo TC, Hoefling N, Layden-Almer JE. Intracardiac migration of inferior vena cava filters: review of published data. Chest. 2009 Sep;136(3):877-887. doi: 10.1378/chest.09-0153. Epub 2009 Apr	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7210	Owens, C.A., et al., Endovascular retrieval of intracardiac inferior vena cava filters: a review of published techniques. J Vasc Interv Radiol, 2009. 20(11): 1418-	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7211	Oxford Centre for Evidence-based Medicine http://www.cebm.net/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/ (https://www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/uspstf/index.html) accessed on March 6, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7212	Palestrant AM, Prince M, Simon M. Comparative in vitro evaluation of the nitinol inferior vena cava filter. Radiology. 1982 Nov;145(2):351-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7213	Pan Y, Zhao J, Mei J, Shao M, Zhang J, Wu H. Retrievable Inferior Vena Cava Filters in Trauma Patients: Prevalence and Management of Thrombus Within the Filter. Eur J Vasc Endovasc Surg. 2016 Dec;52(6):830-837. doi: 10.1016/j.ejvs.2016.08.012. Epub 2016 Sep 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7214	Pandhi MB, Desai KR, Ryu RK, Lewandowski RJ. The Role of Inferior Vena Cava Filters in Cancer Patients. Semin Intervent Radiol. 2016 Jun;33(2):71-4. doi: 10.1055/s-0036-1581090.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7215	Parker, N.A., et al., Complication and Retrieval Rates of Inferior Vena Cava Filters, a Single-Center Retrospective Study. Journal of Vascular Surgery, 2016. 64(3): 868-869.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7216	Passman M. Vena Cava Interruption and Pulmonary Embolism. In: Rutherford's Vascular Surgery, Cronenwett JL (ed). Elsevier 2014. 816.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7217	Patel A, Cholkankaril J. Case of the migrating embolic filter. Hosp Pract (Off Ed). 1991 Apr 15;26(4):129-32.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7218	Patton JH Jr, Fabian TC, Croce MA, Minard G, Pritchard FE, Kudsk KA. Prophylactic Greenfield Filters: Acute Complications and Long-Term Follow-up. J Trauma. 1996 Aug;41(2):231-6; discussion 236-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7219	Peters, M.N., et al., Inferior vena cava filter migration to the right ventricle causing nonsustained ventricular tachycardia. Tex Heart Inst J, 2013. 40(3): 316-9	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7220	Peterson EA, Yenson PR, Liu D, Lee AYY. Predictors of attempted inferior vena cava filters retrieval in a tertiary care centre. Thromb Res 2014; 134:300-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7221	Piano G, Ketteler ER, Prachand V, Devalk E, Van Ha TG, Gewertz BL, Alverdy JC. Safety, feasibility, and outcome of retrievable vena cava filters in high-risk surgical patients. J Vasc Surg. 2007 Apr;45(4):784-8; discussion 788.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7222	Piercecchi, C.W., et al., Cardiac Perforation by Migrated Fractured Strut of Inferior Vena Cava Filter Mimicking Acute Coronary Syndrome. Heart Lung Circ, 2017. 26(2): e11-e13.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7223	Pierfitte C, Bégaud B, Lagnaoui R, Moore ND. Is Reporting Rate a Good Predictor of Risks Associated with Drugs? Br J Clin Pharmacol. 1999 Mar;47(3):329-31.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7224	Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-Effectiveness Analyses of Colorectal Cancer Screening – A Systematic Review for the US Preventative Services Task Force. Ann Intern Med. 2002 Jul 16;137(2):96-104.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7225	Piotrowski, Is Deep Vein Thrombosis Surveillance Warranted in High-Risk Trauma Patients?	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7226	Poletti PA, Becker CD, Prina L, Ruijs P, Bounameaux H, Didier D, Schneider PA, Terrier F. Long-term results of the Simon nitinol inferior vena cava filter. Eur Radiol. 1998;8(2):289-94.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7227	Porcellini, M., et al., Intracardiac migration of nitinol TrapEase vena cava filter and paradoxical embolism. Eur J Cardiothorac Surg. 2002. 22(3): 460-1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7228	Prasad V, Rho J, Cifu, A. The Inferior Vena Cava Filter, How Could a Medical Device Be So Well Accepted Without Any Evidence of Efficacy? JAMA Intern Med. 2013;173(7):493-495. doi:10.1001/jamainternmed.2013.2725	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7229	Pratt WB, MD, Leake SS, Afaq S, Sandhu HK, Safi HJ, Azizzadeh A, Charlton-Ouw KM. Asymptomatic Patients With Inferior Vena Cava Filter Penetration Through the Wall May be Managed Conservatively. Journal of Vascular Surgery, March 2017, Volume 65, Issue 3, Pages e7-e8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7230	PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22. Epub 2005 Jul 11.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7231	PRESERVE Trial (Predicting the Safety and Effectiveness of Inferior Vena Cava Filters) http://www.preservetrial.com/Study-Design accessed on February 26, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7232	Proctor MC, Cho KJ, Greenfield LJ. In Vivo Evaluation of Vena Caval Filters- Can Function Be Linked to Design Characteristics? Cardiovasc Intervent Radiol. 2000 Nov-Dec;23(6):460-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7233	Proctor MC, Greenfield LJ. Pulmonary embolism: diagnosis, incidence and implications. Cardiovasc Surg. 1997; 5:77-81.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7234	Pryor HI 2nd, Singleton A, Lin E, Lin P, Vaziri K. Practice Patterns in High-Risk Bariatric Venous Thromboembolism Prophylaxis. Surg Endosc. 2013 Mar;27(3):843-8. doi: 10.1007/s00464-012-2521-z. Epub 2012 Oct 6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7235	Prystowsky JB, Morasch MD, Eskandari MK, Hungness ES, Nagle AP. Prospective Analysis of the Incidence of Deep Venous Thrombosis in Bariatric Surgery Patients. Surgery. 2005 Oct;138(4):759-63; discussion 763-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7236	Puram B, Maley TJ, White NM, Rotman HH, Miller G. Acute myocardial infarction resulting from a migration of a Greenfield filter. Chest. 1990 Dec;98(6):1510-1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7237	Purcell, S.T., et al., PS232. Complications Associated With IVC Filters: A large, Single Institution Review. <i>Journal of Vascular Surgery</i> , 2014. 59(6): 88S	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7238	Putterman D, Niman D, Cohen G. Aortic Pseudoaneurysm after Penetration by a Simon Nitinol Inferior Vena Cava Filter. <i>J Vasc Interv Radiol</i> . 2005 Apr;16(4):535-	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7239	Queiroz R, Waldman DL. Transvenous retrieval of a Greenfield filter lodged in the tricuspid valve. <i>Cathet Cardiovasc Diagn</i> . 1998 Jul;44(3):310-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7240	Radiation Dose in X-ray and CT Exams. http://www.radiologyinfo.org/en/info.cfm?pg=safety-xray Accessed on February 20, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7241	Raghavan S, Akhtar A, Bastani B. Migration of inferior vena cava filter into renal hilum. <i>Nephron</i> . 2002 Jun;91(2):333-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7242	Rajasekhan A, Elmariah H, Lottenberg L, et al: Inferior Vena Cava Filters in Trauma Patients: A National Practice Patterns Survey of US Trauma Centers: The American Surgeon 2014; 80: 1237-1244.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7243	Rajasekhar A, Crowther MA. ASH evidence-based guidelines: what is the role of inferior vena cava filters in the perioperative prevention of venous thromboembolism in bariatric surgery patients? <i>Hematology Am Soc Hematol Educ Program</i> . 2009:302-4. doi: 10.1182/asheducation-2009.1.302.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7244	Rajasekhar A, Lottenberg L, Lottenberg R, Feezor RJ, Armen SB, Liu H, Efron PA, Crowther M, Ang D. A pilot study on the randomization of inferior vena cava filter placement for venous thromboembolism prophylaxis in high-risk trauma patients. <i>J Trauma</i> . 2011 Aug;71(2):323-8; discussion 328-9. doi: 10.1097/TA.0b013e318226ecce1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7245	Rajasekhar A, Lottenberg R, Lottenberg L, Liu H, Ang D. Pulmonary embolism prophylaxis with inferior vena cava filters in trauma patients: a systemic review using the meta-analysis of observational studies in epidemiology (MOOSE) guidelines. <i>J Thromb Thrombolysis</i> . 2011; 32(1):40-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7246	Rajasekhar A, Streiff MB. Vena cava filters for management of venous thromboembolism: a clinical review. <i>Blood Rev</i> . 2013 Sep;27(5):225-41. doi: 10.1016/j.blre.2013.07.001. Epub 2013 Aug 7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7247	Rajasekhar A., Crowther M. Inferior vena caval filter insertion prior to bariatric surgery: a systematic review of the literature. <i>J Thromb Haemost</i> . 2010;8:1266-	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7248	Rao KM, Simons AJ, Hare CL, Smulyan H. Migration of a Kimray-Greenfield filter into the pulmonary artery: localization by transesophageal echocardiography. <i>Am Heart J</i> . 1993 Feb;125(2 Pt 1):543-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7249	Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. A randomized controlled trial. <i>Ann Intern Med</i> 1993;119(9):874-881.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7250	Rasuli P, Mehran R, French G, Turek M, Lalonde KA, Cardinal P. Percutaneous retrieval of a vena cava filter from the right atrium: case report. <i>Can Assoc Radiol J</i> . 2000 Feb;51(1):30-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7251	Rasuli P. Inferior vena cava penetration by g�nther tulip filter? <i>J Vasc Interv Radiol</i> . 2013 May;24(5):752. doi: 10.1016/j.jvir.2013.01.501.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7252	Ray CE Jr, Kaufman JA. Complications of inferior vena cava filters. <i>Abdom Imaging</i> . 1996 Jul-Aug;21(4):368-74.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7253	Ray CE Jr, Mitchell E, Zipser S, Kao EY, Brown CF, Moneta GL. Outcomes with retrievable inferior vena cava filters: a multicenter study. <i>J Vasc Interv Radiol</i> . 2006 Oct;17(10):1595-604.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7254	Redberg R. Continued High Rates of IVC Filter Use After US Food and Drug Safety Warning. <i>JAMA Intern Med</i> . 2017 Sep 1;177(9):1374-1375. doi: 10.1001/jamainternmed.2017.2724.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7255	Redberg, R.F., Medical devices and the FDA approval process: balancing safety and innovation; comment on "prevalence of fracture and fragment embolization of bard retrievable vena cava filters and clinical implications including cardiac perforation and tamponade". <i>Arch Intern Med</i> . 2010. 170(20): 1831-3	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7256	Redberg, Rita F., "Comment on 'Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Tamponade'", <i>Archives of Internal Medicine</i> 2010;	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7257	Reis SP, Kovoov J, Sutphin PD, Toomay S, Trimmer C, Pillai A, Reddick M, Kalva SP. Safety and Effectiveness of the Denali Inferior Vena Cava Filter: Intermediate Follow-Up Results. <i>Vasc Endovascular Surg.</i> 2016 Aug;50(6):385-90. doi: 10.1177/1538574416666223. Epub 2016 Aug 31.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7258	Renno, A., et al., A single center experience with retrievable IVC filters. <i>Vascular</i> , 2015. 23(4): 350-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7259	Ritchie AJ, Mitchell L, Forty J. Migration of a vena caval filter to the pulmonary artery. <i>Br J Surg.</i> 1995 Feb;82(2):207.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7260	Roberts AC. Inferior Vena Cava Filters, Today's clot filtration technologies offer a variety of options. <i>Endovascular Today</i> , February 2003.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7261	Roberts PR. Follow up and optimization of cardiac pacing. <i>Heart.</i> 2005; 91(9):1229-34.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7262	Rodriguez JL, Lopez JM, Proctor MC, Conley JL, Gerndt SJ, Marx MV, Taheri PA, Greenfield LJ. Early Placement of Prophylactic Vena Cava Filters in Injured Patients at High Risk for Pulmonary Embolism. <i>J Trauma.</i> 1996 May;40(5):797-802; discussion 802-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7263	Rodriguez LF, Saltiel FS. Long-term follow-up of ectopic intracardiac Greenfield filter. <i>Chest.</i> 1993 Aug;104(2):611-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7264	Rogers FB, Cipolle MD, Velmahos G, Luchette F. Practice Management Guidelines for the Prevention of Venous Thromboembolism in Trauma Patients. The EAST Practice Management Guidelines Work Group. <i>J Trauma Acute Care Surg.</i> 2002; 53:142-164.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7265	Rogers FB, Osler TM, Shackford SR: Immediate Pulmonary Embolism after Trauma. <i>Trauma</i> 2000; 48:146-148.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7266	Rogers FB, Shackford SR, Horst MA, Miller JA, Wu D, Bradburn E, Rogers A, Krasne M. Determining venous thromboembolic risk assessment for patients with trauma: The Trauma Embolic Scoring System. <i>J Trauma Acute Care Surg.</i> 2012; 73(2):511-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7267	Rogers FB, Shackford SR, Miller JA, et al. Improved recovery of prophylactic inferior vena cava filters in trauma patients: the results of a dedicated filter registry and critical pathway for filter removal. <i>J Trauma</i> 2012; 72:381-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7268	Rogers FB, Shackford SR, Miller JA, Wu D, Rogers A, Gambler A. Improved Recovery of Prophylactic Inferior Vena Cava Filters in Trauma Patients: The Results of a Dedicated Filter Registry and Critical Pathway for Filter Removal. <i>J Trauma Acute Care Surg.</i> 2012 Feb;72(2):381-4. doi:	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7269	Rogers FB, Shackford SR, Wilson J, Ricci MA, Morris CS. Prophylactic vena cava filter insertion in severely injured trauma patients: Indications and preliminary results. <i>J Trauma</i> 1993; 35:637-641.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7270	Rogers FB, Strindberg G, Shackford SR, Osler TM, Morris CS, Ricci MA, Najarian KE, D'Agostino R, Pilcher DB. Five-year follow-up of prophylactic vena cava filters in high-risk trauma patients. <i>Arch Surg</i> 1998; 133:406-411.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7271	Rogers FB, Strindberg G, Shackford SR, Osler TM, Morris CS, Ricci MA, Najarian KE, D'Agostino R, Pilcher DB. Five-year Follow-up of Prophylactic Vena Cava Filters in High-Risk Trauma Patients. <i>Arch Surg.</i> 1998 Apr;133(4):406-11; discussion 412.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7272	Rogoff, P.A., et al., Cephalic migration of the bird's nest inferior vena caval filter: report of two cases. <i>Radiology.</i> 1992. 184(3): 819-22.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7273	Rose SC, Kinney TB, Valji K, Winchell RJ. Placement of Inferior Vena Caval Filters in the Intensive Care Unit. <i>J Vasc Interv Radiol.</i> 1997 Jan-Feb;8(1 Pt 1):61-70; discussion 901.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7274	Rosenthal D, Kochupura PV, Wellons ED, Burkett AB, Methodius-Rayford WC. Gunther Tulip and Celect IVC Filters in Multiple-Trauma Patients. <i>J Endovasc Ther.</i> 2009 Aug;16(4):494-9. doi: 10.1583/09-2728.1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7275	Rosenthal D, McKinsey JF, Levy AM, Lamis PA, Clark MD. Use of Greenfield filter in patients with major trauma. <i>Cardiovasc Surg.</i> 1994 Feb;2(1):52-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7276	Rosenthal D, Wellons ED, Levitt AB, Shuler FW, O'Conner RE, Henderson VJ. Role of prophylactic temporary inferior vena cava filters placed at the ICU bedside under intravascular ultrasound guidance in patients with multiple trauma. <i>J Vasc Surg.</i> 2004 Nov;40(5):958-64.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7277	Rossi, P., et al., Fatal outcome in atrial migration of the Tempofilter. Cardiovasc Intervent Radiol. 1999. 22(3): 227-31.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7278	Rozin L, Perper JA. Spontaneous Fatal Perforation of Aorta and Vena Cava by Mobin-Uddin Umbrella. Am J Forensic Med Pathol. 1989 Jun;10(2):149-51.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7279	Rubenstein L, Chun AK, Chew M, Binkert CA. Loop Snare Technique for Difficult Inferior Vena Cava Filter Retrievals. J Vasc Interv Radiol. 2007 Oct;18(10):1315-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7280	Ryu RK, Desai K, Karp J, et al. A comparison of retrievability: Celect versus Option filter. J Vasc Interv Radiol 2015;26:865-869.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7281	Saeed, I., M. Garcia and K. McNicholas, Right ventricular migration of a recovery IVC filter's fractured wire with subsequent pericardial tamponade. Cardiovasc Intervent Radiol. 2006. 29(4): 685-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7282	Sag AA, Stavas JM, Burke CT, Dixon RG, Marquess JS, Mauro MA. Analysis of Tilt of the Gunther Tulip Filter. J Vasc Interv Radiol. 2008 May;19(5):669-76. doi: 10.1016/j.jvir.2008.01.020. Epub 2008 Mar 24.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7283	Sagai HC, Ahn J, Cresla D, et al: Venous Thromboembolism in Orthopedic Patients: A Survey of OTA Member Practice Patterns and OTA Expert Panel Recommendations: 2015; <i>J Orthop Trauma</i> 29(10) e355-e362.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7284	Sakuma M, Nakamura M, Nakanishi N, et al. Inferior vena cava filter is a new additional therapeutic option to reduce mortality from acute pulmonary embolism. Circ J. 2004; 68:816-21.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7285	Sangwaiya MJ, Marentis TC, Walker TG, Stecker M, Wicky ST, Kalva SP. Safety and Effectiveness of the Celect Inferior Vena Cava Filter: Preliminary Results. J Vasc Interv Radiol. 2009 Sep;20(9):1188-92. doi: 10.1016/j.jvir.2009.05.033. Epub 2009 Jul 23.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7286	Sano M, Unno N, Yamamoto N, Tanaka H, Konno H. Frequent fracture of TrapEase inferior vena cava filters: a long-term follow-up assessment. Arch Intern Med. 2012 Jan 23;172(2):189-91. doi: 10.1001/archinternmed.2011.548. Epub	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7287	Sapala JA, Wood MH, Schuhknecht MP, Sapala MA. Fatal Pulmonary Embolism after Bariatric Operations for Morbid Obesity: A 24-yr retro analysis. Obes Surg. 2003 Dec;13(6):819-25.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7288	Sarosiek (2016)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7289	Sarosiek S, Crowther M, Sloan JM. Indications, complications, and management of inferior vena cava filters: The experience in 952 patients at an academic hospital with a level I trauma center. JAMA Intern Med 2013; 173:513-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7290	Sarosiek S, Rybin D, Weinberg J, Burke PA, Kasotakis G, Sloan JM. Association Between Inferior Vena Cava Filter Insertion in Trauma Patients and In Hospital and Overall Mortality. JAMA Surg. 2017 Jan 1;152(1):75-81. doi: 10.1001/jamasurg.2016.3091.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7291	Sathyanarayana R, Tan GX, Van Tonder F, Szkla C, Jhamb A. Bard DENALI Inferior Vena Cava Filter Another "Arm" Fracture. J Vasc Interv Radiol. 2016 Nov;27(11):1722-1724. doi: 10.1016/j.jvir.2016.05.025.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7292	Satya R, Anderson J, Lievano G, Satya RJ. Inferior Vena Cava (IVC) Rupture and Retroperitoneal Hemorrhage Caused by IVC Filter Migration. J Vasc Interv Radiol. 2009 Aug;20(8):1102-4. doi: 10.1016/j.jvir.2009.05.001.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7293	Schmidt U, Enderson BL, Chen JP, Maul KI: D-dimer levels correlate with pathologic thrombosis in trauma patients. J Trauma 1992; 33:312-320.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7294	Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342-52. doi: 10.1056/NEJMoa0906598.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7295	Schuster R, Hagedorn JC, Curet MJ, Morton JM. Retrievable inferior vena cava filters may be safely applied in gastric bypass surgery. Surg Endosc. 2007 Dec;21(12):2277-9. Epub 2007 Apr 13.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7296	Scientific Session 1 IVC Filters, Venous Thromboembolic Disease	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7297	Seyfer AR, Saeber AV, Dambrose FA, et al: Coagulation changes after elective surgery and trauma. Ann. Surg. 1981; 193:210-213.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7298	Shackford SR, Cook A, Rogers FB, Littenberg B, Osler T. The Increasing Use of Vena Cava Filters in Adult Trauma Victims: Data From the American College of Surgeons National Trauma Data Bank. <i>J Trauma</i> . 2007 Oct;63(4):764-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7299	Shackford SR, Mackersic RC, Holbrook TL, et al: The Epidemiology of Trauma Death: A Population-Based Analysis. <i>Arch Surg</i> . 1993;128:571-575.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7300	Shah AH, Lichliter A, Cura M. Inferior Vena Cava Filter Removal After Prolonged Dwell Time of 2310 Days. <i>Proc (Bayl Univ Med Cent)</i> . 2016 Jul;29(3):292-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7301	Shamian B, Chamberlain RS. The role for prophylaxis inferior vena cava filters in patients undergoing bariatric surgery: Replacing Anecdote with Evidence. <i>Am Surg</i> . 2012 Dec;78(12):1349-61.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7302	Shang EK, Nathan DP, Carpenter JP, Fairman RM, Jackson BM. Delayed Complications of Inferior Vena Cava Filters: Case Report and Literature Review. <i>Vasc Endovascular Surg</i> . 2011 Apr;45(3):290-4. doi: 10.1177/1538574410395038. Epub 2011 Jan 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7303	Sharifi M, Bay C, Skrocki L, Lawson D, Mazdeh S. Role of IVC filters in endovenous therapy for deep venous thrombosis: the FILTER-PEVI (filter implantation to lower thromboembolic risk in percutaneous endovenous intervention) trial. <i>Cardiovasc Intervent Radiol</i> . 2012 Dec;35(6):1408-13. doi: 10.1007/s00270-012-0342-z. Epub 2012 Jan 20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7304	Shaw, C.M., et al., Optional vena cava filter use in the elderly population. <i>J Vasc Interv Radiol</i> . 2011. 22(6): 824-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7305	Shimizu, M., et al., Retrievable Gunther Tulip filter complicated by sepsis and retroperitoneal hemorrhage: successful management by filter retrieval. <i>Intern Med</i> . 2005. 44(6): 593-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7306	Simon M, Athanasoulis CA, Kim D, Steinberg FL, Porter DH, Byse BH, Kleshinski S, Geller S, Orron DE, Waltman AC. Simon nitinol inferior vena cava filter: initial clinical experience. <i>Work in progress. Radiology</i> . 1989 Jul;172(1):99-103.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7307	Simon M, Athanasoulis CA, Kim D, Steinberg FL, Porter DH, Byse BH, Kleshinski S, Geller S, Orron DE, Waltman AC. Simon nitinol inferior vena cava filter: initial clinical experience. <i>Work in progress. Radiology</i> . 1989 Jul;172(1):99-103.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7308	Sing RF, Fischer PE. Inferior Vena Cava Filters: Indications and Management. <i>Curr Opin Cardiol</i> . 2013 Nov;28(6):625-31. doi: 10.1097/HCO.0b013e3283655b97.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7309	Sing RF, Rogers FB, Novitsky YW, Heniford T. Optional vena cava filters for patients with high thromboembolic risk: questions to be answered. <i>Surgical Innovation</i> 2005; 12:195-202.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7310	Singer MA, Wang SL. Modeling blood flow in a tilted inferior vena cava filter: does tilt adversely affect hemodynamics? <i>J Vasc Interv Radiol</i> . 2011 Feb;22(2):229-35. doi: 10.1016/j.jvir.2010.09.032. Epub 2011 Jan 6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7311	Singh S, Haut ER, Brotman DJ, Sharma R, Chelladurai Y, Shermock KM, Kebede S, Stevens KA, Prakasa KR, Shihab HM, Akande TO, Zeidan AM, Garcia LJ, Segal JB. Pharmacologic and Mechanical Prophylaxis of Venous Thromboembolism Among Special Populations [Internet]. Agency for Healthcare Research and Quality (US); 2013 May. Report No.: 13-EHC082-1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7312	2001 SIR Guidelines for IVC filters, Grassi et al., <i>J Vasc Interv Radiol</i> .	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7313	Smith A, Adrahtas D, Elitharp D, Gasparis A, Labropoulos N, Tassiopoulos A. Changes in the Rate of Prophylactic Vena Cava Filter Insertion at a University Hospital. <i>Phlebology</i> . 2016 Jul;31(6):403-8. doi: 10.1177/0268355515592769. Epub 2015 Jun 19.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7314	Smith BA, Vena Caval Filters. <i>Emerg Med Clin North Am</i> . 1994 Aug;12(3):645-56.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7315	Smouse B, Johar A. Is Market Growth of Vena Cava Filters Justified? A review of indications, use, and market analysis. <i>Endoscopy Today</i> , Feb. 2010.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7316	Smouse HB, Rosenthal D, Thuong VH, Knox MF, Dixon RG, Voorhees WD 3rd, McCann-Brown JA. Long-term Retrieval Success Rate Profile for the Gunther Tulip Vena Cava Filter. <i>J Vasc Interv Radiol</i> . 2009 Jul;20(7):871-7; quiz 878. doi: 10.1016/j.jvir.2009.03.033. Epub 2009 May 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7317	Smouse HB, Trost D, Rectenwald JE, Arko FR, Kaufman JA, Plant G, Atkins MD, Razavi MK, Uberoi R. One Question...How Have Your Protocols for IVC Filter Placement, Monitoring, and Retrieval Changed in the Past Several Years? Endovascular Today, July 2012. [not a peer-reviewed article]	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7318	Society of Interventional Radiology Responds to FDA Blood Clot Device (IVC Filter) Advisory	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7319	Society of Interventional Radiology Responds to FDA Blood Clot Device (IVC Filter) Advisory, 08/12/2010.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7320	Spencer FA, Bates SM, Goldbert RJ. A population-based study of inferior vena cava filters in patients with acute venous thromboembolism. Arch Intern Med 2010; 170:1456-62.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7321	Spinal Cord Injury Thromboprophylaxis Investigators, Prevention of Venous Thromboembolism in the Acute Treatment Phase after Spinal Cord Injury: A Randomized, Multicenter Trial Comparing Low-Dose Heparin Plus Intermittent Pneumatic Compression with Enoxaparin. J Trauma. 2003 Jun;54(6):1116-24; discussion 1125-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7322	Stavropoulos SW, Dixon RG, Burke CT, Stavas JM, Shah A, Shlansky-Goldberg RD, Trerotola SO. Embedded inferior vena cava filter removal: use of endobronchial forceps. J Vasc Interv Radiol. 2008 Sep;19(9):1297-301. doi: 10.1016/j.jvir.2008.04.012. Epub 2008 Jun 2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7323	Stavropoulos, S.W., Chen, J.X., Sing, R.F. et al. Analysis of the final DENALI trial data: a prospective, multicenter study of the DENALI inferior vena cava filter. J Vasc Interv Radiol. 2016; 27: 1531-1538.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7324	Stavropoulos, S.W., et al., Retrieval of Tip-embedded Inferior Vena Cava Filters by Using the Endobronchial Forceps Technique: Experience at a Single Institution. Radiology, 2015. 275(3): 900-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7325	Stavropoulos, S.W., et al., The DENALI Trial: an interim analysis of a prospective, multicenter study of the Denali retrievable inferior vena cava filter. J Vasc Interv Radiol, 2014. 25(10): 1497-505, 1505 e1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7326	Steele JR, Wallace MJ, Hovsepian DM, James BC, Kundu S, Miller DL, Rose SC, Sacks D, Shah SS, Cardella JF. Guidelines for Establishing a Quality Improvement Program in Interventional Radiology. J Vasc Interv Radiol. 2010 May;21(5):617-25. doi: 10.1016/j.jvir.2010.01.010. Epub 2010 Mar 17.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7327	Stein PD, Alnas M, Skaf E, Kayali F, Siddiqui T, Olson RE, Patel K. Outcome and Complications of Retrievable Inferior Vena Cava Filters. Am J Cardiol. 2004 Oct 15;94(8):1090-3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7328	Stein PD, Kayali F, Olson RE. Twenty-one-year trends in the use of inferior vena cava filters. Arch Intern Med 2004; 164:1541-1545.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7329	Stein PD, Matta F, Huges MJ. Inferior Vena Cava Filters in Stable Patients with Acute Pulmonary Embolism Who Receive Thrombolytic Therapy. Am J Med. 2018 Jan;131(1):97-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7330	Stein PD, Matta F, Jull RD. Increasing use of vena cava filters for prevention of pulmonary embolism. Am J Med 2011; 124:655-61.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7331	Stein PD, Matta F, Keyes DC, Willyerd G. Impact of vena cava filters on in-hospital case fatality rate from pulmonary embolism. Am J Med 2012; 125:478-84.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7332	Stein PD, Matta F, Lawrence FR, Huges MJ. Inferior Vena Cava Filters in Patients with Acute Pulmonary Embolism and Cancer. Am J Med. Epub 2017 Nov10.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7333	Stein PD, Matta F, Lawrence FR, Huges MJ. Usefulness of Inferior Vena Cava Filters in Unstable Patients With Acute Pulmonary Embolism and Patients Who Underwent Pulmonary Embolectomy. Am J Cardio. 2018 Jan;121(4):495-00.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7334	Stein PD, Matta F, Sabra MJ. Case fatality rate with vena cava filters in hospitalized stable patients with cancer and pulmonary embolism. Am J Med.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7335	Stein PD, Matta F. Vena cava filters in unstable elderly patients with acute pulmonary embolism. Am J Med 2014; 127:222-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7336	Stösslein F, Altmann E. A rare complication with an Antheor cava filter. Cardiovasc Intervent Radiol. 1998 Mar-Apr;21(2):165-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7337	Streib EW, Wagner JW. Complications of vascular access procedures in patients with vena cava filters. J Trauma. 2000 Sep;49(3):553-7; discussion 557-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7338	Streiff MB. Vena Caval Filters: A Comprehensive Review. Blood. 2000 Jun 15;95(12):3669-77.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7339	Sudheendra D, Giroux MF, Johnson MS, Murphy E, Garcia, MJ. Ask the Experts: What is your practice's current IVC filter retrieval protocol, and in which cases do you deviate from it? [not a peer-reviewed article]	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7340	Sutphin PD, Reis SP, McKune A, et al. Improving inferior vena cava filter retrieval rates with the define, measure, analyze, improve, control methodology. J Vasc Interv Radiol 2015; 26:491-8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7341	Swami, U., G. Annunziata and I. Fulger, Experience with vena cava filters at a large community hospital and level-I trauma center: indications, complications, and compliance barriers. Clin Appl Thromb Hemost. 2014. 20(5): 546-52	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7342	Sweeney TJ, Van Aman ME. Deployment Problems with the Titanium Greenfield Filter. J Vasc Interv Radiol. 1993 Sep-Oct;4(5):691-4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7343	Sweet PH III, Armstrong T, Chen J, Masliah E, Witucki P. Fatal pulmonary embolism update: 10 years of autopsy experience at an academic medical center. JRSMD Short Rep. 2013; 4(9):2042533313489824.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7344	Świątkowska B, Szeszenia-Dąbrowska N, Wilczyńska U. Medical Monitoring of Asbestos-Exposed Workers – Experience from Poland. Bull World Health Organ. 2016 Aug 1;94(8):599-604. doi: 10.2471/BLT.15.159426. Epub 2016 Jun 2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7345	Taksler GB, Keshner M, Fagerlin A, Hajizadeh N, Braithwaite RS. Personalized Estimates of Benefit from Preventative Care Guidelines – A Proof of Concept. Ann Intern Med. 2013 Aug 6;159(3):161-8. doi: 10.7326/0003-4819-159-3-201308060-00005.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7346	Tam MD, Spain J, Lieber M, Geisinger M, Sands MJ, Wang W. Fracture and distant migration of the Bard Recovery filter: a retrospective review of 363 implantations for potentially life-threatening complications. J Vasc Interv Radiol. 2012 Feb;23(2):199-205.e1. doi: 10.1016/j.jvir.2011.10.017. Epub 2011 Dec 20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7347	Tam MD, Zhu X, McLennan G, Sands MJ, W. Wang. Complications of the Bard Recovery Filter and Their Effect on Attempted Retrieval in 107 Patients. Abstract No. 2. Journal of Vascular and Interventional Radiology, February 2010Volume 21, Issue 2, Supplement, Page S3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7348	Tan XL, Tam C, McKellar R, Nandurkar H, Bazargan A. Out of sight, out of mind: an audit of inferior vena cava filter insertion and clinical follow up in an Australian institution and literature review. Intern Med J 2013; 43(4):365-72.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7349	Tanner L. FDA clot device advisory tells of patients' risks. The San Diego Union-Tribune, August 9, 2010.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7350	Tao MJ, Montbriand JM, Eisenberg N, Sniderman KW, Roche-Nagle G. Temporary inferior vena cava filter indications, retrieval rates, and follow up management at a multicenter tertiary care institution. J Vasc Surg. 2016 Aug;64(2):430-437. doi: 10.1016/j.jvs.2016.02.034. Epub 2016 Mar 30.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7351	Tatonetti, N.P., G.H. Fernald and R.B. Altman, A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. J Am Med Inform Assoc. 2012. 19(1): 79-85	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7352	Taylor FC, Awh MH, Kahn CE Jr, Lu CT. Vena Tech vena cava filter: experience and early follow-up. J Vasc Interv Radiol. 1991 Nov;2(4):435-40.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7353	The Guide to Clinical Preventative Services. US Preventative Services Task Force.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7354	The Society for Interventional Radiology and the Society for Vascular Surgery have initiated the PRESERVE study	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7355	Thonar B, Patel NH, Ferral H, Behrens G. AJR teaching file: chest pain in a woman with an inferior vena cava filter. AJR Am J Roentgenol. 2007 Sep;189(3)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7356	Torbicki A, Perrier A, Konstantinides S, et al., Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Eur Heart J	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7357	Trerotola SO, Stavropoulos SW. Management of Fractured Inferior Vena Cava Filters: Outcomes by Fragment Location. Radiology. 2017 Sep;284(3):887-896. doi: 10.1148/radiol.2017162005. Epub 2017 Apr 19.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7358	Tribe CR. Causes of Death in the Early and Late Stages of Paraplegia. Paraplegia. 1963 May;1:19-47.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7359	Trigilio-Black CM, Ringley CD, McBride CL, Sorensen VJ, Thompson JS, Longo GM, Pipinos II, Johannig JM. Inferior Vena Cava Filter Placement for Pulmonary Embolism Risk Reduction in Super Morbidly Obese Undergoing Bariatric Surgery. Surg Obes Relat Dis. 2007 Jul-Aug;3(4):461-4. Epub 2007 Jun 4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7360	Tschoe M, Kim HS, Brotman DJ, Streiff MB. Retrievable Vena Cava Filters: A Clinical Review. J Hosp Med. 2009 Sep;4(7):441-8. doi: 10.1002/jhm.439.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7361	Tse G, Cleveland T, Goode S. Ten-Year Experience of Retrievable Inferior Vena Cava Filters in a Tertiary Referral Center. Diagn Interv Radiol. 2017 Mar-Apr;23(2):144-149. doi: 10.5152/dir.2016.16022.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7362	Turba UC, Glaiberman C, Picus D, Arslan B, Angle JF, Matsumoto AH. Management of severe vena cava filter tilting: experience with Bard G-2 filters. J Vasc Interv Radiol. 2008 Mar;19(3):449-53. doi: 10.1016/j.jvir.2007.11.020.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7363	U.S. Preventive Services Task Force https://www.uspreventiveservicestaskforce.org/Page/Name/grade-definitions accessed on March 6, 2017.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7364	Uberoi R, Tapping CR, Chalmers N, Allgar V. British Society of Interventional Radiology (BSIR) Inferior Vena Cava (IVC) Filter Registry. Cardiovasc Intervent Radiol. 2013 Dec;36(6):1548-1561. doi: 10.1007/s00270-013-0606-2. Epub 2013 Mar 20. Erratum in: Cardiovasc Intervent Radiol. 2017 Dec 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7365	Urbankova J, Quiroz R, Kucher N, Goldhaber SZ. Intermittent pneumatic compression and DVT prevention in postoperative patients. Thromb Haemost. 2005 Dec;94(6):1181-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7366	Urena, R. and L. Greenwood, Bird's nest filter migration to the right atrium. AJR Am J Roentgenol. 2004. 183(4): 1037-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7367	Urias D, Silvius J, Mesropyan L, Oberlander E, Simunich T, Tretter J. Retrievable Inferior Vena Cava Filters in Geriatric Trauma: Is There an Age Bias? Injury. 2017 Jan;48(1):148-152. doi: 10.1016/j.injury.2016.07.008. Epub 2016 Jul 15.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7368	Van Ha, T.G., Complications of inferior vena caval filters. Semin Intervent Radiol. 2006. 23(2): 150-5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7369	Vaziri K, Bhanot P, Hungness ES, Morasch MD, Prystowsky JB, Nagle AP. Retrievable IVC Filters in High Risk Patients Undergoing Bariatric Surgery. Surg Endosc. 2009 Oct;23(10):2203-7. doi: 10.1007/s00464-008-0307-0. Epub 2009 Jan 28.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7370	Veerapong J, Wahlgren CM, Jolly N, Bassiouny H. Successful percutaneous retrieval of an inferior vena cava filter migrating to the right ventricle in a bariatric patient. Cardiovasc Intervent Radiol. 2008 Jul;31 Suppl 2:S177-81. doi: 10.1007/s00270-007-9278-0. Epub 2008 Jan 17.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7371	Velmahos GC, et al: Prevention of venous thromboembolism after injury: an evidence-based report: part II: analysis of risk factors and evaluation of the role of vena caval filters. J Trauma 49:140-144, 2000	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7372	Vena Caval Filter Consensus Conference. Recommended reporting standards for vena caval filter placement and patient follow-up. The Participants in the Vena Caval Filter Consensus Conference. J Vasc Surg 1999;30:573-9.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7373	Vergara, G.R., W.F. Wallace and K.R. Bennett, Spontaneous migration of an inferior vena cava filter resulting in cardiac tamponade and percutaneous filter retrieval. Catheter Cardiovasc Interv. 2007. 69(2): 300-2.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7374	Vijay K, Hughes JA, Burdette AS, et al. Fractured Bard Recovery, G2, and G2 express inferior vena cava filters: incidence, clinical consequences, and outcomes of removal attempts. J Vasc Interv Radiol 2012; 23:188-94.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7375	Vladimir, F.G., et al., Complications and Outcomes Associated With the Use Of Retrievable Vena Cava Filters: A Review of the Manufacturer and User Facility Device Experience Database (MAUDE) Database. NESVS: 2005 Annual Meeting - 2005 Abstracts, 2005.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7376	Vossen, J.A., et al., Recurrent fracture of a recovery inferior vena cava filter with pulmonary migration. <i>Yale J Biol Med</i> , 2012. 85(2): 255-9	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7377	Walsh J, Safety and Effectiveness of Inferior Vena Cava Filters Used to Protect Against Pulmonary Embolus: A Technology Assessment. http://ctaf.org/sites/default/files/assessments/1247_file_IVC_Filters_final_W.pdf	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7378	Waltz P, Zuckerbraun BS. Commentary – Inferior Vena Cava Filters in Trauma Patients – For Whom the Benefit Tolls? <i>JAMA Surg</i> . 2017 Jan 1;152(1):81. doi: 10.1001/jamasurg.2016.3121.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7379	Wang SL, Lloyd AJ. Clinical review: inferior vena cava filters in the age of patient-centered outcomes. <i>Ann Med</i> . 2013 Nov;45(7):474-81.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7380	Wang W, Spain J, Tam MD. Acute Abdominal Pain After Retrievable Inferior Vena Cava Filter Insertion: Case Report of Caval Perforation by an Option Filter. <i>Cardiovasc Intervent Radiol</i> . 2011 Aug;34(4):883-5. doi: 10.1007/s00270-010-0080-z.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7381	Wang W, Zhou D, Obuchowski N et al. Fracture and Migration of Celect Inferior Vena Cava Filters: A Retrospective Review of 741 Consecutive Implantations. <i>J Vasc Interv Radiol</i> . 2013;24:1710-1722.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7382	Waring WP, Karunas RS. Acute Spinal Cord Injuries and the Incidence of Clinically Occurring Thromboembolic Disease. <i>Paraplegia</i> . 1991 Jan;29(1):8-16.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7383	Webb LX, Rush PT, Fuller SB, Meredith JW. Greenfield Filter Prophylaxis of Pulmonary Embolism in Patients Undergoing Surgery for Acetabular Fracture. <i>J Orthop Trauma</i> . 1992;6(2):139-45.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7384	Wehrenberg-Klee E, Stavropoulos SW. Inferior Vena Cava Filters for Primary Prophylaxis: When are they indicated? <i>Semin Intervent Radiol</i> . 2012 Mar;29(1):29-35. doi: 10.1055/s-0032-1302449.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7385	Weinberg I, Abtathian F, Debiosi R, et al: Effect of Delayed Inferior Vena Cava Filter Retrieval after Early Initiation of Anticoagulation. 2014 <i>Am. J. Cardiology</i> ; 113:389-394.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7386	Weinberg I, Kaufman J, Jaff MR. Inferior vena cava filters. <i>JACC Cardiovasc Interv</i> . 2013;6(6):539-547.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7387	Whedon JM, Beaver TA, Hernandez RA, Burchard KW. Paradoxical Thromboembolism After Blunt Lower Extremity Trauma: A Management Strategy to Prevent Additional Sequelae Where Anticoagulation is Contraindicated. <i>Am Surg</i> . 2014 Nov;80(11):E309-11.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7388	White RH, Brunson A, Romano PS, Li Z, Wun T. Outcomes after vena cava filter use in noncancer patients with acute venous thromboembolism: A Population-Based Study. <i>Circulation</i> . 2016 May 24;133(21):2018-29. doi: 10.1161/CIRCULATIONAHA.115.020338. Epub 2016 Apr 5.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7389	White RH, Geraghty EM, Brunson A, Murin S, Wun T, Spencer F, Romano PS. High Variation Between Hospitals in Vena Cava Filter Use for Venous Thromboembolism. <i>JAMA Intern Med</i> . 2013 Apr 8;173(7):506-12. doi: 10.1001/jamainternmed.2013.2352.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7390	White RH: The epidemiology of venous thromboembolism. <i>Circulation</i> 107:14-18, 2003.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7391	Wicky S, Doenz F, Meuwly JY, Portier F, Schnyder P, Denys A. Clinical Experience with Retrievable Gunther Tulip Vena Cava Filters. <i>J Endovasc Ther</i> . 2003 Oct;10(5):994-1000.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7392	Winters JP, Morris CS, Holmes CE, Lewis P, Bhawe AD, Najarian KE, Shields JT, Charash W, Cushman M. A multidisciplinary quality improvement program increases the inferior vena cava filter retrieval rate. <i>Vasc Med</i> . 2017 Feb;22(1):51-56. doi: 10.1177/1358863X16676658. Epub 2016 Nov 3.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7393	Wojcik R, Cipolle MD, Fearon I, Jaffe J, Newcomb J, Pasquale MD. Long-Term Follow-up of Trauma Patients with a Vena Caval Filter. <i>J Trauma</i> . 2000 Nov;49(5):839-43.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7394	Wones R, Pinney SM, Buckholz JM, Deck-Tebbe C, Freyberg R, Pesce A. Medical Monitoring – A Beneficial Remedy for Residents Living Near an Environmental Hazard Site. <i>J Occup Environ Med</i> . 2009 Dec;51(12):1374-83. doi: 10.1097/JOM.0b013e3181c558f1.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7395	Wood, E.A., et al., Reporting the Impact of Inferior Vena Cava Perforation by Filters. (Abstract from the 2012 American Venous Forum Annual Meeting). J Vasc Surg. 2012. 55(1): 301	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7396	Woodward, E.B., et al., Delayed retroperitoneal arterial hemorrhage after inferior vena cava (IVC) filter insertion: case report and literature review of caval perforations by IVC filters. Ann Vasc Surg. 2002. 16(2): 193-6.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7397	Wu A, Moon E, Wang DS, Hertz B, Wang W. Bard Meridian Filter Fracture. Cardiovasc Intervent Radiol. 2015 Feb;38(1):251-2. doi: 10.1007/s00270-014-0935-9. Epub 2014 Jun 20.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7398	Wu EC, Barba CA. Current Practices in the Prophylaxis of Venous Thromboembolism in Bariatric Surgery. Obes Surg. 2000 Feb;10(1):7-13;	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7399	Wu EC, Barba CA. Endovascular Treatment of Late Aortic Perforation due to Vena Cava Filter. Obes Surg. 2000 Feb;10(1):7-13; discussion 14.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7400	Wu, G.S., et al., Inferior vena cava filter migration with severe deformity of filter. J Vasc Interv Radiol. 2009. 20(9): 1257-9	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7401	Yamagami T., Kato T., Hirota T., Yoshimatsu R., Matsumoto T., Nishimura T. Prophylactic implantation of inferior vena cava filter during interventional radiological treatment for deep venous thrombosis of the lower extremity. Br J Radiol. 2006;79:584-591.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7402	Young T, Tang H, Hughes R. Vena caval filters for the prevention of pulmonary embolism. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD006212. doi: 10.1002/14651858.CD006212.pub4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7403	Zektser M, Bartal C, Zeller L et al. Effectiveness of inferior vena cava filters without anticoagulation therapy for prophylaxis of recurrent pulmonary embolism. Rambam Maimonides Med J. 2016 Jul 28;7(3).	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7404	Zhou, D., et al., Penetration of Celect inferior vena cava filters: retrospective review of CT scans in 265 patients. AJR Am J Roentgenol. 2014. 202(3): 643-7.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7405	Zhou, D., et al., Retrospective review of 120 celect inferior vena cava filter retrievals: experience at a single institution. J Vasc Interv Radiol. 2012. 23(12):	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7406	Zhu Indications, complications and outcomes of G2 retrievable IVC filters in 765 patients: A single institute experience. Abstract No. 3. Journal of Vascular and Interventional Radiology. February 2010Volume 21, Issue 2, Supplement, Pages S3-S4.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7407	Zhu X, Tam MD, Bartholomew J, Newman JS, Sands MJ, Wang W. Retrievability and device-related complications of the G2 filter: a retrospective study of 139 filter retrievals. J Vasc Interv Radiol. 2011 Jun;22(6):806-12. doi: 10.1016/j.jvir.2011.01.430. Epub 2011 Apr 8.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7408	Zolfaghari D, Johnson B, Weireter LJ, Britt LD. Expanded Use of Inferior Vena Cava Filters in the Trauma Population. Surg Annu. 1995;27:99-105.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7409	Goldman, Limitations and Strengths of Spontaneous Reports Data (1998)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7410	1997 GAO Report Excerpt (Medical Device Reporting: Improvements Needed in FDA's System for Monitoring Problems With Approved Devices)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7411	2008 Surgeon General's Call to Action re PE and DVT	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7412	April 14, 2017 Report of Dr. Fasching, Medical Literature - James, B, Medical Device Failure Analysis, ASM Handbook, Volume 23, Materials for Medical Devices, ASM International, Materials Park, OH, 2012, p. 346.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7413	April 14, 2017 Report of Dr. Fasching, Medical Literature - Angel LF, Tapson V, Galgon RE, Restrepo MI, Kaufman J. Systematic Review of the use of Retrievable Inferior Vena Cava Filters. J Vasc Interv Radiol 2011; 22:1522-1530.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7414	April 14, 2017 Report of Dr. Fasching, Medical Literature - Hull JE, Robertson SW. Bard Recovery Filter: Evaluation and Management of vena Cava Limb Perforation, Fracture, and Migration. J Vasc Interv Radiol 2009; 20:52-60.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7415	April 14, 2017 Report of Dr. Fasching, Medical Literature - Tam MD, Spain J, Lieber M, Geisinger M, Sands MJ, Wang W. Fracture and Distant Migration of the Bard Recovery Filter: A Retrospective Review of 363 Implantations for Potentially Life-Threatening Complications. J Vasc Interv Radiol 2013; 23:199-205.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7416	April 14, 2017 Report of Dr. Fasching, Medical Literature - Kuo WT Robertson SW, Odegaard JI Hofmann LV. Complex Retrieval of Fractured, Embedded, and Penetrating Inferior Vena Cava Filters: A prospective Study with Histologic and Electron Microscopic Analysis. J Vasc Interv Radiol 2013; 24:622-630.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7417	April 14, 2017 Report of Dr. Fasching, Medical Literature - McMeeking RM, Assessment of the Designs of Bard Inferior Vena Cava Filters: The Recovery, G2, G2 Express, Eclipse, Meridian, and Denali Models, Re: MDL3.3.17.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7418	April 14, 2017 Report of Dr. Fasching, Medical Literature - Hodgson DE. Fabrication, Heat Treatment and Joining of Nitinol Components. SMST-2000 Proceedings of the International Conference on Shape Memory and Superelastic Technologies (Pacific Grove, CA, April 30 to May 4, 2000), P. 11-24.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7419	April 14, 2017 Report of Dr. Fasching, Medical Literature - Trepanier C, Tabrizian M, Yahia LH, Bilodeau L, Piron DL. Improvement of the Corrosion Resistance of NiTi Stents by Surface Treatments. Mat. Res. Soc. Symp. Proc. Vol. 459 (1997).	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7420	April 14, 2017 Report of Dr. Fasching, Medical Literature - Trepanier C, Tabrizian M, Yahia LH, Bilodeau L, Piron DL. Effect of Modification of Oxide Layer on NiTi Stent Corrosion Resistance. J. Biomed. Mat. Research, 1998; 43:433-440.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7421	April 14, 2017 Report of Dr. Fasching, Medical Literature - Steegmueller R, Fleckenstein T, Schuessler A. Is Electropolishing equal Electropolishing? A Comparison Study for Nitinol Stents. Proceed. Mat. & Proc. for Med. Dev. Conf., November 14-16, Boston, MA, 2006, p. 163-168.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7422	April 14, 2017 Report of Dr. Fasching, Medical Literature - https://emea.cordis.com/ma/product/smart-control-self-expanding-nitinol-stent#overview	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7423	April 14, 2017 Report of Dr. Fasching, Medical Literature - Patel MM, Gordon RF, An Investigation of Diverse Surface Finishes on Fatigue Properties of Superelastic Nitinol Wire, Proceedings of International Conference on Shape Memory and Superelastic Technology, ASM International, 2006, p. 61-70.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7424	April 14, 2017 Report of Dr. Fasching, Medical Literature - Kuo WT Robertson SW, Odegaard JI Hofmann LV. Complex Retrieval of Fractured, Embedded, and Penetrating Inferior Vena Cava Filters: A prospective Study with Histologic and Electron Microscopic Analysis. J Vasc Interv Radiol 2013; 24:622-630.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7425	April 14, 2017 Report of Dr. Fasching, Medical Literature - McMeeking RM, Begley MR, Mechanical Reliability Assessment of the Bard G2 Filter, Re: Ebert v CR Bard, January 2014.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7426	April 14, 2017 Report of Dr. Fasching, Medical Literature - McMeeking RM, Begley MR, Finite Element Modeling of the Bard Filters, June 2011.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7427	April 14, 2017 Report of Dr. Fasching, Medical Literature - Gong XY, Pelton AR, Finite Element Analysis on Nitinol Medical Applications, Proceedings of IMECE-2002, Vol. 53, 2002.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7428	April 14, 2017 Report of Dr. Fasching, Medical Literature - Rebelo N, Gong XY, Hall A, Pelton AR, Duerig TW, Finite Element Analysis on the Cyclic Properties of Superelastic Nitinol, Proceedings 2004 ABAQUS Users' Conference, p. 601-	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7429	April 14, 2017 Report of Dr. Fasching, Medical Literature - Pelton AR, Schroeder V, Mitchell MR, Gong XY, Barney M, Robertson SW, Fatigue and Durability of Nitinol Stents, J of Mech Behavior Biomed Mater, 1, 153-164 (2008)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7430	April 14, 2017 Report of Dr. Fasching, Medical Literature - McMeeking RM, Begley MR, Mechanical Reliability Assessment of the Bard IVC Recovery Filters, Re: Katrina Newton et. al. v CR Bard, March 2011.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7431	March 17, 2017 Report of Dr. Fasching, Medical Literature - R. Ritchie, Assessment of the Structural Integrity of Bard IVC Filters: Recovery, G2, G2-Express and Eclipse, March 2, 2017, Re: MDL 3.2.17	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7432	March 17, 2017 Report of Dr. Fasching, Medical Literature - Lin ZC, Denison A, Nitinol Fatigue Resistance – A Strong Function of Surface Quality, Proceedings from the Materials & Processes for Medical Devices Conference, 8-10 Sept 2003, ASM International, 2003.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7433	March 17, 2017 Report of Dr. Fasching, Medical Literature - McMeeking RM, Assessment of the Designs of Bard Inferior Vena Cava Filters: The Recovery, G2, G2 Express, Eclipse, Meridian, and Denali Models, Re: MDL3.3.17.	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7434	Vogelzang, Providing Context: Medical Device Litigation and Inferior Vena Cava Filters (2016)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7435	Greenfield, et al., Recommended reporting standards for vena cava filter placement and patient follow-up (1999)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7436	Hull, Bard Recovery Filter Evaluation and Management (2009)	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7437	"Comparison of complication rates associated with permanent and retrievable inferior vena cava filters: a review of the MAUDE database."	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7438	Looby, S., Cardiovascular Interventional Radiology, 2007 Jan – Feb 30(1): 59 – 65. "Gunther Tulip retrievable inferior vena caval filters, indications, efficacy, retrieval, and complications". Study of 147 patients with Tulip filter 2001 to 2005, failed retrievals in 20%	Medical Literature		FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; 702; 703; 801; 802; MIL #1
7449	Attorney John A. Dalimonte Answers to Defendants' Interrogatories and Response to Production of Documents			FRE 401, 402, 403, 602, 801, 802	401; 402; 403; 801; 802
7450	Emails produced by John Dalimonte re communications with the FDA			FRE 401, 402, 403, 602, 801, 802	401; 402; 403; 801; 802; 407; MIL 1; MIL 2
7459	Defendants' Response to Plaintiffs' Brief in Opposition to Bard's Request to Depose PLC Counsel Exhibit A			FRE 401, 402, 403, 602, 801, 802	
7460	Defendants' Response to Plaintiffs' Brief in Opposition to Bard's Request to Depose PLC Counsel Exhibit B			FRE 401, 402, 403, 602, 801, 802	
7461	Defendants' Response to Plaintiffs' Brief in Opposition to Bard's Request to Depose PLC Counsel Exhibit C			FRE 401, 402, 403, 602, 801, 802	
7462	Defendants' Response to Plaintiffs' Brief in Opposition to Bard's Request to Depose PLC Counsel Exhibit D			FRE 401, 402, 403, 602, 801, 802	
7463	Defendants' Response to Plaintiffs' Brief in Opposition to Bard's Request to Depose PLC Counsel Exhibit E			FRE 401, 402, 403, 602, 801, 802	
7464	Defendants' Response to Plaintiffs' Brief in Opposition to Bard's Request to Depose PLC Counsel Exhibit F			FRE 401, 402, 403, 602, 801, 802	
7465	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 1			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7466	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 2			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7467	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 3			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7468	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 4			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7469	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 5			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7470	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 6			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7471	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 7			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7472	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 8			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7473	July 31, 2017 Report of Dr. Fasching, Pictures from Figure 9			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7474	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 1			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7475	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 2			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7476	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 3			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7477	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 4			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7478	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 5			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7479	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 6			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7480	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 7			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7481	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 8			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7482	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 9			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7483	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7484	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7485	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7486	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7487	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7488	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7489	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 16			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7490	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 17			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7491	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 18			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7492	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 19			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7493	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 20			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7494	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 21			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7495	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 22			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7496	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 23			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7497	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 24			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7498	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 25			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7499	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 26			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7500	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 27			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7501	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 28			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7502	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 29			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7503	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 30			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7504	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 31			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7505	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 32			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7506	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 33			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

76

77

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7565	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 92			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7566	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 93			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7567	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 94			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7568	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 95			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7569	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 96			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7570	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 97			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7571	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 98			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7572	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 99			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7573	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 100			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7574	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 101			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7575	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 102			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7576	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 103			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7577	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 104			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7578	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 105			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7579	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 106			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7580	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 107			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7581	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 108			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7582	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 109			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7583	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 110			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7584	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 111			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7585	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 112			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7586	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 113			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7587	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 114			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7588	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 115			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7589	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 116			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7590	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 117			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7591	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 118			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7592	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 119			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7593	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 120			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7594	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 121			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7595	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 122			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7596	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 123			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7597	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 124			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7598	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 125			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7599	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 126			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7600	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 127			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7601	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 128			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7602	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 129			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7603	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 130			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7604	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 131			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7605	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 132			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7606	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 133			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7607	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 134			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7608	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 135			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7609	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 136			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7610	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 137			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7611	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 138			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7612	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 139			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7613	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 140			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7614	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 141			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7615	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 142			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7616	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 143			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7617	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 144			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7618	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 145			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7619	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 146			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7620	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 147			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7621	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 148			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7622	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 149			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

80

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7652	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 177			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7653	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 178			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7654	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 179			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7655	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 180			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7656	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 181			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7657	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 182			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7658	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 183			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7659	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 184			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7660	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 185			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7661	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 186			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7662	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 187			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7663	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 188			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7664	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 189			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7665	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 190			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7666	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 191			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7667	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 192			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7668	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 193			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7669	April 14, 2017 Report of Dr. Fasching, Pictures from Figure 194			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7670	Fasching MDL Report dated May 11, 2017; Interaction with sharp chamfer, Figures 14a, 17a, 85a			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7671	Fasching MDL Report dated May 11, 2017; Fracture of outside of a high stress area, Figures 63a (Arm 2), 94 (Arm 1), 156 (Arm 1)			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7672	Fasching MDL Report dated May 11, 2017; Inclusions at initiation site: Figures 83 a & b, 44 b, and 123 b			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7673	Fasching MDL Report dated May 11, 2017 ; Initiations not at surface defect, Figures 142 a & b; 146 a & b, 65 b.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7674	April 14, 2017 Report of Dr. Briant, Pictures from Figure 1			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7675	April 14, 2017 Report of Dr. Briant, Pictures from Figure 2			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7676	April 14, 2017 Report of Dr. Briant, Pictures from Figure 3			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7677	April 14, 2017 Report of Dr. Briant, Pictures from Figure 4			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7678	April 14, 2017 Report of Dr. Briant, Pictures from Figure 5			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7679	April 14, 2017 Report of Dr. Briant, Pictures from Figure 6			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7680	April 14, 2017 Report of Dr. Briant, Pictures from Figure 7			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7681	April 14, 2017 Report of Dr. Briant, Pictures from Figure 8			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7682	April 14, 2017 Report of Dr. Briant, Pictures from Figure 9			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7683	April 14, 2017 Report of Dr. Briant, Pictures from Figure 10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7684	April 14, 2017 Report of Dr. Briant, Pictures from Figure 11			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7685	April 14, 2017 Report of Dr. Briant, Pictures from Figure 12			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7686	April 14, 2017 Report of Dr. Briant, Pictures from Figure 13			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7687	April 14, 2017 Report of Dr. Briant, Pictures from Figure 14			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7688	April 14, 2017 Report of Dr. Briant, Pictures from Figure 15			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7689	April 14, 2017 Report of Dr. Briant, Pictures from Figure 16			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7690	April 14, 2017 Report of Dr. Briant, Pictures from Figure 17			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7691	April 14, 2017 Report of Dr. Briant, Pictures from Figure 18			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7692	April 14, 2017 Report of Dr. Briant, Pictures from Figure 19			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7693	April 14, 2017 Report of Dr. Briant, Pictures from Figure 20			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7694	April 14, 2017 Report of Dr. Briant, Pictures from Figure 21			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7695	April 14, 2017 Report of Dr. Briant, Pictures from Figure 22			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7696	April 14, 2017 Report of Dr. Briant, Pictures from Figure 23			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7697	April 14, 2017 Report of Dr. Briant, Pictures from Figure 24			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7698	April 14, 2017 Report of Dr. Briant, Pictures from Figure 25			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7699	April 14, 2017 Report of Dr. Briant, Pictures from Figure 26			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7700	April 14, 2017 Report of Dr. Briant, Pictures from Figure 27			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7701	April 14, 2017 Report of Dr. Briant, Pictures from Figure 28			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7702	April 14, 2017 Report of Dr. Briant, Pictures from Figure 29			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7703	April 14, 2017 Report of Dr. Briant, Pictures from Figure 30			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7704	April 14, 2017 Report of Dr. Briant, Pictures from Figure 31			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7705	April 14, 2017 Report of Dr. Briant, Pictures from Figure 32			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7706	April 14, 2017 Report of Dr. Briant, Pictures from Figure 33			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7707	April 14, 2017 Report of Dr. Briant, Pictures from Figure 34			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7708	April 14, 2017 Report of Dr. Briant, Pictures from Figure 35			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7709	April 14, 2017 Report of Dr. Briant, Pictures from Figure 36			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7710	April 14, 2017 Report of Dr. Briant, Pictures from Table 1			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7711	April 14, 2017 Report of Dr. Briant, Pictures from Table 2			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7712	April 14, 2017 Report of Dr. Briant, Pictures from Table 3			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7713	April 14, 2017 Report of Dr. Briant, Pictures from Table 4			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7714	April 14, 2017 Report of Dr. Briant, Pictures from Table 5			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7715	April 14, 2017 Report of Dr. Briant, Pictures from Table 6			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7716	April 14, 2017 Report of Dr. Briant, Pictures from Table 7			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7717	April 14, 2017 Report of Dr. Briant, Pictures from Table 8			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7718	http://www.preservetrial.com			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7719	https://clinicaltrials.gov/ct2/show/study/NCT02381509			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7720	July 12, 2017, Expert Report of Paul Briant, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7721	June 29, 2017, Expert Report of Daniel Cousin, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7722	July 31, 2017, Expert Report of Audrey Fasching, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7723	July 10, 2017, Expert Report of Audrey Fasching, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7724	July 9, 2017, Expert Report of Piotr Sobieszczyk, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7725	April 13, 2017, Expert Report of Christine L. Brauer			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7726	April 14, 2017, Expert Report of Paul Briant, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7727	April 14, 2017, Expert Report of Audrey Fasching, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7728	April 14, 2017, Expert Report of David W. Fiegall, Jr., M.D., M.P.H.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7729	April 14, 2017, Expert Report of Clement J. Grassi, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7730	April 14, 2017, Expert Report of Christopher S. Morris, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7731	April 14, 2017, Expert Report of Ronald A. Thisted, Ph.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7732	April 14, 2017, Expert Report of Donna-Bea Tillman, Ph.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7733	May 12, 2017, Expert Report of Christine L. Brauer			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7734	May 12, 2017, Expert Report of Audrey Fasching, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7735	May 12, 2017, Expert Report of Donna-Bea Tillman, Ph.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403; MIL #1
7736	CV of Christine L. Brauer			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7737	CV of Paul Briant, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7738	CV of Daniel Cousin, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7739	CV of Audrey Fasching, Ph.D., P.E.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7740	CV of David W. Fiegall, Jr., M.D., M.P.H.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7741	CV of Clement J. Grassi, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7742	CV of Christopher S. Morris, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7743	CV of Piotr Sobieszczyk, M.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7744	CV of Ronald A. Thisted, Ph.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7745	CV of Donna-Bea Tillman, Ph.D.			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7746	Photos from Dr. Morris re SNF			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7747	Bard Filter Complication Rates			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7748	NMT's 510(k) (K963014) for modifications to the SNF/Straight Line System (Summary)			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
7749	FDA concurrence letter for K963014			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
7750	FDA concurrence letter for K970099			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 403
7751	1989 FDA Guidance re Medical Device Labeling			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7752	2005 FDA Guidance re Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment			FRE 801; 802	
7753	2014 Draft FDA Guidance re Benefit-Risk Factors When Determining Substantial Equivalence in Premarket Notifications 510k with Different Technological Characteristics			FRE 801; 802	
7754	2014 FDA Guidance re Distinguishing Medical Device Recalls from Medical Device Enhancements			FRE 801; 802	
7755	2011 Draft FDA Guidance re Responding to Unsolicited Requests for Off-Label Information			FRE 801; 802	
7756	2017 FDA Guidance Deciding When to Submit a 510k for a Change to an Existing Device			FRE 801; 802	
7757	2002 FDA Guidance re Determination of Intended Use for 510k Devices			FRE 801; 802	
7758	2014 FDA Guidance re 510k Evaluating Substantial Equivalence in Premarket Notifications			FRE 801; 802	
7759	CDRH Preliminary Internal Evaluations - Volume I			FRE 801; 802	
7760	2017 Public Health Interests and First Amendment Consideration Related to Manufacturer Communications			FRE 801; 802	
7761	2015 Draft Public Notification of Emerging Postmarket Medical Device Signals			FRE 801; 802	
7762	2016 FDA Guidance Medical Device Reporting for Manufacturers			FRE 801; 802	
7763	Braun Vena Tech Jugular – 2010			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7764	Braun Vena Tech Jugular – 2015			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7765	Braun Vena Tech Femoral – 2015			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7766	Cook Select Platinum Jugular and Femoral – 2015 deployment guide			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7767	Boston Scientific Greenfield Stainless Steel and Titanium – 2011 brochure with performance stats			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7768	Cordis Optease Femoral Jugular Antecubital – 2017			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7769	ALN Jugular-Brachial and Femoral-Popliteal – 2013 procedure guide			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7770	Braun Vena Tech Convertible Femoral & Jugular – February 2016			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7771	Braun Vena Tech LP Femoral – October 2010			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7772	Greenfield Stainless Steel – November 2001			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7773	Argon Option IFU - 2017			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7774	Argon Option Elite IFU - 2017			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7775	Cook Celect Femoral 2008			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7776	Cook Celect Femoral & Jugular 2009			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7777	Cook Celect Platinum Femoral & Jugular 2012			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7778	Cool Giantruco-Roehm Bird's Nest Femoral & Jugular 2008			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7779	Cool Giantruco-Roehm Bird's Nest Radoipaque band Femoral & Jugular 2008			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7780	Cook Gunther Tulip Jugular 2003			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7781	Cook Gunther Tulip Jugular 2005			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7782	Cook Gunther Tulip Jugular & Femoral 2006			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7783	Cook Gunther Tulip Femoral 2006			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7784	Cook Gunther Tulip Jugular 2008			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7785	Cook Gunther Tulip Jugular & Femoral 2009			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7786	Greenfield Over the Wire Femoral & Jugular 2004			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7787	Cordis Optease Femoral Jugular Antecubital – 2013			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7788	ALN Filter with Hook Jugular 2014			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7789	Volcano Crux VCF Femoral Jugular 2016			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7790	Coumadin Package Inserts			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7791	Lovenox Package Inserts			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7792	Various Anticoagulant Package Inserts			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7793	G2 Filter exemplar			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7794	Screenshot from FDA, Manufacturer and User Facility Device Experience Database - (MAUDE), available online at https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/PostmarketRequirements/ReportingAdverseEvents/ucm127891.htm			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7795	Screenshot from FDA, MAUDE - Manufacturer and User Facility Device Experience, available online at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7796	Removable Embolus Blood Clot Filter and Filter Delivery System, January 1, 2008, US Patent No. 7,314,477 B1			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7797	G2 Bench testing videos			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7798	2010 FDA Safety Communication: Removing Retrievable Inferior Vena Cava Filters			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
7799	2014 FDA Safety Communication: Removing Retrievable Inferior Vena Cava Filters			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	401; 402; 801; 802
7800	David Kessler Invoices			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7801	Demonstrative (Chart of Complication Rates)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7802	Demonstrative (IVC Filter Implant and Explant Animations)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7803	Demonstrative (IVC Filter Clot Trapping Animations)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7804	Demonstrative (Diagram of Venous System)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7805	Demonstrative (Picture of Bard G2 Filter)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7806	Demonstrative (Pulmonary Embolism Statistics)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7807	Demonstrative (Animations of Plaintiff's Medical Course)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7808	Demonstrative (Timeline of Plaintiff's Medical Course)			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7809	Demonstrative Slides for Dr. Paul Briant			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7810	Flip Chart and/or demonstrative exhibit describing reporting trends for Dr. Ronald Thisted			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7811	Briant Demonstrative Exhibit, Definitions – Stress, Strain and Stiffness			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7812	Briant Demonstrative Exhibit, Exponent and McMeeking Calculation Approach Comparison			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7813	Briant Demonstrative Exhibit, IVC and Surrounding Tissues			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7814	Briant Demonstrative Exhibit, Exponent and McMeeking Strain Calculation Input Comparison			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7815	Briant Demonstrative Exhibit, Exponent Model Validation			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7816	Briant Demonstrative Exhibit, Exponent and McMeeking Strain Results Comparison			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7817	Briant Demonstrative Exhibit, Summary of Exponent versus McMeeking Analysis			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7818	US Patent No. 6,007,558 titled "Removable Embolus Blood Clot Filter" assigned on 12/28/1999			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7819	G2 technical drawings			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7820	American National Standard ANSI AAMI ISO 25539-3 (2011)			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7821	Demonstrative depiction of inferior vena cava			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7822	Demonstrative depiction of dynamic environment of inferior vena cava			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7823	Demonstrative depiction of pulmonary embolism			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7824	Demonstrative depiction of IVC filter catching a clot			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7825	Demonstrative depiction of the development of a deep vein thrombosis			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7826	Demonstrative depiction of abdominal anatomy			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7827	Demonstrative depiction of IVC filter placement			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7828	Demonstrative depiction of IVC filter retrieval			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7829	Demonstrative depiction of CT scans			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7830	Demonstrative depiction of IVC filter migration			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7831	Demonstrative depiction of IVC filter appearing to migrate			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7857	Demonstrative depiction of endothelialization of filter strut			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7858	Demonstrative depiction of leads in the heart			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7859	Demonstrative depiction of non-filter mechanical devices in the heart			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7860	Demonstrative depiction of kidney stones			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7861	Demonstrative depiction of abdominal hernias			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7862	Demonstrative depiction of colitis			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7863	Demonstrative depiction of pericarditis			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7864	Demonstrative depiction of costochondritis			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7865	Demonstrative depiction of medical literature regarding complications of IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7866	Demonstrative depicture of medical literature regarding efficacy of IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7867	Demonstrative depiction of the medical literature regarding complications associated with the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7868	Demonstrative depiction of the medical literature regarding complications associated with the Simon Nitinol Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7869	Demonstrative depiction of the medical literature regarding complications associated with the Recovery Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7870	Demonstrative depiction of the medical literature regarding complications associated with non-Bard IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7871	Demonstrative depiction of IVC filter design considerations			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7872	Demonstrative depiction of the Recovery Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7873	Demonstrative depiction of the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7874	Demonstrative depiction of the Simon Nitinol Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7875	Demonstrative depiction of differences between the Recovery Filter and the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7876	Demonstrative depiction of Instructions for Use regarding non-Bard IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7877	Demonstrative depiction of the G2 Filter Instructions for Use			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7878	Demonstrative depiction of MAUDE database disclaimers			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7879	Demonstrative depiction of spontaneous adverse event reporting biases and limitations			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7880	Demonstrative depiction of errors in Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Perforation and Tamponade			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7881	Demonstrative depiction of errors in Fracture and distant migration of the Bard Recovery filter: a retrospective review of 363 implantations for potentially life-threatening complications			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7882	Demonstrative depiction of errors in Prevalence and clinical consequences of fracture and fragment migration of the Bard G2 filter: imaging and clinical follow-up in 684 implantations			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7883	Demonstrative depiction regarding hierarchy of scientific evidence			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7884	Demonstrative depiction of where the medical literature regarding IVC filters falls within the hierarchy of scientific evidence			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7885	Demonstrative depiction comparing the medical literature regarding the G2 Filter and the Simon Nitinol Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7886	Demonstrative depiction comparing the medical literature regarding the Recovery Filter and the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7887	Demonstrative depiction comparing the medical literature regarding the G2 Filter and non-Bard IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7888	Demonstrative depiction comparing complication rates of the G2 Filter to rates of complication identified in the 2001 "SIR Guidelines"			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7889	Demonstrative depiction comparing complication rates of the G2 Filter to rates of complication identified in the 2017 "SIR Guidelines"			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7890	Demonstrative depiction of the process by which the 2001 Quality Improvement Guidelines for Percutaneous Permanent Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism were created			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7891	Demonstrative depiction of the process by which the 2003 Quality Improvement Guidelines for Percutaneous Permanent Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism were created			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7892	Demonstrative depiction regarding the 2011 Quality Improvement Guidelines for the Performance of Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7893	Demonstrative depiction regarding the 2014 ACR-SIR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7894	Demonstrative depiction regarding the 2016 ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7895	Demonstrative depiction regarding the 2017 ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7896	Demonstrative depiction of Bard's internal complication rates for the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7897	Demonstrative depiction of Bard's internal complication rates for the Recovery Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7898	Demonstrative depiction of sales of the Simon Nitinol Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7899	Demonstrative depiction of sales of the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7900	Demonstrative depiction of sales of Bard's retrievable IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7901	Demonstrative depiction of bench testing regarding the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7902	Demonstrative depiction of animal testing regarding the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7903	Demonstrative depiction of clinical trial testing regarding the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7904	Demonstrative depiction of Bard's interaction with the FDA regarding the G2 Filter before clearance on August 29, 2005			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7905	Demonstrative depiction of Bard's interaction with the FDA regarding the G2 Filter after clearance on August 29, 2005			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7906	Demonstrative depiction of Bard's interaction with the FDA regarding the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7907	Demonstrative depiction of Bard's interaction with the FDA regarding the clinical trial EVEREST			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7908	Demonstrative depiction regarding EVEREST clinical trial material			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7909	Demonstrative depiction of post-market adverse event tracking regarding the G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7910	Demonstrative depiction of Bard's actions concerning caudal migration investigation			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7911	Demonstrative depiction of Weber effect			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7912	Demonstrative depiction of adverse event reporting trends			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7913	Demonstrative depiction of the physicians who read imaging regarding the plaintiff's G2 Filter			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7914	Demonstrative regarding mission statement / core values			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7915	Placeholder/demonstrative for Bard's community activities/engagement			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7916	21 CFR 803.50 - Individual adverse event reports; manufacturers			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7917	Dr. Vogelzang's invoices			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7918	Dr. Desai's invoices			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7919	Screenshots of NWIR Filter Clinic website - http://ivcfilter.nm.org/about-ivc-filters.html			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7920	Screenshots of NWIR Filter Clinic website - http://ivcfilter.nm.org/for-physicians.html			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7921	Screenshots of NWIR Filter Clinic website - http://ivcfilter.nm.org/after-placement.html			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7922	NWIR Calculator Screenshots - http://ivcfilter.nm.org/calculator.html			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7923	Meridian Femoral IFU, 10/10			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7924	2017 Arizona Bioindustry Association Publication			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7925	Bard Filter Rate information for Recovery, G2, and G2X			FRE 401; 402; 403; 602; 702; 703; 801; 802; 901	
7926	Demonstrative depiction of permanent IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7927	Demonstrative depiction of retrievable IVC filters			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7928	Demonstrative: Tillman- 2004-2005 recovery filter regulatory history			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7929	Demonstrative: Tillman- regulatory process			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7930	Demonstrative: Tillman Opinions			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7931	Demonstrative: Everest			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7932	Demonstrative: The Design Environment			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7933	Demonstrative: Powerpoint slides prepared by Dr Morris			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7934	Demonstrative: Summary of TR EX 5022			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7935	Demonstrative: Briant- compilation of exhibits 7708 and 7717			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7936	Demonstrative: Briant- compilation of exhibits 7703 and 7704			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7937	Fasching Demonstrative – Recovery & G2 Filter Fracture Data Summary			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7938	Overview of Dr. Grassi's opinions			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7939	Description of the process by which the 2001 SIR Guidelines were written			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7940	Table 1 from the 2001 SIR Guidelines			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	
7941	Table 2 from the 2001 SIR Guidelines			Plaintiff preserves any and all objections until all demonstrive evidence is inspected	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7942	Complication rates through 2016			Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7943	Demonstrative - SIR Guidelines			Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7944	Demonstrative - Briant Opinions Summary			Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7945	Demonstrative- Briant- Tissue Stress-Strain Response			Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7946	Demonstrative- Briant- Bard Analysis and Testing Summary			Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7947	Demonstrative- Briant- animation of filter pulsation			Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7952	G2 Platinum, Project #8088- Meeting Minutes- 4/14/09			Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7957	Whitehall, T.; Caval Interruption Method: Comparison of Options, Seminary in Vascular Surgery, Vol. 9, No 1 (March), 1966: pp 59-69			Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7960	Chart: IVC Filters, Clinical Overview	BPV-17-01-00255260	BPV-17-01-00255261	Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7961	Coroporate Quality Assurance Manual, Standard for Product Complaint Handling	BPV-17-01-00200167	BPV-17-01-00200187	Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7962	Coroporate Quality Assurance Manual, Standard for Medical Device Reporting	BPV-17-01-002022921	BPV-17-01-002022934	Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7963	G2 Filter FAQ's	BPV-17-01-00060150	BPV-17-01-00060153	Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7964	G2X IFU - Rev. 6, 6/10			Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7965	Images of Greenfield filters			Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7966	FDA Regulatory Procedures Manual, Chapter 4 "Advisory Actions"			Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7967	FDA Website, About Warning and Close-Out Letters			Plaintiff preserves any and all objections until all demonstrative evidence is inspected	
7968	Michael Streiff, 7/12/17 deposition Exhibit 04			401; 402; 403; 801; 802	801; 802
7969	Michael Streiff, 7/12/17 deposition Exhibit 05			401; 402; 403; 801; 802	801; 802
7970	Michael Streiff, 7/12/17 deposition Exhibit 07			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7971	Aujesky, A prediction rule to identify low risk patients with pulmonary embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7972	Goldhaber, Acute pulmonary embolism clinical outcomes in the International Cooperative Pulmonary Embolism Registry			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7973	Soloff, Acute pulmonary embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
7974	Trujillo-Santos, Analysis of clinical factors affecting the rates of fatal pulmonary embolism and bleeding in cancer patients with venous thromboembolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7975	Shoeb, Assessing Bleeding Risk in Patients Taking Anticoagulants			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7976	Carson, Clinical Course of PE			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7977	Coon, Deep venous thrombosis and pulmonary embolism prediction prevention and treatment			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7978	Nieto, Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7979	Levine, Hemorrhagic Complications of Anticoagulant Treatment			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7980	Rubboli, Incidence, clinical impact and risk of bleeding during oral anticoagulation therapy			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7981	Horlander, Pulmonary Embolism Mortality in the United States 1979 to 1998			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7982	Streiff 2000 - Vena Caval Filters- A comprehensive review			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7983	Streiff 2003 - Outpatient therapy with low molecular weight heparin for treatment of venous thromboembolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7984	Streiff 2003 - Vena Caval Filters- A Review for Intensive Care Specialists			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7985	Streiff 2003 -Diagnosis and treatment of deep venous thrombosis and pulmonary embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7986	Streiff 2005 Hann 2005 - The role of vena caval filters in the management of venous thromboembolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7987	Streiff 2006 - Kaufman 2006 - Guidelines for the use of retrievable and convertible vena cava filters - SIR			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7988	Streiff 2006 - Kaufman Guidelines for the use of retrievable and convertible vena cava filters - SIR Multidisciplinary Consensus Conference			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7989	Streiff 2007 - A Management of Venous Thromboembolism A Systematic Review for Practice Guidelines			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7990	Streiff 2007 - Segal - Management of Venous Thromboembolism A Systematic Review for a Practice Guideline			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7991	Streiff 2007 - The NCCN guidelines on venous thromboembolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7992	Streiff 2008 - Kim A comparison of clinical outcomes with retrievable and permanent inferior vena cava filters			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7993	Streiff 2008 Catheter-directed thrombolysis of inferior vena cava thrombosis in a 13-day old neonate and review of literature			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7994	Streiff 2009 - Development of a research agenda for inferior vena cava filters-multidisciplinary research consensus panel.			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7995	Streiff 2009 - Tschoe 2009 - Retrievable vena cava filters- A clinical review			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7996	Streiff 2010 -Raman Inferior vena cava filters in the management of cancer-associated venous thromboembolism- a systematic review			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7997	Streiff 2012 - Thromboprophylaxis in nonsurgical patients			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7998	Streiff 2013 - Rajasekhar 2013 - Use of vena cava filters and venous access devices			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
7999	Streiff 2013 - Rajasekhar 2013 - Vena cava filters for management of venous thromboembolism- A clinical review			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8000	Streiff 2013 - Thromboprophylaxis in nonsurgical patients			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8001	Streiff 2015 - Predicting the risk of recurrent venous thromboembolism (VTE)			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8002	Nijkeuter, The Natural Course of Hemodynamically Stable Pulmonary Embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8003	Konstantinides, Trends in incidence versus case fatality rates of pulmonary embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8004	Jimenez, Trends in the Management and Outcomes of Acute Pulmonary Embolism Analysis From Acute Pulmonary Embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8005	Nieto, Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8006	Witt, What to do after the bleed resuming anticoagulation after major bleeding			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8007	Marconi - Five year follow up of pulmonary embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8008	Kuo - Image Guided Interventions			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8009	Olin - Pulmonary Embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8010	Wood - Major Pulmonary Embolism			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8011	Gerber - The incidence of and risk factors for venous thromboembolism and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8012	Petty - Complications of Long Term Anticoagulation			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8013	Lankiewicz - Urgent reversal of warfarin with prothrombin complex concentrate			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8014	Schulman - Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients			401; 402; 403; 801; 802	401; 402; 403; 702; 703; 801; 802; MIL #1
8140	Darren Hurst, 11/1/16 deposition Exhibit 10			801; 802	801; 802
8141	Darren Hurst, 11/1/16 deposition Exhibit 11			801; 802	801; 802
8142	Darren Hurst, 11/1/16 deposition Exhibit 12			801; 802	801; 802
8143	Darren Hurst, 11/1/16 deposition Exhibit 13			801; 802	801; 802
8144	Darren Hurst, 11/1/16 deposition Exhibit 14			801; 802	801; 802
8145	Darren Hurst, 11/1/16 deposition Exhibit 15			801; 802	801; 802
8146	Darren Hurst, 11/1/16 deposition Exhibit 16			801; 802	801; 802
8147	Darren Hurst, 11/1/16 deposition Exhibit 17			801; 802	801; 802
8148	Darren Hurst, 11/1/16 deposition Exhibit 18			801; 802	801; 802
8149	Darren Hurst, 11/1/16 deposition Exhibit 19			801; 802	801; 802
8150	Darren Hurst, 11/1/16 deposition Exhibit 20			801; 802	801; 802
8151	Darren Hurst, 11/1/16 deposition Exhibit 21			801; 802	801; 802
8152	Darren Hurst, 11/1/16 deposition Exhibit 22			801; 802	801; 802
8153	Darren Hurst, 11/1/16 deposition Exhibit 23			801; 802	801; 802
8154	Darren Hurst, 11/1/16 deposition Exhibit 24			801; 802	801; 802
8155	Darren Hurst, 11/1/16 deposition Exhibit 25			801; 802	801; 802
8156	Darren Hurst, 11/1/16 deposition Exhibit 26			801; 802	801; 802
8157	Darren Hurst, 11/1/16 deposition Exhibit 27			801; 802	801; 802
8158	Darren Hurst, 7/21/17 deposition Exhibit 01			801; 802	801; 802
8159	Darren Hurst, 7/21/17 deposition Exhibit 02			801; 802	801; 802
8160	Darren Hurst, 7/21/17 deposition Exhibit 03			801; 802	801; 802
8161	Darren Hurst, 7/21/17 deposition Exhibit 04			801; 802	801; 802
8162	Darren Hurst, 7/21/17 deposition Exhibit 05			801; 802	801; 802
8163	Darren Hurst, 7/21/17 deposition Exhibit 06			801; 802	801; 802
8164	Darren Hurst, 7/21/17 deposition Exhibit 07			801; 802	801; 802
8165	Darren Hurst, 7/21/17 deposition Exhibit 08			801; 802	801; 802
8166	Darren Hurst, 7/21/17 deposition Exhibit 09			801; 802	801; 802
8167	Darren Hurst, 7/21/17 deposition Exhibit 10			801; 802	801; 802
8168	Darren Hurst, 7/21/17 deposition Exhibit 11			801; 802	801; 802
8169	Darren Hurst, 7/21/17 deposition Exhibit 12			801; 802	801; 802
8170	Darren Hurst, 7/21/17 deposition Exhibit 13			801; 802	801; 802
8171	Darren Hurst, 7/21/17 deposition Exhibit 14			801; 802	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8172	Darren Hurst, 7/21/17 deposition Exhibit 15			801; 802	801; 802
8173	Darren Hurst, 8/19/16 deposition Exhibit 01			801; 802	801; 802
8174	Darren Hurst, 8/19/16 deposition Exhibit 02			801; 802	801; 802
8175	Darren Hurst, 8/19/16 deposition Exhibit 03			801; 802	801; 802
8176	Darren Hurst, 8/19/16 deposition Exhibit 04			801; 802	801; 802
8177	Darren Hurst, 8/19/16 deposition Exhibit 05			801; 802	801; 802
8178	Darren Hurst, 8/19/16 deposition Exhibit 06			801; 802	801; 802
8179	Darren Hurst, 8/19/16 deposition Exhibit 07			801; 802	801; 802
8180	Darren Hurst, 8/19/16 deposition Exhibit 08			801; 802	801; 802
8181	Darren Hurst, 8/19/16 deposition Exhibit 09			801; 802	801; 802
8182	Darren Hurst, 8/7/17 deposition Exhibit 16			801; 802	801; 802
8183	Darren Hurst, 8/7/17 deposition Exhibit 17			801; 802	801; 802
8184	Darren Hurst, 8/7/17 deposition Exhibit 18			801; 802	801; 802
8185	Darren Hurst, 8/7/17 deposition Exhibit 19			801; 802	801; 802
8186	Darren Hurst, 8/7/17 deposition Exhibit 20			801; 802	801; 802
8187	Darren Hurst, 8/7/17 deposition Exhibit 21			801; 802	801; 802
8188	Darren Hurst, 8/7/17 deposition Exhibit 22			801; 802	801; 802
8189	Darren Hurst, 8/7/17 deposition Exhibit 23			801; 802	801; 802
8190	Darren Hurst, 8/7/17 deposition Exhibit 24			801; 802	801; 802
8191	Darren Hurst, 8/7/17 deposition Exhibit 25			801; 802	801; 802
8192	Darren Hurst, 8/7/17 deposition Exhibit 26			801; 802	801; 802
8196	David Garcia, 6/21/2017 deposition Exhibit 01			801; 802	801; 802
8197	David Garcia, 6/21/2017 deposition Exhibit 02			801; 802	801; 802
8198	David Garcia, 6/21/2017 deposition Exhibit 02a			801; 802	801; 802
8199	David Garcia, 6/21/2017 deposition Exhibit 03			801; 802	801; 802
8200	David Garcia, 6/21/2017 deposition Exhibit 04			801; 802	801; 802
8201	David Garcia, 6/21/2017 deposition Exhibit 05			801; 802	801; 802
8202	David Garcia, 6/21/2017 deposition Exhibit 06			801; 802	801; 802
8203	David Garcia, 6/21/2017 deposition Exhibit 07			801; 802	801; 802
8204	David Garcia, 6/21/2017 deposition Exhibit 08			801; 802	801; 802
8205	David Garcia, 6/21/2017 deposition Exhibit 09			801; 802	801; 802
8206	David Garcia, 6/21/2017 deposition Exhibit 10			801; 802	801; 802
8207	David Garcia, 6/21/2017 deposition Exhibit 11			801; 802	801; 802
8208	David Garcia, 6/21/2017 deposition Exhibit 12			801; 802	801; 802
8209	Derek Muehrcke, 7/21/15 deposition Exhibit 01			801; 802	801; 802
8210	Derek Muehrcke, 7/21/15 deposition Exhibit 02			801; 802	801; 802
8211	Derek Muehrcke, 7/21/15 deposition Exhibit 03			801; 802	801; 802
8212	Derek Muehrcke, 7/21/15 deposition Exhibit 04			801; 802	801; 802
8213	Derek Muehrcke, 7/21/15 deposition Exhibit 05			801; 802	801; 802
8214	Derek Muehrcke, 7/21/15 deposition Exhibit 06			801; 802	801; 802
8215	Derek Muehrcke, 7/21/15 deposition Exhibit 07			801; 802	801; 802
8216	Derek Muehrcke, 7/21/15 deposition Exhibit 08			801; 802	801; 802
8217	Derek Muehrcke, 7/21/15 deposition Exhibit 09			801; 802	801; 802
8218	Derek Muehrcke, 7/21/15 deposition Exhibit 10			801; 802	801; 802
8219	Derek Muehrcke, 7/21/15 deposition Exhibit 11			801; 802	801; 802
8220	Derek Muehrcke, 7/21/15 deposition Exhibit 12			801; 802	801; 802
8221	Derek Muehrcke, 7/21/15 deposition Exhibit 13			801; 802	801; 802
8222	Derek Muehrcke, 7/21/15 deposition Exhibit 14			801; 802	801; 802
8223	Derek Muehrcke, 7/21/15 deposition Exhibit 15			801; 802	801; 802
8224	Derek Muehrcke, 7/21/15 deposition Exhibit 16			801; 802	801; 802
8225	Derek Muehrcke, 7/21/15 deposition Exhibit 17			801; 802	801; 802
8226	Derek Muehrcke, 7/21/15 deposition Exhibit 18			801; 802	801; 802
8227	Derek Muehrcke, 7/21/15 deposition Exhibit 19			801; 802	801; 802
8228	Derek Muehrcke, 7/21/15 deposition Exhibit 20			801; 802	801; 802
8229	Derek Muehrcke, 7/24/17 deposition Exhibit 01			801; 802	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8230	Derek Muehrcke, 7/24/17 deposition Exhibit 02			801; 802	801; 802
8231	Derek Muehrcke, 7/24/17 deposition Exhibit 03			801; 802	801; 802
8232	Derek Muehrcke, 7/24/17 deposition Exhibit 04			801; 802	801; 802
8233	Derek Muehrcke, 7/24/17 deposition Exhibit 05			801; 802	801; 802
8234	Derek Muehrcke, 7/24/17 deposition Exhibit 06			801; 802	801; 802
8235	Derek Muehrcke, 7/24/17 deposition Exhibit 07			801; 802	801; 802
8236	Derek Muehrcke, 7/24/17 deposition Exhibit 08			801; 802	801; 802
8237	Derek Muehrcke, 7/24/17 deposition Exhibit 09			801; 802	801; 802
8238	Derek Muehrcke, 7/24/17 deposition Exhibit 10			801; 802	801; 802
8239	Derek Muehrcke, 7/24/17 deposition Exhibit 11			801; 802	801; 802
8240	Derek Muehrcke, 7/24/17 deposition Exhibit 12			801; 802	801; 802
8241	Derek Muehrcke, 7/24/17 deposition Exhibit 13			801; 802	801; 802
8242	Derek Muehrcke, 7/24/17 deposition Exhibit 14			801; 802	801; 802
8243	Derek Muehrcke, 7/24/17 deposition Exhibit 15			801; 802	801; 802
8247	James Matthew Sims, 7/26/17 deposition Exhibit 01			801; 802	801; 802
8248	James Matthew Sims, 7/26/17 deposition Exhibit 02			801; 802	801; 802
8249	James Matthew Sims, 7/26/17 deposition Exhibit 03			801; 802	801; 802
8250	James Matthew Sims, 7/26/17 deposition Exhibit 04			801; 802	801; 802
8251	James Matthew Sims, 7/26/17 deposition Exhibit 05			801; 802	801; 802
8252	James Matthew Sims, 7/26/17 deposition Exhibit 06			801; 802	801; 802
8253	James Matthew Sims, 7/26/17 deposition Exhibit 07			801; 802	801; 802
8254	James Matthew Sims, 7/26/17 deposition Exhibit 08			801; 802	801; 802
8255	James Matthew Sims, 7/26/17 deposition Exhibit 09			801; 802	801; 802
8256	James Matthew Sims, 7/26/17 deposition Exhibit 10			801; 802	801; 802
8257	James Matthew Sims, 7/26/17 deposition Exhibit 11			801; 802	801; 802
8258	James Matthew Sims, 7/26/17 deposition Exhibit 12			801; 802	801; 802
8259	Kenneth Herbst, 10/7/14 deposition Exhibit 01			801; 802	801; 802
8260	Kenneth Herbst, 10/7/14 deposition Exhibit 02			801; 802	801; 802
8261	Kenneth Herbst, 10/7/14 deposition Exhibit 03			801; 802	801; 802
8262	Kenneth Herbst, 10/7/14 deposition Exhibit 04			801; 802	801; 802
8263	Kenneth Herbst, 10/7/14 deposition Exhibit 05			801; 802	801; 802
8264	Kenneth Herbst, 10/7/14 deposition Exhibit 06			801; 802	801; 802
8265	Kenneth Herbst, 10/7/14 deposition Exhibit 07			801; 802	801; 802
8266	Kenneth Herbst, 7/26/17 deposition Exhibit 1018			801; 802	801; 802
8267	Kenneth Herbst, 7/26/17 deposition Exhibit 1019			801; 802	801; 802
8268	Kenneth Herbst, 7/26/17 deposition Exhibit 1022			801; 802	801; 802
8274	Michael Streiff, 7/12/17 deposition Exhibit 01			801; 802	801; 802
8275	Michael Streiff, 7/12/17 deposition Exhibit 02			801; 802	801; 802
8276	Michael Streiff, 7/12/17 deposition Exhibit 03			801; 802	801; 802
8277	Michael Streiff, 7/12/17 deposition Exhibit 04			801; 802	801; 802
8278	Michael Streiff, 7/12/17 deposition Exhibit 05			801; 802	801; 802
8279	Michael Streiff, 7/12/17 deposition Exhibit 06			801; 802	801; 802
8280	Michael Streiff, 7/12/17 deposition Exhibit 07			801; 802	801; 802
8281	Michael Streiff, 7/12/17 deposition Exhibit 08			801; 802	801; 802
8282	Michael Streiff, 7/12/17 deposition Exhibit 09			801; 802	801; 802
8283	Michael Streiff, 7/12/17 deposition Exhibit 10			801; 802	801; 802
8284	Michael Streiff, 7/12/17 deposition Exhibit 11			801; 802	801; 802
8285	Michael Streiff, 7/12/17 deposition Exhibit 12			801; 802	801; 802
8286	Michael Streiff, 7/12/17 deposition Exhibit 13			801; 802	801; 802
8287	Moni Stein, 7/31/17 deposition Exhibit 1023			801; 802	801; 802
8288	Moni Stein, 7/31/17 deposition Exhibit 1024			801; 802	801; 802
8289	Moni Stein, 7/31/17 deposition Exhibit 1025			801; 802	801; 802
8290	Moni Stein, 7/31/17 deposition Exhibit 1026			801; 802	801; 802
8291	Moni Stein, 7/31/17 deposition Exhibit 1027			801; 802	801; 802
8292	Moni Stein, 7/31/17 deposition Exhibit 1028			801; 802	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8312	Affidavit of Marlene Bobka, FOI Services			801; 802	
8313	Photo of filter catching clot			801; 802	
8314	Murray Asch, 5/2/16 deposition Exhibit 206			801; 802	401; 402; 403; 801; 802; MIL #1; MIL #2
8315	Murray Asch, 5/2/16 deposition Exhibit 213			801; 802	401; 402; 403; 801; 802; MIL #1; MIL #2
8316	Murray Asch, 5/2/16 deposition Exhibit 214			801; 802	401; 402; 403; 801; 802; MIL #1; MIL #2
8317	Murray Asch, 5/2/16 deposition Exhibit 215			801; 802	401; 402; 403; 801; 802; MIL #1; MIL #2
8318	Murray Asch, 5/2/16 deposition Exhibit 216			801; 802	401; 402; 403; 801; 802; MIL #1; MIL #2
8319	Murray Asch, 5/2/16 deposition Exhibit 219			801; 802	401; 402; 403; 801; 802; MIL #1; MIL #2
8320	Poruk, et al., Functioning inferior vena cava filter caught in the act, J. Vasc. Surg., 2015			401; 402; 403; 801; 802	801; 802
8321	Invoices of Dr. Kinney			401; 402; 403; 801; 802	801; 802
8322	Invoices of Dr. Hurst			401; 402; 403; 801; 802	801; 802
8323	Bard filter rates through September 2010			401; 402; 403; 801; 802	801; 802
8324	March 24, 2005 FDA Meeting PPT	BPV-17-01-00098020	BPV-17-01-00098076	401; 402; 403; 801; 802	801; 802
8325	Eclipse IFU 02.2010 PK5100600 Rev. 1	BPVEFILTER-20-00001738	BPVEFILTER-20-00001749	401; 402; 403; 801; 802	
8326	August 31, 2010, Bard Letter to Clinical Care Givers Folder - G62243	BPV-17-01-00255229	BPV-17-01-00255248	401; 402; 403; 801; 802	801; 802
8327	IVC Filters Clinical Overview Folder - G62244	BPV-17-01-00255249	BPV-17-01-00255378	401; 402; 403; 801; 802	801; 802
8328	Sept 2, 2010, Dear Sales Rep Letter Folder - G62247	BPV-17-01-00257454	BPV-17-01-00257489	401; 402; 403; 801; 802	801; 802
8329	Sept 7, 2010 International Dear Clinical Care Giver Folder - G62252	BPV-17-01-00257490	BPV-17-01-00257510	401; 402; 403; 801; 802	801; 802
8330	Bard Position Statement & Key Points / Talking Points Folder - G62234	BPV-17-01-00255007	BPV-17-01-00255055	401; 402; 403; 801; 802	801; 802
8331	Chum/Everest/Charles Clinical overview Folder - G61745	BPV-17-01-00256022	BPV-17-01-00256191	401; 402; 403; 801; 802	801; 802
8332	Eclipse Patient Q&A Rev 1 Folder - S11733	BPV-17-01-00251429	BPV-17-01-00251468	401; 402; 403; 801; 802	801; 802
8333	Eclipse Patient Q&A Rev 2 Folder - S11733	BPV-17-01-00251469	BPV-17-01-00251509	401; 402; 403; 801; 802	801; 802
8334	August 31, 2010, Bard Letter to Clinical Care Givers Distribution Email	BPVEFILTER-05-00054173	BPVEFILTER-05-00054175	401; 402; 403; 801; 802	801; 802
8335	CQA-STD-24 Rev 12 -- Standard for Product Complaint Handling	BPV-17-01-00200167	BPV-17-01-00200184	401; 402; 403; 801; 802	801; 802
8336	CQA-STD-54 Rev. 04 (Standard for Medical Device Reporting	BPV-17-01-00202921	BPV-17-01-00202934	401; 402; 403; 801; 802	801; 802
8337	Eclipse™ Filter Design History File	BPV-17-01-00108342	BPV-17-01-00109314	401; 402; 403; 801; 802	801; 802
8338	Eclipse Design History File Index	BPV-17-01-00108342	BPV-17-01-00108344	401; 402; 403; 801; 802	801; 802
8339	Eclipse Concept Product Opportunity Appraisal POA	BPV-17-01-00108346	BPV-17-01-00108353	401; 402; 403; 801; 802	801; 802
8340	Eclipse MS&S TD-01304	BPV-17-01-00108355	BPV-17-01-00108360	401; 402; 403; 801; 802	801; 802
8341	Eclipse Field Assurance Training	BPV-17-01-00108362	BPV-17-01-00108383	401; 402; 403; 801; 802	801; 802
8342	Eclipse Design and Development Plan DDP-8113 FM1160805	BPV-17-01-00108384	BPV-17-01-00108410	401; 402; 403; 801; 802	801; 802
8343	Eclipse Corporate Labeling Approval Form Brochure	BPV-17-01-00108412	BPV-17-01-00108420	401; 402; 403; 801; 802	801; 802
8344	Eclipse Launch Plan, TD-01289	BPV-17-01-00108422	BPV-17-01-00108433	401; 402; 403; 801; 802	801; 802
8345	Eclipse DIS Design Input Summary	BPV-17-01-00108435	BPV-17-01-00108438	401; 402; 403; 801; 802	801; 802
8346	Eclipse Product Performance Specification PPS	BPV-17-01-00108440	BPV-17-01-00108508	401; 402; 403; 801; 802	801; 802
8347	Eclipse Risk Analysis RA070079	BPV-17-01-00108510	BPV-17-01-00108529	401; 402; 403; 801; 802	801; 802
8348	Eclipse Design Failure Mode and Effects Analysis DFMEA070077 Rev 1	BPV-17-01-00108532	BPV-17-01-00108578	401; 402; 403; 801; 802	801; 802
8349	Eclipse Process Failure Mode and Effects Analysis PFMEA070069 Rev 1	BPV-17-01-00108580	BPV-17-01-00108598	401; 402; 403; 801; 802	801; 802
8350	Eclipse Risk Management Report TR-09-11-16	BPV-17-01-00108600	BPV-17-01-00108605	401; 402; 403; 801; 802	801; 802
8351	Eclipse Technical Drawings	BPV-17-01-00108623	BPV-17-01-00108624	401; 402; 403; 801; 802	801; 802
8352	Eclipse IFUs from DHF	BPV-17-01-00108694	BPV-17-01-00108730	401; 402; 403; 801; 802	801; 802
8353	Eclipse Packaging and Labeling Review TD-01318	BPV-17-01-00108732	BPV-17-01-00108739	401; 402; 403; 801; 802	801; 802
8354	Eclipse TD-01249 (Eclipse Test Method Matrix)	BPV-17-01-00108839	BPV-17-01-00108844	401; 402; 403; 801; 802	801; 802
8355	Eclipse Biocompatibility Requirements	BPV-17-01-00108862	BPV-17-01-00108891	401; 402; 403; 801; 802	801; 802
8356	Comparison of G2 Express Filter Snare Tip and Vail Filter Wire	BPV-17-01-00108894	BPV-17-01-00108968	401; 402; 403; 801; 802	801; 802
8357	TR-09-11-08 Eclipse (Corrosion Testing of the Vail Filter (Eclipse)	BPV-17-01-00108994	BPV-17-01-00109014	401; 402; 403; 801; 802	801; 802
8358	TR-09-10-15 -- Eclipse Flat Plate Fatigue and Corrosion Examination of the Vail (Eclipse) Filter	BPV-17-01-00109017	BPV-17-01-00109024	401; 402; 403; 801; 802	801; 802
8359	TR-09-10-16 DV&V Eclipse Filter Arm Fatigue Comparison Study (Project #8113)	BPV-17-01-00109027	BPV-17-01-00109036	401; 402; 403; 801; 802	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8360	Eclipse Process Validation	BPV-17-01-00109065	BPV-17-01-00109082	401; 402; 403; 801; 802	801; 802
8361	Eclipse™ Filter Vail Phase Review Books	BPV-17-01-00145634	BPV-17-01-00146922	401; 402; 403; 801; 802	801; 802
8362	Eclipse Filter Patient Questions & Answers	BPV-17-01-00142907	BPV-17-01-00142909	401; 402; 403; 801; 802	801; 802
8363	Eclipse Filter Patient Card	BPV-17-01-00142910	BPV-17-01-00142911	401; 402; 403; 801; 802	801; 802
8364	Eclipse Post-Market Design Review Customer Complaint Review and Risk Assessment	BPV-17-01-00170317	BPV-17-01-00170348	401; 402; 403; 801; 802	801; 802
8365	Eclipse Post-Market Review Regulatory TD-01619 Sept 27, 2010	BPV-17-01-00170349	BPV-17-01-00170355	401; 402; 403; 801; 802	801; 802
8366	Eclipse Post-Market Manufacturing Assessment TD-01620	BPV-17-01-00170356	BPV-17-01-00170357	401; 402; 403; 801; 802	801; 802
8367	Eclipse Post-Market Design Review Marketing TD-01621	BPV-17-01-00170358	BPV-17-01-00170361	401; 402; 403; 801; 802	801; 802
8368	TP-09-10-15 Rev. 0 - Eclipse DV&V Flat Plate Fatigue and Corrosion Test	BPVEFILTER-42-00017728	BPVEFILTER-42-00017743	401; 402; 403; 801; 802	801; 802
8369	TR-09-10-16 Rev. 0 - Eclipse Filter Arm Fatigue Comparison Study Test Report	BPVEFILTER-20-00129357	BPVEFILTER-20-00129366	401; 402; 403; 801; 802	801; 802
8370	TM1133800 Rev. 4 - Recovery Filter Diaphragmatic Arm Fatigue Test	BPVEFILTER-20-00039457	BPVEFILTER-20-00039465	401; 402; 403; 801; 802	801; 802
8371	TM1141700 Rev. 1 - Flat Plate Filter Fatigue and Corrosion Examination Test	BPVEFILTER-20-00124281	BPVEFILTER-20-00124297	401; 402; 403; 801; 802	801; 802
8372	TM1141300 Rev. 4 - Filter Wire Weld Tensile Strength Test Method	BPVEFILTER-20-00124229	BPVEFILTER-20-00124236	401; 402; 403; 801; 802	801; 802
8373	TP-09-10-16 Rev. 0 - Eclipse Filter DV&V Arm Fatigue Evaluation Test Protocol	BPVEFILTER-20-00043369	BPVEFILTER-20-00043377	401; 402; 403; 801; 802	801; 802
8374	TP-09-11-08 Rev. 0 (Test Protocol for Corrosion Testing of the Vail Filter)	BPVEFILTER-20-00043399	BPVEFILTER-20-00043404	401; 402; 403; 801; 802	801; 802
8375	Eclipse DFMEA Rev. 0	BPV-17-01-00191079	BPV-17-01-00191122	401; 402; 403; 801; 802	801; 802
8376	Eclipse DFMEA Rev. 1	BPV-17-01-00191123	BPV-17-01-00191166	401; 402; 403; 801; 802	801; 802
8377	Eclipse DFMEA Rev. 2	BPV-17-01-00191167	BPV-17-01-00191229	401; 402; 403; 801; 802	801; 802
8378	Eclipse DFMEA Rev. 3	BPV-17-01-00223323	BPV-17-01-00223383	401; 402; 403; 801; 802	801; 802
8379	Expert Report from Dr. Garcia in Cook litigation			401; 402; 403; 801; 802	801; 802
8394	Demonstrative depiction of the IVC filter fragment in the plaintiff's artery			Plaintiffs reserve the right to object until the demonstrative is produced.	
8395	Demonstrative depiction of the procedure to remove the plaintiff's IVC filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8396	Demonstrative depiction of endothelialization of filter strut			Plaintiffs reserve the right to object until the demonstrative is produced.	
8397	Demonstrative depiction of peptic ulcer disease			Plaintiffs reserve the right to object until the demonstrative is produced.	
8398	Demonstrative depiction of lap band procedure			Plaintiffs reserve the right to object until the demonstrative is produced.	
8399	Demonstrative depiction of afferent loop syndrome			Plaintiffs reserve the right to object until the demonstrative is produced.	
8400	Demonstrative depiction of duodenal ulcers			Plaintiffs reserve the right to object until the demonstrative is produced.	
8408	Demonstrative depiction of medical literature regarding complications of IVC filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8409	Demonstrative depiction of medical literature regarding efficacy of IVC filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8410	Demonstrative depiction of the medical literature regarding complications associated with the G2 Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8411	Demonstrative depiction of the medical literature regarding complications associated with the Simon Nitinol Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8412	Demonstrative depiction of the medical literature regarding complications associated with the Recovery Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8413	Demonstrative depiction of the medical literature regarding complications associated with the G2X Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8414	Demonstrative depiction of the medical literature regarding complications associated with the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8415	Demonstrative depiction of the medical literature regarding complications associated with non-Bard IVC filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8416	Demonstrative depiction of IVC filter design considerations			Plaintiffs reserve the right to object until the demonstrative is produced.	
8417	Demonstrative depiction of the Recovery Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8418	Demonstrative depiction of the G2 Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8419	Demonstrative depiction of the G2X Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8420	Demonstrative depiction of the Simon Nitinol Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8421	Demonstrative depiction of the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8422	Demonstrative depiction of differences between generations of Bard's filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8423	Demonstrative depiction of Instructions for Use regarding non-Bard IVC filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8424	Demonstrative depiction of the Eclipse Filter Instructions for Use			Plaintiffs reserve the right to object until the demonstrative is produced.	
8425	Demonstrative depiction of MAUDE database disclaimers			Plaintiffs reserve the right to object until the demonstrative is produced.	
8426	Demonstrative depiction of spontaneous adverse event reporting biases and limitations			Plaintiffs reserve the right to object until the demonstrative is produced.	
8427	Demonstrative depiction of errors in Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Perforation and Tamponade			Plaintiffs reserve the right to object until the demonstrative is produced.	
8428	Demonstrative depiction of errors in Fracture and distant migration of the Bard Recovery filter: a retrospective review of 363 implantations for potentially life-threatening complications			Plaintiffs reserve the right to object until the demonstrative is produced.	
8429	Demonstrative depiction of errors in Prevalence and clinical consequences of fracture and fragment migration of the Bard G2 filter: imaging and clinical follow-up in 684 implantations			Plaintiffs reserve the right to object until the demonstrative is produced.	
8430	Demonstrative depiction regarding hierarchy of scientific evidence			Plaintiffs reserve the right to object until the demonstrative is produced.	
8431	Demonstrative depiction of where the medical literature regarding IVC filters falls within the hierarchy of scientific evidence			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8432	Demonstrative depiction comparing the medical literature regarding the Eclipse and/or G2/G2X Filters and the Simon Nitinol Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8433	Demonstrative depiction comparing the medical literature regarding the Recovery Filter and the G2 Filter and/or G2X and/or Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8434	Demonstrative depiction comparing the medical literature regarding the G2 Filter and/or Eclipse Filter and non-Bard IVC filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8435	Demonstrative depiction comparing complication rates of the Eclipse Filter to rates of complication identified in the 2001 "SIR Guidelines"			Plaintiffs reserve the right to object until the demonstrative is produced.	
8436	Demonstrative depiction comparing complication rates of the Eclipse Filter to rates of complication identified in the 2017 "SIR Guidelines"			Plaintiffs reserve the right to object until the demonstrative is produced.	
8437	Demonstrative depiction of the process by which the 2001 Quality Improvement Guidelines for Percutaneous Permanent Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism were created			Plaintiffs reserve the right to object until the demonstrative is produced.	
8438	Demonstrative depiction of the process by which the 2003 Quality Improvement Guidelines for Percutaneous Permanent Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism were created			Plaintiffs reserve the right to object until the demonstrative is produced.	
8439	Demonstrative depiction regarding the 2011 Quality Improvement Guidelines for the Performance of Inferior Vena Cava Filter Placement for the Prevention of Pulmonary Embolism			Plaintiffs reserve the right to object until the demonstrative is produced.	
8440	Demonstrative depiction regarding the 2014 ACR-SIR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism			Plaintiffs reserve the right to object until the demonstrative is produced.	
8441	Demonstrative depiction regarding the 2016 ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism			Plaintiffs reserve the right to object until the demonstrative is produced.	
8442	Demonstrative depiction regarding the 2017 ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism			Plaintiffs reserve the right to object until the demonstrative is produced.	
8443	Demonstrative depiction of Bard's internal complication rates for the G2 Filter and/or G2X Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8444	Demonstrative depiction of Bard's internal complication rates for the Recovery Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8445	Demonstrative depiction of Bard's internal complication rates for the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8446	Demonstrative depiction of sales of the Simon Nitinol Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8447	Demonstrative depiction of sales of the G2 and/or G2X and/or Eclipse Filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8448	Demonstrative depiction of sales of Bard's retrievable IVC filters			Plaintiffs reserve the right to object until the demonstrative is produced.	
8449	Demonstrative depiction of bench testing regarding the G2 Filter and/or G2X and/or Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8450	Demonstrative depiction of animal testing regarding the G2 Filter and/or G2X and/or Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8451	Demonstrative depiction of clinical trial testing regarding the G2 Filter and/or G2X and/or Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8452	Demonstrative depiction of Bard's interaction with the FDA before clearance of the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8453	Demonstrative depiction of Bard's interaction with the FDA after clearance of the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8454	Demonstrative depiction of Bard's interaction with the FDA regarding the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8455	Demonstrative depiction of Bard's interaction with the FDA regarding the clinical trial EVEREST			Plaintiffs reserve the right to object until the demonstrative is produced.	
8456	Demonstrative depiction regarding EVEREST clinical trial material			Plaintiffs reserve the right to object until the demonstrative is produced.	
8457	Demonstrative depiction of post-market adverse event tracking regarding the Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8458	Demonstrative depiction of Bard's actions concerning caudal migration investigation			Plaintiffs reserve the right to object until the demonstrative is produced.	
8459	Demonstrative depiction of Weber effect			Plaintiffs reserve the right to object until the demonstrative is produced.	
8460	Demonstrative depiction of adverse event reporting trends			Plaintiffs reserve the right to object until the demonstrative is produced.	
8461	Demonstrative depiction of the physicians who read imaging regarding the plaintiff's Eclipse Filter			Plaintiffs reserve the right to object until the demonstrative is produced.	
8462	Demonstrative Slides with Attorney Advertising Information			Plaintiffs reserve the right to object until the demonstrative is produced.	
8463	Demonstrative regarding electropolishing for Dr. Briant			Plaintiffs reserve the right to object until the demonstrative is produced.	
8464	Demonstrative regarding electropolishing for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8465	Demonstrative regarding Eclipse filter for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8466	Demonstrative regarding Eclipse filter for Dr. Briant			Plaintiffs reserve the right to object until the demonstrative is produced.	
8467	Demonstrative regarding Eclipse filter for Dr. Feigal			Plaintiffs reserve the right to object until the demonstrative is produced.	
8468	Demonstrative regarding Eclipse filter for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
8469	Demonstrative regarding Eclipse filter for Dr. Brauer			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8470	Demonstrative regarding Eclipse filter for Dr. Tillman			Plaintiffs reserve the right to object until the demonstrative is produced.	
8471	Demonstrative regarding Eclipse filter for Dr. Stein			Plaintiffs reserve the right to object until the demonstrative is produced.	
8472	Demonstrative regarding Eclipse filter for Dr. Herbst			Plaintiffs reserve the right to object until the demonstrative is produced.	
8473	Demonstrative regarding MAUDE search data for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
8474	Demonstrative regarding MAUDE search screenshots for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
8475	MAUDE search data for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
8476	MAUDE search screenshots for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
8477	Exemplar nitinol wire for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8478	Demonstrative regarding figures 180, 191 -193 for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8479	Demonstrative regarding figures 179a, 190a, 186-187 for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8480	Demonstrative regarding Recovery cross-section photos for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8481	Demonstrative regarding warning timeline			Plaintiffs reserve the right to object until the demonstrative is produced.	
8482	Bard IVC Filter Design/Development Timeline			Plaintiffs reserve the right to object until the demonstrative is produced.	
8483	Parisian Map Demonstrative			Plaintiffs reserve the right to object until the demonstrative is produced.	
8484	Bard filter regulatory history			Plaintiffs reserve the right to object until the demonstrative is produced.	
8485	Wheaton Franciscan- CT Scan Images			Plaintiffs reserve the right to object until the demonstrative is produced.	
8486	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8487	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8488	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8489	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8490	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8491	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8492	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8493	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8494	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8495	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8496	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8497	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8498	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8499	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8500	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8501	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8502	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8503	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8504	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8505	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8506	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8507	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8508	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8509	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8510	Demonstrative Placeholder			Plaintiffs reserve the right to object until the demonstrative is produced.	
8511	FDA Close Out Letter from FDA Website			Plaintiffs reserve the right to object until the demonstrative is produced.	
8512	IVC Filter placement- Tabular trends			Plaintiffs reserve the right to object until the demonstrative is produced.	
8513	5/4/2015 Progress Notes, Dr Nicole Moss			Plaintiffs reserve the right to object until the demonstrative is produced.	
8514	11/15/2012 Progress Notes, Dr Amy Sparks				
8515	CT Image from 2/10/12				
8516	CT Image (axial) December 16, 2011, Las Vegas Radiology				
8517	CT Image (axial) June 14, 2013				
8518	CT Image (axial) May 16, 2014				
8519	Side by Side Comparison of CT Images from December 16, 2011, June 14, 2013, and May 16, 2014				
8520	CT Image – Coronal view (5/16/14)				
8521	8/23/2013 Office visit-Tousif Pasha				
8522	6/13/2013 CT Abdomen and Pelvis				
8523	5/16/14 CT Abdomen				
8524	8/25/14 Progress Notes, Kuo				
8525	9/9/14 Event Log, Stanford				
8526	CT Image- 8/26/2014				
8527	CT Image- 2/25/11 compared to 8/26/14				
8528	CT Image- 6/14/2013				
8529	CT Image-12/16/2011 abdomen and pelvis				
8530	CT Image- 6/14/2013				
8531	CT Image- 5/16/2014				
8532	CT Image- implant and explant and KUB				
8533	Parisian March 3 2017 report				
8534	Feb 13 2009 notes				
8535	April 10 2012 Procedure Notes				
8536	Abd Pelvis (Las Vegas)				
8537	Birds Nest Filter				
8538	CT Image- Feb 25 2100				
8539	April 21 2011 consult- Aurora Health Care				
8540	Feigal flip chart				
8545	BS EN 12006-3:1999 - Non-active surgical implants - Particular requirements for cardiac and vascular implants	BPV-17-01-00001518	BPV-17-01-00001542	401; 402; 403; 801; 802	
8546	Draft Test Report re Rotary Beam Fatigue of Nitinol Wire	BPV-17-01-00188406	BPV-17-01-00188410	801; 802	801; 802
8547	Legal Website Customer Letter Folder	BPV-17-01-00254787	BPV-17-01-00254814	401; 402; 403; 801; 802	801; 802
8548	Legal Website Customer Letter	BPV-17-01-00254796	BPV-17-01-00254796	401; 402; 403; 801; 802	801; 802
8549	Clinical Trial Update Poster - Everest	BPV-17-01-00248313	BPV-17-01-00248313	401; 402; 403; 801; 802	801; 802
8550	Laboratory Notebooks	BPV-17-01-00004138	BPV-17-01-00004333	401; 402; 403; 801; 802	801; 802
8551	Laboratory Notebooks	BPV-17-01-00006967	BPV-17-01-00007034	401; 402; 403; 801; 802	801; 802
8552	Laboratory Notebooks	BPV-17-01-00009320	BPV-17-01-00009730	401; 402; 403; 801; 802	801; 802
8553	Laboratory Notebooks	BPV-17-01-00010780	BPV-17-01-00011204	401; 402; 403; 801; 802	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8554	Laboratory Notebooks	BPV-17-01-00012931	BPV-17-01-00012949	401; 402; 403; 801; 802	801; 802
8555	Laboratory Notebooks	BPV-17-01-00013210	BPV-17-01-00013319	401; 402; 403; 801; 802	801; 802
8556	Laboratory Notebooks	BPV-17-01-00014825	BPV-17-01-00014891	401; 402; 403; 801; 802	801; 802
8557	Laboratory Notebooks	BPV-17-01-00015195	BPV-17-01-00015302	401; 402; 403; 801; 802	801; 802
8558	Laboratory Notebooks	BPV-17-01-00015312	BPV-17-01-00015592	401; 402; 403; 801; 802	801; 802
8559	Laboratory Notebooks	BPV-17-01-00021974	BPV-17-01-00022106	401; 402; 403; 801; 802	801; 802
8560	Laboratory Notebooks	BPV-17-01-00026094	BPV-17-01-00026096	401; 402; 403; 801; 802	801; 802
8561	Laboratory Notebooks	BPV-17-01-00069840	BPV-17-01-00069885	401; 402; 403; 801; 802	801; 802
8562	Laboratory Notebooks	BPV-17-01-00069978	BPV-17-01-00070029	401; 402; 403; 801; 802	801; 802
8563	Laboratory Notebooks	BPV-17-01-00070073	BPV-17-01-00070087	401; 402; 403; 801; 802	801; 802
8564	Laboratory Notebooks	BPV-17-01-00070109	BPV-17-01-00070331	401; 402; 403; 801; 802	801; 802
8565	Laboratory Notebooks	BPV-17-01-00070515	BPV-17-01-00070528	401; 402; 403; 801; 802	801; 802
8566	Laboratory Notebooks	BPV-17-01-00082934	BPV-17-01-00082998	401; 402; 403; 801; 802	801; 802
8567	Laboratory Notebooks	BPV-17-01-00110519	BPV-17-01-00110542	401; 402; 403; 801; 802	801; 802
8568	Laboratory Notebooks	BPV-17-01-00167143	BPV-17-01-00169112	401; 402; 403; 801; 802	801; 802
8569	Laboratory Notebooks	BPV-17-01-00236651	BPV-17-01-00237044	401; 402; 403; 801; 802	801; 802
8570	TD-00429 G3 Concept Testing, Project 8049	BPV-17-01-00180270	BPV-17-01-00180273	401; 402; 403; 801; 802	801; 802
8571	G3 DDP Design and Development Plan	BPV-17-01-00180367	BPV-17-01-00180391	401; 402; 403; 801; 802	801; 802
8572	G3 Meeting Minutes July 25, 2006	BPV-17-01-00181762	BPV-17-01-00181763	401; 402; 403; 801; 802	801; 802
8573	G3 Meeting Minutes Nov 27, 2007	BPV-17-01-00181911	BPV-17-01-00181914	401; 402; 403; 801; 802	801; 802
8574	TR 09-10-10, Test Report Cyclic Fatigue Testing of Electropolished Vail Filter	BPVEFILTER-11-00027094	BPVEFILTER-11-00027103	401; 402; 403; 801; 802	801; 802
8575	TP 09-10-10, Test Protocol Cyclic Fatigue Testing of Electropolished Vail Filter Wire	BPVE-01-00930038	BPVE-01-00930050	401; 402; 403; 801; 802	801; 802
8576	TM1144600 G2 Filter Ground Wire Fatigue Test Rev 0	BPVEFILTER-20-00124452	BPVEFILTER-20-00124459	401; 402; 403; 801; 802	801; 802
8577	TM1144600 Filter Ground Wire Fatigue Test Rev 1	BPVEFILTER-20-00040092	BPVEFILTER-20-00040099	401; 402; 403; 801; 802	801; 802
8578	TR-06-12-04, Rotary Beam Fatigue Test of G2 Filter Wire Test Report	BPVEFILTER-20-00126862	BPVEFILTER-20-00126873	401; 402; 403; 801; 802	801; 802
8579	TPR 06-05-17 Rotary Beam Fatigue Testing of G2 Filter Wire	BPVEFILTER-20-00046856	BPVEFILTER-20-00046882	401; 402; 403; 801; 802	801; 802
8580	Project Platinum Project Status Report July 2009	BPVE-01-00699498	BPVE-01-00699499	401; 402; 403; 801; 802	801; 802
8581	Project Platinum Project Status Report Nov. 2008	BPV-17-01-00188798	BPV-17-01-00188798	401; 402; 403; 801; 802	801; 802
8582	G2 Platinum Project Launch Presentation, April 23, 2009	BPV-17-01-00188634	BPV-17-01-00188634	401; 402; 403; 801; 802	801; 802
8583	G3 Project Status Report April 19, 2006	BPV-17-01-00183521	BPV-17-01-00183521	401; 402; 403; 801; 802	801; 802
8584	G3 Project Plan Aug. 1, 2006	BPV-17-01-00183502	BPV-17-01-00183507	401; 402; 403; 801; 802	801; 802
8585	5/6/08 Filter Franchise Review Presentation, Deposition of Brett Baird, Exhibit 301			401; 402; 403; 801; 802	801; 802
8586	FOIA Affidavits			401; 402; 403; 801; 802	801; 802
8587	Karnath (2004) - Anemia in the Adult Patient			401; 402; 403; 801; 802	801; 802
8588	NIH - Anemia			401; 402; 403; 801; 802	801; 802
8589	American Society of Hematology - Anemia & Shortness of Breath			401; 402; 403; 801; 802	801; 802
8590	Byrnes (2017) - Red Blood Cells in Thrombosis			401; 402; 403; 801; 802	801; 802
8591	Franchini (2008) - Iron and Thrombosis			401; 402; 403; 801; 802	801; 802
8592	Hung (2015) - Association Between VTE and Iron Deficiency Anemia			401; 402; 403; 801; 802	801; 802
8593	Potaczek (2016) - Iron Deficiency A Novel Risk Factor of Recurrence in Patients After Unprovoked VTE			401; 402; 403; 801; 802	801; 802
8594	An (2014) -- Prevalence and Clinical Consequences of Fracture and Fragment Migration of the Bard G2 Filter			401; 402; 403; 801; 802	801; 802
8595	Dinglasan (2011) -- Removal of Fractured Inferior Vena Cava Filters Feasibility and Outcomes			401; 402; 403; 801; 802	801; 802
8596	Hudali (2015) --A Fractured IVC Filter Strut Migrating to the Left Pulmonary			401; 402; 403; 801; 802	801; 802
8597	Kuo (2009) -- High Risk Retrieval of Adherent and Chronically Implanted IVC			401; 402; 403; 801; 802	801; 802
8598	Kuo (2013) -- Complex Retrieval of Fractured, Embedded, and Penetrating IVC			401; 402; 403; 801; 802	801; 802
8599	Mehanni (2016) -- Expectoration of an Inferior Vena Cava Filter Strut			401; 402; 403; 801; 802	801; 802
8600	Owens (2009) -- Intracardiac Migration of Inferior Vena Cava Filters			401; 402; 403; 801; 802	801; 802
8601	Tam (2011) -- Fracture and Distant Migration of the Bard Recovery Filter			401; 402; 403; 801; 802	801; 802
8602	Trerotola (2017) -- Management of Fractured Inferior Vena Cava Filters- Outcomes by Fragment Location			401; 402; 403; 801; 802	801; 802
8603	Unai (2017) -- Nonthrombotic Pulmonary Artery Embolism			401; 402; 403; 801; 802	801; 802
8604	Vijay (2012) -- Fractured Bard Recovery G2 and G2 Express Inferior Vena Cava Filters			401; 402; 403; 801; 802	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8605	American Thyroid Association - Hypothyroidism			401; 402; 403; 801; 802	801; 802
8606	Harrison's 19th ed (2015) - Hypothyroidism Symptoms			401; 402; 403; 801; 802	801; 802
8607	Schmidt (2011) - NSAID Use and Risk of VTE			401; 402; 403; 801; 802	801; 802
8608	Ungprasert (2015) - NSAIDs and the Risk of VTE			401; 402; 403; 801; 802	801; 802
8609	American College of Gastroenterology - Understanding Ulcers, NSAIDs & GI Bleeding			401; 402; 403; 801; 802	801; 802
8610	Harrison's 19th ed (2015) - NSAIDs & GI Bleeding			401; 402; 403; 801; 802	801; 802
8611	Harrison's 19th ed (2015) - NSAID-Induced GI Bleed & PUD			401; 402; 403; 801; 802	801; 802
8612	Hernandez-Diaz (2000) - Association Between NSAIDs and Upper GI Tract Bleeding Perforation			401; 402; 403; 801; 802	801; 802
8613	Mellemkjaer (2002) - Upper GI Bleeding Among Users of NSAIDs			401; 402; 403; 801; 802	801; 802
8614	Sostres (2013) - NSAIDs and Upper and Lower GI Mucosal Damage			401; 402; 403; 801; 802	801; 802
8615	American Heart Association - Smoking Risk for Blood Clot			401; 402; 403; 801; 802	801; 802
8616	American Society of Hematology - Smoking Risk for Blood Clot			401; 402; 403; 801; 802	801; 802
8617	Cheng (2013) - Current and Former Smoking and Risk for VTE			401; 402; 403; 801; 802	801; 802
8618	Enga (2012) - Cigarette Smoking and the Risk of VTE			401; 402; 403; 801; 802	801; 802
8619	Harrison's 19th ed (2015) - Smoking Risk for Thrombosis			401; 402; 403; 801; 802	801; 802
8620	Lutsey (2010) - Correlates and Consequences of VTE The Iowa Women's Health Study			401; 402; 403; 801; 802	801; 802
8621	Pomp (2007) - Smoking Increases the Risk of Venous Thrombosis			401; 402; 403; 801; 802	801; 802
8622	Sweetland (2013) - Smoking, Surgery, and VTE Risk in Women			401; 402; 403; 801; 802	801; 802
8623	Tapson (2005) - The Role of Smoking in Coagulation and Thromboembolism			401; 402; 403; 801; 802	801; 802
8624	American Lung Association - Smoking & Shortness of Breath			401; 402; 403; 801; 802	801; 802
8625	Liu (2015) - Smoking Duration, Respiratory Symptoms, and COPD in Adults			401; 402; 403; 801; 802	801; 802
8626	Harrison's Principles of Internal Medicine, 19th ed (2015)			401; 402; 403; 801; 802	801; 802
8627	Original certificate and affidavit of FDA enclosing FDA FOIA Request 2013-5061			401; 402; 403; 801; 802	
8628	Number intentionally skipped- case specific bellwether exhibit				
8629	Number intentionally skipped- case specific bellwether exhibit				
8630	Number intentionally skipped- case specific bellwether exhibit				
8631	Number intentionally skipped- case specific bellwether exhibit				
8632	Number intentionally skipped- case specific bellwether exhibit				
8633	Number intentionally skipped- case specific bellwether exhibit				
8634	Number intentionally skipped- case specific bellwether exhibit				
8635	Number intentionally skipped- case specific bellwether exhibit				
8636	Number intentionally skipped- case specific bellwether exhibit				
8637	Number intentionally skipped- case specific bellwether exhibit				
8638	Number intentionally skipped- case specific bellwether exhibit				
8639	Number intentionally skipped- case specific bellwether exhibit				
8640	Number intentionally skipped- case specific bellwether exhibit				
8641	Number intentionally skipped- case specific bellwether exhibit				
8642	Number intentionally skipped- case specific bellwether exhibit				
8643	Number intentionally skipped- case specific bellwether exhibit				
8644	Number intentionally skipped- case specific bellwether exhibit				
8645	Number intentionally skipped- case specific bellwether exhibit				
8646	Number intentionally skipped- case specific bellwether exhibit				
8647	Number intentionally skipped- case specific bellwether exhibit				
8648	Number intentionally skipped- case specific bellwether exhibit				
8649	Number intentionally skipped- case specific bellwether exhibit				
8650	Number intentionally skipped- case specific bellwether exhibit				
8651	Number intentionally skipped- case specific bellwether exhibit				
8652	Number intentionally skipped- case specific bellwether exhibit				
8653	Number intentionally skipped- case specific bellwether exhibit				
8654	Number intentionally skipped- case specific bellwether exhibit				
8655	Number intentionally skipped- case specific bellwether exhibit				
8656	Number intentionally skipped- case specific bellwether exhibit				

[illegible]

108

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8767	Number intentionally skipped- case specific bellwether exhibit				
8768	Number intentionally skipped- case specific bellwether exhibit				
8769	Number intentionally skipped- case specific bellwether exhibit				
8770	Number intentionally skipped- case specific bellwether exhibit				
8771	Number intentionally skipped- case specific bellwether exhibit				
8772	Number intentionally skipped- case specific bellwether exhibit				
8773	Number intentionally skipped- case specific bellwether exhibit				
8774	Number intentionally skipped- case specific bellwether exhibit				
8775	Number intentionally skipped- case specific bellwether exhibit				
8776	Number intentionally skipped- case specific bellwether exhibit				
8777	Number intentionally skipped- case specific bellwether exhibit				
8778	William Kuo, 3/23/2017 deposition Exhibit 01			401; 402; 403; 801; 802	801; 802
8779	William Kuo, 3/23/2017 deposition Exhibit 02			401; 402; 403; 801; 802	801; 802
8780	William Kuo, 3/23/2017 deposition Exhibit 03			401; 402; 403; 801; 802	801; 802
8781	William Kuo, 3/23/2017 deposition Exhibit 04			401; 402; 403; 801; 802	801; 802
8782	William Kuo, 3/23/2017 deposition Exhibit 05			401; 402; 403; 801; 802	801; 802
8783	William Kuo, 3/23/2017 deposition Exhibit 06			401; 402; 403; 801; 802	801; 802
8784	William Kuo, 3/23/2017 deposition Exhibit 07			401; 402; 403; 801; 802	801; 802
8785	William Kuo, 3/23/2017 deposition Exhibit 08			401; 402; 403; 801; 802	801; 802
8786	William Kuo, 3/23/2017 deposition Exhibit 09			401; 402; 403; 801; 802	801; 802
8787	William Kuo, 3/23/2017 deposition Exhibit 10			401; 402; 403; 801; 802	801; 802
8788	David Poll, 8/3/17 deposition Exhibit 1053			401; 402; 403; 801; 802	801; 802
8789	David Poll, 8/3/17 deposition Exhibit 1054			401; 402; 403; 801; 802	801; 802
8790	David Poll, 8/3/17 deposition Exhibit 1055			401; 402; 403; 801; 802	801; 802
8791	David Poll, 8/3/17 deposition Exhibit 1056			401; 402; 403; 801; 802	801; 802
8792	Number intentionally skipped- case specific bellwether exhibit				
8793	Number intentionally skipped- case specific bellwether exhibit				
8794	Number intentionally skipped- case specific bellwether exhibit				
8795	Number intentionally skipped- case specific bellwether exhibit				
8796	Number intentionally skipped- case specific bellwether exhibit				
8797	Number intentionally skipped- case specific bellwether exhibit				
8798	Number intentionally skipped- case specific bellwether exhibit				
8799	Number intentionally skipped- case specific bellwether exhibit				
8800	Number intentionally skipped- case specific bellwether exhibit				
8801	Number intentionally skipped- case specific bellwether exhibit				
8802	Number intentionally skipped- case specific bellwether exhibit				
8803	Number intentionally skipped- case specific bellwether exhibit				
8804	Number intentionally skipped- case specific bellwether exhibit				
8805	Number intentionally skipped- case specific bellwether exhibit				
8806	Number intentionally skipped- case specific bellwether exhibit				
8807	Number intentionally skipped- case specific bellwether exhibit				
8808	Number intentionally skipped- case specific bellwether exhibit				
8809	Number intentionally skipped- case specific bellwether exhibit				
8810	Number intentionally skipped- case specific bellwether exhibit				
8811	Number intentionally skipped- case specific bellwether exhibit				
8812	Number intentionally skipped- case specific bellwether exhibit				
8813	Number intentionally skipped- case specific bellwether exhibit				
8814	Number intentionally skipped- case specific bellwether exhibit				
8815	Number intentionally skipped- case specific bellwether exhibit				
8816	Exemplar Eclipse filter			401; 402; 403; 801; 802	
8817	Exemplar G2X filter			401; 402; 403; 801; 802	
8818	Exemplar SNF filter			401; 402; 403; 801; 802	
8819	MAUDE reports regarding permanent filters			401; 402; 403; 801; 802	801; 802
8820	Number intentionally skipped- case specific bellwether exhibit				
8821	Number intentionally skipped- case specific bellwether exhibit				

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8822	Number intentionally skipped- case specific bellwether exhibit				
8823	Number intentionally skipped- case specific bellwether exhibit				
8824	Number intentionally skipped- case specific bellwether exhibit				
8825	June 19, 2006 EVEREST Medical MonitorMeeting Powerpoint	BPV-17-01-00155189	BPV-17-01-00155204	401; 402; 403; 801; 802	801; 802
8826	Product identification sales document	BPV-17-01-00262748	BPV-17-01-00262748	401; 402; 403; 801; 802	801; 802
8827	Product identification invoice documents	BPV-17-01-00262749	BPV-17-01-00262756	401; 402; 403; 801; 802	801; 802
8828	Defendants' Exhibit 1 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8829	Defendants' Exhibit 2 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8830	Defendants' Exhibit 3 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8831	Defendants' Exhibit 4 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8832	Defendants' Exhibit 5 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8833	Defendants' Exhibit 6 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8834	Defendants' Exhibit 7 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8835	Defendants' Exhibit 8 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8836	Defendants' Exhibit 9 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8837	Defendants' Exhibit 10 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8838	Defendants' Exhibit 11 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8839	Defendants' Exhibit 12 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8840	Defendants' Exhibit 13 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8841	Defendants' Exhibit 14 to Joint Report on Determining Filter Type			401; 402; 403; 801; 802	801; 802
8842	Number intentionally skipped- case specific bellwether exhibit				
8843	Number intentionally skipped- case specific bellwether exhibit				
8844	Number intentionally skipped- case specific bellwether exhibit				
8845	Number intentionally skipped- case specific bellwether exhibit				
8846	Number intentionally skipped- case specific bellwether exhibit				
8847	Number intentionally skipped- case specific bellwether exhibit				
8848	Number intentionally skipped- case specific bellwether exhibit				
8849	Number intentionally skipped- case specific bellwether exhibit				
8850	Number intentionally skipped- case specific bellwether exhibit				
8851	Number intentionally skipped- case specific bellwether exhibit				
8852	Number intentionally skipped- case specific bellwether exhibit				
8853	Number intentionally skipped- case specific bellwether exhibit				
8854	Number intentionally skipped- case specific bellwether exhibit				
8855	Number intentionally skipped- case specific bellwether exhibit				
8856	Number intentionally skipped- case specific bellwether exhibit				
8857	Number intentionally skipped- case specific bellwether exhibit				
8858	Demonstrative regarding G2X and/or Eclipse filter for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
8859	Demonstrative regarding G2X and/or Eclipse filter for Dr. Briant			Plaintiffs reserve the right to object until the demonstrative is produced.	
8860	Demonstrative regarding G2X and/or Eclipse filter for Dr. Feigal			Plaintiffs reserve the right to object until the demonstrative is produced.	
8861	Demonstrative regarding G2X and/or Eclipse filter for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
8862	Demonstrative regarding G2X and/or Eclipse filter for Dr. Brauer			Plaintiffs reserve the right to object until the demonstrative is produced.	
8863	Demonstrative regarding G2X and/or Eclipse filter for Dr. Tillman			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8864	Demonstrative regarding G2X and/or Eclipse filter for Dr. Stein			Plaintiffs reserve the right to object until the demonstrative is produced.	
8865	Demonstrative regarding G2X and/or Eclipse filter for Dr. Herbst			Plaintiffs reserve the right to object until the demonstrative is produced.	
8866	Demonstrative regarding G2X and/or Eclipse filter for Dr. Morris			Plaintiffs reserve the right to object until the demonstrative is produced.	
8867	Demonstrative regarding G2X and/or Eclipse filter for Dr. Poll			Plaintiffs reserve the right to object until the demonstrative is produced.	
8868	Demonstrative regarding the plaintiff's medical care for Dr. Morris			Plaintiffs reserve the right to object until the demonstrative is produced.	
8869	Demonstrative regarding the plaintiff's medical care for Dr. Poll			Plaintiffs reserve the right to object until the demonstrative is produced.	
8870	Number intentionally skipped- case specific bellwether exhibit				
8871	Number intentionally skipped- case specific bellwether exhibit				
8872	Number intentionally skipped- case specific bellwether exhibit				
8873	Number intentionally skipped- case specific bellwether exhibit				
8874	Number intentionally skipped- case specific bellwether exhibit				
8875	Number intentionally skipped- case specific bellwether exhibit				
8876	Number intentionally skipped- case specific bellwether exhibit				
8877	Number intentionally skipped- case specific bellwether exhibit				
8878	Number intentionally skipped- case specific bellwether exhibit				
8879	Number intentionally skipped- case specific bellwether exhibit				
8880	Number intentionally skipped- case specific bellwether exhibit				
8881	Number intentionally skipped- case specific bellwether exhibit				
8882	Number intentionally skipped- case specific bellwether exhibit				
8883	Number intentionally skipped- case specific bellwether exhibit				
8884	Number intentionally skipped- case specific bellwether exhibit				
8885	Number intentionally skipped- case specific bellwether exhibit				
8886	08.03.18 Ltr Sales to Wheaton Franciscan Healthcare - Franklin	BPV-17-01-00262755	BPV-17-01-00262756	401; 402; 403; 801; 802	
8887	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-28-00402335	BPVEFILTER-28-00402335	401; 402; 403; 801; 802	
8888	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-28-00402336	BPVEFILTER-28-00402336	401; 402; 403; 801; 802	
8889	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-28-00402339	BPVEFILTER-28-00402339	401; 402; 403; 801; 802	
8890	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-28-00402349	BPVEFILTER-28-00402349	401; 402; 403; 801; 802	
8891	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-28-00402621	BPVEFILTER-28-00402621	401; 402; 403; 801; 802	
8892	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-28-00402626	BPVEFILTER-28-00402626	401; 402; 403; 801; 802	
8893	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-28-00485752	BPVEFILTER-28-00485752	401; 402; 403; 801; 802	
8894	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-28-00485753	BPVEFILTER-28-00485753	401; 402; 403; 801; 802	
8895	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-28-00485769	BPVEFILTER-28-00485769	401; 402; 403; 801; 802	
8896	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-32-00000320	BPVEFILTER-32-00000320	401; 402; 403; 801; 802	
8897	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-47-00008673	BPVEFILTER-47-00008673	401; 402; 403; 801; 802	
8898	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-32-0007120	BPVEFILTER-32-0007120	401; 402; 403; 801; 802	
8899	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-30-00238273	BPVEFILTER-30-00238273	401; 402; 403; 801; 802	
8900	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-32-00007116	BPVEFILTER-32-00007116	401; 402; 403; 801; 802	
8901	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-30-00259274	BPVEFILTER-30-00259274	401; 402; 403; 801; 802	
8902	07.31.18 Ltr - Sales to Wheaton Franciscan Healthcare - Franklin	BPVEFILTER-30-00259276	BPVEFILTER-30-00259276	401; 402; 403; 801; 802	
8903	Number intentionally skipped- case specific bellwether exhibit			401; 402; 403; 801; 802	
8904	E-A690 Revision 10	BPV-17-01-00003599	BPV-17-01-00003627	401; 402; 403; 801; 802	
8905	MPA691 Revision 7-B and 7	BPV-17-01-00021556	BPV-17-01-00021578	401; 402; 403; 801; 802	
8906	RA-STD-002, Rev. 08	BPV-17-01-00024679	BPV-17-01-00024679	401; 402; 403; 801; 802	
8907	June 25, 2004 Transcript of Chicago, Illinois Roundtable Discussion	BPV-17-01-00042363	BPV-17-01-00042426	401; 402; 403; 801; 802	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8908	BPV begins distributing DDL	BPV-17-01-00043385	BPV-17-01-00043386	401; 402; 403; 801; 802	
8909	Email chain between BPV and FDA regarding future submission	BPV-17-01-00054617	BPV-17-01-00054619	401; 402; 403; 801; 802	
8910	July 2, 2003 Email from FDA	BPV-17-01-00058144	BPV-17-01-00058144	401; 402; 403; 801; 802	
8911	February 10, 2000 - Conference between NMT and FDA regarding K993809	BPV-17-01-00058856	BPV-17-01-00058856	401; 402; 403; 801; 802	
8912	January 20, 2000 - Letter from NMT to FDA regarding K993809	BPV-17-01-00069610	BPV-17-01-00069711	401; 402; 403; 801; 802	
8913	MPA690 Revision 18-F and 18	BPV-17-01-00079581	BPV-17-01-00079612	401; 402; 403; 801; 802	
8914	MPA678 Revision 11	BPV-17-01-00093768	BPV-17-01-00093779	401; 402; 403; 801; 802	
8915	Conference between Chris Sloan from Quintiles and FDA regarding K050558	BPV-17-01-00098741	BPV-17-01-00098742	401; 402; 403; 801; 802	
8916	MPA676 Revision 11-C and 11	BPV-17-01-00107710	BPV-17-01-00107733	401; 402; 403; 801; 802	
8917	MPA677 Revision 6-C and 6	BPV-17-01-00107734	BPV-17-01-00107743	401; 402; 403; 801; 802	
8918	NMT's 510(k) (K894703) for the Simon Nitinol Filter ("SNF")	BPV-17-01-00112063	BPV-17-01-00112373	401; 402; 403; 801; 802	
8919	Jan. 7, 2010 PPT Shown to FDA	BPV-17-01-00116940	BPV-17-01-00116985	401; 402; 403; 801; 802	
8920	Jan. 7, 2010 FDA Contact Report	BPV-17-01-00116986	BPV-17-01-00116990	401; 402; 403; 801; 802	
8921	Conferences between FDA and BPV regarding recall of K052578 (12/12/2006 & 12/14/2006)	BPV-17-01-00117159	BPV-17-01-00117160	401; 402; 403; 801; 802	
8922	Conference between FDA and BPV regarding recall of K052578	BPV-17-01-00117161	BPV-17-01-00117162	401; 402; 403; 801; 802	
8923	TPR-06-05-02 G2 Filter Clot Trapping Efficiency Protocol	BPV-17-01-00123817	BPV-17-01-00123823	401; 402; 403; 801; 802	
8924	Letter from FDA to BPV regarding recall of K052578	BPV-17-01-00125635	BPV-17-01-00125636	401; 402; 403; 801; 802	
8925	G2 Express 510(k) Excerpt	BPV-17-01-00131035	BPV-17-01-00131035	401; 402; 403; 801; 802	
8926	Letter from FDA to BPV regarding I050537	BPV-17-01-00131598	BPV-17-01-00131598	401; 402; 403; 801; 802	
8927	BPV's Pre-IDE meeting request (I050537)	BPV-17-01-00131608	BPV-17-01-00131661	401; 402; 403; 801; 802	
8928	BPV's Pre-IDE submission for I050537	BPV-17-01-00132005	BPV-17-01-00132050	401; 402; 403; 801; 802	
8929	G2 Express Technical Document TD-00286 -- Feasibility Plan G2 Express Technical Document TD-00286 -- Feasibility Plan	BPV-17-01-00132064	BPV-17-01-00132071	401; 402; 403; 801; 802	
8930	G2 Express Technical Document TD-00285 -- Feasibility Plan G2 Express Technical Document TD-00285 -- Feasibility Plan	BPV-17-01-00132072	BPV-17-01-00132076	401; 402; 403; 801; 802	
8931	G2 Express PPS 8058, Rev. 0 (Concept) G2 Express PPS 8058, Rev. 0 (Concept)	BPV-17-01-00132083	BPV-17-01-00132278	401; 402; 403; 801; 802	
8932	G2 Express DFMEA070044, Rev. 0 G2 Express DFMEA070044, Rev. 0	BPV-17-01-00132285	BPV-17-01-00132327	401; 402; 403; 801; 802	
8933	G2 Express Project Plan 8058 (Concept) G2 Express Project Plan 8058 (Concept)	BPV-17-01-00132328	BPV-17-01-00132337	401; 402; 403; 801; 802	
8934	G2 Express Risk Analysis Plan RA070048 G2 Express Risk Analysis Plan	BPV-17-01-00132338	BPV-17-01-00132353	401; 402; 403; 801; 802	
8935	G2 Express Regulatory and Clinical Strategy Determination G2 Express Regulatory and Clinical Strategy Determination	BPV-17-01-00132354	BPV-17-01-00132371	401; 402; 403; 801; 802	
8936	G2 Express Design Review Summary DRS-8058-J, Rev. 1 G2 Express Design Review Summary DRS-8058-J, Rev. 1	BPV-17-01-00132454	BPV-17-01-00132476	401; 402; 403; 801; 802	
8937	G2 Express DV&V Test Plan TD-00382 G2 Express DV&V Test Plan TD-00382	BPV-17-01-00132477	BPV-17-01-00132489	401; 402; 403; 801; 802	
8938	G2 Express Risk Analysis RA07048, Rev. 0 G2 Express Risk Analysis RA07048, Rev. 0	BPV-17-01-00132559	BPV-17-01-00132574	401; 402; 403; 801; 802	
8939	G2 Express Bill of Materials TD-00379, rev. 4 G2 Express Bill of Materials TD-00379, rev. 4	BPV-17-01-00132575	BPV-17-01-00132648	401; 402; 403; 801; 802	
8940	G2 Express PPS 8058-J, Rev. 1 (Concept, Feasibility, Design and Development Planning) G2 Express PPS 8058-J, Rev. 1 (Concept, Feasibility, Design and Development Planning)	BPV-17-01-00132649	BPV-17-01-00132789	401; 402; 403; 801; 802	
8941	G2 Express Product Validation Master Plan Protocol TP-07-07-01 G2 Express Product Validation Master Plan Protocol TP-07-07-01	BPV-17-01-00132802	BPV-17-01-00132832	401; 402; 403; 801; 802	
8942	G2 Express Project Plan PP-8058, Rev. 2 G2 Express Project Plan PP-8058, Rev. 2	BPV-17-01-00132833	BPV-17-01-00132842	401; 402; 403; 801; 802	
8943	G2 Express Regulatory and Clinical Strategy Determination, Rev. 01 G2 Express Regulatory and Clinical Strategy Determination, Rev. 01	BPV-17-01-00132843	BPV-17-01-00132867	401; 402; 403; 801; 802	
8944	G2 Express PFMEA070040, Rev. 0 G2 Express PFMEA070040, Rev. 0	BPV-17-01-00132868	BPV-17-01-00132933	401; 402; 403; 801; 802	
8945	G2 Express Test Method Matrix TD-00387, Rev. 1 G2 Express Test Method Matrix TD-00387, Rev. 1	BPV-17-01-00132967	BPV-17-01-00132973	401; 402; 403; 801; 802	
8946	G2 Express Jugular Introducer Kit Feasibility Report TR-07-05-02	BPV-17-01-00133081	BPV-17-01-00133095	401; 402; 403; 801; 802	
8947	G2 Express Femoral Feasibility Report TR-07-05-09	BPV-17-01-00133099	BPV-17-01-00133134	401; 402; 403; 801; 802	
8948	G2 Express Jugular Feasibility Stability TR-07-06-10	BPV-17-01-00133135	BPV-17-01-00133156	401; 402; 403; 801; 802	
8949	G2 Express Feasibility Nitinol Af Test TD-00393	BPV-17-01-00133157	BPV-17-01-00133171	401; 402; 403; 801; 802	
8950	G2 Express Radiopacity Test TD-00467, Rev. 0	BPV-17-01-00133172	BPV-17-01-00133176	401; 402; 403; 801; 802	
8951	G2 Express IVC Filter MRI Testing Report TR-07-06-22	BPV-17-01-00133177	BPV-17-01-00133188	401; 402; 403; 801; 802	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8952	G2 Express Jugular Design Review Summary DRS-8058-J, Rev. 0 (Feasibility) G2 Express Jugular Design Review Summary DRS-8058-J, Rev. 0 (Feasibility)	BPV-17-01-00133189	BPV-17-01-00133211	401; 402; 403; 801; 802	
8953	G2 Express Jugular and Femoral Bill of Materials TD-00379, Rev. 4 G2 Express Jugular and Femoral Bill of Materials TD-00379, Rev. 4	BPV-17-01-00133231	BPV-17-01-00133304	401; 402; 403; 801; 802	
8954	G2 Express Manufacturability Assessment TD-00461, Rev. 0 G2 Express Manufacturability Assessment TD-00461, Rev. 0	BPV-17-01-00133305	BPV-17-01-00133308	401; 402; 403; 801; 802	
8955	G2 Express Packing Design Inputs Form G2 Express Packing Design Inputs Form	BPV-17-01-00133309	BPV-17-01-00133336	401; 402; 403; 801; 802	
8956	G2 Express Jugular PPS 8058-J, Rev. 0 G2 Express Jugular PPS 8058-J, Rev. 0	BPV-17-01-00133338	BPV-17-01-00133483	401; 402; 403; 801; 802	
8957	G2 Express Project Plan PP-8058, Rev. 2 G2 Express Project Plan PP-8058, Rev. 2	BPV-17-01-00133484	BPV-17-01-00133493	401; 402; 403; 801; 802	
8958	G2 Express Approved Suppliers TD-00389 G2 Express Approved Suppliers TD-	BPV-17-01-00133520	BPV-17-01-00133521	401; 402; 403; 801; 802	
8959	G2 Express Biocompatibility Requirements BR-8058, Rev. 4 G2 Express Biocompatibility Requirements BR-8058, Rev. 4	BPV-17-01-00133529	BPV-17-01-00133567	401; 402; 403; 801; 802	
8960	G2 Express Proposition 65 Memo TD-00380, Rev. 1 G2 Express Proposition 65 Memo TD-00380, Rev. 1	BPV-17-01-00133568	BPV-17-01-00133572	401; 402; 403; 801; 802	
8961	G2 Express Femoral Design Review Summary DRS-8058-F, Rev. 1 G2 Express Femoral Design Review Summary DRS-8058-F, Rev. 1	BPV-17-01-00133573	BPV-17-01-00133591	401; 402; 403; 801; 802	
8962	G2 Express Femoral V&V Test Plan TD-00382, Rev. 4 G2 Express Femoral V&V Test Plan TD-00382, Rev. 4	BPV-17-01-00133592	BPV-17-01-00133601	401; 402; 403; 801; 802	
8963	G2 Express PPS 8058-F, Rev. 1 G2 Express PPS 8058-F, Rev. 1	BPV-17-01-00133767	BPV-17-01-00133907	401; 402; 403; 801; 802	
8964	G2 Express Femoral Large Spline Feasibility Report TR-07-09-11	BPV-17-01-00134103	BPV-17-01-00134118	401; 402; 403; 801; 802	
8965	G2 Express Femoral Feasibility Stability Report TR-07-06-11	BPV-17-01-00134157	BPV-17-01-00134218	401; 402; 403; 801; 802	
8966	G2 Express Femoral Design Review Summary DRS-8058-F, Rev. 0 (Feasibility) G2 Express Femoral Design Review Summary DRS-8058-F, Rev. 0 (Feasibility)	BPV-17-01-00134224	BPV-17-01-00134237	401; 402; 403; 801; 802	
8967	G2 Express Femoral PPS 8058-F, Rev. 0 G2 Express Femoral PPS 8058-F, Rev. 0	BPV-17-01-00134302	BPV-17-01-00134442	401; 402; 403; 801; 802	
8968	G2 Express Jugular PPS 8058-J, Rev. 5	BPV-17-01-00134501	BPV-17-01-00134563	401; 402; 403; 801; 802	
8969	G2 Express Femoral PPS 8058-F, Rev. 6	BPV-17-01-00134564	BPV-17-01-00134633	401; 402; 403; 801; 802	
8970	G2 Express Delivery System Leveraging Justifications TD-00612, Rev. 1	BPV-17-01-00134634	BPV-17-01-00134649	401; 402; 403; 801; 802	
8971	G2 Express Femoral Kit 1 Year ASLT Testing G2 Express Femoral Kit 1 Year ASLT Testing	BPV-17-01-00134650	BPV-17-01-00134754	401; 402; 403; 801; 802	
8972	G2 Express Product Adoption for RF410F	BPV-17-01-00134758	BPV-17-01-00134762	401; 402; 403; 801; 802	
8973	G2 Express Femoral System Drawings	BPV-17-01-00134764	BPV-17-01-00134766	401; 402; 403; 801; 802	
8974	G2 Express Product Adoption for RF420J	BPV-17-01-00134785	BPV-17-01-00134789	401; 402; 403; 801; 802	
8975	G2 Express Jugular System Drawings	BPV-17-01-00134791	BPV-17-01-00134794	401; 402; 403; 801; 802	
8976	G2 Express DFMEA070044, Rev. 2 G2 Express DFMEA070044, Rev. 2	BPV-17-01-00134873	BPV-17-01-00134915	401; 402; 403; 801; 802	
8977	G2 Express Transfer Plan Project 8058 TD-00300, Rev. 1 G2 Express Transfer Plan Project 8058 TD-00300, Rev. 1	BPV-17-01-00134916	BPV-17-01-00134933	401; 402; 403; 801; 802	
8978	G2 Express Project Plan PP-8058, Rev. 3 G2 Express Project Plan PP-8058, Rev. 3	BPV-17-01-00134935	BPV-17-01-00134947	401; 402; 403; 801; 802	
8979	G2 Express Regulatory and Clinical Strategy Determination, Rev. 2 G2 Express Regulatory and Clinical Strategy Determination, Rev. 2	BPV-17-01-00134948	BPV-17-01-00134971	401; 402; 403; 801; 802	
8980	G2 Express Biocompatibility Requirements BR-8058, Rev. 6 G2 Express Biocompatibility Requirements BR-8058, Rev. 6	BPV-17-01-00134972	BPV-17-01-00135007	401; 402; 403; 801; 802	
8981	G2 Express Test Method Matrix TD-00387, Rev. 4 G2 Express Test Method Matrix TD-00387, Rev. 4	BPV-17-01-00135058	BPV-17-01-00135065	401; 402; 403; 801; 802	
8982	G2 Express Jugular DV&V Protocol TP-07-10-31, Rev. 0 G2 Express Jugular 0-Time DV&V	BPV-17-01-00135066	BPV-17-01-00135086	401; 402; 403; 801; 802	
8983	G2 Express Femoral DV&V Protocol TP-07-10-33, Rev. 0	BPV-17-01-00135087	BPV-17-01-00135124	401; 402; 403; 801; 802	
8984	G2 Express Luer Rotator to Storage Tube Tensile Test Protocol TP-07-12-05	BPV-17-01-00135125	BPV-17-01-00135139	401; 402; 403; 801; 802	
8985	G2 Express Packaging Zero-Time Design Verification Protocol TP-07-10-37	BPV-17-01-00135140	BPV-17-01-00135158	401; 402; 403; 801; 802	
8986	G2 Express Femoral DV&V Report TR-07-10-33, Rev. 1	BPV-17-01-00135159	BPV-17-01-00135181	401; 402; 403; 801; 802	
8987	G2 Express Jugular DV&V Report TR-07-10-31-J, Rev. 2	BPV-17-01-00135182	BPV-17-01-00135199	401; 402; 403; 801; 802	
8988	G2 Express Femoral Luer Storage Tube and Hub Cap DV&V Report TR-07-12-05	BPV-17-01-00135200	BPV-17-01-00135212	401; 402; 403; 801; 802	
8989	G2 Express Zero-Time Design Verification Test Report TR-07-10-37, Rev. 0	BPV-17-01-00135213	BPV-17-01-00135227	401; 402; 403; 801; 802	
8990	G2 Express DV&V Design Review Agenda G2 Express DV&V Design Review	BPV-17-01-00135229	BPV-17-01-00135229	401; 402; 403; 801; 802	
8991	G2 Express DV&V Design Review Sign-In Sheet May 15, 2008 G2 Express DV&V Design Review Sign-In Sheet May 15, 2008	BPV-17-01-00135230	BPV-17-01-00135230	401; 402; 403; 801; 802	
8992	G2 Express Femoral PPS 8058-F, Rev. 8 G2 Express Femoral PPS 8058-F, Rev. 8	BPV-17-01-00135231	BPV-17-01-00135379	401; 402; 403; 801; 802	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
8993	G2 Express 3 Year Accelerated Shelf Life Testing Protocol TP-07-10-30, Rev. 0	BPV-17-01-00135380	BPV-17-01-00135414	401; 402; 403; 801; 802	
8994	G2 Express Femoral 3 Year Accelerated Shelf Life Testing Report TR-07-10-30, Rev. 0	BPV-17-01-00135415	BPV-17-01-00135442	401; 402; 403; 801; 802	
8995	G2 Express Femoral 3 Year ASLT Report TD-00717, Rev. 0	BPV-17-01-00135443	BPV-17-01-00135446	401; 402; 403; 801; 802	
8996	G2 Express Simulated Use Filter Centering Exam of Introducer Hub Assembly TD-00721, Rev. 0	BPV-17-01-00135447	BPV-17-01-00135453	401; 402; 403; 801; 802	
8997	G2 Express Jugular 3 Year Stability Protocol TP-07-10-28, Rev. 1	BPV-17-01-00135454	BPV-17-01-00135476	401; 402; 403; 801; 802	
8998	G2 Express Jugular 3 Year Stability Report TR-07-10-28, Rev. 0	BPV-17-01-00135477	BPV-17-01-00135491	401; 402; 403; 801; 802	
8999	G2 Express Jugular Stability Test Protocol Production Adoption SPAR-0057, Rev.	BPV-17-01-00135492	BPV-17-01-00135494	401; 402; 403; 801; 802	
9000	G2 Express Product Validation Master Plan Protocol Femoral and Jugular G2 Express Product Validation Master Plan Protocol Femoral and Jugular	BPV-17-01-00135496	BPV-17-01-00135516	401; 402; 403; 801; 802	
9001	G2 Express Process Validation Summary Report Femoral and Jugular G2 Express Process Validation Summary Report Femoral and Jugular	BPV-17-01-00135517	BPV-17-01-00135653	401; 402; 403; 801; 802	
9002	G2 Express Product Adoption Materials G2 Express Product Adoption Materials	BPV-17-01-00135654	BPV-17-01-00135776	401; 402; 403; 801; 802	
9003	G2 Express Product Code Transfer of RF410F and RF420J to RF400F and RF400J G2 Express Product Code Transfer of RF410F and RF420J to RF400F and RF400J	BPV-17-01-00135777	BPV-17-01-00135827	401; 402; 403; 801; 802	
9004	Letter from FDA to BPV regarding recall of K052578	BPV-17-01-00135833	BPV-17-01-00135833	401; 402; 403; 801; 802	
9005	Letters from BPV to FDA regarding recall of K052578	BPV-17-01-00135838	BPV-17-01-00135839	401; 402; 403; 801; 802	
9006	Letters from BPV to FDA regarding recall of K052578	BPV-17-01-00135840	BPV-17-01-00135856	401; 402; 403; 801; 802	
9007	Letters from BPV to FDA regarding recall of K052578	BPV-17-01-00135857	BPV-17-01-00135870	401; 402; 403; 801; 802	
9008	Letters from BPV to FDA regarding recall of K052578	BPV-17-01-00135871	BPV-17-01-00135884	401; 402; 403; 801; 802	
9009	Conference between FDA and BPV regarding recall of K052578	BPV-17-01-00135885	BPV-17-01-00135914	401; 402; 403; 801; 802	
9010	Letters from BPV to FDA regarding recall of K052578	BPV-17-01-00135915	BPV-17-01-00135935	401; 402; 403; 801; 802	
9011	Letters from BPV to FDA regarding recall of K052578	BPV-17-01-00135936	BPV-17-01-00135962	401; 402; 403; 801; 802	
9012	BPV sends second recall letter regarding K052578	BPV-17-01-00136611	BPV-17-01-00136613	401; 402; 403; 801; 802	
9013	BPV sends a recall letter regarding K052578	BPV-17-01-00136614	BPV-17-01-00136616	401; 402; 403; 801; 802	
9014	Letter from BPV to FDA regarding recall of K052578	BPV-17-01-00136621	BPV-17-01-00136622	401; 402; 403; 801; 802	
9015	G2 Express IFU (Femoral) PK5022940 Rev. 0 02/08	BPV-17-01-00137349	BPV-17-01-00137352	401; 402; 403; 801; 802	
9016	G2 Express IFU (Jugular) PK5022941 Rev. 0 02/08	BPV-17-01-00137353	BPV-17-01-00137364	401; 402; 403; 801; 802	
9017	G2 Express Training Manual	BPV-17-01-00137449	BPV-17-01-00137587	401; 402; 403; 801; 802	
9018	RNF Marketing Brochure	BPV-17-01-00137593	BPV-17-01-00137593	401; 402; 403; 801; 802	
9019	G2x launch materials	BPV-17-01-00137685	BPV-17-01-00137709	401; 402; 403; 801; 802	
9020	Introducer Sheath Incoming Inspection Procedure RM1088510	BPV-17-01-00138620	BPV-17-01-00138622	401; 402; 403; 801; 802	
9021	G2 Express DFMEA 070044, Rev. 0	BPV-17-01-00139249	BPV-17-01-00139285	401; 402; 403; 801; 802	
9022	G2 Express DFMEA 070044, Rev. 1	BPV-17-01-00139286	BPV-17-01-00139323	401; 402; 403; 801; 802	
9023	G2 Express DFMEA 070044, Rev. 2 (approval page)	BPV-17-01-00139324	BPV-17-01-00139324	401; 402; 403; 801; 802	
9024	G2 Express DFMEA 070044, Rev. 2	BPV-17-01-00139325	BPV-17-01-00139365	401; 402; 403; 801; 802	
9025	G2 Express DFMEA 070044, Rev. 3 (approval page)	BPV-17-01-00139366	BPV-17-01-00139366	401; 402; 403; 801; 802	
9026	G2 Express DFMEA 070044, Rev. 3	BPV-17-01-00139367	BPV-17-01-00139408	401; 402; 403; 801; 802	
9027	G2 Express DFMEA 070044, Rev. 4 (G2x)	BPV-17-01-00139409	BPV-17-01-00139448	401; 402; 403; 801; 802	
9028	G2 Express DFMEA 070063, Rev. 0 (approval page)	BPV-17-01-00139449	BPV-17-01-00139449	401; 402; 403; 801; 802	
9029	G2 Express DFMEA 070063, Rev. 0	BPV-17-01-00139450	BPV-17-01-00139479	401; 402; 403; 801; 802	
9030	G2 Express DFMEA 070063, Rev. 1 (approval page)	BPV-17-01-00139480	BPV-17-01-00139480	401; 402; 403; 801; 802	
9031	G2 Express DFMEA 070063, Rev. 1	BPV-17-01-00139481	BPV-17-01-00139510	401; 402; 403; 801; 802	
9032	G2 Express DFMEA 070063, Rev. 2 (approval page)	BPV-17-01-00139511	BPV-17-01-00139511	401; 402; 403; 801; 802	
9033	G2 Express DFMEA 070063, Rev. 2	BPV-17-01-00139512	BPV-17-01-00139543	401; 402; 403; 801; 802	
9034	G2X Patient Question and Answers	BPV-17-01-00140163	BPV-17-01-00140166	401; 402; 403; 801; 802	
9035	G2 Express marketing material	BPV-17-01-00140167	BPV-17-01-00140170	401; 402; 403; 801; 802	
9036	G2 Express Vena Cava Patient Questions and Answers	BPV-17-01-00140175	BPV-17-01-00140181	401; 402; 403; 801; 802	
9037	Inspections Performed at each G2 Filter Work Step	BPV-17-01-00141884	BPV-17-01-00141886	401; 402; 403; 801; 802	
9038	Flowchart for G2 Work Steps	BPV-17-01-00141887	BPV-17-01-00141887	401; 402; 403; 801; 802	
9039	RNF 0.013" Nitinol Wire Qualification Procedure (IP14500441, Rev. 13) (01/2009)	BPV-17-01-00142001	BPV-17-01-00142022	401; 402; 403; 801; 802	
9040	Inspect G2 Express Filter (IPG642, Rev. 04) (07/2009)	BPV-17-01-00142023	BPV-17-01-00142036	401; 402; 403; 801; 802	
9041	Inspect Loaded G2 Filter (IPG644, Rev. 01) (04/2008)	BPV-17-01-00142037	BPV-17-01-00142044	401; 402; 403; 801; 802	
9042	QC Inspect Ground Nitinol Wire (IPG647, Rev. 03) (04/2009)	BPV-17-01-00142045	BPV-17-01-00142046	401; 402; 403; 801; 802	
9043	Make Nitinol Filter (MPA677, Rev. 16-H) (07/2009)	BPV-17-01-00142047	BPV-17-01-00142062	401; 402; 403; 801; 802	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9044	Exercise RNF Filter (MPA679, Rev. 17-F) (07/2009)	BPV-17-01-00142063	BPV-17-01-00142072	401; 402; 403; 801; 802	
9045	Anneal RNF Filter (MPA691, Rev. 11-E) (07/2009)	BPV-17-01-00142073	BPV-17-01-00142097	401; 402; 403; 801; 802	
9046	Load Filter (MPB286, Rev. 03-B) (03/2009)	BPV-17-01-00142098	BPV-17-01-00142126	401; 402; 403; 801; 802	
9047	Trip / Sharpen Nitinol Filter (MPB292, Rev. 05-B) (07/2009)	BPV-17-01-00142127	BPV-17-01-00142151	401; 402; 403; 801; 802	
9048	Remove Nitinol Filter, G2 Express (MPB298, Rev. 03-B) (07/2009)	BPV-17-01-00142152	BPV-17-01-00142173	401; 402; 403; 801; 802	
9049	Inspect G2 Express Filter (IPG642, Rev. 04) (07/2009)	BPV-17-01-00142296	BPV-17-01-00142309	401; 402; 403; 801; 802	
9050	G2x Sample Physician Training	BPV-17-01-00142347	BPV-17-01-00142370	401; 402; 403; 801; 802	
9051	G2X IFU (Femoral) PK5100060, Rev. 5 10/09	BPV-17-01-00142371	BPV-17-01-00142382	401; 402; 403; 801; 802	
9052	G2X IFU (Jugular) PK5100070, Rev. 5 10/09	BPV-17-01-00142383	BPV-17-01-00142394	401; 402; 403; 801; 802	
9053	G2X IFU (Femoral) PK5100095, Rev. 0 03/09	BPV-17-01-00142395	BPV-17-01-00142406	401; 402; 403; 801; 802	
9054	G2X IFU (Jugular) PK5100100 Rev. 0 03/09	BPV-17-01-00142407	BPV-17-01-00142418	401; 402; 403; 801; 802	
9055	Exemplar Design History Record for G2X	BPV-17-01-00142620	BPV-17-01-00142645	401; 402; 403; 801; 802	
9056	IPG625 Rev 04	BPV-17-01-00142646	BPV-17-01-00142656	401; 402; 403; 801; 802	
9057	IPG634 Rev 02	BPV-17-01-00142657	BPV-17-01-00142667	401; 402; 403; 801; 802	
9058	MPA676 Rev 29	BPV-17-01-00142668	BPV-17-01-00142698	401; 402; 403; 801; 802	
9059	MPA677 Rev 16	BPV-17-01-00142699	BPV-17-01-00142714	401; 402; 403; 801; 802	
9060	MPA678 Rev 25	BPV-17-01-00142715	BPV-17-01-00142738	401; 402; 403; 801; 802	
9061	MPA679 Rev 18	BPV-17-01-00142739	BPV-17-01-00142747	401; 402; 403; 801; 802	
9062	MPA702 Rev 15	BPV-17-01-00142748	BPV-17-01-00142764	401; 402; 403; 801; 802	
9063	MPB227 Rev 05	BPV-17-01-00142765	BPV-17-01-00142793	401; 402; 403; 801; 802	
9064	G2 Express (G2 X) DFMEA070044 Rev. 5	BPV-17-01-00142804	BPV-17-01-00142857	401; 402; 403; 801; 802	
9065	G2 IFU PK5014091, Rev. 1 12/05 (Jugular)	BPV-17-01-00142863	BPV-17-01-00142870	401; 402; 403; 801; 802	
9066	Representative Marketing/Sales/Training Materials: G2 Express Filter Patient Questions & Answers	BPV-17-01-00142932	BPV-17-01-00142937	401; 402; 403; 801; 802	
9067	Representative Marketing/Sales/Training Materials: G2 X Patient Questions & Answers	BPV-17-01-00142982	BPV-17-01-00142983	401; 402; 403; 801; 802	
9068	G2X IFU (Femoral) PK5100060 Rev. 4 6/09	BPV-17-01-00144167	BPV-17-01-00144176	401; 402; 403; 801; 802	
9069	G2X IFU (Jugular) PK5100070 Rev. 4 6/09	BPV-17-01-00144177	BPV-17-01-00144186	401; 402; 403; 801; 802	
9070	G2 X Patient Brochure S11654 Rev 01	BPV-17-01-00144187	BPV-17-01-00144188	401; 402; 403; 801; 802	
9071	Bard Warning Letter Response (August 3 2015) 07 Appendix 4 (part 1 of 2).pdf	BPV-17-01-00200716	BPV-17-01-00201334	401; 402; 403; 801; 802	
9072	Bard Warning Letter Response (August 3 2015) 08 Appendix 4 (part 2 of 2).pdf	BPV-17-01-00201335	BPV-17-01-00201740	401; 402; 403; 801; 802	
9073	Bard Warning Letter Response (August 3 2015) 09 Appendix 5.pdf	BPV-17-01-00201741	BPV-17-01-00201983	401; 402; 403; 801; 802	
9074	G2X (Jugular) 2008.07 - PK5100070 rev. 1 IFU	BPV-17-01-00236527	BPV-17-01-00236538	401; 402; 403; 801; 802	
9075	G2X (Jugular) 2009.06 - PK5100070 rev. 4 IFU	BPV-17-01-00236539	BPV-17-01-00236550	401; 402; 403; 801; 802	
9076	Jan. 22, 2005 Email to FDA	BPVE-01-00303527	BPVE-01-00303528	401; 402; 403; 801; 802	
9077	July 12 2016 notes			401; 402; 403; 801; 802	
9078	June 14 2013 CT report			401; 402; 403; 801; 802	
9079	Email with Dear Colleague Letter Delivery Tracking Chart	BPVE-01-00459040	BPVE-01-00459112	401; 402; 403; 801; 802	
9080	Exhibit Placeholder				
9081	Exhibit Placeholder				
9082	Email with Dear Doctor Letter Delivery Tracking Chart	BPVE-01-00531449		401; 402; 403; 801; 802	
9083	Email with Dear Doctor Letter Delivery Tracking Chart	BPVE-01-00531053		401; 402; 403; 801; 802	
9084	Email with Dear Doctor Letter Delivery Tracking Chart	BPVE-01-00431813		401; 402; 403; 801; 802	
9085	Exhibit Placeholder				
9086	Burnett, Garcia, et al., Heparin-induced thrombocytopenia, 2016			401; 402; 403; 801; 802	
9087	Garcia, Duration of anticoagulant therapy for patients with venous thromboembolism, 2008			401; 402; 403; 801; 802	
9088	Witt, Garcia, et al., Risk of thromboembolism after warfarin therapy for intracranial hemorrhage, 2015			401; 402; 403; 801; 802	
9089	Witt, Garcia, et al., Risk of thromboembolism after warfarin therapy for gastrointestinal bleeding, 2012			401; 402; 403; 801; 802	
9090	Imberti, Garcia, et al., Evidence and Clinical Judgment: Vena cava filters, 2013			401; 402; 403; 801; 802	
9091	Ageno, Garcia, et al., Guidance for the management of venous thrombosis in unusual sites			401; 402; 403; 801; 802	
9092	G2X (Jugular) 2008.07 - PK5100070 rev. 1 IFU			401; 402; 403; 801; 802	
9093	G2X (Jugular) 2009.06 - PK5100070 rev. 4 IFU			401; 402; 403; 801; 802	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9094	Murray Asch, 1/5/11 deposition Exhibit 01			401; 402; 403; 801; 802	
9095	Murray Asch, 1/5/11 deposition Exhibit 02			401; 402; 403; 801; 802	
9096	Murray Asch, 1/5/11 deposition Exhibit 03			401; 402; 403; 801; 802	
9097	Murray Asch, 1/5/11 deposition Exhibit 04			401; 402; 403; 801; 802	
9098	Exhibit Placeholder				
9099	Exhibit Placeholder				
9100	Exhibit Placeholder				
9101	Exhibit Placeholder				
9102	Rebecca Betensky, 6/23/16 deposition Exhibit 01			401; 402; 403; 801; 802	
9103	Rebecca Betensky, 6/23/16 deposition Exhibit 02			401; 402; 403; 801; 802	
9104	Rebecca Betensky, 6/23/16 deposition Exhibit 03			401; 402; 403; 801; 802	
9105	Rebecca Betensky, 6/23/16 deposition Exhibit 04			401; 402; 403; 801; 802	
9106	Rebecca Betensky, 6/23/16 deposition Exhibit 05			401; 402; 403; 801; 802	
9107	Rebecca Betensky, 6/23/16 deposition Exhibit 06			401; 402; 403; 801; 802	
9108	Rebecca Betensky, 6/23/16 deposition Exhibit 07			401; 402; 403; 801; 802	
9109	Rebecca Betensky, 6/23/16 deposition Exhibit 08			401; 402; 403; 801; 802	
9110	Rebecca Betensky, 6/23/16 deposition Exhibit 09			401; 402; 403; 801; 802	
9111	Rebecca Betensky, 6/23/16 deposition Exhibit 10			401; 402; 403; 801; 802	
9112	Rebecca Betensky, 6/23/16 deposition Exhibit 11			401; 402; 403; 801; 802	
9113	Rebecca Betensky, 6/23/16 deposition Exhibit 12			401; 402; 403; 801; 802	
9114	Rebecca Betensky, 6/23/16 deposition Exhibit 13			401; 402; 403; 801; 802	
9115	Rebecca Betensky, 6/23/16 deposition Exhibit 14			401; 402; 403; 801; 802	
9116	Rebecca Betensky, 6/23/16 deposition Exhibit 15			401; 402; 403; 801; 802	
9117	Rebecca Betensky, 6/23/16 deposition Exhibit 16			401; 402; 403; 801; 802	
9118	Darren Hurst, 2/27/18 deposition Exhibit 01			401; 402; 403; 801; 802	
9119	Darren Hurst, 2/27/18 deposition Exhibit 02			401; 402; 403; 801; 802	
9120	Darren Hurst, 2/27/18 deposition Exhibit 03			401; 402; 403; 801; 802	
9121	Darren Hurst, 2/27/18 deposition Exhibit 04			401; 402; 403; 801; 802	
9122	Darren Hurst, 2/27/18 deposition Exhibit 05			401; 402; 403; 801; 802	
9123	Darren Hurst, 2/27/18 deposition Exhibit 06			401; 402; 403; 801; 802	
9124	Darren Hurst, 2/27/18 deposition Exhibit 07			401; 402; 403; 801; 802	
9125	Darren Hurst, 2/27/18 deposition Exhibit 08			401; 402; 403; 801; 802	
9126	Darren Hurst, 2/27/18 deposition Exhibit 09			401; 402; 403; 801; 802	
9127	Darren Hurst, 2/27/18 deposition Exhibit 10			401; 402; 403; 801; 802	
9128	Darren Hurst, 2/27/18 deposition Exhibit 11			401; 402; 403; 801; 802	
9129	Darren Hurst, 2/27/18 deposition Exhibit 12			401; 402; 403; 801; 802	
9130	Darren Hurst, 2/27/18 deposition Exhibit 13			401; 402; 403; 801; 802	
9131	Darren Hurst, 2/27/18 deposition Exhibit 14			401; 402; 403; 801; 802	
9132	Darren Hurst, 2/27/18 deposition Exhibit 15			401; 402; 403; 801; 802	
9133	Darren Hurst, 2/27/18 deposition Exhibit 16			401; 402; 403; 801; 802	
9134	Darren Hurst, 2/27/18 deposition Exhibit 17			401; 402; 403; 801; 802	
9135	Darren Hurst, 5/31/18 deposition Exhibit 01			401; 402; 403; 801; 802	
9136	Darren Hurst, 5/31/18 deposition Exhibit 02			401; 402; 403; 801; 802	
9137	Darren Hurst, 5/31/18 deposition Exhibit 03			401; 402; 403; 801; 802	
9138	David Kessler, 10/5/2016 deposition Exhibit 01			401; 402; 403; 801; 802	
9139	David Kessler, 10/5/2016 deposition Exhibit 02			401; 402; 403; 801; 802	
9140	David Kessler, 10/5/2016 deposition Exhibit 03			401; 402; 403; 801; 802	
9141	David Kessler, 10/5/2016 deposition Exhibit 04			401; 402; 403; 801; 802	
9142	David Kessler, 10/5/2016 deposition Exhibit 05			401; 402; 403; 801; 802	
9143	David Kessler, 10/5/2016 deposition Exhibit 06			401; 402; 403; 801; 802	
9144	David Kessler, 10/5/2016 deposition Exhibit 07			401; 402; 403; 801; 802	
9145	David Kessler, 10/5/2016 deposition Exhibit 08			401; 402; 403; 801; 802	
9146	David Kessler, 10/5/2016 deposition Exhibit 09			401; 402; 403; 801; 802	
9147	David Kessler, 10/5/2016 deposition Exhibit 10			401; 402; 403; 801; 802	
9148	David Kessler, 10/5/2016 deposition Exhibit 11			401; 402; 403; 801; 802	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9149	David Kessler, 10/5/2016 deposition Exhibit 12			401; 402; 403; 801; 802	
9150	David Kessler, 10/5/2016 deposition Exhibit 13			401; 402; 403; 801; 802	
9151	David Kessler, 10/5/2016 deposition Exhibit 14			401; 402; 403; 801; 802	
9152	David Kessler, 10/5/2016 deposition Exhibit 15			401; 402; 403; 801; 802	
9153	David Kessler, 10/5/2016 deposition Exhibit 16			401; 402; 403; 801; 802	
9154	David Kessler, 10/5/2016 deposition Exhibit 17			401; 402; 403; 801; 802	
9155	David Kessler, 10/5/2016 deposition Exhibit 18			401; 402; 403; 801; 802	
9156	David Kessler, 10/5/2016 deposition Exhibit 19			401; 402; 403; 801; 802	
9157	David Kessler, 10/5/2016 deposition Exhibit 20			401; 402; 403; 801; 802	
9158	David Kessler, 10/5/2016 deposition Exhibit 21			401; 402; 403; 801; 802	
9159	David Kessler, 10/5/2016 deposition Exhibit 22			401; 402; 403; 801; 802	
9160	David Kessler, 10/5/2016 deposition Exhibit 23			401; 402; 403; 801; 802	
9161	David Kessler, 10/5/2016 deposition Exhibit 24			401; 402; 403; 801; 802	
9162	David Kessler, 10/5/2016 deposition Exhibit 25			401; 402; 403; 801; 802	
9163	David Kessler, 10/5/2016 deposition Exhibit 26			401; 402; 403; 801; 802	
9164	David Kessler, 10/5/2016 deposition Exhibit 27			401; 402; 403; 801; 802	
9165	David Kessler, 10/5/2016 deposition Exhibit 28			401; 402; 403; 801; 802	
9166	Robert McMeeking 7/19/16 deposition Exhibit 01			401; 402; 403; 801; 802	
9167	Robert McMeeking 7/19/16 deposition Exhibit 02			401; 402; 403; 801; 802	
9168	Robert McMeeking 7/19/16 deposition Exhibit 03			401; 402; 403; 801; 802	
9169	Robert McMeeking 7/19/16 deposition Exhibit 04			401; 402; 403; 801; 802	
9170	Robert McMeeking 7/19/16 deposition Exhibit 05			401; 402; 403; 801; 802	
9171	Robert McMeeking 7/19/16 deposition Exhibit 06			401; 402; 403; 801; 802	
9172	Robert McMeeking 7/19/16 deposition Exhibit 07			401; 402; 403; 801; 802	
9173	Robert McMeeking 7/19/16 deposition Exhibit 08			401; 402; 403; 801; 802	
9174	Robert McMeeking 7/19/16 deposition Exhibit 09			401; 402; 403; 801; 802	
9175	Robert McMeeking 7/19/16 deposition Exhibit 10			401; 402; 403; 801; 802	
9176	Robert McMeeking 7/19/16 deposition Exhibit 11			401; 402; 403; 801; 802	
9177	Robert McMeeking 7/19/16 deposition Exhibit 12			401; 402; 403; 801; 802	
9178	Robert McMeeking 7/19/16 deposition Exhibit 13			401; 402; 403; 801; 802	
9179	Robert McMeeking 7/19/16 deposition Exhibit 14			401; 402; 403; 801; 802	
9180	Robert McMeeking 7/19/16 deposition Exhibit 15			401; 402; 403; 801; 802	
9181	Robert McMeeking 7/19/16 deposition Exhibit 16			401; 402; 403; 801; 802	
9182	Robert McMeeking 7/19/16 deposition Exhibit 17			401; 402; 403; 801; 802	
9183	Robert McMeeking 7/19/16 deposition Exhibit 18			401; 402; 403; 801; 802	
9184	Robert McMeeking 7/19/16 deposition Exhibit 19			401; 402; 403; 801; 802	
9185	Robert McMeeking 7/19/16 deposition Exhibit 20			401; 402; 403; 801; 802	
9186	Robert McMeeking 7/19/16 deposition Exhibit 21			401; 402; 403; 801; 802	
9187	Robert McMeeking 7/19/16 deposition Exhibit 22			401; 402; 403; 801; 802	
9188	Robert McMeeking 7/19/16 deposition Exhibit 23			401; 402; 403; 801; 802	
9189	Derek Muehrcke, 3/12/18 deposition Exhibit 01			401; 402; 403; 801; 802	
9190	Derek Muehrcke, 3/12/18 deposition Exhibit 02			401; 402; 403; 801; 802	
9191	Derek Muehrcke, 3/12/18 deposition Exhibit 03			401; 402; 403; 801; 802	
9192	Derek Muehrcke, 3/12/18 deposition Exhibit 04			401; 402; 403; 801; 802	
9193	Derek Muehrcke, 3/12/18 deposition Exhibit 05			401; 402; 403; 801; 802	
9194	Derek Muehrcke, 3/12/18 deposition Exhibit 06			401; 402; 403; 801; 802	
9195	Derek Muehrcke, 3/12/18 deposition Exhibit 07			401; 402; 403; 801; 802	
9196	Derek Muehrcke, 3/12/18 deposition Exhibit 07.1			401; 402; 403; 801; 802	
9197	Derek Muehrcke, 3/12/18 deposition Exhibit 08			401; 402; 403; 801; 802	
9198	Derek Muehrcke, 3/12/18 deposition Exhibit 08.1			401; 402; 403; 801; 802	
9199	Derek Muehrcke, 3/12/18 deposition Exhibit 09			401; 402; 403; 801; 802	
9200	Derek Muehrcke, 3/12/18 deposition Exhibit 10			401; 402; 403; 801; 802	
9201	Derek Muehrcke, 3/12/18 deposition Exhibit 11			401; 402; 403; 801; 802	
9202	Derek Muehrcke, 3/12/18 deposition Exhibit 12			401; 402; 403; 801; 802	
9203	Derek Muehrcke, 3/12/18 deposition Exhibit 13			401; 402; 403; 801; 802	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9204	Derek Muehrcke, 3/12/18 deposition Exhibit 14			401; 402; 403; 801; 802	
9205	Derek Muehrcke, 3/12/18 deposition Exhibit 15			401; 402; 403; 801; 802	
9206	Derek Muehrcke, 3/12/18 deposition Exhibit 16			401; 402; 403; 801; 802	
9207	Derek Muehrcke, 3/12/18 deposition Exhibit 17			401; 402; 403; 801; 802	
9208	Derek Muehrcke, 3/12/18 deposition Exhibit 18			401; 402; 403; 801; 802	
9209	Derek Muehrcke, 3/12/18 deposition Exhibit 19			401; 402; 403; 801; 802	
9210	Derek Muehrcke, 3/12/18 deposition Exhibit 20			401; 402; 403; 801; 802	
9211	Derek Muehrcke, 8/14/18 deposition Exhibit 01			401; 402; 403; 801; 802	
9212	Derek Muehrcke, 8/14/18 deposition Exhibit 02			401; 402; 403; 801; 802	
9213	Derek Muehrcke, 8/14/18 deposition Exhibit 03			401; 402; 403; 801; 802	
9214	Derek Muehrcke, 8/14/18 deposition Exhibit 04			401; 402; 403; 801; 802	
9215	Derek Muehrcke, 8/14/18 deposition Exhibit 05			401; 402; 403; 801; 802	
9216	Derek Muehrcke, 8/14/18 deposition Exhibit 06			401; 402; 403; 801; 802	
9217	Derek Muehrcke, 8/14/18 deposition Exhibit 07			401; 402; 403; 801; 802	
9218	Derek Muehrcke, 8/14/18 deposition Exhibit 08			401; 402; 403; 801; 802	
9219	S. William Stavropoulos, 4/13/11 deposition Exhibit 01			401; 402; 403; 801; 802	
9220	S. William Stavropoulos, 4/13/11 deposition Exhibit 02			401; 402; 403; 801; 802	
9221	S. William Stavropoulos, 4/13/11 deposition Exhibit 03			401; 402; 403; 801; 802	
9222	S. William Stavropoulos, 4/13/11 deposition Exhibit 04			401; 402; 403; 801; 802	
9223	S. William Stavropoulos, 4/13/11 deposition Exhibit 05			401; 402; 403; 801; 802	
9224	S. William Stavropoulos, 4/13/11 deposition Exhibit 06			401; 402; 403; 801; 802	
9225	S. William Stavropoulos, 4/13/11 deposition Exhibit 07			401; 402; 403; 801; 802	
9226	S. William Stavropoulos, 4/13/11 deposition Exhibit 08			401; 402; 403; 801; 802	
9227	S. William Stavropoulos, 4/13/11 deposition Exhibit 09			401; 402; 403; 801; 802	
9228	S. William Stavropoulos, 4/13/11 deposition Exhibit 10			401; 402; 403; 801; 802	
9229	S. William Stavropoulos, 10/16/12 deposition Exhibit 1			401; 402; 403; 801; 802	
9230	S. William Stavropoulos, 10/16/12 deposition Exhibit 2			401; 402; 403; 801; 802	
9231	S. William Stavropoulos, 2/1/17 deposition Exhibit 803			401; 402; 403; 801; 802	
9232	S. William Stavropoulos, 2/1/17 deposition Exhibit 804			401; 402; 403; 801; 802	
9233	S. William Stavropoulos, 2/1/17 deposition Exhibit 805			401; 402; 403; 801; 802	
9234	S. William Stavropoulos, 2/1/17 deposition Exhibit 806			401; 402; 403; 801; 802	
9235	S. William Stavropoulos, 2/1/17 deposition Exhibit 807			401; 402; 403; 801; 802	
9236	S. William Stavropoulos, 2/1/17 deposition Exhibit 808			401; 402; 403; 801; 802	
9237	S. William Stavropoulos, 2/1/17 deposition Exhibit 809			401; 402; 403; 801; 802	
9238	S. William Stavropoulos, 2/1/17 deposition Exhibit 810			401; 402; 403; 801; 802	
9239	S. William Stavropoulos, 2/1/17 deposition Exhibit 810			401; 402; 403; 801; 802	
9240	S. William Stavropoulos, 2/1/17 deposition Exhibit 812			401; 402; 403; 801; 802	
9241	S. William Stavropoulos, 2/1/17 deposition Exhibit 813			401; 402; 403; 801; 802	
9242	S. William Stavropoulos, 2/1/17 deposition Exhibit 814			401; 402; 403; 801; 802	
9243	S. William Stavropoulos, 2/1/17 deposition Exhibit 815			401; 402; 403; 801; 802	
9244	S. William Stavropoulos, 2/1/17 deposition Exhibit 816			401; 402; 403; 801; 802	
9245	S. William Stavropoulos, 2/1/17 deposition Exhibit 817			401; 402; 403; 801; 802	
9246	S. William Stavropoulos, 2/1/17 deposition Exhibit 818			401; 402; 403; 801; 802	
9247	S. William Stavropoulos, 2/1/17 deposition Exhibit 819			401; 402; 403; 801; 802	
9248	S. William Stavropoulos, 2/1/17 deposition Exhibit 820			401; 402; 403; 801; 802	
9249	S. William Stavropoulos, 2/1/17 deposition Exhibit 821			401; 402; 403; 801; 802	
9250	S. William Stavropoulos, 2/1/17 deposition Exhibit 822			401; 402; 403; 801; 802	
9251	S. William Stavropoulos, 2/1/17 deposition Exhibit 823			401; 402; 403; 801; 802	
9252	S. William Stavropoulos, 2/1/17 deposition Exhibit 824			401; 402; 403; 801; 802	
9253	S. William Stavropoulos, 2/1/17 deposition Exhibit 825			401; 402; 403; 801; 802	
9254	S. William Stavropoulos, 2/1/17 deposition Exhibit 826			401; 402; 403; 801; 802	
9255	S. William Stavropoulos, 2/1/17 deposition Exhibit 827			401; 402; 403; 801; 802	
9256	S. William Stavropoulos, 2/1/17 deposition Exhibit 828			401; 402; 403; 801; 802	
9257	S. William Stavropoulos, 2/1/17 deposition Exhibit 829			401; 402; 403; 801; 802	
9258	S. William Stavropoulos, 2/22/17 deposition Exhibit 01			401; 402; 403; 801; 802	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9259	S. William Stavropoulos, 2/22/17 deposition Exhibit 02			401; 402; 403; 801; 802	
9260	S. William Stavropoulos, 2/22/17 deposition Exhibit 03			401; 402; 403; 801; 802	
9261	S. William Stavropoulos, 2/22/17 deposition Exhibit 04			401; 402; 403; 801; 802	
9262	S. William Stavropoulos, 2/22/17 deposition Exhibit 05			401; 402; 403; 801; 802	
9263	S. William Stavropoulos, 2/22/17 deposition Exhibit 06			401; 402; 403; 801; 802	
9264	S. William Stavropoulos, 2/22/17 deposition Exhibit 07			401; 402; 403; 801; 802	
9265	S. William Stavropoulos, 2/22/17 deposition Exhibit 08			401; 402; 403; 801; 802	
9266	S. William Stavropoulos, 2/22/17 deposition Exhibit 09			401; 402; 403; 801; 802	
9267	S. William Stavropoulos, 2/22/17 deposition Exhibit 10			401; 402; 403; 801; 802	
9268	S. William Stavropoulos, 2/22/17 deposition Exhibit 11			401; 402; 403; 801; 802	
9269	S. William Stavropoulos, 2/22/17 deposition Exhibit 12			401; 402; 403; 801; 802	
9270	S. William Stavropoulos, 2/22/17 deposition Exhibit 13			401; 402; 403; 801; 802	
9271	S. William Stavropoulos, 2/22/17 deposition Exhibit 14			401; 402; 403; 801; 802	
9272	S. William Stavropoulos, 2/22/17 deposition Exhibit 15			401; 402; 403; 801; 802	
9273	S. William Stavropoulos, 2/22/17 deposition Exhibit 16			401; 402; 403; 801; 802	
9274	S. William Stavropoulos, 2/22/17 deposition Exhibit 17			401; 402; 403; 801; 802	
9275	S. William Stavropoulos, 2/22/17 deposition Exhibit 18			401; 402; 403; 801; 802	
9276	S. William Stavropoulos, 2/22/17 deposition Exhibit 19			401; 402; 403; 801; 802	
9277	S. William Stavropoulos, 2/22/17 deposition Exhibit 20			401; 402; 403; 801; 802	
9278	S. William Stavropoulos, 2/22/17 deposition Exhibit 21			401; 402; 403; 801; 802	
9279	S. William Stavropoulos, 2/22/17 deposition Exhibit 22			401; 402; 403; 801; 802	
9280	S. William Stavropoulos, 2/22/17 deposition Exhibit 23			401; 402; 403; 801; 802	
9281	S. William Stavropoulos, 2/22/17 deposition Exhibit 24			401; 402; 403; 801; 802	
9282	Scott Trerotola, 11/15/10 deposition Exhibit 01			401; 402; 403; 801; 802	
9283	Scott Trerotola, 11/15/10 deposition Exhibit 02			401; 402; 403; 801; 802	
9284	Scott Trerotola, 11/15/10 deposition Exhibit 03			401; 402; 403; 801; 802	
9285	Scott Trerotola, 11/15/10 deposition Exhibit 04			401; 402; 403; 801; 802	
9286	Scott Trerotola, 11/15/10 deposition Exhibit 05			401; 402; 403; 801; 802	
9287	Scott Trerotola, 11/15/10 deposition Exhibit 06			401; 402; 403; 801; 802	
9288	Scott Trerotola, 11/15/10 deposition Exhibit 07			401; 402; 403; 801; 802	
9289	Scott Trerotola, 11/15/10 deposition Exhibit 08			401; 402; 403; 801; 802	
9290	Competitor Filter IFUs	BPV-17-01-00095800	BPV-17-01-00095894	401; 402; 403; 801; 802	
9291	filterlaw.com printout			401; 402; 403; 801; 802	
9292	Lopez McHugh legal advertising			401; 402; 403; 801; 802	
9293	2018 Final FDA Guidance re: Risk Benefit			401; 402; 403; 801; 802	
9294	Recovery Filter Drawing	BPV-17-01-00033692	BPV-17-01-00033692	401; 402; 403; 801; 802	
9295	Number intentionally skipped- case specific AZ Consolidated exhibit				
9296	Number intentionally skipped- case specific AZ Consolidated exhibit				
9297	Number intentionally skipped- case specific AZ Consolidated exhibit				
9298	Number intentionally skipped- case specific AZ Consolidated exhibit				
9299	Number intentionally skipped- case specific AZ Consolidated exhibit				
9300	Number intentionally skipped- case specific AZ Consolidated exhibit				
9301	Number intentionally skipped- case specific AZ Consolidated exhibit				
9302	Number intentionally skipped- case specific AZ Consolidated exhibit				
9303	Number intentionally skipped- case specific AZ Consolidated exhibit				
9304	Number intentionally skipped- case specific AZ Consolidated exhibit				
9305	Number intentionally skipped- case specific AZ Consolidated exhibit				
9306	Number intentionally skipped- case specific AZ Consolidated exhibit				
9307	Number intentionally skipped- case specific AZ Consolidated exhibit				
9308	Number intentionally skipped- case specific AZ Consolidated exhibit				
9309	Number intentionally skipped- case specific AZ Consolidated exhibit				
9310	Number intentionally skipped- case specific AZ Consolidated exhibit				
9311	Number intentionally skipped- case specific AZ Consolidated exhibit				
9312	Number intentionally skipped- case specific AZ Consolidated exhibit				
9313	Number intentionally skipped- case specific AZ Consolidated exhibit				

121

[illegible]

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9479	Number intentionally skipped- case specific AZ Consolidated exhibit				
9480	Darren Hurst, 9/13/18 deposition exhibit 1			401; 402; 403; 801; 802	
9481	Darren Hurst, 9/13/18 deposition exhibit 2			401; 402; 403; 801; 802	
9482	Darren Hurst, 9/13/18 deposition exhibit 3			401; 402; 403; 801; 802	
9483	Darren Hurst, 9/13/18 deposition exhibit 4			401; 402; 403; 801; 802	
9484	Darren Hurst, 9/13/18 deposition exhibit 5			401; 402; 403; 801; 802	
9485	Darren Hurst, 9/13/18 deposition exhibit 6			401; 402; 403; 801; 802	
9486	Derek Muehrcke, 10/18/18 deposition exhibit 01			401; 402; 403; 801; 802	
9487	Derek Muehrcke, 10/18/18 deposition exhibit 02			401; 402; 403; 801; 802	
9488	Derek Muehrcke, 10/18/18 deposition exhibit 03			401; 402; 403; 801; 802	
9489	Derek Muehrcke, 10/18/18 deposition exhibit 04			401; 402; 403; 801; 802	
9490	Derek Muehrcke, 10/18/18 deposition exhibit 05			401; 402; 403; 801; 802	
9491	Derek Muehrcke, 10/18/18 deposition exhibit 06			401; 402; 403; 801; 802	
9492	Derek Muehrcke, 10/18/18 deposition exhibit 07			401; 402; 403; 801; 802	
9493	Lora White, 10/11/18 deposition exhibit 1			401; 402; 403; 801; 802	
9494	Lora White, 10/11/18 deposition exhibit 2			401; 402; 403; 801; 802	
9495	Lora White, 10/11/18 deposition exhibit 3			401; 402; 403; 801; 802	
9496	Lora White, 10/11/18 deposition exhibit 4			401; 402; 403; 801; 802	
9497	Lora White, 10/11/18 deposition exhibit 5			401; 402; 403; 801; 802	
9498	Lora White, 10/11/18 deposition exhibit 6			401; 402; 403; 801; 802	
9499	Lora White, 10/11/18 deposition exhibit 7			401; 402; 403; 801; 802	
9500	Lora White, 10/11/18 deposition exhibit 8			401; 402; 403; 801; 802	
9501	Number intentionally skipped- case specific AZ Consolidated exhibit				
9502	Number intentionally skipped- case specific AZ Consolidated exhibit				
9503	Number intentionally skipped- case specific AZ Consolidated exhibit				
9504	Number intentionally skipped- case specific AZ Consolidated exhibit				
9505	Number intentionally skipped- case specific AZ Consolidated exhibit				
9506	Number intentionally skipped- case specific AZ Consolidated exhibit				
9507	Number intentionally skipped- case specific AZ Consolidated exhibit				
9508	Number intentionally skipped- case specific AZ Consolidated exhibit				
9509	Number intentionally skipped- case specific AZ Consolidated exhibit				
9510	Number intentionally skipped- case specific AZ Consolidated exhibit				
9511	Number intentionally skipped- case specific AZ Consolidated exhibit				
9512	Number intentionally skipped- case specific AZ Consolidated exhibit				
9513	Number intentionally skipped- case specific AZ Consolidated exhibit				
9514	Number intentionally skipped- case specific AZ Consolidated exhibit				
9515	Number intentionally skipped- case specific AZ Consolidated exhibit				
9516	Number intentionally skipped- case specific AZ Consolidated exhibit				
9517	Number intentionally skipped- case specific AZ Consolidated exhibit				
9518	Number intentionally skipped- case specific AZ Consolidated exhibit				
9519	Number intentionally skipped- case specific AZ Consolidated exhibit				
9520	Number intentionally skipped- case specific AZ Consolidated exhibit				
9521	Number intentionally skipped- case specific AZ Consolidated exhibit				
9522	Number intentionally skipped- case specific AZ Consolidated exhibit				
9523	Number intentionally skipped- case specific AZ Consolidated exhibit				
9524	Number intentionally skipped- case specific AZ Consolidated exhibit				
9525	Number intentionally skipped- case specific AZ Consolidated exhibit				
9526	Number intentionally skipped- case specific AZ Consolidated exhibit				
9527	Number intentionally skipped- case specific AZ Consolidated exhibit				
9528	Number intentionally skipped- case specific AZ Consolidated exhibit				
9529	Number intentionally skipped- case specific AZ Consolidated exhibit				
9530	Number intentionally skipped- case specific AZ Consolidated exhibit				
9531	Number intentionally skipped- case specific AZ Consolidated exhibit				
9532	Number intentionally skipped- case specific AZ Consolidated exhibit				
9533	Exhibit Placeholder				

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9534	Exhibit Placeholder				
9535	Exhibit Placeholder				
9536	Exhibit Placeholder				
9537	Exhibit Placeholder				
9538	Exhibit Placeholder				
9539	Exhibit Placeholder				
9540	Exhibit Placeholder				
9541	Exhibit Placeholder				
9542	Exhibit Placeholder				
9543	Exhibit Placeholder				
9544	Exhibit Placeholder				
9545	Exhibit Placeholder				
9546	Exhibit Placeholder				
9547	Exhibit Placeholder				
9548	Exhibit Placeholder				
9549	Exhibit Placeholder				
9550	Exhibit Placeholder				
9551	Exhibit Placeholder				
9552	Exhibit Placeholder				
9553	Exhibit Placeholder				
9554	Exhibit Placeholder				
9555	Exhibit Placeholder				
9556	Exhibit Placeholder				
9557	Exhibit Placeholder				
9558	Exhibit Placeholder				
9559	Exhibit Placeholder				
9560	Exhibit Placeholder				
9561	Derek Muehrcke, 1/11/19 deposition Exhibit 01 (Tinlin, Debra Ann)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9562	Derek Muehrcke, 1/11/19 deposition Exhibit 01 (Tabb, Alice)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9563	Derek Muehrcke, 1/11/19 deposition Exhibit 02 (Tinlin, Debra Ann)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9564	Derek Muehrcke, 1/11/19 deposition Exhibit 02 (Tabb, Alice)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9565	Derek Muehrcke, 1/11/19 deposition Exhibit 03 (Tabb, Alice)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9566	Derek Muehrcke, 1/11/19 deposition Exhibit 03 (Tinlin, Debra Ann)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9567	Derek Muehrcke, 1/11/19 deposition Exhibit 04 (Tabb, Alice)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9568	Derek Muehrcke, 1/11/19 deposition Exhibit 04 (Tinlin, Debra Ann)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9569	Derek Muehrcke, 1/11/19 deposition Exhibit 05 (Tabb, Alice)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9570	Derek Muehrcke, 1/11/19 deposition Exhibit 05 (Tinlin, Debra Ann)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9571	Derek Muehrcke, 1/11/19 deposition Exhibit 06 (Tinlin, Debra Ann)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9572	Derek Muehrcke, 1/11/19 deposition Exhibit 07 (Tinlin, Debra Ann)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9573	Derek Muehrcke, 1/11/19 deposition Exhibit 08 (Tinlin, Debra Ann)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9574	Derek Muehrcke, 1/11/19 deposition Exhibit 10 (Tinlin, Debra Ann)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9575	Derek Muehrcke, 1/11/19 deposition Exhibit 13 (Tinlin, Debra Ann)			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9576	Derek Muehrcke, 3/16/19 deposition Exhibit 1			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9577	Derek Muehrcke, 3/16/19 deposition Exhibit 2			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9578	Derek Muehrcke, 3/16/19 deposition Exhibit 3			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9579	Derek Muehrcke, 3/16/19 deposition Exhibit 4			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9580	Derek Muehrcke, 3/16/19 deposition Exhibit 5			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9581	Derek Muehrcke, 3/16/19 deposition Exhibit 6			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9582	Robert McMeeking, 1/30/19 deposition Exhibit 1			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9583	Robert McMeeking, 1/30/19 deposition Exhibit 2			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9584	Robert McMeeking, 1/30/19 deposition Exhibit 3			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9585	Robert McMeeking, 1/30/19 deposition Exhibit 4			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9586	Robert McMeeking, 1/31/19 deposition Exhibit 1			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9587	Robert McMeeking, 1/31/19 deposition Exhibit 2			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9588	Robert McMeeking, 1/31/19 deposition Exhibit 3			401; 402; 403; 801; 802	401; 402; 403; 801; 802

[illegible]

[illegible]

127

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9754	Stanko, Heather, MD 1/22/2019 deposition exhibit 17			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9755	Stanko, Heather, MD 1/22/2019 deposition exhibit 18			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9756	Stanko, Heather, MD 1/22/2019 deposition exhibit 19			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9757	Stanko, Heather, MD 1/22/2019 deposition exhibit 20			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9758	Stanko, Heather, MD 1/22/2019 deposition exhibit 21			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9759	Stanko, Heather, MD 1/22/2019 deposition exhibit 22			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9760	Demonstrative based on Dr. Morris's Expert Report Appendix 1			Plaintiffs reserve the right to object until the demonstrative is produced.	
9761	Demonstrative based on Dr. Morris's Expert Report Appendix 2			Plaintiffs reserve the right to object until the demonstrative is produced.	
9762	Demonstrative based on Dr. Morris's Expert Report Appendix 3			Plaintiffs reserve the right to object until the demonstrative is produced.	
9763	Demonstrative based on Dr. Morris's Expert Report Appendix 4			Plaintiffs reserve the right to object until the demonstrative is produced.	
9764	Demonstrative based on Dr. Morris's Expert Report Appendix 5			Plaintiffs reserve the right to	
9765	Demonstrative based on Dr. Morris's Expert Report Appendix 6			Plaintiffs reserve the right to object until the demonstrative is produced.	
9766	Demonstrative based on Dr. Morris's Expert Report Appendix 7			Plaintiffs reserve the right to object until the demonstrative is produced.	
9767	Demonstrative based on Dr. Morris's Expert Report Appendix 8			Plaintiffs reserve the right to object until the demonstrative is produced.	
9768	Bard's Motion in Limine No. 3 re Crisis Communication Plan Exhibit A			401; 402; 403; 801; 802, subject to Court's rulings	401; 402; 403; 801; 802
9769	Bard's Motion in Limine No. 3 re Crisis Communication Plan Exhibit B			401; 402; 403; 801; 802, subject to Court's rulings	401; 402; 403; 801; 802
9770	Plaintiff's Motion to Permit Tinlin to Appear Remotely Exhibit A			401; 402; 403; 801; 802, subject to Court's rulings	401; 402; 403; 801; 802
9771	Plaintiff's Motion to Permit Tinlin to Appear Remotely Exhibit B			401; 402; 403; 801; 802, subject to Court's rulings	401; 402; 403; 801; 802
9772	Demonstrative and/or exemplar of arms up Recovery prototype			401; 402; 403; 801; 802	
9773	Photograph of arms up Recovery prototype			401; 402; 403; 801; 802	
9774	NMT RNF Memo re Removable Filter Concepts (Prototypes)		BPV-17-01-00070688	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9775	ETR-02-06-02 - July 9, 2002, Failure Investigation Report Asch Fracture	BPV-17-01-00052601	BPV-17-01-00052615	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9776	HHE re RNF Migration - March 10, 2004	BPV-17-01-00171302	BPV-17-01-00171313	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9777	SPA-04-03-01 - March 26, 2004, Remedial Action Plan	BPV-17-01-00153654	BPV-17-01-00153772	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9778	SPA-04-04-02 - April 21, 2004, Remedial Action Plan	BPV-17-01-00153134	BPV-17-01-00153204	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9779	HHE re RNF Migration - April 27, 2004	BPV-17-01-00153179	BPV-17-01-00153191	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9780	SPA-04-05-01 - July 13, 2004, Remedial Action Plan	BPV-17-01-00153496	BPV-17-01-00153577	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9781	Updated HHE re RNF Migration - June 30, 2004	BPV-17-01-00152880	BPV-17-01-00152883	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9782	SPA-04-05-01 - June 30, 2004, Remedial Action Plan	BPV-17-01-00152929	BPV-17-01-00152935	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9783	HHE re RNF Fractures - July 9, 2004	BPV-17-01-00002145	BPV-17-01-00002148	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9784	SPA-04-04-01 - July 12, 2004, Remedial Action Plan Fracture	BPV-17-01-00002137	BPV-17-01-00002148	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9785	SPA-04-05-01 - July 13, 2004, Remedial Action Plan	BPV-17-01-00153496	BPV-17-01-00153577	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9786	SPA-04-04-01 - Sept. 2, 2004, Remedial Action Plan Fracture	BPV-17-01-00034860	BPV-17-01-00034887	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9787	FIR-04-09-02 - Sept. 22, 2004, Failure Investigation Report	BPV-17-01-00164624	BPV-17-01-00164662	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9788	FIR-04-09-01 - Sept. 24, 2004, Failure Investigation Report Fracture	BPV-17-01-00034657	BPV-17-01-00034855	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9789	FIR-04-10-01 - Oct. 12, 2004, Failure Investigation Report	BPV-17-01-00152963	BPV-17-01-00152971	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9790	Updated HHE re RNF Fractures - Nov. 17, 2004	BPV-17-01-00103875	BPV-17-01-00103878	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9791	HHE re Migration - Dec. 17, 2004	BPV-17-01-00141950	BPV-17-01-00141954	401; 402; 403; 801; 802	401; 402; 403; 801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9792	SPA-04-12-01 - Jan. 4, 2005, Remedial Action Plan	BPV-17-01-00154954	BPV-17-01-00155012	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9793	FIR-04-11-03 - Jan. 11, 2005, Failure Investigation Report	BPVE-01-01545070	BPVE-01-01545076	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9794	FIR-04-12-01 - Feb. 7, 2005, Failure Investigation Report	BPVEFILTER-01-00004139	BPVEFILTER-01-000041396	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9795	FIR-04-12-02 - Feb. 7, 2005, Failure Investigation Report	BPVEFILTER-01-00004179	BPVEFILTER-01-00004186	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9796	SPA-04-12-01 Amendment - March 10, 2005, Remedial Action Plan	BPV-17-01-00153233	BPV-17-01-00153494	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9797	SPA-04-12-01 Amendment 2 - Sept. 15, 2005, Remedial Action Plan	BPV-17-01-00034857	BPV-17-01-00034858	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9798	SPA-04-04-01 - Feb. 27, 2006, Revised Remedial Action Plan Fracture	BPV-17-01-00101586	BPV-17-01-00101587	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9799	Complaint MDR - Feb. 9, 2004, First Migration Death Report	BPV-COMP-00004516	BPV-COMP-00004549	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9800	Complaint MDR - Apr. 14, 2004, Second Migration Death Report	BPV-COMP-00000173	BPV-COMP-00000193	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9801	Complaint MDR - May 10, 2004, Third Migration Death Report	BPV-COMP-00000310	BPV-COMP-00000365	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9802	Complaint MDR - June 8, 2004, Fourth Migration Death Report	BPV-COMP-00000593	BPV-COMP-00000629	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9803	Complaint MDR - July 29, 2004, Fifth Migration Death Report	BPV-COMP-00000900	BPV-COMP-00000935	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9804	Complaint MDR - Aug. 23, 2004, Sixth Migration Death Report	BPV-COMP-00001040	BPV-COMP-00001055	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9805	Complaint MDR - Sept. 16, 2004, Seventh Migration Death Report	BPV-COMP-00001193	BPV-COMP-00001226	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9806	Complaint MDR - Nov. 17, 2004, Eighth Migration Death Report	BPV-COMP-00001481	BPV-COMP-00001579	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9807	Complaint MDR - Dec. 4, 2004, Ninth Migration Death Report	BPV-COMP-00001641	BPV-COMP-00001669	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9808	Filter Weekly Complaint Review	BPVEFILTER-30-00008370	BPVEFILTER-30-00008381	401; 402; 403; 801; 802	401; 402; 403; 801; 802
9809	FDA's guidance "Format for Traditional and Abbreviated 510(k)s" (August 12,			401; 402; 403; 801; 802	401; 402; 403; 801; 802
9810	Demonstrative depiction of IFU			Plaintiffs reserve the right to object until the demonstrative is produced.	
9811	Demonstrative depiction of Dear Doctor Letter Delivery			Plaintiffs reserve the right to object until the demonstrative is produced.	
9812	Demonstrative depiction of timeline of plaintiff's relevant medical events			Plaintiffs reserve the right to object until the demonstrative is produced.	
9813	Demonstrative depiction of the plaintiff's IVC filter at placement			Plaintiffs reserve the right to object until the demonstrative is produced.	
9814	Demonstrative depiction of the plaintiff's IVC filter at retrieval attempt			Plaintiffs reserve the right to object until the demonstrative is produced.	
9815	Demonstrative depiction of the plaintiff's IVC filter in 2005			Plaintiffs reserve the right to object until the demonstrative is produced.	
9816	Demonstrative depiction of the plaintiff's IVC filter in 2006			Plaintiffs reserve the right to object until the demonstrative is produced.	
9817	Demonstrative depiction of the plaintiff's IVC filter in 2007			Plaintiffs reserve the right to object until the demonstrative is produced.	
9818	Demonstrative depiction of the plaintiff's IVC filter and/or fragment in 2008			Plaintiffs reserve the right to object until the demonstrative is produced.	
9819	Demonstrative depiction of the plaintiff's IVC filter and/or fragment in 2009			Plaintiffs reserve the right to object until the demonstrative is produced.	
9820	Demonstrative depiction of the plaintiff's IVC filter and/or fragment in 2010			Plaintiffs reserve the right to object until the demonstrative is produced.	
9821	Demonstrative depiction of the plaintiff's IVC filter and/or fragment in 2011			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9822	Demonstrative depiction of the plaintiff's IVC filter and/or fragment in 2012			Plaintiffs reserve the right to object until the demonstrative is produced.	
9823	Demonstrative depiction of the plaintiff's IVC filter and/or fragment in 2013			Plaintiffs reserve the right to object until the demonstrative is produced.	
9824	Demonstrative depiction of the plaintiff's heart surgery			Plaintiffs reserve the right to object until the demonstrative is produced.	
9825	Demonstrative depiction of the plaintiff's IVC filter in 2014			Plaintiffs reserve the right to object until the demonstrative is produced.	
9826	Demonstrative depiction of the plaintiff's IVC filter in 2015			Plaintiffs reserve the right to object until the demonstrative is produced.	
9827	Demonstrative depiction of the plaintiff's IVC filter in 2016			Plaintiffs reserve the right to object until the demonstrative is produced.	
9828	Demonstrative depiction of the plaintiff's IVC filter in 2017			Plaintiffs reserve the right to object until the demonstrative is produced.	
9829	Demonstrative depiction of the plaintiff's IVC filter in 2018			Plaintiffs reserve the right to object until the demonstrative is produced.	
9830	Demonstrative depiction of the plaintiff's IVC filter in 2019			Plaintiffs reserve the right to object until the demonstrative is produced.	
9831	Demonstrative depiction of the plaintiff's heart at different times			Plaintiffs reserve the right to object until the demonstrative is produced.	
9832	Demonstrative depiction of the procedure to remove the plaintiff's filter strut			Plaintiffs reserve the right to object until the demonstrative is produced.	
9833	Demonstrative depiction of timeline of plaintiff's relevant medical events			Plaintiffs reserve the right to object until the demonstrative is produced.	
9834	Demonstrative regarding timeline of the plaintiff's medical course			Plaintiffs reserve the right to object until the demonstrative is produced.	
9835	Demonstrative depiction of Ms. Tinlin's 05/04/05 CTA chest PE protocol			Plaintiffs reserve the right to object until the demonstrative is produced.	
9836	Demonstrative depiction of Ms. Tinlin's 05/07/05 IVCF placement			Plaintiffs reserve the right to object until the demonstrative is produced.	
9837	Demonstrative depiction of Ms. Tinlin's 05/08/05 Abdominal and pelvic CT Scan			Plaintiffs reserve the right to object until the demonstrative is produced.	
9838	Demonstrative depiction of Ms. Tinlin's 05/09/05 CT scan of lumbar spine			Plaintiffs reserve the right to object until the demonstrative is produced.	
9839	Demonstrative depiction of Ms. Tinlin's 05/26/05 PA and lateral chest radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9840	Demonstrative depiction of Ms. Tinlin's 06/28/05 PA and lateral chest radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9841	Demonstrative depiction of Ms. Tinlin's 10/31/05 PA and lateral chest radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9842	Demonstrative depiction of Ms. Tinlin's 01/27/06 Thoracic and lumbar spine radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9843	Demonstrative depiction of Ms. Tinlin's 01/30/06 Pelvis radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9844	Demonstrative depiction of Ms. Tinlin's 07/27/06 CT scan of chest with intravenous contrast media enhancement			Plaintiffs reserve the right to object until the demonstrative is produced.	
9845	Demonstrative depiction of Ms. Tinlin's 09/26/06 PA and lateral chest radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9846	Demonstrative depiction of Ms. Tinlin's 10/27/06 CT scan and chest with intravenous contrast media enhancement			Plaintiffs reserve the right to object until the demonstrative is produced.	
9847	Demonstrative depiction of Ms. Tinlin's 2/23/07 AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9848	Demonstrative depiction of Ms. Tinlin's 4/5/07 PA and lateral chest radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9849	Demonstrative depiction of Ms. Tinlin's 6/11/07 Abdominal radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9850	Demonstrative depiction of Ms. Tinlin's 4/15/08 PA and lateral chest radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9851	Demonstrative depiction of Ms. Tinlin's 4/15/08 CT scan of the chest without iodinated contrast media enhancement			Plaintiffs reserve the right to object until the demonstrative is produced.	
9852	Demonstrative depiction of Ms. Tinlin's 4/10/09 Lumbar spine radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9853	Demonstrative depiction of Ms. Tinlin's 3/25/11 AP and lateral cervical spine radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9854	Demonstrative depiction of Ms. Tinlin's 2/3/12 AP abdominal radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9855	Demonstrative depiction of Ms. Tinlin's 2/7/12 CT scan of abdomen and pelvis with intravenous contrast media enhancement			Plaintiffs reserve the right to object until the demonstrative is produced.	
9856	Demonstrative depiction of Ms. Tinlin's 6/10/13 Cardiac Catheterization			Plaintiffs reserve the right to object until the demonstrative is produced.	
9857	Demonstrative depiction of Ms. Tinlin's 6/10/13 CT angiogram of the chest (PE study protocol)			Plaintiffs reserve the right to object until the demonstrative is produced.	
9858	Demonstrative depiction of Ms. Tinlin's 6/10/13 11:37 hours AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9859	Demonstrative depiction of Ms. Tinlin's 6/10/13 Abdominal radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9860	Demonstrative depiction of Ms. Tinlin's 6/10/13 14:12 hours AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9861	Demonstrative depiction of Ms. Tinlin's 6/11/13 05:11 hours AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9862	Demonstrative depiction of Ms. Tinlin's 6/11/13 12:42 hours AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9863	Demonstrative depiction of Ms. Tinlin's 6/12/13 0510 hours AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9864	Demonstrative depiction of Ms. Tinlin's 6/12/13 Abdominal radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9865	Demonstrative depiction of Ms. Tinlin's 6/13/13 AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9866	Demonstrative depiction of Ms. Tinlin's 6/13/13 Duplex ultrasound of bilateral lower extremities			Plaintiffs reserve the right to object until the demonstrative is produced.	
9867	Demonstrative depiction of Ms. Tinlin's 6/14/13 0505 hours AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9868	Demonstrative depiction of Ms. Tinlin's 6/14/13 1734 hours Abdominal radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9869	Demonstrative depiction of Ms. Tinlin's 6/14/13 1824 hours Abdominal radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9870	Demonstrative depiction of Ms. Tinlin's 6/14/13 2040 hours Abdominal radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9871	Demonstrative depiction of Ms. Tinlin's 6/15/13 0524 hours AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9872	Demonstrative depiction of Ms. Tinlin's 6/16/13 AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9873	Demonstrative depiction of Ms. Tinlin's 6/17/13 AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9874	Demonstrative depiction of Ms. Tinlin's 7/3/13 PA and lateral chest radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9875	Demonstrative depiction of Ms. Tinlin's 7/29/13 PA and lateral chest radiographs (2 views only)			Plaintiffs reserve the right to object until the demonstrative is produced.	
9876	Demonstrative depiction of Ms. Tinlin's 7/30/13 AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9877	Demonstrative depiction of Ms. Tinlin's 7/31/13 AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9878	Demonstrative depiction of Ms. Tinlin's 8/1/13 AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9879	Demonstrative depiction of Ms. Tinlin's 8/2/13 AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9880	Demonstrative depiction of Ms. Tinlin's 8/4/13 AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9881	Demonstrative depiction of Ms. Tinlin's 8/5/13 AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9882	Demonstrative depiction of Ms. Tinlin's 8/6/13 AP chest radiograph			Plaintiffs reserve the right to object until the demonstrative is produced.	
9883	Demonstrative depiction of Ms. Tinlin's 8/7/13 CT angiogram of chest			Plaintiffs reserve the right to object until the demonstrative is produced.	
9884	Demonstrative depiction of Ms. Tinlin's 8/22/13 PA and lateral chest radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9885	Demonstrative depiction of Ms. Tinlin's 8/22/13 CT angiogram of the chest (PE protocol)			Plaintiffs reserve the right to object until the demonstrative is produced.	
9886	Demonstrative depiction of Ms. Tinlin's 10/23/13 CT scan of chest without contrast media enhancement (5 mm thick sections)			Plaintiffs reserve the right to object until the demonstrative is produced.	
9887	Demonstrative depiction of Ms. Tinlin's 11/11/13 PA and lateral chest radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9888	Demonstrative depiction of Ms. Tinlin's 11/11/13 CT scan of chest without contrast media enhancement (5 mm thick sections)			Plaintiffs reserve the right to object until the demonstrative is produced.	
9889	Demonstrative depiction of Ms. Tinlin's 3/12/14 CT scan of chest without contrast media enhancement (5 mm thick sections)			Plaintiffs reserve the right to object until the demonstrative is produced.	
9890	Demonstrative depiction of Ms. Tinlin's 7/17/14 CT scan of neck with contrast media enhancement (2 mm thick sections)			Plaintiffs reserve the right to object until the demonstrative is produced.	
9891	Demonstrative depiction of Ms. Tinlin's 8/5/14 CT scan of chest with contrast media enhancement (PE protocol) (5 mm thick sections)			Plaintiffs reserve the right to object until the demonstrative is produced.	
9892	Demonstrative depiction of Ms. Tinlin's 12/10/14 PA and lateral chest radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9893	Demonstrative depiction of Ms. Tinlin's 8/19/15 CT scan of abdomen and pelvis without contrast media enhancement (5 mm thick sections)			Plaintiffs reserve the right to object until the demonstrative is produced.	
9894	Demonstrative depiction of Ms. Tinlin's 12/3/15 PA and lateral chest radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9895	Demonstrative depiction of Ms. Tinlin's 12/16/15 Sternoclavicular joint radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9896	Demonstrative depiction of Ms. Tinlin's 2/26/16 Right shoulder radiographs			Plaintiffs reserve the right to object until the demonstrative is produced.	
9897	Demonstrative depiction of Ms. Tinlin's 10/18/16 CT scan of chest without contrast media enhancement (5 mm thick sections)			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9898	Demonstrative depiction of Ms. Tinlin's 2/14/17 PA and lateral chest			Plaintiffs reserve the right to object until the demonstrative is produced.	
9899	Demonstrative depiction of Ms. Tinlin's 3/29/18 Endoscopic retrograde cholangiopancreatography (ERCP)			Plaintiffs reserve the right to object until the demonstrative is produced.	
9900	Demonstrative depiction of Ms. Tinlin's 3/29/18 AP chest			Plaintiffs reserve the right to object until the demonstrative is produced.	
9901	Demonstrative depiction of Ms. Tinlin's 3/29/18 CT abdomen and pelvis with contrast media enhancement			Plaintiffs reserve the right to object until the demonstrative is produced.	
9902	Demonstrative depiction of Ms. Tinlin's 8/29/18 PA and lateral chest			Plaintiffs reserve the right to object until the demonstrative is produced.	
9903	Plaintiff Profile Form and accompanying medical records, served 3/26/16			401; 402; 403	401; 402; 403; 801; 802
9904	Plaintiff Fact Sheet and accompanying documents, served 7/29/16			401; 402; 403	401; 402; 403; 801; 802
9905	Defense Profile Form and accompanying documents, served 4/27/206	DPF_TinlinD_CV-16-000001	DPF_TinlinD_CV-16-000015	401; 402; 403	401; 402; 403; 801; 802
9906	Defense Fact Sheet served 8/29/2016			401; 402; 403	401; 402; 403; 801; 802
9907	Bard complaint file- produce with DFS	DFS_TinlinD_CV-16-000001	DFS_TinlinD_CV-16-000019	401; 402; 403	401; 402; 403; 801; 802
9908	Sales rep information- produced with DFS	DFS_TinlinD_CV-16-000020	DFS_TinlinD_CV-16-000022	401; 402; 403	401; 402; 403; 801; 802
9909	Sales rep information- produced with DFS	DFS_TinlinD_CV-16-000023	DFS_TinlinD_CV-16-000026	401; 402; 403	401; 402; 403; 801; 802
9910	Physician search information- produced with DFS	DFS_TinlinD_CV-16-000027	DFS_TinlinD_CV-16-000027	401; 402; 403	401; 402; 403; 801; 802
9911	Sales history- produced with DFS	DFS_TinlinD_CV-16-000028	DFS_TinlinD_CV-16-000028	401; 402; 403	401; 402; 403; 801; 802
9912	Social media- Ms Tinlin			401; 402; 403	
9913	Social media- Mr Tinlin			401; 402; 403	
9914	Tinlin Expert report of Dr Brauer			401; 402; 403	
9915	Tinlin Expert report of Dr Briant			401; 402; 403	
9916	Tinlin Expert report of Dr Fasching			401; 402; 403	
9917	Tinlin Expert report of Dr Miller			401; 402; 403	
9918	Tinlin Expert report of Dr Morris			401; 402; 403	
9919	Tinlin Expert report of Dr Owens			401; 402; 403	
9920	Tinlin Expert report of Dr Sobieczczyk			401; 402; 403	
9921	Tinlin Expert report of Dr Tillman			401; 402; 403	
9922	Expert report of Dr Feigal			401; 402; 403	
9923	Expert report of Dr Thisted			401; 402; 403	
9924	Expert report of Dr Grassi			401; 402; 403	
9925	Demonstrative regarding Recovery filter for Dr. Fasching			Plaintiffs reserve the right to object until the demonstrative is produced.	
9926	Demonstrative regarding Recovery filter for Dr. Briant			Plaintiffs reserve the right to object until the demonstrative is produced.	
9927	Demonstrative regarding Recovery filter for Dr. Feigal			Plaintiffs reserve the right to object until the demonstrative is produced.	
9928	Demonstrative regarding Recovery filter for Dr. Thisted			Plaintiffs reserve the right to object until the demonstrative is produced.	
9929	Demonstrative regarding Recovery filter for Dr. Brauer			Plaintiffs reserve the right to object until the demonstrative is produced.	
9930	Demonstrative regarding Recovery filter for Dr. Tillman			Plaintiffs reserve the right to object until the demonstrative is produced.	

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9931	Demonstrative regarding Recovery filter for Dr. Morris			Plaintiffs reserve the right to object until the demonstrative is produced.	
9932	Demonstrative regarding Recovery filter for Dr. Miller			Plaintiffs reserve the right to object until the demonstrative is produced.	
9933	Demonstrative regarding Recovery filter for Dr. Owens			Plaintiffs reserve the right to object until the demonstrative is produced.	
9934	Demonstrative regarding Recovery filter for Dr. Sobiechczyk			Plaintiffs reserve the right to object until the demonstrative is produced.	
9935	Demonstrative regarding the plaintiff's medical care for Dr. Morris			Plaintiffs reserve the right to object until the demonstrative is produced.	
9936	Demonstrative regarding the plaintiff's medical care for Dr. Poll			Plaintiffs reserve the right to object until the demonstrative is produced.	
9937	Northwestern social media			401; 402; 403	
9938	Letter from Nitke regarding plaintiff's inability to travel			401; 402; 403	
9939	Letter from Stanko regarding plaintiff's inability to travel			401; 402; 403	
9940	Advanced Pain Management	TINLIND ADVPM MDR00001	TINLIND ADVPM MDR00027	401; 402; 403	801; 802
9941	Aetna U.S. Healthcare	TINLIND AUSH INS00001	TINLIND AUSH INS00151	401; 402; 403	801; 802
9942	Atrium Post Acute Care of Shawano	TINLIND APACS MDR00001	TINLIND APACS MDR00490	401; 402; 403	801; 802
9943	Aurora Bay Area - Gastroenterology	TINLIND ABAG MDR00001	TINLIND ABAG MDR00592	401; 402; 403	801; 802
9944	Aurora Bay Area Healthcare Center	TINLIND ABAHC MDR00001	TINLIND ABAHC MDR00601	401; 402; 403	801; 802
9945	Aurora BayCare Clinic Urological Surgeons	TINLIND ABAYCCUS MDR00001	TINLIND ABAYCCUS MDR00004	401; 402; 403	801; 802
9946	Aurora BayCare Health Center	TINLIND ABHC MDR00001	TINLIND ABHC MDR00039	401; 402; 403	801; 802
9947	Aurora Baycare Medical Center	TINLIND ABMC CATH00001	TINLIND ABMC CATH00001	401; 402; 403	801; 802
9948	Aurora Baycare Medical Center	TINLIND ABMC MDR00001	TINLIND ABMC MDR16654	401; 402; 403	801; 802
9949	Aurora Baycare Medical Center	TINLIND ABMC PAT00001	TINLIND ABMC PAT00001	401; 402; 403	801; 802
9950	Aurora Baycare Medical Center	TINLIND ABMC RAD00001	TINLIND ABMC RAD00106	401; 402; 403	801; 802
9951	Aurora BayCare Medical Center General and Vascular Surgery	TINLIND ABMCGVS MDR00001	TINLIND ABMCGVS MDR00152	401; 402; 403	801; 802
9952	Aurora BayCare Orthopedic & Sports Medicine Center	TINLIND ABOSMC MDR00001	TINLIND ABOSMC MDR00025	401; 402; 403	801; 802
9953	Aurora BayCare-Gastroenterology	TBD	TBD	401; 402; 403	801; 802
9954	Aurora Health Care	TINLIND AHCAR MDR00001	TINLIND AHCAR MDR02139	401; 402; 403	801; 802
9955	Aurora Health Care	TINLIND AURHC_BIL00001	TINLIND AURHC_BIL00706	401; 402; 403	801; 802
9956	Aurora Health Center Rheumatology	TINLIND AHCR MDR00001	TINLIND AHCR MDR00003	401; 402; 403	801; 802
9957	Aurora Manitowoc Clinic	TINLIND AUOMC MDR00001	TINLIND AUOMC MDR00001	401; 402; 403	801; 802
9958	Aurora Medical Group	TINLIND AURMG MDR00001	TINLIND AURMG MDR03352	401; 402; 403	801; 802
9959	Aurora Medical Group Cardiovascular and Thoracic Surgery	TINLIND AMG MDR00001	TINLIND AMG MDR00028	401; 402; 403	801; 802
9960	Aurora Medical Group Women's Center	TINLIND AMGWC MDR00001	TINLIND AMGWC_MDR00210	401; 402; 403	801; 802
9961	Aurora Sleep Medicine Center	TBD	TBD	401; 402; 403	801; 802
9962	Aurora Specialty Pharmacy #1169	TINLIND ASP_PHARM00001	TINLIND ASP_PHARM00004	401; 402; 403	801; 802
9963	Aurora St. Luke's Medical Center	TINLIND ASLMC CAD00001	TINLIND ASLMC CAD00013	401; 402; 403	801; 802
9964	Aurora St. Luke's Medical Center	TINLIND ASLMC MDR00001	TINLIND ASLMC_MDR03217	401; 402; 403	801; 802
9965	Aurora St. Luke's Medical Center	TINLIND ASLMC PAT00001	TINLIND ASLMC PAT00004	401; 402; 403	801; 802
9966	Aurora St. Luke's Medical Center	TINLIND ASLMC_RAD00001	TINLIND ASLMC_RAD00012	401; 402; 403	801; 802
9967	BayCare Clinic Ear, Nose and Throat	TINLIND BAYCCENT MDR00001	TINLIND BAYCCENT MDR00025	401; 402; 403	801; 802
9968	BayCare Clinic, LLP	TINLIND BAYCAREC MDR00001	TINLIND BAYCAREC MDR00397	401; 402; 403	801; 802
9969	BayCare Clinic, LLP	TINLIND BAYCC_BIL00001	TINLIND BAYCC_BIL00088	401; 402; 403	801; 802
9970	BayCare Clinic, LLP	TINLIND BAYCC MDR00001	TINLIND BAYCC MDR00251	401; 402; 403	801; 802
9971	Bellin Health Cardiology Associates	TINLIND BHCA_CAR00001	TINLIND BHCA_CAR00001	401; 402; 403	801; 802
9972	Centers for Medicare & Medicaid Services (CMS) (Region 5) (CMS) (Region 5)	TINLIND_CMS5_INS00001	TINLIND_CMS5_INS02538	401; 402; 403	801; 802
9973	Clement J. Zablocki VA Medical Center	TINLIND CJZVA_BIL00001	TINLIND CJZVA_BIL00001	401; 402; 403	801; 802
9974	Clement J. Zablocki VA Medical Center	TINLIND CJZVA MDR00001	TINLIND CJZVA MDR00002	401; 402; 403	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
9975	Door County Department of Human Services	TINLIND_DCDHS_MDR00001	TINLIND_DCDHS_MDR00002	401; 402; 403	801; 802
9976	Dreier Pharmacy	TINLIND_DP_PHARM00001	TINLIND_DP_PHARM000061	401; 402; 403	801; 802
9977	Froedtert Memorial Lutheran Hospital	TINLIND_FMLH_BIL00001	TINLIND_FMLH_BIL00005	401; 402; 403	801; 802
9978	Froedtert Memorial Lutheran Hospital	TINLIND_FMLH_MDR00001	TINLIND_FMLH_MDR000010	401; 402; 403	801; 802
9979	Froedtert Memorial Lutheran Hospital	TINLIND_FMLH_RAD00001	TINLIND_FMLH_RAD00002	401; 402; 403	801; 802
9980	GJB Health Services	TINLIND_GJBHS_MDR00001	TINLIND_GJBHS_MDR00002	401; 402; 403	801; 802
9981	Jo's Alternative Healing, LLC	TINLIND_JOSAH_MDR00001	TINLIND_JOSAH_MDR00001	401; 402; 403	801; 802
9982	Medical College of Wisconsin	TINLIND_MCW_MDR00001	TINLIND_MCW_MDR00152	401; 402; 403	801; 802
9983	Network Health Plan	TINLIND_NHPLAN_INS00001	TINLIND_NHPLAN_INS00052	401; 402; 403	801; 802
9984	Neurology Consultants of Bellin Health-Green Bay	TINLIND_NCBHGB_MDR00001	TINLIND_NCBHGB_MDR00045	401; 402; 403	801; 802
9985	Northwestern Interventional Radiology Department	TBD	TBD	401; 402; 403	801; 802
9986	Northwestern IVC Filter Clinic	TBD	TBD	401; 402; 403	801; 802
9987	Northwestern Memorial Hospital	TBD	TBD	401; 402; 403	801; 802
9988	Prevea Allouez Health Center	TINLIND_PAHC_MDR00001	TINLIND_PAHC_MDR02438	401; 402; 403	801; 802
9989	Prevea Ambulatory Behavioral Care	TINLIND_PABC_MDR00001	TINLIND_PABC_MDR00005	401; 402; 403	801; 802
9990	Prevea East Mason Pain and Spine Care	TINLIND_PEMPSC_MDR00001	TINLIND_PEMPSC_MDR00041	401; 402; 403	801; 802
9991	Prevea Health	TINLIND_PH_RAD00001	TINLIND_PH_RAD00025	401; 402; 403	801; 802
9992	Prevea Health Center	TINLIND_PREVEAHC_MDR00001	TINLIND_PREVEAHC_MDR00019	401; 402; 403	801; 802
9993	Prevea360 Health Plan	TINLIND_PREVHP_INS00001	TINLIND_PREVHP_INS00001	401; 402; 403	801; 802
9994	Social Security Administration	TINLIND_SOSA_SSA00001	TINLIND_SOSA_SSA00554	401; 402; 403	801; 802
9995	St. Mary's Hospital Medical Center	TINLIND_SMHMC_BIL00001	TINLIND_SMHMC_BIL00027	401; 402; 403	801; 802
9996	St. Mary's Hospital Medical Center	TINLIND_SMHMC_MDR00001	TINLIND_SMHMC_MDR00891	401; 402; 403	801; 802
9997	St. Mary's Hospital Medical Center	TINLIND_SMHMC_PAT00001	TINLIND_SMHMC_PAT00002	401; 402; 403	801; 802
9998	St. Mary's Hospital Medical Center	TINLIND_SMHMC_RAD00001	TINLIND_SMHMC_RAD00017	401; 402; 403	801; 802
9999	St. Vincent Hospital	TINLIND_STVH_BIL00001	TINLIND_STVH_BIL00062	401; 402; 403	801; 802
10000	St. Vincent Hospital	TINLIND_STVH_MDR00001	TINLIND_STVH_MDR01122	401; 402; 403	801; 802
10001	St. Vincent Hospital	TINLIND_STVH_PAT00001	TINLIND_STVH_PAT00005	401; 402; 403	801; 802
10002	St. Vincent Hospital	TINLIND_STVH_RAD00001	TINLIND_STVH_RAD00001	401; 402; 403	801; 802
10003	St. Vincent Hospital	TINLIND_STVH_RAD00001	TINLIND_STVH_RAD00010	401; 402; 403	801; 802
10004	ThedaCare Medical Center-Shawano	TINLIND_TMCS_00001	TINLIND_TMCS_00001	401; 402; 403	801; 802
10005	ThedaCare Medical Center-Shawano	TINLIND_TMCS_BIL00001	TINLIND_TMCS_BIL00007	401; 402; 403	801; 802
10006	ThedaCare Medical Center-Shawano	TINLIND_TMCS_MDR00001	TINLIND_TMCS_MDR00077	401; 402; 403	801; 802
10007	ThedaCare Pharmacy	TINLIND_TPHAR_PHARM00001	TINLIND_TPHAR_PHARM00054	401; 402; 403	801; 802
10008	ThedaCare Physicians	TINLIND_THEDACP_MDR00001	TINLIND_THEDACP_MDR00011	401; 402; 403	801; 802
10009	University of Wisconsin Pain Management Clinic	TINLIND_UWPMC_BIL00001	TINLIND_UWPMC_BIL00002	401; 402; 403	801; 802
10010	University of Wisconsin Pain Management Clinic	TINLIND_UWPMC_MDR00001	TINLIND_UWPMC_MDR00001	401; 402; 403	801; 802
10011	Walgreen Company	TINLIND_WC_PHARM00001	TINLIND_WC_PHARM00039	401; 402; 403	801; 802
10012	Wienkers, Kevin Paul, M.D.	TINLIND_KWIEN_MDR00001	TINLIND_KWIEN_MDR00122	401; 402; 403	801; 802
10013	Wisconsin Colon & Rectal Clinic	TINLIND_WCRC_BIL00001	TINLIND_WCRC_BIL00009	401; 402; 403	801; 802
10014	Wisconsin Colon & Rectal Clinic	TINLIND_WCRC_MDR00001	TINLIND_WCRC_MDR00018	401; 402; 403	801; 802
10015	Wisconsin Department of Health Services	TINLIND_WDHS_INS00001	TINLIND_WDHS_INS00146	401; 402; 403	801; 802
10016	Chest X-ray and Lung Perfusion Scan	SMHMC_MDR00309	SMHMC_MDR00309	401; 402; 403	801; 802
10017	Echocardiogram	SMHMC_MDR00310	SMHMC_MDR00311	401; 402; 403	801; 802
10018	Cardiolite Stress Test	SMHMC_MDR00320	SMHMC_MDR00323	401; 402; 403	801; 802
10019	Cardiolite Stress Test	STVH_MDR00004	STVH_MDR00005	401; 402; 403	801; 802
10020	Chest CT	STVH_MDR01113	STVH_MDR01113	401; 402; 403	801; 802
10021	Labs	STVH_MDR01114	STVH_MDR01117	401; 402; 403	801; 802
10022	Head MRI/MRA	PAHC_MDR00560	PAHC_MDR00560	401; 402; 403	801; 802
10023	Patient Questionnaire	PAHC_MDR01557	PAHC_MDR01560	401; 402; 403	801; 802
10024	Neurology Evaluation (Sluss)	PAHC_MDR01555	PAHC_MDR01556	401; 402; 403	801; 802
10025	Cervical Spine MRI	PAHC_MDR00559	PAHC_MDR00559	401; 402; 403	801; 802
10026	Physical Therapy Evaluation	PAHC_MDR01036	PAHC_MDR01037	401; 402; 403	801; 802
10027	Neurology Visit	PAHC_MDR01553	PAHC_MDR01553	401; 402; 403	801; 802
10028	Thoracic Spine MRI	PAHC_MDR00558	PAHC_MDR00558	401; 402; 403	801; 802
10029	Neurology Visit	PAHC_MDR01551	PAHC_MDR01551	401; 402; 403	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
10030	Neurology Visit	PAHC_MDR01550	PAHC_MDR01550	401; 402; 403	801; 802
10031	Internal Medicine Visit (Christel)	PAHC_MDR01412	PAHC_MDR01412	401; 402; 403	801; 802
10032	Neurology Visit	PAHC_MDR01549	PAHC_MDR01549	401; 402; 403	801; 802
10033	Internal Medicine Visit	PAHC_MDR01410	PAHC_MDR01411	401; 402; 403	801; 802
10034	Neurology Evaluation (Heather Stanko)	PAHC_MDR01545	PAHC_MDR01547	401; 402; 403	801; 802
10035	Neurology Visit	PAHC_MDR01542	PAHC_MDR01543	401; 402; 403	801; 802
10036	Neurology Visit	PAHC_MDR01540	PAHC_MDR01541	401; 402; 403	801; 802
10037	Head CT	PAHC_MDR00561	PAHC_MDR00561	401; 402; 403	801; 802
10038	Neurology Visit	PAHC_MDR01538	PAHC_MDR01539	401; 402; 403	801; 802
10039	Neurology Visit	PAHC_MDR01534	PAHC_MDR01535	401; 402; 403	801; 802
10040	Neurology Visit	PAHC_MDR01532	PAHC_MDR01533	401; 402; 403	801; 802
10041	Internal Medicine Visit	PAHC_MDR01398	PAHC_MDR01399	401; 402; 403	801; 802
10042	Neurology Visit	PAHC_MDR01529	PAHC_MDR01530	401; 402; 403	801; 802
10043	Neurology Visit	PAHC_MDR01100	PAHC_MDR01101	401; 402; 403	801; 802
10044	Gastroenterology Evaluation (Peter Stanko)	PAHC_MDR01335	PAHC_MDR01336	401; 402; 403	801; 802
10045	Neurology Visit	PAHC_MDR01097	PAHC_MDR01098	401; 402; 403	801; 802
10046	Neurology Telephone Note	PAHC_MDR01164	PAHC_MDR01164	401; 402; 403	801; 802
10047	Head MRI	PAHC_MDR01287	PAHC_MDR01287	401; 402; 403	801; 802
10048	Cervical Spine MRI	PAHC_MDR01286	PAHC_MDR01286	401; 402; 403	801; 802
10049	Thoracic Spine MRI	PAHC_MDR01288	PAHC_MDR01288	401; 402; 403	801; 802
10050	Neurology Admission Note	PAHC_MDR01310	PAHC_MDR01311	401; 402; 403	801; 802
10051	Rehabilitation Evaluation	PAHC_MDR01308	PAHC_MDR01309	401; 402; 403	801; 802
10052	Physical Therapy Evaluation	STVH_MDR00867	STVH_MDR00868	401; 402; 403	801; 802
10053	Neurology Progress Note	STVH_MDR00572	STVH_MDR00572	401; 402; 403	801; 802
10054	Discharge Summary	PAHC_MDR01306	PAHC_MDR01307	401; 402; 403	801; 802
10055	Evoked Potentials Testing	PAHC_MDR01093	PAHC_MDR01095	401; 402; 403	801; 802
10056	Physical Therapy Evaluation	PAHC_MDR01047	PAHC_MDR01048	401; 402; 403	801; 802
10057	Neurology Visit	PAHC_MDR01090	PAHC_MDR01092	401; 402; 403	801; 802
10058	Bilateral Lower Extremity Doppler	PAHC_MDR01089	PAHC_MDR01089	401; 402; 403	801; 802
10059	Internal Medicine Visit	PAHC_MDR01514	PAHC_MDR01515	401; 402; 403	801; 802
10060	ER Visit	SMHMC_MDR00075	SMHMC_MDR00076	401; 402; 403	801; 802
10061	Admission History & Physical	SMHMC_MDR00070	SMHMC_MDR00071	401; 402; 403	801; 802
10062	Physician Progress Note	SMHMC_MDR00146	SMHMC_MDR00146	401; 402; 403	801; 802
10063	Admission Interview	SMHMC_MDR194	SMHMC_MDR197	401; 402; 403	801; 802
10064	Pain Flow Sheet	SMHMC_MDR00187	SMHMC_MDR00187	401; 402; 403	801; 802
10065	Chest CTA	SMHMC_MDR00082	SMHMC_MDR00082	401; 402; 403	801; 802
10066	Bilateral Lower Extremity Doppler	SMHMC_MDR00079	SMHMC_MDR00079	401; 402; 403	801; 802
10067	Pain Flow Sheet	SMHMC_MDR00188	SMHMC_MDR00188	401; 402; 403	801; 802
10068	Echocardiogram	SMHMC_MDR00083	SMHMC_MDR00084	401; 402; 403	801; 802
10069	Pulmonary Progress Note (Bittorf)	SMHMC_MDR00140	SMHMC_MDR00140	401; 402; 403	801; 802
10070	Pulmonary Consultation (Bittorf)	SMHMC_MDR00066	SMHMC_MDR00069	401; 402; 403	801; 802
10071	Pulmonary Progress Note (Andrews)	SMHMC_MDR00139	SMHMC_MDR00139	401; 402; 403	801; 802
10072	Filter Consent	SMHMC_MDR00219	SMHMC_MDR00220	401; 402; 403	801; 802
10073	Cavagram & IVC Filter Placement (Riebe)	SMHMC_MDR00077	SMHMC_MDR00078	401; 402; 403	801; 802
10074	Physician Progress Note	SMHMC_MDR00136	SMHMC_MDR00137	401; 402; 403	801; 802
10075	Abdomen CT	SMHMC_MDR00081	SMHMC_MDR00081	401; 402; 403	801; 802
10076	Pulmonary Progress Note (Andrews)	SMHMC_MDR00136	SMHMC_MDR00136	401; 402; 403	801; 802
10077	Physician Progress Note	SMHMC_MDR00134	SMHMC_MDR00134	401; 402; 403	801; 802
10078	Lumbar Spine CT	SMHMC_MDR00080	SMHMC_MDR00080	401; 402; 403	801; 802
10079	Hematology Consultation (Volk)	SMHMC_MDR00062	SMHMC_MDR00065	401; 402; 403	801; 802
10080	Rehabilitation Consultation (Hudson)	SMHMC_MDR00057	SMHMC_MDR00059	401; 402; 403	801; 802
10081	Discharge Summary	SMHMC_MDR00055	SMHMC_MDR00056	401; 402; 403	801; 802
10082	Hematology Visit	PAHC_MDR01457 & 1329	PAHC_MDR01457 & 1329	401; 402; 403	801; 802
10083	Hematology Visit	PAHC_MDR01455 & 1328	PAHC_MDR01455 & 1328	401; 402; 403	801; 802
10084	Chest CT	SMHMC_MDR00245	SMHMC_MDR00245	401; 402; 403	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
10085	Neurology Visit	PAHC MDR01087	PAHC MDR01088	401; 402; 403	801; 802
10086	Neurology Correspondence	PAHC MDR01326	PAHC MDR01326	401; 402; 403	801; 802
10087	Internal Medicine Visit	PAHC MDR01501	PAHC MDR01502	401; 402; 403	801; 802
10088	Bilateral Lower Extremity Doppler	PAHC MDR01268	PAHC MDR01268	401; 402; 403	801; 802
10089	ER Visit	SMHMC MDR00266	SMHMC MDR00268	401; 402; 403	801; 802
10090	Sleep Study	PREVEAHC MDR00008	PREVEAHC MDR00009	401; 402; 403	801; 802
10091	Head CT	STVH MDR00369	STVH MDR00369	401; 402; 403	801; 802
10092	Admission History & Physical	PAHC MDR01292	PAHC MDR01293	401; 402; 403	801; 802
10093	Case Management Note	STVH MDR00393	STVH MDR00394	401; 402; 403	801; 802
10094	Discharge Summary	PAHC MDR01290	PAHC MDR01291	401; 402; 403	801; 802
10095	Hematology Visit	PAHC MDR01317	PAHC MDR01317	401; 402; 403	801; 802
10096	Neurology Visit	PAHC MDR01525	PAHC MDR01528	401; 402; 403	801; 802
10097	Medicaid Health Report	PAHC MDR01354	PAHC MDR01354	401; 402; 403	801; 802
10098	Neurology Visit	PAHC MDR01521	PAHC MDR01523	401; 402; 403	801; 802
10099	Physician's Statement of Disability	PAHC MDR01350	PAHC MDR01350	401; 402; 403	801; 802
10100	Gynecology Evaluation	PAHC MDR00610	PAHC MDR00613	401; 402; 403	801; 802
10101	Chest X-ray	PAHC MDR00768	PAHC MDR00768	401; 402; 403	801; 802
10102	Pre-op Clearance Visit	PAHC MDR00487	PAHC MDR00489	401; 402; 403	801; 802
10103	Neuropsychological Questionnaire	PAHC MDR00907	PAHC MDR00918	401; 402; 403	801; 802
10104	Operative Report - Hysterectomy	SMHMC MDR00884	SMHMC MDR00885	401; 402; 403	801; 802
10105	Neurology Visit	PAHC MDR00535	PAHC MDR00536	401; 402; 403	801; 802
10106	Pulmonary Visit	PAHC MDR00785	PAHC MDR00786	401; 402; 403	801; 802
10107	Neuropsychological Evaluation	PAHC MDR00538	PAHC MDR00546	401; 402; 403	801; 802
10108	Psychotherapy Evaluation	PABC MDR00002	PABC MDR00003	401; 402; 403	801; 802
10109	Neuropsychology Notes	PAHC MDR00893 & 891	PAHC MDR00893 & 891	401; 402; 403	801; 802
10110	Lumbar X-ray	PAHC MDR00762	PAHC MDR00762	401; 402; 403	801; 802
10111	ER Visit	SMHMC MDR00591	SMHMC MDR00592	401; 402; 403	801; 802
10112	ER Physician Assistant Note	SMHMC MDR00596	SMHMC MDR00597	401; 402; 403	801; 802
10113	ER Physician Note	SMHMC MDR00594	SMHMC MDR00595	401; 402; 403	801; 802
10114	Admission History & Physical	SMHMC MDR00626	SMHMC MDR00628	401; 402; 403	801; 802
10115	Admission Interview	SMHMC MDR00647	SMHMC MDR00650	401; 402; 403	801; 802
10116	Lumbar MRI	PAHC MDR00759	PAHC MDR00760	401; 402; 403	801; 802
10117	Pelvis X-ray	SMHMC MDR00743	SMHMC MDR00743	401; 402; 403	801; 802
10118	Rehabilitation Consultation	SMHMC MDR00584	SMHMC MDR00586	401; 402; 403	801; 802
10119	Discharge Summary	SMHMC MDR00588	SMHMC MDR00590	401; 402; 403	801; 802
10120	Chest CTA	SMHMC MDR00570	SMHMC MDR00570	401; 402; 403	801; 802
10121	Neurology Visit	PAHC MDR00518	PAHC MDR00520	401; 402; 403	801; 802
10122	Patient History Questionnaire	PAHC MDR01477	PAHC MDR01482	401; 402; 403	801; 802
10123	Pain Consultation	PAHC MDR01473	PAHC MDR01475	401; 402; 403	801; 802
10124	Brain MRI	PAHC MDR00583	PAHC MDR00584	401; 402; 403	801; 802
10125	Neurology Progress Note	STVH MDR00154	STVH MDR00154	401; 402; 403	801; 802
10126	Case Management Note	STVH MDR00196	STVH MDR00196	401; 402; 403	801; 802
10127	Discharge Summary	STVH MDR00144	STVH MDR00145	401; 402; 403	801; 802
10128	Neurology Visit	PAHC MDR00516	PAHC MDR00517	401; 402; 403	801; 802
10129	Internal Medicine Visit	PAHC MDR00468	PAHC MDR00469	401; 402; 403	801; 802
10130	Lumbar Spine MRI	ADVPM MDR00017	ADVPM MDR00018	401; 402; 403	801; 802
10131	Internal Medicine Visit	PAHC MDR00464	PAHC MDR00466	401; 402; 403	801; 802
10132	ER Visit	SMHMC MDR00547	SMHMC MDR00548	401; 402; 403	801; 802
10133	Neurology Evaluation (Bannasch)	PAHC MDR00514	PAHC MDR00515	401; 402; 403	801; 802
10134	Brain MRI	PAHC MDR00747	PAHC MDR00749	401; 402; 403	801; 802
10135	Surgical Evaluation (Seccombe)	PAHC MDR00498	PAHC MDR00501	401; 402; 403	801; 802
10136	Internal Medicine Visit	PAHC MDR00457	PAHC MDR00458	401; 402; 403	801; 802
10137	Neurology Visit	PAHC MDR00512	PAHC MDR00512	401; 402; 403	801; 802
10138	Chest CT	PAHC MDR00735	PAHC MDR00735	401; 402; 403	801; 802
10139	Telephone Note	PAHC MDR00208	PAHC MDR00208	401; 402; 403	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
10140	Telephone Note	PAHC_MDR00209	PAHC_MDR00209	401; 402; 403	801; 802
10141	Neurology Evaluation (Woo)	PAHC_MDR000070	PAHC_MDR000077	401; 402; 403	801; 802
10142	Chest X-ray	SMHMC_MDR00530	SMHMC_MDR00530	401; 402; 403	801; 802
10143	Chest X-ray	SMHMC_MDR00531	SMHMC_MDR00531	401; 402; 403	801; 802
10144	Discharge Summary	SMHMC_MDR00444	SMHMC_MDR00445	401; 402; 403	801; 802
10145	Internal Medicine Visit	PAHC_MDR00258	PAHC_MDR00258	401; 402; 403	801; 802
10146	Pain Management Visit	PAHC_MDR00266	PAHC_MDR00266	401; 402; 403	801; 802
10147	Abdomen X-ray	SMHMC_MDR00436	SMHMC_MDR00436	401; 402; 403	801; 802
10148	Chest X-ray	SMHMC_MDR00437	SMHMC_MDR00437	401; 402; 403	801; 802
10149	Labs	SMHMC_MDR00370	SMHMC_MDR00370	401; 402; 403	801; 802
10150	Echocardiogram	SMHMC_MDR00340	SMHMC_MDR00343	401; 402; 403	801; 802
10151	Discharge Summary	SMHMC_MDR00350	SMHMC_MDR00352	401; 402; 403	801; 802
10152	Pain Management Visit	PAHC_MDR00312	PAHC_MDR00313	401; 402; 403	801; 802
10153	Pain Management Evaluation (Rudin)	PAHC_MDR00100	PAHC_MDR00103	401; 402; 403	801; 802
10154	Neurology Evaluation (Teetzen)	AHCAR_MDR00255	AHCAR_MDR00258	401; 402; 403	801; 802
10155	Neurology Visit	AHCAR_MDR00250	AHCAR_MDR00251	401; 402; 403	801; 802
10156	Internal Medicine Visit	PAHC_MDR00351	PAHC_MDR00353	401; 402; 403	801; 802
10157	Pain Management Evaluation (Neuman)	PEMPSC_MDR00008	PEMPSC_MDR00010	401; 402; 403	801; 802
10158	Neurology Visit	AHCAR_MDR00244	AHCAR_MDR00245	401; 402; 403	801; 802
10159	Neurology Visit	AHCAR_MDR00239	AHCAR_MDR00240	401; 402; 403	801; 802
10160	Telephone Note	PEMPSC_MDR00013	PEMPSC_MDR00013	401; 402; 403	801; 802
10161	Telephone Notes	PEMPSC_MDR00014	PEMPSC_MDR00016	401; 402; 403	801; 802
10162	Neurology Visit	AHCAR_MDR00232	AHCAR_MDR00233	401; 402; 403	801; 802
10163	Pulmonary Evaluation (Gapinski)	AHCAR_MDR00229	AHCAR_MDR00231	401; 402; 403	801; 802
10164	Lumbar Spine MRI	PAHC_MDR00015	PAHC_MDR00016	401; 402; 403	801; 802
10165	Pulmonary Function Test	ABMC_MDR07250	ABMC_MDR07250	401; 402; 403	801; 802
10166	Chest CT	ABMC_MDR07248	ABMC_MDR07248	401; 402; 403	801; 802
10167	Chest X-ray	ABMC_MDR07247	ABMC_MDR07247	401; 402; 403	801; 802
10168	Neurology Visit	AHCAR_MDR00220	AHCAR_MDR00221	401; 402; 403	801; 802
10169	Neurology Visit	AHCAR_MDR00215	AHCAR_MDR00216	401; 402; 403	801; 802
10170	Neurology Visit	AHCAR_MDR00210	AHCAR_MDR00211	401; 402; 403	801; 802
10171	Pain Management Visit	PEMPSC_MDR00019	PEMPSC_MDR00020	401; 402; 403	801; 802
10172	Primary Care Visit (Nitke)	AURMG_MDR00002	AURMG_MDR00004	401; 402; 403	801; 802
10173	Neurology Visit	AHCAR_MDR00205	AHCAR_MDR00206	401; 402; 403	801; 802
10174	Neurology Visit	AHCAR_MDR00198	AHCAR_MDR00200	401; 402; 403	801; 802
10175	Pain Management Note	PEMPSC_MDR00022	PEMPSC_MDR00022	401; 402; 403	801; 802
10176	Pain Management Note	PEMPSC_MDR00025	PEMPSC_MDR00026	401; 402; 403	801; 802
10177	Primary Care Visit	AURMG_MDR00007	AURMG_MDR00009	401; 402; 403	801; 802
10178	Neurology Consultation	ABMC_MDR07213	ABMC_MDR07215	401; 402; 403	801; 802
10179	Chest X-ray	ABMC_MDR07223	ABMC_MDR07223	401; 402; 403	801; 802
10180	Discharge Summary	ABMC_MDR07221	ABMC_MDR07222	401; 402; 403	801; 802
10181	Neurology Visit	AHCAR_MDR00184	AHCAR_MDR00186	401; 402; 403	801; 802
10182	Neurology Visit	AHCAR_MDR00173	AHCAR_MDR00175	401; 402; 403	801; 802
10183	Lumbar X-ray	PH_RAD00016	PH_RAD00016	401; 402; 403	801; 802
10184	Admission History & Physical	ABMC_MDR07020	ABMC_MDR07021	401; 402; 403	801; 802
10185	Discharge Summary	ABMC_MDR07022	ABMC_MDR07022	401; 402; 403	801; 802
10186	Neurology Visit	AHCAR_MDR00167	AHCAR_MDR00169	401; 402; 403	801; 802
10187	Patient Questionnaire	ABMC_MDR13036	ABMC_MDR13038	401; 402; 403	801; 802
10188	Rehabilitation Evaluation	ABMC_MDR13029	ABMC_MDR13032	401; 402; 403	801; 802
10189	Therapy Note	ABMC_MDR13034	ABMC_MDR13035	401; 402; 403	801; 802
10190	Neurology Visit	AHCAR_MDR00156	AHCAR_MDR00158	401; 402; 403	801; 802
10191	Pulmonary Visit	AHCAR_MDR00147	AHCAR_MDR00148	401; 402; 403	801; 802
10192	Primary Care Visit	AURMG_MDR00031	AURMG_MDR00033	401; 402; 403	801; 802
10193	Pain Management Visits	ADVPM_MDR00002	ADVPM_MDR00011	401; 402; 403	801; 802
10194	Neurology Visit	AHCAR_MDR00130	AHCAR_MDR00132	401; 402; 403	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
10195	Neurology Visit	AHCAR_MDR00120	AHCAR_MDR00121	401; 402; 403	801; 802
10196	Patient Questionnaire	AMGWC_MDR00011	AMGWC_MDR00012	401; 402; 403	801; 802
10197	Discharge Summary	ABMC_MDR06901	ABMC_MDR06901	401; 402; 403	801; 802
10198	Neurology Visit	AHCAR_MDR00111	AHCAR_MDR00113	401; 402; 403	801; 802
10199	Brain MRI	ABMC_RAD00008	ABMC_RAD00008	401; 402; 403	801; 802
10200	Neurology Visit	AHCAR_MDR00087	AHCAR_MDR00088	401; 402; 403	801; 802
10201	Neurology Visit	AHCAR_MDR00079	AHCAR_MDR00080	401; 402; 403	801; 802
10202	Neurology Visit	AHCAR_MDR00073	AHCAR_MDR00074	401; 402; 403	801; 802
10203	Primary Care Visit	AURMG_MDR00037	AURMG_MDR00038	401; 402; 403	801; 802
10204	Internal Medicine Visit	AHCAR_MDR00061	AHCAR_MDR00062	401; 402; 403	801; 802
10205	Neurology Visit	AHCAR_MDR00049	AHCAR_MDR00050	401; 402; 403	801; 802
10206	Pulmonary Visit	AHCAR_MDR00039	AHCAR_MDR00039	401; 402; 403	801; 802
10207	Primary Care Visit	AURMG_MDR00039	AURMG_MDR00041	401; 402; 403	801; 802
10208	Primary Care Visit	AURMG_MDR00042	AURMG_MDR00045	401; 402; 403	801; 802
10209	Admission History & Physical	ABMC_MDR06523	ABMC_MDR06524	401; 402; 403	801; 802
10210	Abdomen X-ray	ABMC_MDR06547	ABMC_MDR06548	401; 402; 403	801; 802
10211	Abdomen CT	ABMC_MDR06549	ABMC_MDR06551	401; 402; 403	801; 802
10212	Discharge Summary	ABMC_MDR06525	ABMC_MDR06528	401; 402; 403	801; 802
10213	Primary Care Visit	AURMG_MDR00046	AURMG_MDR00048	401; 402; 403	801; 802
10214	Neurology Visit	AHCAR_MDR00026	AHCAR_MDR00028	401; 402; 403	801; 802
10215	Rheumatology Evaluation	AHCAR_MDR00014	AHCAR_MDR00016	401; 402; 403	801; 802
10216	Primary Care Visit	AURMG_MDR00049	AURMG_MDR00051	401; 402; 403	801; 802
10217	Neurology Visit	AHCAR_MDR00003	AHCAR_MDR00004	401; 402; 403	801; 802
10218	Anticoagulation Note	AURMG_MDR00101	AURMG_MDR00101	401; 402; 403	801; 802
10219	Anticoagulation Note	AURMG_MDR00108	AURMG_MDR00108	401; 402; 403	801; 802
10220	Primary Care Note	AURMG_MDR00118	AURMG_MDR00118	401; 402; 403	801; 802
10221	Anticoagulation Note	AURMG_MDR00134	AURMG_MDR00134	401; 402; 403	801; 802
10222	Primary Care Visit	AURMG_MDR00147	AURMG_MDR00153	401; 402; 403	801; 802
10223	Neurology Visit	AHCAR_MDR00288	AHCAR_MDR00291	401; 402; 403	801; 802
10224	Anticoagulation Note	AURMG_MDR00165	AURMG_MDR00165	401; 402; 403	801; 802
10225	Anticoagulation Note	AURMG_MDR00189	AURMG_MDR00189	401; 402; 403	801; 802
10226	Primary Care Notes	AURMG_MDR00215	AURMG_MDR00217	401; 402; 403	801; 802
10227	Anticoagulation Note	AURMG_MDR00224	AURMG_MDR00224	401; 402; 403	801; 802
10228	Anticoagulation Note	AURMG_MDR00236	AURMG_MDR00236	401; 402; 403	801; 802
10229	Anticoagulation Note	AURMG_MDR00243	AURMG_MDR00243	401; 402; 403	801; 802
10230	Primary Care Notes	AURMG_MDR00255	AURMG_MDR00256	401; 402; 403	801; 802
10231	Anticoagulation Note	AURMG_MDR00263	AURMG_MDR00263	401; 402; 403	801; 802
10232	Primary Care Visit	AURMG_MDR00265	AURMG_MDR00274	401; 402; 403	801; 802
10233	Anticoagulation Note	AURMG_MDR00280	AURMG_MDR00280	401; 402; 403	801; 802
10234	Neurology Visit	AHCAR_MDR00336	AHCAR_MDR00340	401; 402; 403	801; 802
10235	Anticoagulation Note	AURMG_MDR00292	AURMG_MDR00292	401; 402; 403	801; 802
10236	ENT History	BAYCAREC_MDR00387	BAYCAREC_MDR00387	401; 402; 403	801; 802
10237	Anticoagulation Note	AURMG_MDR00299	AURMG_MDR00299	401; 402; 403	801; 802
10238	Anticoagulation Note	AURMG_MDR00306	AURMG_MDR00306	401; 402; 403	801; 802
10239	Gastroenterology Evaluation	ABHC_MDR00002	ABHC_MDR00012	401; 402; 403	801; 802
10240	Anticoagulation Note	AURMG_MDR00312	AURMG_MDR00313	401; 402; 403	801; 802
10241	Anticoagulation Note	AURMG_MDR00324	AURMG_MDR00326	401; 402; 403	801; 802
10242	Anticoagulation Note	AURMG_MDR00331	AURMG_MDR00331	401; 402; 403	801; 802
10243	Labs	ABMC_MDR07467	ABMC_MDR07468	401; 402; 403	801; 802
10244	Cardiology Consult (Fenton)	ABMC_MDR07743	ABMC_MDR07749	401; 402; 403	801; 802
10245	Cardiac Cath Report	BAYCC_MDR00079	BAYCC_MDR00081	401; 402; 403	801; 802
10246	Chest CTA	ABMC_MDR000651	ABMC_MDR000652	401; 402; 403	801; 802
10247	Abdomen X-ray	ABMC_MDR000648	ABMC_MDR000648	401; 402; 403	801; 802
10248	Intraoperative Echocardiogram (TEE)	BAYCC_MDR00082	BAYCC_MDR00084	401; 402; 403	801; 802
10249	Operative Report – Subxyphoid Window (Roitstein)	ABMC_MDR00405	ABMC_MDR00406	401; 402; 403	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
10250	Chest X-ray	ABMC_MDR00655	ABMC_MDR00655	401; 402; 403	801; 802
10251	Critical Care Note	ABMC_MDR00422	ABMC_MDR00426	401; 402; 403	801; 802
10252	Critical Care Note	ABMC_MDR00436	ABMC_MDR00441	401; 402; 403	801; 802
10253	Cardiology Note	ABMC_MDR00442	ABMC_MDR00446	401; 402; 403	801; 802
10254	Cardiology Note	ABMC_MDR00446	ABMC_MDR00450	401; 402; 403	801; 802
10255	Critical Care Note	ABMC_MDR00456	ABMC_MDR00460	401; 402; 403	801; 802
10256	Abdomen Ultrasound	BAYCC_MDR00086	BAYCC_MDR00086	401; 402; 403	801; 802
10257	Cardiology Note	ABMC_MDR00463	ABMC_MDR00467	401; 402; 403	801; 802
10258	Neurology Consult	ABMC_MDR00395	ABMC_MDR00398	401; 402; 403	801; 802
10259	Critical Care Note	ABMC_MDR00468	ABMC_MDR00473	401; 402; 403	801; 802
10260	Cardiology Note	ABMC_MDR00473	ABMC_MDR00476	401; 402; 403	801; 802
10261	Psychiatry Consult	ABMC_MDR00398	ABMC_MDR00402	401; 402; 403	801; 802
10262	Critical Care Note	ABMC_MDR00477	ABMC_MDR00481	401; 402; 403	801; 802
10263	Hematology Consult	ABMC_MDR00402	ABMC_MDR00404	401; 402; 403	801; 802
10264	Cardiology Note	ABMC_MDR00486	ABMC_MDR00489	401; 402; 403	801; 802
10265	Cardiology Note	ABMC_MDR00498	ABMC_MDR00502	401; 402; 403	801; 802
10266	Neurology Note	ABMC_MDR00502	ABMC_MDR00506	401; 402; 403	801; 802
10267	Hematology Note	ABMC_MDR00506	ABMC_MDR00510	401; 402; 403	801; 802
10268	Echocardiogram	BAYCC_MDR00077	BAYCC_MDR00077	401; 402; 403	801; 802
10269	Critical Care Note	ABMC_MDR00520	ABMC_MDR00525	401; 402; 403	801; 802
10270	Case Management Note	ABMC_MDR07861	ABMC_MDR07861	401; 402; 403	801; 802
10271	Cardiology Note	ABMC_MDR00525	ABMC_MDR00528	401; 402; 403	801; 802
10272	Discharge Summary	ABMC_MDR00416	ABMC_MDR00421	401; 402; 403	801; 802
10273	Primary Care Visit	AURMG_MDR00350	AURMG_MDR00356	401; 402; 403	801; 802
10274	Hematology Visit	ABMC_MDR01966	ABMC_MDR01968	401; 402; 403	801; 802
10275	Pain Management Visit	BAYCAREC_MDR00365	BAYCAREC_MDR00366	401; 402; 403	801; 802
10276	Cardiac Surgery Visit	BAYCC_MDR00133	BAYCC_MDR00134	401; 402; 403	801; 802
10277	Chest X-ray	ABMC_MDR09337	ABMC_MDR09337	401; 402; 403	801; 802
10278	Cardiology Visit	ABMC_MDR02033	ABMC_MDR02039	401; 402; 403	801; 802
10279	Cardiothoracic Surgery Evaluation (Kress)	ASLMC_MDR00725	ASLMC_MDR00730	401; 402; 403	801; 802
10280	Cardiac Bypass Timeline	ASLMC_MDR00192	ASLMC_MDR00198	401; 402; 403	801; 802
10281	Brief Op Note	ASLMC_MDR00730	ASLMC_MDR00731	401; 402; 403	801; 802
10282	Operative Report – Strut Removal (Kress)	ASLMC_MDR00760	ASLMC_MDR00763	401; 402; 403	801; 802
10283	Intraoperative Echocardiogram (TEE)	ASLMC_MDR00960	ASLMC_MDR00961	401; 402; 403	801; 802
10284	Surgical Pathology Report	ASLMC_MDR00992	ASLMC_MDR00993	401; 402; 403	801; 802
10285	Endocrinology Consult	ASLMC_MDR00525	ASLMC_MDR00534	401; 402; 403	801; 802
10286	Neurology Consult	ASLMC_MDR00555	ASLMC_MDR00561	401; 402; 403	801; 802
10287	Chest CT	ASLMC_MDR00130	ASLMC_MDR00131	401; 402; 403	801; 802
10288	Psychiatry Consult	ASLMC_MDR00562	ASLMC_MDR00570	401; 402; 403	801; 802
10289	Discharge Summary	ASLMC_MDR01179	ASLMC_MDR01182	401; 402; 403	801; 802
10290	ER Visit	ABMC_MDR02081	ABMC_MDR02090	401; 402; 403	801; 802
10291	Chest X-ray	ABMC_MDR02098	ABMC_MDR02098	401; 402; 403	801; 802
10292	Chest CTA	ABMC_MDR02097	ABMC_MDR02097	401; 402; 403	801; 802
10293	Primary Care Visit	BAYCC_MDR00087	BAYCC_MDR00092	401; 402; 403	801; 802
10294	Cardiology Visit	ABMC_MDR09445	ABMC_MDR09449	401; 402; 403	801; 802
10295	Chest CT	ABMC_MDR02186	ABMC_MDR02187	401; 402; 403	801; 802
10296	Cardiac Surgery Visit	BAYCC_MDR00127	BAYCC_MDR00128	401; 402; 403	801; 802
10297	Urogynecology Visit	AMGWC_MDR00108	AMGWC_MDR00108	401; 402; 403	801; 802
10298	Neurology Visit	AHCAR_MDR00378	AHCAR_MDR00379	401; 402; 403	801; 802
10299	ER Visit	ABMC_MDR02230	ABMC_MDR02246	401; 402; 403	801; 802
10300	Chest X-ray	ABMC_MDR02249	ABMC_MDR02249	401; 402; 403	801; 802
10301	Chest CT	ABMC_RAD00065	ABMC_RAD00065	401; 402; 403	801; 802
10302	Cardiac Surgery Visit	BAYCC_MDR00124	BAYCC_MDR00125	401; 402; 403	801; 802
10303	Cardiology Visit	ABMC_MDR09656	ABMC_MDR09661	401; 402; 403	801; 802
10304	Pulmonary Evaluation	AHCAR_MDR00425	AHCAR_MDR00431	401; 402; 403	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
10305	Echocardiogram	ABMC_MDR05390	ABMC_MDR05391	401; 402; 403	801; 802
10306	Bronchoscopy	ABMC_MDR02642	ABMC_MDR02643	401; 402; 403	801; 802
10307	Chest CT	ABMC_RAD00066	ABMC_RAD00066	401; 402; 403	801; 802
10308	Cardiac Surgery Visit	BAYCC_MDR00121	BAYCC_MDR00122	401; 402; 403	801; 802
10309	Pain Management Visit	BAYCAREC_MDR00360	BAYCAREC_MDR00361	401; 402; 403	801; 802
10310	Neurology Visit	ABAHC_MDR00078	ABAHC_MDR00083	401; 402; 403	801; 802
10311	EGD	ABMC_MDR10267	ABMC_MDR10268	401; 402; 403	801; 802
10312	Hematology Evaluation	ABMC_MDR03058	ABMC_MDR03062	401; 402; 403	801; 802
10313	Pulmonary Visit	AHCAR_MDR00466	AHCAR_MDR00472	401; 402; 403	801; 802
10314	Cardiology Visit	ABMC_MDR03134	ABMC_MDR03138	401; 402; 403	801; 802
10315	Neurology Visit	ABAHC_MDR00117	ABAHC_MDR00122	401; 402; 403	801; 802
10316	Chest CT	ABMC_RAD00068	ABMC_RAD00068	401; 402; 403	801; 802
10317	ENT Visit	BAYCAREC_MDR00157	BAYCAREC_MDR00164	401; 402; 403	801; 802
10318	Pulmonary Visit	ABMC_MDR03748	ABMC_MDR03754	401; 402; 403	801; 802
10319	Chest X-ray	ABMC_RAD00059	ABMC_RAD00059	401; 402; 403	801; 802
10320	Bronchoscopy	ABMC_MDR03747	ABMC_MDR03747	401; 402; 403	801; 802
10321	Cardiology Visit	ABMC_MDR03842	ABMC_MDR03846	401; 402; 403	801; 802
10322	Cardiac Event Monitor Report	ABMC_MDR03849	ABMC_MDR03849	401; 402; 403	801; 802
10323	Echocardiogram	ABMC_MDR05388	ABMC_MDR05389	401; 402; 403	801; 802
10324	Pulmonary Visit	AHCAR_MDR00567	AHCAR_MDR00572	401; 402; 403	801; 802
10325	Neurology Visit	ABAHC_MDR00202	ABAHC_MDR00207	401; 402; 403	801; 802
10326	EGD	ABMC_MDR11421	ABMC_MDR11422	401; 402; 403	801; 802
10327	Neurology Visit	ABAHC_MDR00304	ABAHC_MDR00309	401; 402; 403	801; 802
10328	Pain Management Visit	BAYCAREC_MDR00186	BAYCAREC_MDR00199	401; 402; 403	801; 802
10329	Primary Care Visit	AURMG_MDR01500	AURMG_MDR01510	401; 402; 403	801; 802
10330	Abdomen CT	ABMC_MDR04384	ABMC_MDR04385	401; 402; 403	801; 802
10331	Surgical Evaluation (McKenna)	ABMC_MDR04400	ABMC_MDR04408	401; 402; 403	801; 802
10332	Cardiology Evaluation (Weslow)	ABMC_MDR04560	ABMC_MDR04566	401; 402; 403	801; 802
10333	Operative Report – Incisional Hernia	ABMC_MDR04557	ABMC_MDR04559	401; 402; 403	801; 802
10334	Surgery Post-op Visit	ABMC_MDR12566	ABMC_MDR12566	401; 402; 403	801; 802
10335	Neurology Note	ABAHC_MDR00346	ABAHC_MDR00346	401; 402; 403	801; 802
10336	Neurology Note	ABAHC_MDR00371	ABAHC_MDR00371	401; 402; 403	801; 802
10337	Surgery Follow-up Visit	ABMC_MDR05259	ABMC_MDR05259	401; 402; 403	801; 802
10338	Chest X-ray	ABMC_RAD00060	ABMC_RAD00060	401; 402; 403	801; 802
10339	Primary Care Note	AURMG_MDR01692	AURMG_MDR01692	401; 402; 403	801; 802
10340	Sternoclavicular Joint X-ray	ABMC_MDR05302	ABMC_MDR05302	401; 402; 403	801; 802
10341	Laryngoscopy	BAYCAREC_MDR00213	BAYCAREC_MDR00213	401; 402; 403	801; 802
10342	Neurology Visit	ABAHC_MDR00560	ABAHC_MDR00566	401; 402; 403	801; 802
10343	Primary Care Visit	AURMG_MDR01732	AURMG_MDR01739	401; 402; 403	801; 802
10344	Orthopedic Evaluation	ABOSMC_MDR00008	ABOSMC_MDR00009	401; 402; 403	801; 802
10345	Primary Care Notes	AURMG_MDR01775	AURMG_MDR01776	401; 402; 403	801; 802
10346	Neurology Visit	ABAHC_MDR00482	ABAHC_MDR00487	401; 402; 403	801; 802
10347	Neurology Visit	ABAHC_MDR00513	ABAHC_MDR00518	401; 402; 403	801; 802
10348	Primary Care Visit	AURMG_MDR01880	AURMG_MDR01890	401; 402; 403	801; 802
10349	Cardiology Note	ABMC_MDR14707	ABMC_MDR14707	401; 402; 403	801; 802
10350	Echocardiogram	ABMC_MDR14719	ABMC_MDR14720	401; 402; 403	801; 802
10351	Cardiology Visit	ABMC_MDR14733	ABMC_MDR14738	401; 402; 403	801; 802
10352	Chest CT	ABMC_RAD00072	ABMC_RAD00072	401; 402; 403	801; 802
10353	Cardiology Note	ABMC_MDR14762	ABMC_MDR14762	401; 402; 403	801; 802
10354	Primary Care Note	AURMG_MDR01923	AURMG_MDR01923	401; 402; 403	801; 802
10355	Primary Care Visit	AURMG_MDR01931	AURMG_MDR01937	401; 402; 403	801; 802
10356	Neurology Evaluation (Bubolz)	AHCAR_MDR00626	AHCAR_MDR00635	401; 402; 403	801; 802
10357	Abdomen Ultrasound	TMCS_MDR00075	TMCS_MDR00076	401; 402; 403	801; 802
10358	Hematology Visit	ABMC_MDR14807	ABMC_MDR14813	401; 402; 403	801; 802
10359	Primary Care Note	AURMG_MDR02018	AURMG_MDR02019	401; 402; 403	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
10360	EGD	ABMC_MDR14833	ABMC_MDR14834	401; 402; 403	801; 802
10361	Primary Care Visit	AURMG_MDR02057	AURMG_MDR02064	401; 402; 403	801; 802
10362	Orthopedic Visit	BAYCC_MDR00152	BAYCC_MDR00154	401; 402; 403	801; 802
10363	Endocrinology Visit	AHCAR_MDR00773	AHCAR_MDR00774	401; 402; 403	801; 802
10364	Neurology Evaluation (Stanko)	NCBHGB_MDR00003	NCBHGB_MDR00007	401; 402; 403	801; 802
10365	ENT Evaluation	BAYCC_MDR00160	BAYCC_MDR00168	401; 402; 403	801; 802
10366	Endocrinology Visit	AHCAR_MDR00836	AHCAR_MDR00845	401; 402; 403	801; 802
10367	Neurology Note	NCBHGB_MDR00010	NCBHGB_MDR00010	401; 402; 403	801; 802
10368	Endocrinology Note	AHCAR_MDR00871	AHCAR_MDR00873	401; 402; 403	801; 802
10369	ER Visit	ABMC_MDR15049	ABMC_MDR15058	401; 402; 403	801; 802
10370	Endocrinology Visit	AHCAR_MDR00945	AHCAR_MDR00956	401; 402; 403	801; 802
10371	Primary Care Visit	AURMG_MDR02235	AURMG_MDR02235	401; 402; 403	801; 802
10372	Ophthalmology Visit	BAYCC_MDR00201	BAYCC_MDR00207	401; 402; 403	801; 802
10373	Cardiology Note	ABMC_MDR15111	ABMC_MDR15111	401; 402; 403	801; 802
10374	Echocardiogram	ABMC_MDR15097	ABMC_MDR15097	401; 402; 403	801; 802
10375	Cardiology Note	ABMC_MDR15118	ABMC_MDR15118	401; 402; 403	801; 802
10376	Neurology Visit	NCBHGB_MDR00011	NCBHGB_MDR00015	401; 402; 403	801; 802
10377	Primary Care Visit	AHCAR_MDR01063	AHCAR_MDR01074	401; 402; 403	801; 802
10378	Endocrinology Visit	AHCAR_MDR01094	AHCAR_MDR01107	401; 402; 403	801; 802
10379	Endocrinology Visit	AHCAR_MDR01185	AHCAR_MDR01196	401; 402; 403	801; 802
10380	Nutrition/Diabetes Visit	AHCAR_MDR01258	AHCAR_MDR01262	401; 402; 403	801; 802
10381	Primary Care Note	AURMG_MDR02402	AURMG_MDR02402	401; 402; 403	801; 802
10382	ENT Visit	BAYCC_MDR00214	BAYCC_MDR00222	401; 402; 403	801; 802
10383	ER Visit	TMCS_MDR00018	TMCS_MDR00025	401; 402; 403	801; 802
10384	Abdomen CT	TMCS_MDR00025	TMCS_MDR00026	401; 402; 403	801; 802
10385	Admission History & Physical	ABMC_MDR15165	ABMC_MDR15175	401; 402; 403	801; 802
10386	Anesthesia Evaluation	ABMC_MDR15983	ABMC_MDR15987	401; 402; 403	801; 802
10387	Operative Report – Laparoscopic Cholecystectomy	ABMC_MDR15264	ABMC_MDR15265	401; 402; 403	801; 802
10388	Case Management Note	ABMC_MDR15244	ABMC_MDR15246	401; 402; 403	801; 802
10389	Echocardiogram	ABMC_MDR15395	ABMC_MDR15396	401; 402; 403	801; 802
10390	Discharge Summary	ABMC_MDR15156	ABMC_MDR15165	401; 402; 403	801; 802
10391	Case Management Note	ABMC_MDR15261	ABMC_MDR15262	401; 402; 403	801; 802
10392	Surgery Follow-up Visit	ABMC_MDR16045	ABMC_MDR16046	401; 402; 403	801; 802
10393	Primary Care Visit	AURMG_MDR02452	AURMG_MDR02460	401; 402; 403	801; 802
10394	Telephone Note	ABMC_MDR16054	ABMC_MDR16054	401; 402; 403	801; 802
10395	Endocrinology Visit	AHCAR_MDR01369	AHCAR_MDR01381	401; 402; 403	801; 802
10396	Gastroenterology Visit	ABHC_MDR00019	ABHC_MDR00028	401; 402; 403	801; 802
10397	Urogynecology Visit	AMGWC_MDR00148	AMGWC_MDR00153	401; 402; 403	801; 802
10398	Endocrinology Visit	AHCAR_MDR01597	AHCAR_MDR01608	401; 402; 403	801; 802
10399	Primary Care Visit	AHCAR_MDR01616	AHCAR_MDR01625	401; 402; 403	801; 802
10400	Pain Management Visit	BAYCC_MDR00229	BAYCC_MDR00238	401; 402; 403	801; 802
10401	Neurology Visit	NCBHGB_MDR00019	NCBHGB_MDR00022	401; 402; 403	801; 802
10402	ER Visit	ABMC_MDR16105	ABMC_MDR16119	401; 402; 403	801; 802
10403	Chest X-ray	ABMC_MDR16129	ABMC_MDR16129	401; 402; 403	801; 802
10404	Primary Care Visit	AURMG_MDR02812	AURMG_MDR02814	401; 402; 403	801; 802
10405	Abdomen CT	AURMG_MDR02867	AURMG_MDR02868	401; 402; 403	801; 802
10406	Urogynecology Note	AMGWC_MDR00176	AMGWC_MDR00177	401; 402; 403	801; 802
10407	Primary Care Note	AHCAR_MDR01893	AHCAR_MDR01894	401; 402; 403	801; 802
10408	Endocrinology Visit	AHCAR_MDR01904	AHCAR_MDR01916	401; 402; 403	801; 802
10409	Primary Care Visit	AHCAR_MDR01923	AHCAR_MDR01925	401; 402; 403	801; 802
10410	EKG	AHCAR_01926	AHCAR_01928	401; 402; 403	801; 802
10411	Labs	AHCAR_MDR01935	AHCAR_MDR01936	401; 402; 403	801; 802
10412	Holter Monitor	ABMC_MDR16184	ABMC_MDR16185	401; 402; 403	801; 802
10413	Primary Care Note	AHCAR_MDR01960	AHCAR_MDR01961	401; 402; 403	801; 802
10414	Echocardiogram	ABMC_MDR16185	ABMC_MDR16186	401; 402; 403	801; 802

Defendants' Exhibit List

Tinlin v. C.R. Bard, et al.

Exhibits	Description	Beg. Bates Number	End Bates Number	Plaintiffs' Objection	Defendants' Objection
10415	Urogynecology Note	AMGWC_MDR00194	AMGWC_MDR00195	401; 402; 403	801; 802
10416	Primary Care Note	AHCAR_MDR01986	AHCAR_MDR01986	401; 402; 403	801; 802
10417	Hematology Note	ABMC_MDR16327	ABMC_MDR16329	401; 402; 403	801; 802
10418	Cardiology Visit	ABMC_MDR16330	ABMC_MDR16343	401; 402; 403	801; 802
10419	Gastroenterology Visit	AURMG_MDR03168	AURMG_MDR03180	401; 402; 403	801; 802
10420	Video Swallow	ABMC_RAD00104	ABMC_RAD00104	401; 402; 403	801; 802
10421	EGD with dilatation	ABMC_MDR16209	ABMC_MDR16210	401; 402; 403	801; 802
10422	Patient Questionnaire	ABMC_MDR16564	ABMC_MDR16565	401; 402; 403	801; 802
10423	Hematology Evaluation	ABMC_MDR16544	ABMC_MDR16563	401; 402; 403	801; 802
10424	Neurology Note	NCBHGB_MDR00041	NCBHGB_MDR00041	401; 402; 403	801; 802
10425	Primary Care Visit	AURMG_MDR03181	AURMG_MDR03203	401; 402; 403	801; 802
10426	Pulmonary Visit	AURMG_MDR03211	AURMG_MDR03224	401; 402; 403	801; 802
10427	Sleep Study Order	ABMC_MDR16645	ABMC_MDR16645	401; 402; 403	801; 802
10428	Hematology Note	ABMC_MDR16579	ABMC_MDR16579	401; 402; 403	801; 802
10429	Radiology Note	ABMC_MDR16599	ABMC_MDR16599	401; 402; 403	801; 802
10430	Neurology Note and Letter	NCBHGB_MDR00042	NCBHGB_MDR00044	401; 402; 403	801; 802
10431	Bilateral Lower Extremity Doppler	ABMC_MDR16618	ABMC_MDR16618	401; 402; 403	801; 802
10432	Sleep Questionnaire	ABMC_MDR16628	ABMC_MDR16633	401; 402; 403	801; 802
10433	Aurora Baycare Medical Center- CD/DVD of cardiac clips	TINLIND_ABMC_CAD00001CD	TINLIND_ABMC_CAD00001CD	401; 402; 403	801; 802
10434	Aurora Baycare Medical Center- CD/DVD of radiology	TINLIND_ABMC_RAD00001DVD	TINLIND_ABMC_RAD00009CD	401; 402; 403	801; 802
10435	Aurora St. Luke's Medical Center- CD/DVD of cardiac clips	TINLIND_ASLMC_CAD00001CD	TINLIND_ASLMC_CAD00001CD	401; 402; 403	801; 802
10436	Aurora St. Luke's Medical Center- CD/DVD of radiology	TINLIND_ASLMC_RAD00001CD	TINLIND_ASLMC_RAD00003CD	401; 402; 403	801; 802
10437	Froedtert Memorial Lutheran Hospital- CD/DVD of radiology	TINLIND_FMLH_RAD00001CD	TINLIND_FMLH_RAD00001CD	401; 402; 403	801; 802
10438	Prevea Health- CD/DVD of radiology	TINLIND_PH_RAD00001CD	TINLIND_PH_RAD00002CD	401; 402; 403	801; 802
10439	St. Mary's Hospital Medical Center- CD/DVD of radiology	TINLIND_SMHMC_RAD00001CD	TINLIND_SMHMC_RAD00003CD	401; 402; 403	801; 802
10440	St. Vincent Hospital- CD/DVD of radiology	TINLIND_STVH_RAD00001DVD	TINLIND_STVH_RAD00001DVD	401; 402; 403	801; 802
10441	ThedaCare Medical Center-Shawano- CD/DVD of radiology	TINLIND_TMCS_RAD00001CD	TINLIND_TMCS_RAD00001CD	401; 402; 403	801; 802
10442	White, Lora, 1/14/2019, deposition exhibit 01			401; 402; 403	401; 402; 403; 801; 802
10443	White, Lora, 1/14/2019, deposition exhibit 02			401; 402; 403	401; 402; 403; 801; 802
10444	White, Lora, 1/14/2019, deposition exhibit 03			401; 402; 403	401; 402; 403; 801; 802
10445	White, Lora, 1/14/2019, deposition exhibit 04			401; 402; 403	401; 402; 403; 801; 802
10446	White, Lora, 1/14/2019, deposition exhibit 05			401; 402; 403	401; 402; 403; 801; 802
10447	White, Lora, 1/14/2019, deposition exhibit 06			401; 402; 403	401; 402; 403; 801; 802
10448	White, Lora, 1/14/2019, deposition exhibit 07			401; 402; 403	401; 402; 403; 801; 802
10449	White, Lora, 1/14/2019, deposition exhibit 08			401; 402; 403	401; 402; 403; 801; 802
10450	White, Lora, 1/14/2019, deposition exhibit 09			401; 402; 403	401; 402; 403; 801; 802
10451	White, Lora, 1/14/2019, deposition exhibit 10			401; 402; 403	401; 402; 403; 801; 802
10452	White, Lora, 1/14/2019, deposition exhibit 11			401; 402; 403	401; 402; 403; 801; 802
10453	White, Lora, 1/14/2019, deposition exhibit 12			401; 402; 403	401; 402; 403; 801; 802
10454	White, Lora, 1/14/2019, deposition exhibit 13			401; 402; 403	401; 402; 403; 801; 802
10455	White, Lora, 1/14/2019, deposition exhibit 14			401; 402; 403	401; 402; 403; 801; 802
10456	White, Lora, 1/14/2019, deposition exhibit 15			401; 402; 403	401; 402; 403; 801; 802
10457	White, Lora, 1/14/2019, deposition exhibit 16			401; 402; 403	401; 402; 403; 801; 802
10458	White, Lora, 1/14/2019, deposition exhibit 17			401; 402; 403	401; 402; 403; 801; 802
10459	White, Lora, 1/14/2019, deposition exhibit 18			401; 402; 403	401; 402; 403; 801; 802
10460	White, Lora, 1/14/2019, deposition exhibit 19			401; 402; 403	401; 402; 403; 801; 802
10461	Horos User Guide			401; 402; 403	401; 402; 403; 801; 802
10462	Horos Website			401; 402; 403	401; 402; 403; 801; 802
10463	Tinlin Complaint File MDR	BPV-TINLIN-000001	BPV-TINLIN-000039	401; 402; 403; 801; 802	401; 402; 403; 801; 802
10464	MAUDE and Sales Data Q2 2004	BPV-17-01-00097589	BPV-17-01-00097622	401; 402; 403; 801; 802	401; 402; 403; 801; 802
10465	MAUDE and Sales Data Q1 2005	BPV-17-01-00097459	BPV-17-01-00097490	401; 402; 403; 801; 802	401; 402; 403; 801; 802